
<html lang="en"     class="pb-page"  data-request-id="103c5210-fe93-48c7-b8b1-7d7604f7498b"  
><head data-pb-dropzone="head"><meta name="pbContext" content=";requestedJournal:journal:jmcmar;issue:issue:10.1021/jmcmar.2014.57.issue-5;article:article:10.1021/jm4012643;journal:journal:jmcmar;page:string:Article/Chapter View;ctype:string:Journal Content;wgroup:string:ACHS website Group;website:website:acspubs;pageGroup:string:Publication Pages;subPage:string:Full Text"/></meta>




        <link rel="schema.DC" href="http://purl.org/DC/elements/1.0/" /></link><meta name="dc.Title" content="Discovery of a Novel Class of Potent HCV NS4B Inhibitors: SAR Studies on Piperazinone Derivatives" /></meta><meta name="dc.Creator" content="Ramesh  Kakarla" /></meta><meta name="dc.Creator" content="Jian  Liu" /></meta><meta name="dc.Creator" content="Devan  Naduthambi" /></meta><meta name="dc.Creator" content="Wonsuk  Chang" /></meta><meta name="dc.Creator" content="Ralph T.  Mosley" /></meta><meta name="dc.Creator" content="Donghui  Bao" /></meta><meta name="dc.Creator" content="Holly M. Micolochick  Steuer" /></meta><meta name="dc.Creator" content="Meg  Keilman" /></meta><meta name="dc.Creator" content="Shalini  Bansal" /></meta><meta name="dc.Creator" content="Angela M.  Lam" /></meta><meta name="dc.Creator" content="William  Seibel" /></meta><meta name="dc.Creator" content="Sandra  Neilson" /></meta><meta name="dc.Creator" content="Phillip A.  Furman" /></meta><meta name="dc.Creator" content="Michael J.  Sofia" /></meta><meta name="dc.Description" content="HTS screening identified compound 2a (piperazinone derivative) as a low micromolar HCV genotype 1 (GT-1) inhibitor. Resistance mapping studies suggested that this piperazinone chemotype targets the..." /></meta><meta name="Description" content="HTS screening identified compound 2a (piperazinone derivative) as a low micromolar HCV genotype 1 (GT-1) inhibitor. Resistance mapping studies suggested that this piperazinone chemotype targets the..." /></meta><meta name="dc.Publisher" content="American Chemical Society" /></meta><meta name="dc.Date" scheme="WTN8601" content="January 29, 2014" /></meta><meta name="dc.Type" content="research-article" /></meta><meta name="dc.Format" content="text/HTML" /></meta><meta name="dc.Identifier" scheme="doi" content="10.1021/jm4012643" /></meta><meta name="dc.Language" content="EN" /></meta><meta name="dc.Coverage" content="world" /></meta><meta name="dc.Rights" content="© 2014 American Chemical Society" /></meta>
        
        

        
            <link rel="meta" type="application/atom+xml" href="https://doi.org/10.1021%2Fjm4012643" /></link>
            <link rel="meta" type="application/rdf+json" href="https://doi.org/10.1021%2Fjm4012643" /></link>
            <link rel="meta" type="application/unixref+xml" href="https://doi.org/10.1021%2Fjm4012643" /></link>
        
    
    

<title>Discovery of a Novel Class of Potent HCV NS4B Inhibitors: SAR Studies on Piperazinone Derivatives | Journal of Medicinal Chemistry</title>












<meta charset="UTF-8">




<meta name="robots" content="noarchive"/></meta>
<meta name="pb-robots-disabled">









        <meta property="og:url" content="https://pubs.acs.org/doi/full/10.1021/jm4012643" /></meta><meta property="og:title" content="Discovery of a Novel Class of Potent HCV NS4B Inhibitors: SAR Studies on Piperazinone Derivatives" /></meta><meta property="og:image" content="https://pubs.acs.org/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-5/jm4012643/production/images/large/jm-2013-012643_0026.jpeg" /></meta><meta property="og:description" content="HTS screening identified compound 2a (piperazinone derivative) as a low micromolar HCV genotype 1 (GT-1) inhibitor. Resistance mapping studies suggested that this piperazinone chemotype targets the HCV nonstructural protein NS4B. Extensive SAR studies were performed around 2a and the amide function and the C-3/C-6 cis stereochemistry of the piperazinone core were essential for HCV activity. A 10-fold increase in GT-1 potency was observed when the chiral phenylcyclopropyl amide side chain of 2a was replaced with p-fluorophenylisoxazole-carbonyl moiety (67). Replacing the C-6 nonpolar hydrophobic moiety of 67 with a phenyl moiety (95) did not diminish the GT-1 potency. A heterocyclic thiophene moiety (103) and an isoxazole moiety (108) were incorporated as isosteric replacements for the C-6 phenyl moiety (95), resulting in significant improvement in GT-1b and 1a potency. However, the piperazonone class of compounds lacks GT-2 activity and, consequently, were not pursued further into development." /></meta><meta property="og:type" content="Article" /></meta><meta property="og:site_name" content="ACS Publications" /></meta><meta name="twitter:card" content="summary_large_image" /></meta><meta name="twitter:site" content="@ACSPublications" /></meta>
    


    <meta name="viewport" content="width=device-width,initial-scale=1,maximum-scale=10, user-scalable=0"/></meta>















    

    <meta name="dc.identifier" content="10.1021/jm4012643"/></meta>



<meta name="format-detection" content="telephone=no">













<link rel="stylesheet" type="text/css" href="/wro/kfa7~product.css">


    <link rel="stylesheet" href="/products/achs/releasedAssets/fonts/achs-fonts/font-roboto/font-roboto.css"/></link><link rel="stylesheet" href="/products/achs/releasedAssets/css/build-f32cfd249ff7cb4cf9c7.css"/></link><link rel="stylesheet" href="/products/achs/releasedAssets/fonts/achs-fonts/font-lato/font-lato.css"/></link>




<meta http-equiv="X-UA-Compatible" content="IE=edge">
<meta http-equiv="content-type" content="text/html; charset=UTF-8">
<link rel="stylesheet" type="text/css" href="/pb-assets/styles/achs-1625058702970.css">
<link rel="stylesheet" type="text/css" href="/pb-assets/styles/acs-1622125181777.css">
<script type="text/javascript" src="/templates/jsp/js/jquery-3.1.1.min.js"></script>
<script type="text/javascript" src="/pb-assets/javascript/eloqua-1619549134767.js"></script>
<script async="" type="text/javascript" src="https://www.googletagservices.com/tag/js/gpt.js" rel="preconnect"></script>

<script defer src="https://static.cloudflareinsights.com/beacon.min.js" data-cf-beacon='{"rayId":"5200035e6e4d5180","startTime":1570117212010}'></script>






    








    
        
            <script type="text/javascript">
                (function (i, s, o, g, r, a, m) {
                    i['GoogleAnalyticsObject'] = r;
                    i[r] = i[r] || function () {
                        (i[r].q = i[r].q || []).push(arguments)
                    }, i[r].l = 1 * new Date();
                    a = s.createElement(o), m = s.getElementsByTagName(o)[0];
                    a.async = 1;
                    a.src = g;
                    m.parentNode.insertBefore(a, m)
                })(window, document, 'script', '//www.google-analytics.com/analytics.js', 'ga');
                ga('create', 'UA-7663985-4'
                    
                    
                    , 'auto'
                    
                    );
                
                
                ga('send', 'pageview');
            </script>
            
        
    















    
    
            
                
                

                <link rel="canonical" href="https://pubs.acs.org/doi/10.1021/jm4012643">
            
        




























    
    

    
    
    
    
    <script src="//unpkg.com/@theidentityselector/thiss-ds"></script>

    <script type="text/javascript">

        var SeamlessAccessService = {
            spUrl: "/action/ssostart",
            returnURL: window.location.href,
            my_context: 'seamlessaccess.org',
            timeout: 5000,

            getWAYFLessUrl: function (entityId) {
                return this.spUrl + "?idp=" + encodeURIComponent(entityId)
                    + "&redirectUri=" + encodeURIComponent(this.returnURL);
            },
            retrieveEntity: function (ms) {
                var self = this;
                var persistService = new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                if(ms == undefined || ms === ''){
                    ms = this.timeout;
                }

                return new Promise(function (resolve, reject) {
                    persistService.entities(self.my_context)
                        .then(function (res) {
                            // get the results
                            var results = res.data;
                            return resolve(results);
                        }, function (err) {
                            // failed
                            reject('retrieve entity error: ' + err);
                        });
                        // Set up the timeout
                        setTimeout(function() {
                            reject('Promise timed out ' + ms + ' ms');
                        }, ms);
                });
            },
            updateEntity: function (entitydata) {
                var self = this;
                var persistService =  new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                var jsonObj = {};
                try {
                    //try to parse it, if it is a json string
                    jsonObj = JSON.parse(entitydata.val());
                } catch (e) {
                    jsonObj = entitydata;
                }
                return new Promise(function (resolve, reject) {
                    persistService.update(self.my_context, jsonObj)
                        .then(function (res) {
                            // Process the results
                            var ssoInstitutions = res.data;
                            return resolve(ssoInstitutions);
                        }, function (err) {
                            // failed
                            console.log('failed to update the local storage duo to: ' + err);
                            reject(err);
                        });
                })
            },
            removeEntity: function (entityId) {
                var self = this;
                var persistService =  new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                return new Promise(function (resolve) {
                    persistService.remove(self.my_context, entityId)
                        .then(function (res) {
                            return resolve(res);
                        }, function (err) {
                            // failed
                            console.log('failed to remove from local storage duo to: ' + err);
                        });
                })
            },
            getAccessibleEntityStatus: function (doi, entityId) {
                return new Promise(function (resolve) {
                    $.ajax({
                        type: 'POST',
                        url: '/action/seamlessAccess',
                        accept: {
                            text: "application/json"
                        },
                        data: {doi: doi, entityid: entityId}

                    }).done(function (status) {
                        return resolve(status);
                    });
                });
            },
            getEntitiesWithAllInfo: function (doi) {
                let self = this,
                    arrayOfPromises = [];
                return new Promise(function (resolve, reject) {
                    self.retrieveEntity().then(function (res) {
                        let allSsoInstitutions = res;
                        for (i = 0; i < allSsoInstitutions.length; i++) {
                            let ssoInstitution = allSsoInstitutions[i];
                            arrayOfPromises.push(new Promise(function (resolve) {
                                self.getAccessibleEntityStatus(doi, ssoInstitution.entity.entityID)
                                    .then(function (entityStatus) {
                                        resolve({
                                            entityID: ssoInstitution.entity.entityID,
                                            entityTitle: ssoInstitution.entity.title,
                                            entityStatusObj: entityStatus,
                                            entitySsoUrl: self.getWAYFLessUrl(ssoInstitution.entity.entityID)
                                        });
                                    }, function (err) {
                                        console.log('failed to get the entity status: ' + err);
                                    });
                            }));
                        }
                        Promise.all(arrayOfPromises)
                            .then(function (finalResponse) {
                                resolve(finalResponse);
                            });

                    }).catch(function (err) {
                        reject(err);
                    })
                });
            }
        };

        window.addEventListener('load', function () {
            document.querySelectorAll(".sso-institution").forEach(function (institution) {
                var entityId = institution.getAttribute('data-entityid');
                var entityName = institution.getAttribute('data-name');
                var entitydata = {
                    entityID: entityId,
                    title: entityName
                };
                institution.addEventListener("click", function (e) {
                    e.preventDefault();
                    var self = this;
                    SeamlessAccessService.updateEntity(entitydata).then(function (res) {
                        console.log(res);
                        window.location.href = self.href;
                    }).catch(function (err){
                        window.location.href = self.href;
                    });
                });
            });
        });

    </script>




























    






    <meta name="google-site-verification" content="uBHpu2M2kL7VihPCSRXWyBSxooDf7L_BGgfHA3cjSfY" /></meta>


<link rel="prefetch" href="https://tpc.googlesyndication.com/safeframe/1-0-29/html/container.html"></head>
<body class="pb-ui">


























<script type="text/javascript">

    if(false) {
        document.getElementById("skipNavigationLink").onclick =function skipElement () {
            var element = document.getElementById('');
            if(element == null || element == undefined) {
                element = document.getElementsByClassName('').item(0);
            }
            element.setAttribute('tabindex','0');
            element.focus();

        }

    }

</script>











    <div id="pb-page-content" data-ng-non-bindable>
        <div data-pb-dropzone="main" data-pb-dropzone-name="Main">










        <div data-widget-def="UX3HTMLWidget" data-widget-id="ed6ae788-7707-48f4-b02c-3187c75e10db" class="hide">
        



        
        

        </div>
    




        
        




        
        



        <div class="pb-ad">
            <script type="text/javascript">
	var dartInstitutionType = 'none';
	var dartMember = 'false';
</script>
        </div>
    





        
        <script type="text/javascript">
$(document).ready(function() {
	setTimeout(function() {
		// var journalTitle = 'medicinal_chemistry';
		var taxonomyKeywords = $('.article_header-taxonomy');
		var articleKeyword = $('meta[name="keywords"]');
		var articleTitle = $('meta[name="dc.Title"]');
		var articleDescription = $('meta[name="dc.Description"]');
		var abstractKeyword = $('p.articleBody_abstractText:contains("Keywords: ")');
		var searchTerms = [];

		if (taxonomyKeywords.length > 0) {
			$(taxonomyKeywords).children(".rlist--inline").children("li").each(function() {
				searchTerms.push($(this).text());
			});
		}
		else if (articleKeyword.length > 0) { 
			searchTerms = searchTerms.concat(articleKeyword.prop('content').split(', '));
		}
		else if (abstractKeyword.length > 0) {
			searchTerms = searchTerms.concat(abstractKeyword.text().split("Keywords: ")[1].split('; '));
		}
		else if (articleDescription.length > 0) {
			$(articleDescription).each(function() {
				articleDescriptionKeywords = $(this).prop('content');
				articleDescriptionKeywords = articleDescriptionKeywords.replace(/.,/g,"");
				articleDescriptionKeywords = articleDescriptionKeywords.replace(/\s{2,}/g," ");
				searchTerms = searchTerms.concat(articleDescriptionKeywords.split(' '));
			});
		}

		if (articleTitle.length > 0) {
			searchTerms = searchTerms.concat(articleTitle.prop('content').split(' '));
		}

		googletag.cmd.push(function() {
			var mappingLeader = googletag.sizeMapping().
			addSize([320, 400], [320, 50]).
			addSize([320, 700], [320, 50]).
			addSize([750, 200], [728, 90]). 
			addSize([980, 690], [728, 90]).
			addSize([1024, 768], [728, 90]).
			build();
			//leaderboard
			googletag.defineSlot('/8868/journal/medicinal_chemistry/article', [728, 90], 'dfp-journal-article-leaderboard').defineSizeMapping(mappingLeader).setTargeting('location', 'leaderboard1').setTargeting('Keyword', searchTerms).addService(googletag.pubads());
			//recommend
			googletag.defineSlot("/8868/journal/medicinal_chemistry/article", [1, 1], "dfp-journal-article-recommend").setTargeting("ntvPlacement", ["1100167"]).setTargeting("location", "recommend").setTargeting('Keyword', searchTerms).addService(googletag.pubads());
			//googletag.pubads().enableSingleRequest();
			googletag.pubads().collapseEmptyDivs();
			googletag.pubads().setTargeting('inst',dartInstitutionType).setTargeting('memb',dartMember);
			googletag.pubads().addEventListener("slotRenderEnded", function(event) {
				if((event.isEmpty === false) && (event.slot.getSlotElementId() != "dfp-journal-article-recommend")) {
					$("#" + event.slot.getSlotElementId()).parents(".advertisement").slideDown();
				}
			});
			googletag.enableServices();
		});
	}, 1000);
});
</script>





        
        <script src="https://common.ccdc.cam.ac.uk/ccdc-widget/1.0.0.76/Widget.min.js"></script>




        
        <header class="header header_article_inactive">



        
        <div class="header_topbar hidden-sm hidden-xs">



        
        <div class="container"><div class="row"><div class="col-lg-3 col-md-4 col-sm-5 header_topbar_left">









        <div data-widget-def="UX3HTMLWidget" data-widget-id="0be92cec-36a8-4b4d-9a08-a28c790ce306" class="header_mainmenu">
        



        
        <ul>
	<li>
		<a href="http://www.acs.org">ACS</a>
	</li>
	<li class="header_mainmenu_current">
		<a href="/">ACS Publications</a>
	</li>
	<li>
		<a href="https://cen.acs.org">C&EN</a>
	</li>
	<li>
		<a href="https://www.cas.org">CAS</a>
	</li>
</ul>

        </div>
    
</div><div class="col-lg-9 col-md-8 col-sm-7 header_topbar_right">



        
        <div class="institution"><span class="institution-info-wrapper"><span class="institution__intro">Access provided by</span><span class="institution__name">Hong Kong University of Science and Technology Library</span></span></div>




        
        <div class="user-login-bar"><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><input type="hidden" name="heartBeatReloadInterval" value="1740000" class="heartBeatReloadInterval"/></input><input type="hidden" name="logoutUrl" value="https://pubs.acs.org/action/doLogout?logoutRedirectUrl=https%3A%2F%2Fsso.acs.org%2Fidp%2Fglogout%3Fappid%3Datypon-live%26returnURL%3Dhttps%253A%252F%252Fpubs.acs.org%252F" class="logoutUrl"/></input><img src="https://sso.acs.org/idp/heartbeat?appid=atypon-lives&amp;max_auth_age=2592000" alt="Blank image" class="ssoHeartBeatImg"/></img><span class="user-login-bar__value"><a href="https://pubs.acs.org/action/ssoRequestForLoginPage" class="user-login-bar__Login">Log In</a></span><input type="hidden" name="isUserLoggedIn" value="false" class="user-login-bar_is-loggedin"/></input><input type="hidden" name="isPaired" value="false" class="pair-device-is-paired"/></input><input type="hidden" name="isStronglyAuthenticated" value="false" class="isStronglyAuthenticated"/></input></div>
</div></div></div>
</div>




        
        <div class="header_content">



        
        <div class="container"><div class="row"><div class="header_content_main">



        
        <div class="header_content_row">



        
        <div class="header_content_left pull-left">



        
        <a href="/" title="ACS Publications. Most Trusted. Most Cited. Most Read"><img id="" alt="ACS Publications. Most Trusted. Most Cited. Most Read" src="/pb-assets/ux3/pubs-logo-481x82-1523435513963.png"/></img></a>




        
        <div class="pj-badge"></div><a href="/journal/jmcmar" title="journal logo" class="header_article-logo"><img src="/na101/home/literatum/publisher/achs/journals/covergifs/jmcmar/title.png" alt="Journal Logo"></a><div class="header_article-separator"></div>
</div><div class="header_content_center">



        
        <div class="header_contnav">
    <div class="header_contnav-row">
         <a href="#" title="Previous" class="header_contnav-pre">
                <i class="icon-angle-left"></i>
        </a>
       <div class="header_contnav-title">
            <span>
                <a href="#" title=""></a>
            </span>
        </div>
         <a href="#" title="Next" class="header_contnav-next">
                <i class="icon-angle-right"></i>
            </a>
    </div>
</div>
</div><div class="header_content_right pull-right">



        
        <div class="header_qv-link"><a href="#" title="Quick View" data-slide-target=".article_qv-xs-container" class="w-slide__btn slide-active icon-quickview">Quick View</a></div>




        
        <div class="header_article-share">



        
        <script type="text/javascript" async="async" src="//s7.addthis.com/js/300/addthis_widget.js#pubid=xa-4faab26f2cff13a7"></script><div class="share"><div class="share_button"><span class="share__label">Share</span><a href="#" data-db-target-for="527d28d6-3414-4cb2-9560-99e677e62c0d" data-db-switch="icon-close_thin" aria-label="share button" class="share__ctrl"><i aria-hidden="true" class="icon-Icon_Share"></i></a></div><div class="pb-dropzone" data-pb-dropzone="ShareDropzone1" title="ShareDropzone1"></div><div class="pb-dropzone" data-pb-dropzone="ShareDropzone2" title="ShareDropzone2"></div><div data-db-target-of="527d28d6-3414-4cb2-9560-99e677e62c0d" id="527d28d6-3414-4cb2-9560-99e677e62c0d_Pop" class="share__block dropBlock__holder fixed"><div class="pb-dropzone" data-pb-dropzone="shareBlock" title="shareBlock"></div><span class="sr-only">Share on</span><ul class="rlist w-slide--list addthis addthis_toolbox addthis_default_style addthis_32x32_style"><li><a role="link" class="addthis_button_facebook"><i aria-hidden="true" class="at-icon-wrapper icon-facebook"></i>Facebook</a></li><li><a role="link" class="addthis_button_twitter"><i aria-hidden="true" class="at-icon-wrapper icon-twitter"></i>Twitter</a></li><li><a role="link" class="addthis_button_wechat"><i aria-hidden="true" class="at-icon-wrapper icon-wechat"></i>WeChat</a></li><li><a role="link" class="addthis_button_linkedin"><i aria-hidden="true" class="at-icon-wrapper icon-linkedin"></i>Linked In</a></li><li><a role="link" class="addthis_button_reddit"><i aria-hidden="true" class="at-icon-wrapper icon-reddit"></i>Reddit</a></li><li><a role="link" class="addthis_button_email"><i aria-hidden="true" class="at-icon-wrapper icon-envelope-o"></i>Email</a></li></ul></div></div>
</div>




        
        <div class="header_article-separator"></div>




        
        <div class="quick-search"><a href="#" aria-label="quick search" class="quick-search_icon icon-search"></a><div class="quick-search_content"><form action="/action/checkIsValidDoi" name="defaultQuickSearch" method="get" title="Quick Search" autocomplete="off" class="quick-search_default"><input type="search" name="AllField" placeholder="Search text, DOI, authors, etc." aria-label="Search text, DOI, authors, etc." data-auto-complete-max-words="7" data-auto-complete-max-chars="32" data-contributors-conf="3" data-topics-conf="3" data-publication-titles-conf="3" data-history-items-conf="3" value="" required="true" class="quick-search_all-field autocomplete"/></input><button type="submit" title="Search" class="icon-search"></button><div role="radiogroup" aria-labelledby="journal filter" class="quick-search_journal-filter"><label for="thisJournalRadio" tabindex="0" aria-checked="true" role="radio" class="radio--primary"><input id="thisJournalRadio" type="radio" value="jmcmar" name="SeriesKey" checked="checked" class="all-content"/></input><span>J. Med. Chem.</span></label><label for="allPubRadio" tabindex="0" aria-checked="false" role="radio" class="radio--primary"><input id="allPubRadio" type="radio" value="" name="SeriesKey" class="all-content"/></input><span>All Publications/Website</span></label></div></form><p>OR SEARCH CITATIONS</p><form action="/action/quickLink" name="citationQuickSearch" method="get" title="Quick Search" class="quick-search_citation"><input type="hidden" name="quickLink" value="true"/></input><select name="quickLinkJournal" class="quick-search_journals-select"><option value="jmcmar">Journal of Medicinal Chemistry</option><option value="achre4">Accounts of Chemical Research</option><option value="amrcda">Accounts of Materials Research</option><option value="aastgj">ACS Agricultural Science & Technology</option><option value="aabmcb">ACS Applied Bio Materials</option><option value="aaembp">ACS Applied Electronic Materials</option><option value="aaemcq">ACS Applied Energy Materials</option><option value="aamick">ACS Applied Materials & Interfaces</option><option value="aanmf6">ACS Applied Nano Materials</option><option value="aapmcd">ACS Applied Polymer Materials</option><option value="abmcb8">ACS Bio & Med Chem Au</option><option value="abseba">ACS Biomaterials Science & Engineering</option><option value="accacs">ACS Catalysis</option><option value="acscii">ACS Central Science</option><option value="acbcct">ACS Chemical Biology</option><option value="achsc5">ACS Chemical Health & Safety</option><option value="acncdm">ACS Chemical Neuroscience</option><option value="acsccc">ACS Combinatorial Science</option><option value="aesccq">ACS Earth and Space Chemistry</option><option value="aelccp">ACS Energy Letters</option><option value="aeacb3">ACS Engineering Au</option><option value="aeacc4">ACS Environmental Au</option><option value="aeecco">ACS ES&T Engineering</option><option value="aewcaa">ACS ES&T Water</option><option value="afsthl">ACS Food Science & Technology</option><option value="aidcbc">ACS Infectious Diseases</option><option value="amlccd">ACS Macro Letters</option><option value="amacgu">ACS Materials Au</option><option value="amlcef">ACS Materials Letters</option><option value="amachv">ACS Measurement Science Au</option><option value="amclct">ACS Medicinal Chemistry Letters</option><option value="ancac3">ACS Nano</option><option value="anaccx">ACS Nanoscience Au</option><option value="acsodf">ACS Omega</option><option value="aoiab5">ACS Organic & Inorganic Au</option><option value="aptsfn">ACS Pharmacology & Translational Science</option><option value="apchd5">ACS Photonics</option><option value="apcach">ACS Physical Chemistry Au</option><option value="apaccd">ACS Polymers Au</option><option value="ascefj">ACS Sensors</option><option value="ascecg">ACS Sustainable Chemistry & Engineering</option><option value="asbcd6">ACS Synthetic Biology</option><option value="ancham">Analytical Chemistry</option><option value="bichaw">Biochemistry</option><option value="bcches">Bioconjugate Chemistry</option><option value="bomaf6">Biomacromolecules</option><option value="bipret">Biotechnology Progress</option><option value="cgeabj">C&EN Global Enterprise</option><option value="cenear">Chemical & Engineering News Archive</option><option value="chlseg">Chemical Health & Safety</option><option value="chlseg0">Chemical Health & Safety</option><option value="crtoec">Chemical Research in Toxicology</option><option value="chreay">Chemical Reviews</option><option value="cmatex">Chemistry of Materials</option><option value="cgdefu">Crystal Growth & Design</option><option value="enfuem">Energy & Fuels</option><option value="esthag">Environmental Science & Technology</option><option value="estlcu">Environmental Science & Technology Letters</option><option value="iepra6.2">I&EC Product Research and Development</option><option value="iechad">Industrial & Engineering Chemistry</option><option value="iecac0">Industrial & Engineering Chemistry Analytical Edition</option><option value="iecjc0">Industrial & Engineering Chemistry Chemical & Engineering Data Series</option><option value="iecfa7">Industrial & Engineering Chemistry Fundamentals</option><option value="iepdaw">Industrial & Engineering Chemistry Process Design and Development</option><option value="iepra6">Industrial & Engineering Chemistry Product Research and Development</option><option value="iecred">Industrial & Engineering Chemistry Research</option><option value="iecnav">Industrial and Engineering Chemistry, News Edition</option><option value="inocaj">Inorganic Chemistry</option><option value="jaaucr">JACS Au</option><option value="jacsat">Journal of the American Chemical Society</option><option value="jafcau">Journal of Agricultural and Food Chemistry</option><option value="jceaax">Journal of Chemical & Engineering Data</option><option value="jci001">Journal of Chemical Documentation</option><option value="jceda8">Journal of Chemical Education</option><option value="jchsc2">Journal of Chemical Health & Safety</option><option value="jchsc20">Journal of Chemical Health & Safety</option><option value="jcics1">Journal of Chemical Information and Computer Sciences</option><option value="jcisd8">Journal of Chemical Information and Modeling</option><option value="jctcce">Journal of Chemical Theory and Computation</option><option value="jcchff">Journal of Combinatorial Chemistry</option><option value="iechad.1">Journal of Industrial & Engineering Chemistry</option><option value="jmcmar.1">Journal of Medicinal and Pharmaceutical Chemistry</option><option value="jnprdf">Journal of Natural Products</option><option value="joceah">The Journal of Organic Chemistry</option><option value="jpchax">The Journal of Physical Chemistry</option><option value="jpchax.2">The Journal of Physical Chemistry</option><option value="jpcafh">The Journal of Physical Chemistry A</option><option value="jpcbfk">The Journal of Physical Chemistry B</option><option value="jpccck">The Journal of Physical Chemistry C</option><option value="jpclcd">The Journal of Physical Chemistry Letters</option><option value="jprobs">Journal of Proteome Research</option><option value="jamsef">Journal of the American Society for Mass Spectrometry</option><option value="jamsef1">Journal of the American Society for Mass Spectrometry</option><option value="jamsef0">Journal of the American Society for Mass Spectrometry</option><option value="langd5">Langmuir</option><option value="mamobx">Macromolecules</option><option value="mpohbp">Molecular Pharmaceutics</option><option value="nalefd">Nano Letters</option><option value="neaca9">News Edition, American Chemical Society</option><option value="orlef7">Organic Letters</option><option value="oprdfk">Organic Process Research & Development</option><option value="orgnd7">Organometallics</option><option value="iepra6.1">Product R&D</option><option value="scimts">SciMeetings</option><option value="jpchax.1">The Journal of Physical and Colloid Chemistry</option></select><input type="search" inputmode="numeric" pattern="[0-9]*" name="quickLinkVolume" autoComplete="false" placeholder="Vol" required="required" class="quick-search_volume-input"/></input><input type="search" inputmode="numeric" pattern="[0-9]*" name="quickLinkPage" autoComplete="false" placeholder="Page" required="required" class="quick-search_page-input"/></input><button type="submit" title="Search" class="icon-search"></button></form></div></div>




        
        <div class="header_my-activity">



        
        <a href="#"><i class="icon-id-badge" aria-hidden=”true”></i><span>My Activity</span></a>
<div class="header_my-activity-content">
    <div class="header_my-activity-single">
        <i aria-hidden="true" aria-label="close" class="icon-close"></i>
        <div class="" data-name="recentlyViewedDropzone">



        
        <div class="show-recently"><div class="show-recently-header">Recently Viewed</div><h6 class="show-recently-empty">You have not visited any articles yet, Please visit some articles to see contents here. </h6></div>
</div>
    </div>
</div>
</div>




        
        <div class="header_publications">



        
        <a href="#" class="pubModal_button"><i class="icon-book" aria-hidden=”true”></i><span>Publications</span></a>

</div>




        
        <div class="header_burger-menu">



        
        <a href="#?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuIcon&amp;utm_campaign=Pubs_Refere" class="header_burger-menu_button" title="menu button" aria-label="menu button"><i class="icon-navicon"></i><i
        class="icon-close"></i></a>
<div class="header_burger-menu_content">
    <ul class="hidden-lg">
        <li><a href="#" class="pubModal_button"><i class="icon-book" aria-hidden=”true”></i><span>publications</span></a></li>
        <li class="myActivityMobile"><a href="#" class="openTabletActivity"><i class="icon-id-badge" aria-hidden=”true”></i><span>my Activity</span></a>
            <ul>
                <li><a href="javascript:void(0)" class="recentlyViewed--open">Recently Viewed</a></li>
            </ul>
        </li>
    </ul>
    <ul>
        <li><a href="#">user resources</a>
            <ul>
                <li><a href="/page/remoteaccess"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Access Options');">Access Options</a></li>
                <li><a href="https://publish.acs.org/publish/"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Authors & Reviewers');">Authors &
                        Reviewers</a></li>
                <li><a href="http://www.acs.org/content/acs/en/membership-and-networks/acs/benefits/professional/publications-benefits.html"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'ACS Members');">ACS Members</a></li>
                <li><a href="https://preferences.acspubs.org/journals"
                        onclick="ga('send', 'event', 'Home_MainMenu', 'Click', 'eAlert');">eAlerts</a></li>
                <li><a href="/page/follow.html?widget=follow-pane-mobile"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'RSS & Mobile');">RSS & Mobile</a></li>
            </ul>
        </li>
		<li><a href="#">for organizations</a>
			<ul>
			    <li><a href="https://solutions.acs.org/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Products & Services');">Products & Services</a></li>
				<li><a href="https://solutions.acs.org/access-options/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Get Access');">Get Access</a></li>
				<li><a href="https://solutions.acs.org/resources/manage-my-account/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Manage My Account');">Manage My Account</a></li>
			</ul>
		</li>
        <li><a href="#">support</a>
            <ul>
                <li><a href="/page/demo/index.html">Website Demos & Tutorials</a></li>
                <li><a href="https://acs.service-now.com/acs"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Support FAQs');">Support FAQs </a></li>
                <li><a href="#"
                        onClick="SnapEngage.startLink();return false; ga('send', 'event', 'Top Nav', 'Menu', 'Live Chat with Agent');"
                        class="help help-chat">Live Chat with Agent</a></li>
                <li><a href="https://acsmediakit.org/digital/acs-pubs/?utm_source=Nav&amp;utm_medium=Pubs&amp;utm_campaign=CEN"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'For Advertisers');">For Advertisers</a></li>
                <li><a href="https://solutions.acs.org/help/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'For Librarians & Account Managers');">For
                        Librarians & Account Managers</a></li>
            </ul>
        </li>
        <li class="hidden-sm hidden-xs"><a href="#">pairing</a>
            <ul>
                <li><a class="header_burger-menu_pairadevice-link" href="/pairdevice">Pair a device</a></li>
                <li><a class="header_burger-menu_pairthisdevice-link" href="/action/devicePairingSubmitCode"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Pair this device');">Pair this device</a></li>
                <li><a class="header_burger-menu_pairedstatus" href="/action/devicePairingSubmitCode">Paired status</a>
                </li>
            </ul>
        </li>
        <li class="hidden-lg hidden-md">
            <a class="header_burger-menu_my-profile-link" href="/action/showPreferences">My Profile</a>
            <a class="header_burger-menu_login-link" href="/action/ssoRequestForLoginPage">Login</a>
            <a class="header_burger-menu_logout-link" href="#">Logout</a>
            <a class="header_burger-menu_pairadevice-link" href="/pairdevice">Pair a device</a>
            <a class="header_burger-menu_pairthisdevice-link" href="/action/devicePairingSubmitCode">Pair this
                device</a>
            <a class="header_burger-menu_pairedstatus" href="/action/devicePairingSubmitCode">Paired status</a>
        </li>
        <li><a href="#">about us</a>
            <ul>
                <li><a href="/page/about-us.html"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Overview');">Overview</a></li>
                <li><a href="http://acsopenscience.org"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'ACS & Open Access');">ACS & Open Access</a>
                </li>
                <li><a href="/#partners" onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Partners');">Partners</a></li>
                <li><a href="http://acsoncampus.acs.org"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Events');">Events</a></li>
            </ul>
        </li>
    </ul>
</div>
<div class="activity-container-tablet"><i aria-hidden="true" class="icon-close"></i></div>


<script type="text/javascript">
  (function() {
    var se = document.createElement('script'); se.type = 'text/javascript'; se.async = true;
    se.src = 'https://storage.googleapis.com/code.snapengage.com/js/921a4ec7-cecf-43a6-afa5-6cd1346520b1.js';
    var done = false;
    se.onload = se.onreadystatechange = function() {
      if (!done&&(!this.readyState||this.readyState==='loaded'||this.readyState==='complete')) {
        done = true;
        /* Place your SnapEngage JS API code below */
        /* SnapEngage.allowChatSound(true); Example JS API: Enable sounds for Visitors. */
      }
    };
    var s = document.getElementsByTagName('script')[0]; s.parentNode.insertBefore(se, s);
  })();
</script>

<style>
    #SnapABug_Button,
    #designstudio-button {
        display: none;
    }
</style>

</div>
</div>
</div>
</div></div></div>
</div>




        
        <div class="pub"><div aria-live="polite" aria-atomic="true" class="pub-modal"><div class="pub-modal_content loop-trap"><a href="#" aria-label="close" tabindex="0" class="pub-modal_close icon-close pull-right"></a><div class="pub-modal_row"><div class="pub-modal_left"><div class="pub-modal_left-content"><div class="pub-modal_control hidden-lg hidden-md"><span class="pub-modal_control-text">Publications</span><a href="#" title="Back button" class="pub-modal_back"><i class="icon-angle-left"></i></a></div><div class="pub-modal_types"><h6>CONTENT TYPES</h6><ul class="pub-modal_types-list"><li data-type="all" id="allID" class="pub-modal_types-active"><a href="#"><h4>All Types</h4></a></li></ul></div><div class="pub-modal_subjects hidden-sm hidden-xs"><h6>SUBJECTS</h6><ul class="pub-modal_subjects-list"></ul></div></div></div><div class="pub-modal_right"><div class="pub-modal_control hidden-lg hidden-md"><span class="pub-modal_control-text">Publications: All Types</span><a href="#" title="Back button" class="pub-modal_back"><i class="icon-angle-left"></i></a></div><div class="pub-modal_right--inner"><div class="pub-content"></div></div></div></div></div><input type="hidden" name="pubModalData" value="{&quot;types&quot;:[{&quot;code&quot;:&quot;journals&quot;,&quot;label&quot;:&quot;Journals&quot;},{&quot;code&quot;:&quot;books&quot;,&quot;label&quot;:&quot;Books and Reference&quot;},{&quot;code&quot;:&quot;news&quot;,&quot;label&quot;:&quot;News&quot;}],&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;,&quot;label&quot;:&quot;Analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;,&quot;label&quot;:&quot;Applied&quot;},{&quot;code&quot;:&quot;cat_biological&quot;,&quot;label&quot;:&quot;Biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;,&quot;label&quot;:&quot;Materials Science &amp; Engineering&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;,&quot;label&quot;:&quot;Organic-Inorganic&quot;},{&quot;code&quot;:&quot;cat_physical&quot;,&quot;label&quot;:&quot;Physical&quot;}],&quot;publications&quot;:[{&quot;char&quot;:&quot;A&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/achre4/2021/achre4.2021.54.issue-15/achre4.2021.54.issue-15/20210803/achre4.2021.54.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;achre4&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Accounts of Chemical Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/achre4&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amrcda/2021/amrcda.2021.2.issue-7/amrcda.2021.2.issue-7/20210723/amrcda.2021.2.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amrcda&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Accounts of Materials Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amrcda&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aastgj/2021/aastgj.2021.1.issue-3/aastgj.2021.1.issue-3/20210621/aastgj.2021.1.issue-3.largecover.jpg&quot;,&quot;code&quot;:&quot;aastgj&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;ACS Agricultural Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aastgj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aabmcb/2021/aabmcb.2021.4.issue-7/aabmcb.2021.4.issue-7/20210719/aabmcb.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aabmcb&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Bio Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aabmcb&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aaembp/2021/aaembp.2021.3.issue-7/aaembp.2021.3.issue-7/20210727/aaembp.2021.3.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aaembp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Electronic Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aaembp&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aaemcq/2021/aaemcq.2021.4.issue-7/aaemcq.2021.4.issue-7/20210726/aaemcq.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aaemcq&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Energy Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aaemcq&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aamick/2021/aamick.2021.13.issue-30/aamick.2021.13.issue-30/20210804/aamick.2021.13.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;aamick&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Materials &amp; Interfaces&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aamick&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aanmf6/2021/aanmf6.2021.4.issue-7/aanmf6.2021.4.issue-7/20210723/aanmf6.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aanmf6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Nano Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aanmf6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aapmcd/2021/aapmcd.2021.3.issue-7/aapmcd.2021.3.issue-7/20210709/aapmcd.2021.3.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aapmcd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Polymer Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aapmcd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/abmcb8/largecover.png&quot;,&quot;code&quot;:&quot;abmcb8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;}],&quot;name&quot;:&quot;ACS Bio &amp; Med Chem Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/abmcb8&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/abseba/2021/abseba.2021.7.issue-7/abseba.2021.7.issue-7/20210712/abseba.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;abseba&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Biomaterials Science &amp; Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/abseba&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/accacs/2021/accacs.2021.11.issue-14/accacs.2021.11.issue-14/20210716/accacs.2021.11.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;accacs&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Catalysis&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/accacs&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acscii/2021/acscii.2021.7.issue-7/acscii.2021.7.issue-7/20210728/acscii.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;acscii&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Central Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acscii&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acbcct/2021/acbcct.2021.16.issue-7/acbcct.2021.16.issue-7/20210716/acbcct.2021.16.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;acbcct&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Biology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acbcct&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/achsc5/2021/achsc5.2021.28.issue-4/achsc5.2021.28.issue-4/20210726/achsc5.2021.28.issue-4.largecover.jpg&quot;,&quot;code&quot;:&quot;achsc5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Health &amp; Safety&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/achsc5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acncdm/2021/acncdm.2021.12.issue-15/acncdm.2021.12.issue-15/20210804/acncdm.2021.12.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;acncdm&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Neuroscience&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acncdm&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acsccc/2020/acsccc.2020.22.issue-12/acsccc.2020.22.issue-12/20201214/acsccc.2020.22.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;acsccc&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Combinatorial Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acsccc&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aesccq/2021/aesccq.2021.5.issue-7/aesccq.2021.5.issue-7/20210715/aesccq.2021.5.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aesccq&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Earth and Space Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aesccq&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aelccp/2021/aelccp.2021.6.issue-7/aelccp.2021.6.issue-7/20210709/aelccp.2021.6.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aelccp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Energy Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aelccp&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aeacb3/largecover.png&quot;,&quot;code&quot;:&quot;aeacb3&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;}],&quot;name&quot;:&quot;ACS Engineering Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeacb3&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aeacc4/largecover.png&quot;,&quot;code&quot;:&quot;aeacc4&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;}],&quot;name&quot;:&quot;ACS Environmental Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeacc4&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aeecco/2021/aeecco.2021.1.issue-7/aeecco.2021.1.issue-7/20210709/aeecco.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aeecco&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;ACS ES&amp;T Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeecco&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aewcaa/2021/aewcaa.2021.1.issue-7/aewcaa.2021.1.issue-7/20210709/aewcaa.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aewcaa&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS ES&amp;T Water&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aewcaa&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/afsthl/2021/afsthl.2021.1.issue-6/afsthl.2021.1.issue-6/20210716/afsthl.2021.1.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;afsthl&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Food Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/afsthl&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;styleguide&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;}],&quot;name&quot;:&quot;ACS Guide to Scholarly Communication&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/styleguide&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;infocus&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;ACS In Focus&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/infocus&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aidcbc/2021/aidcbc.2021.7.issue-7/aidcbc.2021.7.issue-7/20210709/aidcbc.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aidcbc&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Infectious Diseases&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aidcbc&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amlccd/2021/amlccd.2021.10.issue-7/amlccd.2021.10.issue-7/20210720/amlccd.2021.10.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amlccd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Macro Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amlccd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/amacgu/largecover.png&quot;,&quot;code&quot;:&quot;amacgu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Materials Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amacgu&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amlcef/2021/amlcef.2021.3.issue-8/amlcef.2021.3.issue-8/20210802/amlcef.2021.3.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;amlcef&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Materials Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amlcef&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/amachv/largecover.png&quot;,&quot;code&quot;:&quot;amachv&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;}],&quot;name&quot;:&quot;ACS Measurement Science Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amachv&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amclct/2021/amclct.2021.12.issue-7/amclct.2021.12.issue-7/20210708/amclct.2021.12.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amclct&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Medicinal Chemistry Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amclct&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ancac3/2021/ancac3.2021.15.issue-7/ancac3.2021.15.issue-7/20210727/ancac3.2021.15.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;ancac3&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Nano&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ancac3&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/anaccx/largecover.png&quot;,&quot;code&quot;:&quot;anaccx&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Nanoscience Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/anaccx&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acsodf/2021/acsodf.2021.6.issue-30/acsodf.2021.6.issue-30/20210803/acsodf.2021.6.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;acsodf&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Omega&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acsodf&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aoiab5/largecover.png&quot;,&quot;code&quot;:&quot;aoiab5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;}],&quot;name&quot;:&quot;ACS Organic &amp; Inorganic Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aoiab5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aptsfn/2021/aptsfn.2021.4.issue-3/aptsfn.2021.4.issue-3/20210611/aptsfn.2021.4.issue-3.largecover.jpg&quot;,&quot;code&quot;:&quot;aptsfn&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Pharmacology &amp; Translational Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aptsfn&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/apchd5/2021/apchd5.2021.8.issue-7/apchd5.2021.8.issue-7/20210721/apchd5.2021.8.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;apchd5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Photonics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apchd5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/apcach/largecover.png&quot;,&quot;code&quot;:&quot;apcach&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;}],&quot;name&quot;:&quot;ACS Physical Chemistry Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apcach&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/apaccd/largecover.png&quot;,&quot;code&quot;:&quot;apaccd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Polymers Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apaccd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/books/content/reagents/2017/acsreagents/acsreagents/20170228/acsreagents.largecover.png&quot;,&quot;code&quot;:&quot;reagents&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;ACS Reagent Chemicals&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/reagents&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ascefj/2021/ascefj.2021.6.issue-7/ascefj.2021.6.issue-7/20210723/ascefj.2021.6.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;ascefj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Sensors&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ascefj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ascecg/2021/ascecg.2021.9.issue-30/ascecg.2021.9.issue-30/20210802/ascecg.2021.9.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;ascecg&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Sustainable Chemistry &amp; Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ascecg&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/books/content/symposium/2021/bk-2021-1379/bk-2021-1379/20210430-01/bk-2021-1379.largecover.jpg&quot;,&quot;code&quot;:&quot;symposium&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;383784032&quot;}],&quot;name&quot;:&quot;ACS Symposium Series&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/symposium&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/asbcd6/2021/asbcd6.2021.10.issue-7/asbcd6.2021.10.issue-7/20210716/asbcd6.2021.10.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;asbcd6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Synthetic Biology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/asbcd6&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;advances&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;383784032&quot;}],&quot;name&quot;:&quot;Advances in Chemistry&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/advances&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ancham/2021/ancham.2021.93.issue-30/ancham.2021.93.issue-30/20210803/ancham.2021.93.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;ancham&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Analytical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ancham&quot;}]},{&quot;char&quot;:&quot;B&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bichaw/2021/bichaw.2021.60.issue-30/bichaw.2021.60.issue-30/20210803/bichaw.2021.60.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;bichaw&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Biochemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bichaw&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bcches/2021/bcches.2021.32.issue-7/bcches.2021.32.issue-7/20210721/bcches.2021.32.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;bcches&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Bioconjugate Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bcches&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bomaf6/2021/bomaf6.2021.22.issue-7/bomaf6.2021.22.issue-7/20210712/bomaf6.2021.22.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;bomaf6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Biomacromolecules&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bomaf6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/bipret/largecover.jpg&quot;,&quot;code&quot;:&quot;bipret&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;Biotechnology Progress&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bipret&quot;}]},{&quot;char&quot;:&quot;C&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cgeabj/2021/cgeabj.2021.99.issue-28/cgeabj.2021.99.issue-28/20210802/cgeabj.2021.99.issue-28.largecover.jpg&quot;,&quot;code&quot;:&quot;cgeabj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;C&amp;EN Global Enterprise&quot;,&quot;type&quot;:&quot;news&quot;,&quot;url&quot;:&quot;/journal/cgeabj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/crtoec/2021/crtoec.2021.34.issue-7/crtoec.2021.34.issue-7/20210719/crtoec.2021.34.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;crtoec&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemical Research in Toxicology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/crtoec&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/chreay/2021/chreay.2021.121.issue-14/chreay.2021.121.issue-14/20210728/chreay.2021.121.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;chreay&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;articletoc&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemical Reviews&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/chreay&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cmatex/2021/cmatex.2021.33.issue-14/cmatex.2021.33.issue-14/20210727/cmatex.2021.33.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;cmatex&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemistry of Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/cmatex&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cgdefu/2021/cgdefu.2021.21.issue-8/cgdefu.2021.21.issue-8/20210804/cgdefu.2021.21.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;cgdefu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Crystal Growth &amp; Design&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/cgdefu&quot;}]},{&quot;char&quot;:&quot;E&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/enfuem/2021/enfuem.2021.35.issue-14/enfuem.2021.35.issue-14/20210715/enfuem.2021.35.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;enfuem&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Energy &amp; Fuels&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/enfuem&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/esthag/2021/esthag.2021.55.issue-15/esthag.2021.55.issue-15/20210803/esthag.2021.55.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;esthag&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Environmental Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/esthag&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/estlcu/2021/estlcu.2021.8.issue-7/estlcu.2021.8.issue-7/20210713/estlcu.2021.8.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;estlcu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Environmental Science &amp; Technology Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/estlcu&quot;}]},{&quot;char&quot;:&quot;I&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6.2&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;I&amp;EC Product Research and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6.2&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iechad&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iechad&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecac0&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Analytical Edition&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecac0&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecjc0&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Chemical &amp; Engineering Data Series&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecjc0&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecfa7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Fundamentals&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecfa7&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepdaw&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Process Design and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepdaw&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Product Research and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/iecred/2021/iecred.2021.60.issue-30/iecred.2021.60.issue-30/20210804/iecred.2021.60.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;iecred&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecred&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/inocaj/2021/inocaj.2021.60.issue-15/inocaj.2021.60.issue-15/20210802/inocaj.2021.60.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;inocaj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Inorganic Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/inocaj&quot;}]},{&quot;char&quot;:&quot;J&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jaaucr/2021/jaaucr.2021.1.issue-7/jaaucr.2021.1.issue-7/20210726/jaaucr.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jaaucr&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;JACS Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jaaucr&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jafcau/2021/jafcau.2021.69.issue-30/jafcau.2021.69.issue-30/20210804/jafcau.2021.69.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;jafcau&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Agricultural and Food Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jafcau&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jceaax/2021/jceaax.2021.66.issue-7/jceaax.2021.66.issue-7/20210708/jceaax.2021.66.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jceaax&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical &amp; Engineering Data&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jceaax&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jci001&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Documentation&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jci001&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jceda8/2021/jceda8.2021.98.issue-7/jceda8.2021.98.issue-7/20210713/jceda8.2021.98.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jceda8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;divched&quot;}],&quot;name&quot;:&quot;Journal of Chemical Education&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jceda8&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jcics1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Information and Computer Sciences&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jcics1&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jcisd8/2021/jcisd8.2021.61.issue-7/jcisd8.2021.61.issue-7/20210726/jcisd8.2021.61.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jcisd8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Information and Modeling&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jcisd8&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jctcce/2021/jctcce.2021.17.issue-7/jctcce.2021.17.issue-7/20210713/jctcce.2021.17.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jctcce&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Theory and Computation&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jctcce&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iechad.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Industrial &amp; Engineering Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iechad.1&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jmcmar.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Medicinal and Pharmaceutical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jmcmar.1&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-14/jmcmar.2021.64.issue-14/20210722/jmcmar.2021.64.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;jmcmar&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Medicinal Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jmcmar&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jnprdf/2021/jnprdf.2021.84.issue-7/jnprdf.2021.84.issue-7/20210723/jnprdf.2021.84.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jnprdf&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Natural Products&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jnprdf&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/joceah/2021/joceah.2021.86.issue-14/joceah.2021.86.issue-14/20210716/joceah.2021.86.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;joceah&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Organic Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/joceah&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jpchax&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpchax&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpcafh/2021/jpcafh.2021.125.issue-29/jpcafh.2021.125.issue-29/20210729/jpcafh.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpcafh&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry A&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpcafh&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpcbfk/2021/jpcbfk.2021.125.issue-29/jpcbfk.2021.125.issue-29/20210729/jpcbfk.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpcbfk&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry B&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpcbfk&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpccck/2021/jpccck.2021.125.issue-29/jpccck.2021.125.issue-29/20210729/jpccck.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpccck&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry C&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpccck&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpclcd/2021/jpclcd.2021.12.issue-29/jpclcd.2021.12.issue-29/20210729/jpclcd.2021.12.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpclcd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpclcd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jprobs/2021/jprobs.2021.20.issue-7/jprobs.2021.20.issue-7/20210702/jprobs.2021.20.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jprobs&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Proteome Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jprobs&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jacsat/2021/jacsat.2021.143.issue-30/jacsat.2021.143.issue-30/20210804/jacsat.2021.143.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;jacsat&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of the American Chemical Society&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jacsat&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jamsef/2021/jamsef.2021.32.issue-8/jamsef.2021.32.issue-8/20210804/jamsef.2021.32.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;jamsef&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of the American Society for Mass Spectrometry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jamsef&quot;}]},{&quot;char&quot;:&quot;L&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/langd5/2021/langd5.2021.37.issue-30/langd5.2021.37.issue-30/20210803/langd5.2021.37.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;langd5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Langmuir&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/langd5&quot;}]},{&quot;char&quot;:&quot;M&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/mamobx/2021/mamobx.2021.54.issue-14/mamobx.2021.54.issue-14/20210727/mamobx.2021.54.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;mamobx&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Macromolecules&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/mamobx&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/mpohbp/2021/mpohbp.2021.18.issue-8/mpohbp.2021.18.issue-8/20210802/mpohbp.2021.18.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;mpohbp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Molecular Pharmaceutics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/mpohbp&quot;}]},{&quot;char&quot;:&quot;N&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/nalefd/2021/nalefd.2021.21.issue-14/nalefd.2021.21.issue-14/20210728/nalefd.2021.21.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;nalefd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Nano Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/nalefd&quot;}]},{&quot;char&quot;:&quot;O&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/orlef7/2021/orlef7.2021.23.issue-14/orlef7.2021.23.issue-14/20210716/orlef7.2021.23.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;orlef7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organic Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/orlef7&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/oprdfk/2021/oprdfk.2021.25.issue-7/oprdfk.2021.25.issue-7/20210716/oprdfk.2021.25.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;oprdfk&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organic Process Research &amp; Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/oprdfk&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/orgnd7/2021/orgnd7.2021.40.issue-14/orgnd7.2021.40.issue-14/20210726/orgnd7.2021.40.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;orgnd7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organometallics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/orgnd7&quot;}]},{&quot;char&quot;:&quot;P&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Product R&amp;D&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6.1&quot;}]}]}"/></input></div></div>
</header>




        
        <main data-widget-id="28284a6d-730d-4a56-93ad-909787c5ac1b" id="" class="content article"><article data-figures="https://pubs.acs.org/action/ajaxShowFigures?doi=10.1021%2Fjm4012643&amp;ajax=true" data-references="https://pubs.acs.org/action/ajaxShowEnhancedAbstract?doi=10.1021%2Fjm4012643&amp;ajax=true" data-enable-mathjax="true"><div class="figure-viewer"><div class="figure-viewer_row"><div class="figure-viewer_col loop-trap"><div aria-live="polite" aria-atomic="true" class="figure-viewer_modal"><a href="#" title="Close" aria-label="close" tabindex="0" class="figure-viewer_close icon-close"></a><h2 class="figure-viewer_label"><span class="figure-viewer_current"></span></h2><div class="figure-viewer_image"><a href="#" title="Next" class="figure-viewer_next icon-angle-right"></a><a href="#" title="Previous" class="figure-viewer_prev icon-angle-left"></a><div class="figure-viewer_image-content"><img src="" alt="Figure 1" class="fv-img"/></img><img src="/pb-assets/ux3/loading-1525090748317.gif" alt="Loading Img" class="loading-img"/></img></div></div><div class="figure-viewer_links"><a href="#" title="Download Hi-Res Image" target="_blank" class="figure-viewer_hi-res-link"><i class="icon-file-image-o"></i><span>Download Hi-Res Image</span></a><span class="fv-separator"></span><a href="#" title="Download to MS-PowerPoint" class="figure-viewer_ms-p-link"><i class="icon-file-powerpoint-o"></i><span>Download to MS-PowerPoint</span></a><span class="cit-this-container"><a href="/action/showCitFormats?doi=10.1021/jm4012643&amp;href=/doi/10.1021/jm4012643" title="Cite This" class="figure-viewer-cite-this-link"><i class="icon-check-circle"></i><span><strong>Cite This:</strong></span></a><span class="article_header-cite-this figure-viewer-cite-this"><span class="cit-fg-title"><i>J. Med. Chem.</i></span><span class="cit-fg-year"> 2014</span><span class="cit-fg-volume">, 57</span><span class="cit-fg-issue">, 5</span><span class="cit-fg-pageRange">, 2136-2160</span></span></span></div></div></div></div></div><div class="article_fullPage"><div class="article_header"><div class="articleHeaderDropzone5" data-pb-dropzone="articleHeaderDropzone5"><div class="advertisement">
	<div class="advertisement-link">
		<a href="http://acsmediakit.org">ADVERTISEMENT</a>
	</div>
	<div id="dfp-journal-article-leaderboard">
		<script type="text/javascript">
			$(document).ready(function() {
				setTimeout(function() {
					googletag.cmd.push(function() { googletag.display("dfp-journal-article-leaderboard"); });
				}, 1400);
			});
		</script>
	</div>
</div></div><div class="container container_scaled-down"><div class="row"><div class="col-xs-12.clearfix"><div class="article_header-left pull-left"><div class="article_header-dropzone-1"><div class="articleHeaderDropzone1" data-pb-dropzone="articleHeaderDropzone1"><div class="content-navigation clearfix"><a href="/toc/jmcmar/57/5" title="Return to Issue" id="returnToIssues" class="content-navigation__btn--return"><span>RETURN TO ISSUE</span></a><a href="/doi/10.1021/jm401621g" title="Previous" id="prevID" class="content-navigation__btn--pre"><i class="icon-angle-left"></i><span>PREV</span></a><span class="content-navigation__contentType">Article</span><a href="/doi/10.1021/jm401646w" title="Next" id="nextID" class="content-navigation__btn--next"><span>NEXT</span><i class="icon-angle-right"></i></a></div></div></div><div class="headerLogo_e-alertsMobile_container"><div class="article_header-logo hidden-lg"><div class="pj-badge"></div><a href="/journal/jmcmar" title="Journal Logo"><img src="/specs/ux3/releasedAssets/images/loader.gif" data-src="/na101/home/literatum/publisher/achs/journals/covergifs/jmcmar/title.png" alt="Journal Logo" /></img></a></div><div class="e-alertsMobile_container hidden-md hidden-lg"></div></div><h1 class="article_header-title"><span class="hlFld-Title">Discovery of a Novel Class of Potent HCV NS4B Inhibitors: SAR Studies on Piperazinone Derivatives</span></h1><ul class="loa non-jats-loa"><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Ramesh++Kakarla">Ramesh Kakarla</a></span><span class="author-xref-symbol "><sup>*</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Jian++Liu">Jian Liu</a></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Devan++Naduthambi">Devan Naduthambi</a></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Wonsuk++Chang">Wonsuk Chang</a></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Ralph+T.++Mosley">Ralph T. Mosley</a></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Donghui++Bao">Donghui Bao</a></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Holly+M.+Micolochick++Steuer">Holly M. Micolochick Steuer</a></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Meg++Keilman">Meg Keilman</a></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Shalini++Bansal">Shalini Bansal</a></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Angela+M.++Lam">Angela M. Lam</a></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=William++Seibel">William Seibel</a></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Sandra++Neilson">Sandra Neilson</a></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Phillip+A.++Furman">Phillip A. Furman</a></span></span></li><span class="comma-separator">, and </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Michael+J.++Sofia">Michael J. Sofia</a></span></span></li><span class="comma-separator"></span></ul><div class="affiliations"><div class="view-affs"><span class="title">View Author Information</span><i class="caret-icon icon-angle-down"></i></div><div class="all-aff-infos hlFld-Affiliation"><div class="aff-info" id="aff1"><span class="aff-text">Pharmasset, Inc. 303A College Road East, Princeton, New Jersey 08540, United States</span></div><div class="corresp-info"><strong>*</strong>Phone: 860-460-3706. E-mail: <a href="/cdn-cgi/l/email-protection#f98b98949c8a91929892988b9598b98098919696d79a9694"><span class="__cf_email__" data-cfemail="0775666a62746f6c666c66756b66477e666f68682964686a">[email protected]</span></a>. Address: 9 Chamberlain Lane, South Glastonbury, Connecticut 06073, United States.</div></div></div><div class="article_header-meta clearfix"><div class="article_header-meta-left pull-left"><input type="hidden" name="journalCodeForjhpLink" value="jmcmar" /></input><input type="hidden" name="journalNameForjhpLink" value="Journal of Medicinal Chemistry" /></input><div class="article_header-cite-this"><a href="/action/showCitFormats?doi=10.1021%2Fjm4012643&amp;href=/doi/10.1021%2Fjm4012643" title="Cite This"><i class="icon-check-circle"></i><strong>Cite this: </strong></a><span class="cit-title"><i>J. Med. Chem.</i></span> <span class="cit-year-info"><span>2014</span></span><span class="cit-volume">, 57</span><span class="cit-issue">, 5</span><span class="cit-pageRange">, 2136–2160</span></div><div class="article_header-epubdate"><span class="pub-date epub-date">Publication Date</span><span class="web-text"> (Web)</span><span class="date-separator">:</span><span class="pub-date-value">January 29, 2014</span><div class="article_header-history base dropBlock"><a href="#" data-db-target-for="article_header-history" title="History" target="_self" class="" aria-expanded="false"><i class="icon-angle-down"></i><i class="icon-angle-up"></i></a><div data-db-target-of="article_header-history" class="dropBlock__holder" aria-hidden="true"><div class="articleHeaderHistoryDropzone" data-pb-dropzone="articleHeaderHistoryDropzone"><h4>Publication History</h4>




        
        <ul class="rlist article-chapter-history-list"><li><span class="item_label"><b>Received</b></span>15 August 2013</li><li><span class="item_label"><b>Published</b> online</span>29 January 2014</li><li><span class="item_label"><b>Published</b> in</span><span class="item_label-issue">issue</span> 13 March 2014</li></ul></div></div></div></div><div class="article_header-doiurl"><a href="https://doi.org/10.1021/jm4012643" title="DOI URL">https://doi.org/10.1021/jm4012643</a></div><div class="article_header-article-copyright"><strong>Copyright © 2014 American Chemical Society</strong></div><div class="article_rightPermissionsLink"><div class="articleHeaderDropzone4" data-pb-dropzone="articleHeaderDropzone4"><div class="articleRightsPermissionsLink"><a href="/servlet/linkout?type=rightslink&amp;url=startPage%3D2136%26pageCount%3D25%26copyright%3DAmerican%2BChemical%2BSociety%26author%3DRamesh%2BKakarla%252C%2BJian%2BLiu%252C%2BDevan%2BNaduthambi%252C%2Bet%2Bal%26orderBeanReset%3Dtrue%26imprint%3DAmerican%2BChemical%2BSociety%26volumeNum%3D57%26issueNum%3D5%26contentID%3Djm4012643%26title%3DDiscovery%2Bof%2Ba%2BNovel%2BClass%2Bof%2BPotent%2BHCV%2BNS4B%2BInhibitors%253A%2BSAR%2BStudies%2Bon%2BPiperazinone%2BDerivatives%26numPages%3D25%26pa%3D%26issn%3D0022-2623%26publisherName%3Dacs%26publication%3Djmcmar%26rpt%3Dn%26endPage%3D2160%26publicationDate%3DMarch%2B2014">RIGHTS & PERMISSIONS</a></div></div></div><div class="article_header-access-block"><div class="article_header-open-access"></div><div class="article_header-access-icon"><img src="/products/achs/releasedAssets/images/subscribed.svg" alt="Subscribed Access" /></img></div></div></div><div class="article_header-meta-center pull-left"><div class="articleHeaderDropzone3" data-pb-dropzone="articleHeaderDropzone3"><div class="articleMetrics"><div class="articleMetrics_table"><div class="articleMetrics_row"><input type="hidden" name="articleMetricsDoi" value="10.1021/jm4012643"/></input><div class="articleMetrics_metric"><h6>Article Views</h6><div class="articleMetrics-val">2160</div></div><div class="articleMetrics_altmetric"><h6>Altmetric</h6><div class="articleMetrics-val articleMetrics_score">-</div><div class="altmetric-donut hidden"><div data-badge-details="right" data-badge-type="donut" data-hide-no-mentions="false" data-condensed="true" class="altmetric-embed"></div></div></div><div class="articleMetrics_count"><h6>Citations</h6><div class="articleMetrics-val"><a href="#citeThis" class="internalNav">40</a></div></div></div></div><div class="articleMetrics_about"><div class="base dropBlock"><a href="#" data-db-target-for="aboutArticleMetrics" class="article_aboutLink">LEARN ABOUT THESE METRICS</a><div data-db-target-of="aboutArticleMetrics" aria-live="polite" aria-atomic="true" role="alert" class="dropBlock__holder"><i aria-hidden="true" class="icon-close_thin"></i><p>Article Views are the COUNTER-compliant sum of full text article downloads since November 2008 (both PDF and HTML) across all institutions and individuals. These metrics are regularly updated to reflect usage leading up to the last few days.</p><p>Citations are the number of other articles citing this article, calculated by Crossref and updated daily.<a href="https://www.crossref.org/services/cited-by/" title="Find more information about Crossref citation counts"> Find more information about Crossref citation counts.</a></p><p>The Altmetric Attention Score is a quantitative measure of the attention that a research article has received online. Clicking on the donut icon will load a page at altmetric.com with additional details about the score and the social media presence for the given article. Find more information on<a href="https://help.altmetric.com/support/solutions/articles/6000233311-how-is-the-altmetric-attention-score-calculated" title="The Altmetric Attention Score and how the score is calculated"> the Altmetric Attention Score and how the score is calculated.</a></p></div></div></div></div></div></div><div class="article_header-meta-right"><div class="articleHeaderDropzone6" data-pb-dropzone="articleHeaderDropzone6"><div data-widget-def="UX3share" data-widget-id="787b5b92-0445-40f4-bdd2-9591d56f4a67" class="article_header-share share_label_visible">
        



        
        <script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script><script type="text/javascript" async="async" src="//s7.addthis.com/js/300/addthis_widget.js#pubid=xa-4faab26f2cff13a7"></script><div class="share"><div class="share_button"><span class="share__label">Share</span><a href="#" data-db-target-for="787b5b92-0445-40f4-bdd2-9591d56f4a67" data-db-switch="icon-close_thin" aria-label="share button" class="share__ctrl"><i aria-hidden="true" class="icon-Icon_Share"></i></a></div>



        
        <div class="achs-addto-mendeley"><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><input type="hidden" class="doi" value="10.1021/jm4012643" /></input><span class="achs-addto-mendeley_label achs-addto-mendeley_addToLabel">Add to</span><span class="achs-addto-mendeley_label achs-addto-mendeley_viewInLabel">View In</span><a title="Add to mendeley button" class="achs-addto-mendeley_button" tabindex="0"><i class="achs-addto-mendeley_icon icon-mendeley"></i><i class="achs-addto-mendeley_close icon-close"></i></a><div data-db-target-of="5423a74c-bbd8-47b1-9f43-99423ee72e5c" class="achs-addto-mendeley_list dropBlock__holder"><ul><li><a href="#" title="Add Full Text with Reference" class="achs-addto-mendeley_disabled-button add-full-document"><i class="icon-bookmark-o"></i><span>Add Full Text with Reference</span></a></li><li><a href="#" title="Add Description" class="achs-mendeley_button add-metadata-description"><i class="icon-mendeley"></i><span>Add Description</span></a></li></ul></div><a href="#" title="View in mendeley button" class="achs-addto-mendeley_viewin-button"><i class="icon-mendeley"></i></a><div class="achs_loader"><div class="achs_loader_dot"></div><div class="achs_loader_dot"></div><div class="achs_loader_dot"></div></div><input type="hidden" name="meta-data" value="{&quot;title&quot;:&quot;Discovery of a Novel Class of Potent HCV NS4B Inhibitors: SAR Studies on Piperazinone Derivatives&quot;,&quot;type&quot;:&quot;journal&quot;,&quot;authors&quot;:[{&quot;first_name&quot;:&quot;Ramesh&quot;,&quot;last_name&quot;:&quot;Kakarla&quot;},{&quot;first_name&quot;:&quot;Jian&quot;,&quot;last_name&quot;:&quot;Liu&quot;},{&quot;first_name&quot;:&quot;Devan&quot;,&quot;last_name&quot;:&quot;Naduthambi&quot;},{&quot;first_name&quot;:&quot;Wonsuk&quot;,&quot;last_name&quot;:&quot;Chang&quot;},{&quot;first_name&quot;:&quot;Ralph&quot;,&quot;last_name&quot;:&quot;T. Mosley&quot;},{&quot;first_name&quot;:&quot;Donghui&quot;,&quot;last_name&quot;:&quot;Bao&quot;},{&quot;first_name&quot;:&quot;Holly&quot;,&quot;last_name&quot;:&quot;M. Micolochick Steuer&quot;},{&quot;first_name&quot;:&quot;Meg&quot;,&quot;last_name&quot;:&quot;Keilman&quot;},{&quot;first_name&quot;:&quot;Shalini&quot;,&quot;last_name&quot;:&quot;Bansal&quot;},{&quot;first_name&quot;:&quot;Angela&quot;,&quot;last_name&quot;:&quot;M. Lam&quot;},{&quot;first_name&quot;:&quot;William&quot;,&quot;last_name&quot;:&quot;Seibel&quot;},{&quot;first_name&quot;:&quot;Sandra&quot;,&quot;last_name&quot;:&quot;Neilson&quot;},{&quot;first_name&quot;:&quot;Phillip&quot;,&quot;last_name&quot;:&quot;A. Furman&quot;},{&quot;first_name&quot;:&quot;Michael&quot;,&quot;last_name&quot;:&quot;J. Sofia&quot;}],&quot;source&quot;:&quot;Journal of Medicinal Chemistry&quot;,&quot;year&quot;:&quot;2014&quot;,&quot;month&quot;:&quot;01&quot;,&quot;day&quot;:&quot;29&quot;,&quot;issue&quot;:&quot;5&quot;,&quot;volume&quot;:&quot;57&quot;,&quot;pages&quot;:&quot;2136-2160&quot;,&quot;identifiers&quot;:{&quot;doi&quot;:&quot;10.1021/jm4012643&quot;},&quot;abstract&quot;:&quot;HTS screening identified compound 2a (piperazinone derivative) as a low micromolar HCV genotype 1 (GT-1) inhibitor. Resistance mapping studies suggested that this piperazinone chemotype targets the HCV nonstructural protein NS4B. Extensive SAR studies were performed around 2a and the amide function and the C-3/C-6 cis stereochemistry of the piperazinone core were essential for HCV activity. A 10-fold increase in GT-1 potency was observed when the chiral phenylcyclopropyl amide side chain of 2a was replaced with p-fluorophenylisoxazole-carbonyl moiety (67). Replacing the C-6 nonpolar hydrophobic moiety of 67 with a phenyl moiety (95) did not diminish the GT-1 potency. A heterocyclic thiophene moiety (103) and an isoxazole moiety (108) were incorporated as isosteric replacements for the C-6 phenyl moiety (95), resulting in significant improvement in GT-1b and 1a potency. However, the piperazonone class of compounds lacks GT-2 activity and, consequently, were not pursued further into development.&quot;}" class="meta-data"/></input><input type="hidden" name="mendeley-api-endpoint" value="https://api.mendeley.com/documents" class="mendeley-api-endpoint"/></input><input type="hidden" name="pub-access" value="full" class="pub-access"/></input><input type="hidden" name="library-url" value="https://www.mendeley.com/library/" class="library-url"/></input><input type="hidden" name="selected-share-option" class="selected-share-option"/></input></div>




        
        <div class="cit-download-dropdown"><span class="cit-download-dropdown_label">Export</span><a href="#" data-db-target-for="cit-download-dropdown_content" title="Download citation button" class="cit-download-dropdown_button"><span>RIS</span><i aria-hidden="true" aria-label="close" class="icon-close"></i></a><div data-db-target-of="cit-download-dropdown_content" class="cit-download-dropdown_content"><ul><li><a href="/action/downloadCitation?doi=10.1021%2Fjm4012643&amp;include=cit&amp;format=ris&amp;direct=true&amp;downloadFileName=jm4012643" title="Citation"><span>Citation</span></a></li><li><a href="/action/downloadCitation?doi=10.1021%2Fjm4012643&amp;include=abs&amp;format=ris&amp;direct=true&amp;downloadFileName=jm4012643" title="Citation and abstract"><span>Citation and abstract</span></a></li><li><a href="/action/downloadCitation?doi=10.1021%2Fjm4012643&amp;include=ref&amp;format=ris&amp;direct=true&amp;downloadFileName=jm4012643" title="Citation and references"><span>Citation and references</span></a></li><li><a href="/action/showCitFormats?doi=10.1021%2Fjm4012643&amp;include=cit&amp;format=ris&amp;direct=true&amp;downloadFileName=jm4012643&amp;href=/doi/10.1021/jm4012643" title="Cite This"><i class="icon-plus-square"></i><span>More Options</span></a></li></ul></div></div>
<div data-db-target-of="787b5b92-0445-40f4-bdd2-9591d56f4a67" id="787b5b92-0445-40f4-bdd2-9591d56f4a67_Pop" class="share__block dropBlock__holder fixed"><span class="sr-only">Share on</span><ul class="rlist w-slide--list addthis addthis_toolbox addthis_default_style addthis_32x32_style"><li><a role="link" class="addthis_button_facebook"><i aria-hidden="true" class="at-icon-wrapper icon-facebook"></i>Facebook</a></li><li><a role="link" class="addthis_button_twitter"><i aria-hidden="true" class="at-icon-wrapper icon-twitter"></i>Twitter</a></li><li><a role="link" class="addthis_button_wechat"><i aria-hidden="true" class="at-icon-wrapper icon-wechat"></i>Wechat</a></li><li><a role="link" class="addthis_button_linkedin"><i aria-hidden="true" class="at-icon-wrapper icon-linkedin"></i>Linked In</a></li><li><a role="link" class="addthis_button_reddit"><i aria-hidden="true" class="at-icon-wrapper icon-reddit"></i>Reddit</a></li></ul></div></div>

        </div></div></div></div><div class="article_header-footer"><div class="article_header-footer-left pull-left clearfix"><div class="article_header-links pull-left"><input class="pub-doi" type="hidden" name="pub-doi" value="10.1021/jm4012643" /></input><a href="/doi/pdf/10.1021/jm4012643" title="PDF" target="_blank" class="button_primary pdf-button"><i class="icon-file-pdf-o"></i><span>PDF (1 MB)
                            </span></a><a href="/servlet/linkout?suffix=s0&amp;dbid=16384&amp;doi=10.1021/jm4012643&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fid%3Ddoi%3A10.1021%252Fjm4012643%26sid%3Dliteratum%253Aachs%26pmid%3D24476391%26genre%3Darticle%26aulast%3DKakarla%26date%3D2014%26atitle%3DDiscovery%2Bof%2Ba%2BNovel%2BClass%2Bof%2BPotent%2BHCV%2BNS4B%2BInhibitors%253A%2BSAR%2BStudies%2Bon%2BPiperazinone%2BDerivatives%26jtitle%3DJournal%2Bof%2BMedicinal%2BChemistry%26title%3DJournal%2Bof%2BMedicinal%2BChemistry%26volume%3D57%26issue%3D5%26spage%3D2136%26epage%3D2160%26issn%3D0022-2623" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a><div class="articleHeaderDropzone8" data-pb-dropzone="articleHeaderDropzone8"><div class="external-alerts-management"><input type="hidden" name="pub-type" value="article" class="pub-type"/></input><input type="hidden" name="is-enabled" value="true" class="is-enabled"/></input><input type="hidden" name="is-authenticated" value="false" class="is-authenticated"/></input><input type="hidden" name="pub-code" value="jmcmar" class="pub-code"/></input><input type="hidden" name="linkout-url" value="https://preferences.acspubs.org/journals" class="linkout-url"/></input><button data-toggle="modal" data-target="#ealertsModal" class="ealerts-toggle-btn hidden"></button><a class="button_primary_2 niHeader_getEAlerts jhHeader_sub_info"><i class="icon-send"></i><i class="icon-envelope"></i><i class="icon-check"></i><span class="ealerts-btn-text">Get e-Alerts</span><i aria-hidden="true" aria-label="close" class="icon-close"></i></a><div class="ux-modal-container"><div id="ealertsModal" style="display: none;" aria-live="polite" aria-atomic="true" class="modal"><div class="modal__dialog"><div class="modal__body"><iframe src="" class="ealerts-frame"></iframe></div></div></div></div><input type="hidden" id="ealertsModalSrc" value="https://preferences.acspubs.org/jmcmar?ifr=1"/></input></div></div></div></div><div class="article_header-footer-right"><div class="articleHeaderDropzone7" data-pb-dropzone="articleHeaderDropzone7"><div class="article_header-footer-right"><div class="article_header-taxonomy"><span>SUBJECTS:</span><ul class="rlist--inline loa"><li><a href="/action/doSearch?ConceptID=290676" title="Substituents">Substituents</a>,</li><li><a href="/action/doSearch?ConceptID=292528" title="Inhibitors">Inhibitors</a>,</li><li><a href="/action/doSearch?ConceptID=290658" title="Amides">Amides</a>,</li><li><a href="/action/doSearch?ConceptID=291788" title="Reaction products">Reaction products</a>,</li><li><a href="/action/doSearch?ConceptID=291241" title="Phenyls">Phenyls</a></li></ul></div></div></div></div></div></div><div class="article_header-right pull-left hidden-md hidden-sm hidden-xs"><div class="articleHeaderDropzone2" data-pb-dropzone="articleHeaderDropzone2"><div class="cover-image"><div class="cover-image__image"><a href="/toc/jmcmar/57/5" title="Go to Journal of Medicinal Chemistry "><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-5/jmcmar.2014.57.issue-5/production/jmcmar.2014.57.issue-5.largecover.jpg" alt="Go to Journal of Medicinal Chemistry "/></img></a></div></div>




        
        
<script>
 $(document).ready(function() {
   $('.article_header .external-alerts-management .niHeader_getEAlerts').each(function(){
	 var Tab = $(this).attr("href");
	   if(typeof Tab != undefined && Tab != false){
		 console.log("Testing Tab");
		 $(this).attr('href','#');
	   }
   });
 });
 $(document).on('click', '.article_header .external-alerts-management .niHeader_getEAlerts', function (e) {
	 //do something
	 if($(this).hasClass('registered')){
	  //send data to analytics for registered users
	      ga('send','event','Registered e-Alert','Article Page Click','jmcmar');
	  }else{
	     //send data to analytics for non-registered users
	      ga('send','event','Get e-Alert','Article Page Click','jmcmar');
	  }
  });
</script>





        
        <div class="pj-badge"></div>




        
        <div class="aJhp_link"></div>
<a href="/action/doUpdateAlertSettings?action=addJournal&amp;journalCode=jmcmar" class="button_primary_2"><i class="icon-send"></i><span>Get e-Alerts</span></a></div></div></div></div></div></div></div><div class="article_abstract"><div class="container container_scaled-down"><div class="row"><div class="col-xs-12"><h2 class="article_abstract-title" id="Abstract">Abstract</h2><div class="article_abstract-content hlFld-Abstract" id="abstractBox"><figure id="f_tgr1" data-index="0" class="article__inlineFigure article_abstract-img"><img class="inline-fig internalNav" src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-5/jm4012643/production/images/medium/jm-2013-012643_0026.gif" alt="" id="tgr1" /></img><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-5/jm4012643/production/images/large/jm-2013-012643_0026.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm4012643&amp;id=f_tgr1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><p class="articleBody_abstractText">HTS screening identified compound <b>2a</b> (piperazinone derivative) as a low micromolar HCV genotype 1 (GT-1) inhibitor. Resistance mapping studies suggested that this piperazinone chemotype targets the HCV nonstructural protein NS4B. Extensive SAR studies were performed around <b>2a</b> and the amide function and the <i>C</i>-3/<i>C</i>-6 cis stereochemistry of the piperazinone core were essential for HCV activity. A 10-fold increase in GT-1 potency was observed when the chiral phenylcyclopropyl amide side chain of <b>2a</b> was replaced with <i>p</i>-fluorophenylisoxazole-carbonyl moiety (<b>67</b>). Replacing the <i>C</i>-6 nonpolar hydrophobic moiety of <b>67</b> with a phenyl moiety (<b>95</b>) did not diminish the GT-1 potency. A heterocyclic thiophene moiety (<b>103</b>) and an isoxazole moiety (<b>108</b>) were incorporated as isosteric replacements for the <i>C</i>-6 phenyl moiety (<b>95</b>), resulting in significant improvement in GT-1b and 1a potency. However, the piperazonone class of compounds lacks GT-2 activity and, consequently, were not pursued further into development.</p></div></div></div></div></div><div class="article_content"><ul class="tab-nav-shortcut"><li><i class="icon-image"></i></li><li><i class="icon-link"></i></li></ul><div class="container container_scaled-down"><div class="row"><div class="col-xs-12"><div class="article_content-table hlFld-FullText"><div class="article_content-row"><div class="article_content-left"><div id="specialIssueNotice" class="extra-info-sec articleNote"><h4>SPECIAL ISSUE</h4><p class="last">This article is part of the <a href="/toc/jmcmar/57/5"><issue-title>HCV Therapies</issue-title></a> special issue.</p></div><div id="sec1" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i1">Introduction</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_72115" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_72115" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">Hepatitis C virus (HCV) infection is a major global health problem that affects more than 200 million individuals worldwide and an estimated 4.5 million people in the United States.<a onclick="showRef(event, 'ref1'); return false;" href="javascript:void(0);" class="ref ref1">(1)</a> Ten to twenty percent of chronically infected individuals eventually develop liver-destroying cirrhosis or hepatocellular carcinoma.<a onclick="showRef(event, 'ref2'); return false;" href="javascript:void(0);" class="ref ref2">(2)</a> Recently approved standard of care (SOC) for genotype 1 patients involves the combination of a NS3/4A protease inhibitor, pegylated α-interferon (IFN), and the oral nucleoside ribavirin. The sustained virologic response (SVR or undetectable HCV RNA in serum post treatment) rate for most-difficult-to-treat genotype-1 HCV patients is about 70% with approved drugs boceprevir and telaprevir in combination with ribavirin and IFN.<a onclick="showRef(event, 'ref3'); return false;" href="javascript:void(0);" class="ref ref3">(3)</a> The current SOC provides limited clinical benefit for HCV genotype 2, 3, 4, 5, and 6 infected patients.<a onclick="showRef(event, 'ref4'); return false;" href="javascript:void(0);" class="ref ref4">(4)</a> Moreover, there is no established vaccine for HCV. Consequently, there is an urgent need for improved oral drugs or drug combination therapies that effectively combat chronic HCV infection, are pan-genotypic, have a high barrier to resistance, and are well tolerated.</div><div class="NLM_p">The HCV virion is an enveloped positive-strand RNA virus of the family flaviviridae with a single oligoribonucleotide genomic sequence of about 9600 bases, which encodes a polyprotein of about 3010 amino acids.<a onclick="showRef(event, 'ref5'); return false;" href="javascript:void(0);" class="ref ref5">(5)</a> The protein products of the HCV gene consist of the structural proteins C, E1, and E2 and the nonstructural proteins NS2, NS3, NS4A, NS4B, NS5A, and NS5B. The nonstructural (NS) proteins are believed to provide the catalytic machinery for viral replication. A number of molecular targets have been pursued in an effort to identify direct acting antivirals as anti-HCV therapeutics.<a onclick="showRef(event, 'ref6'); return false;" href="javascript:void(0);" class="ref ref6">(6)</a> These include, but are not limited to, the NS3/4A<a onclick="showRef(event, 'ref7'); return false;" href="javascript:void(0);" class="ref ref7">(7)</a> protease, NS5A,<a onclick="showRef(event, 'ref8'); return false;" href="javascript:void(0);" class="ref ref8">(8)</a> and the NS5B<a onclick="showRef(event, 'ref9'); return false;" href="javascript:void(0);" class="ref ref9">(9)</a> polymerase. Agents targeting these nonstructural proteins have proven to be clinically effective at reducing HCV viral load in infected patients. However, the emergence of resistant virus, and the observation that combining direct acting antivirals appears to be necessary to achieve sustained viral suppression in the absence of IFN, has necessitated the search for novel and safe direct acting antivirals that can be combined with other anti-HCV agents in development.<a onclick="showRef(event, 'ref10'); return false;" href="javascript:void(0);" class="ref ref10">(10)</a></div><div class="NLM_p">One of the HCV auxiliary NS proteins is NS4B. This protein is a relatively poorly characterized 27 kDa protein with at least four predicted transmembrane (TM) domains.<a onclick="showRef(event, 'ref11'); return false;" href="javascript:void(0);" class="ref ref11">(11)</a> It is believed that as a consequence of polyprotein processing by the NS3/4A protease, the N- and C-terminal parts of NS4B are oriented toward the cytosolic side of the endoplasmic reticulum (ER) membrane. Furthermore, it is believed that HCV NS4B associates with a number of additional NS proteins and permits formation of the so-called “membranous web” structure that facilitates HCV replication.<a onclick="showRef(event, 'ref11'); return false;" href="javascript:void(0);" class="ref ref11">(11)</a> Because NS4B plays a key role in HCV replication, disrupting NS4B function represents an attractive new anti-HCV strategy.</div><div class="NLM_p">Efforts to find inhibitors of HCV that act on the NS4B protein utilized either the purified NS4B protein binding assay or the HCV GT1 replicon luciferase reporter-based in vitro assay and resulted in the identificatioin of low μM inhibitors.<a onclick="showRef(event, 'cit12a'); return false;" href="javascript:void(0);" class="ref cit12a">(12a)</a> The first reported potent sub-μM (HCV 1b) NS4B inhibitor was anguizole<a onclick="showRef(event, 'cit12b'); return false;" href="javascript:void(0);" class="ref cit12b">(12b)</a> (<b>1a</b>) (Figure <a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">1</a>), which showed potency in both GT1b and GT1a replicon assays (EC<sub>50</sub>) of 0.31 and 0.56 μM, respectively. Lead optimization studies based on the anguzole core resulted in a novel imidazo[1,2-<i>a</i>]pyridines<a onclick="showRef(event, 'cit12c'); return false;" href="javascript:void(0);" class="ref cit12c">(12c)</a> (<b>1b</b>) series (Figure <a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">1</a>) with low nM HCV GT1a and 1b replicon activity. Further PK profile optimization studies on <b>1b</b> resulted in pyrazolo[1,5-<i>a</i>]pyridine<a onclick="showRef(event, 'cit12d'); return false;" href="javascript:void(0);" class="ref cit12d">(12d)</a> analogue <b>1c</b> (Figure <a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">1</a>) with improved viral resistance profile when compared to compound <b>1b</b>. Recently, a new potent HCV GT1b Inhibitor (<b>1d</b>) based on the 2-(pyridine-2-yl)-indole<a onclick="showRef(event, 'cit12e cit12f cit12g'); return false;" href="javascript:void(0);" class="ref cit12e cit12f cit12g">(12e-12g)</a> (1d) core with 1.7 nM (EC<sub>50</sub>)1b replicon activity was also disclosed (Figure <a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">1</a>). Anguizole and compounds <b>1b</b>, <b>1c</b>, and <b>1d</b> all showed similar resistance profiles at amino acid residues (H94, F98, V105) of TM1 domain. Resistant profile data of <b>1a</b>–<b>1d</b> appears to indicate that each of these molecules are interacting at the same region of NS4B, however, due to the lack of cocrystal data, their specific mode of binding and identification of key molecular interactions with the NS4B protein have not been determined. Although the current clinical status of compounds <b>1c</b> and <b>1d</b> is not available, it is known that anguizole (<b>1a</b>) was evaluated in a phase 1 clinical trial, but no further data has been reported. Herein, we report the identification and SAR development of a novel class of highly potent HCV NS4B inhibitors that is structurally distinct from those that have been previously disclosed.</div><figure id="fig1" data-index="1" class="article__inlineFigure"><h2 class="fig-label">Figure 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-5/jm4012643/production/images/medium/jm-2013-012643_0002.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-5/jm4012643/production/images/large/jm-2013-012643_0002.jpeg" id="gr6" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 1. HCV NS4B inhibitors with sub-μM GT1b potency.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-5/jm4012643/production/images/large/jm-2013-012643_0002.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm4012643&amp;id=fig1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">A high-throughput screen (HTS) was carried out on 277000 compounds using a HCV 1b replicon luciferase reporter-based assay resulted in identification of the active compound <b>2a</b>. Compound <b>2a</b> contained a piperazinone core and a cyclopropylphenyl side chain (Figure <a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">1</a>). The activity of <b>2a</b> was confirmed after resynthesis (Scheme <a class="ref internalNav" href="#sch1" aria-label="1">1</a>) from commercially available <span class="smallcaps smallerCapital">l</span>-leucine derivatives. Compound <b>2a</b> (<i>trans</i>-<i>R</i>,<i>R</i>) exhibited HCV replicon genotype 1b (GT-1b) potency of 0.8 μM and genotype 1a (GT-1a) potency of 1.0 μM. <i>trans</i>-<i>S</i>,<i>S</i> isomer <b>2b</b> did not show any HCV replicon activity (GT-1b or GT-1a) when tested up to a 20 μM concentration. Compound <b>2a</b> was inactive against HIV and inactive as a HCV NS5B inhibitor. Cytotoxicity assessment against a panel of cell lines (Huh7, HepG2, BxPC3, and CEM) showed that <b>2a</b>’s replicon activity could not be attributed to a cytotoxic effect (CC<sub>50</sub> range = 40–76 μM). Compound <b>2a</b> with its unique diisobutylpiperazin-2-one core was further investigated as a novel compound class targeting HCV.</div><figure id="fig2" data-index="2" class="article__inlineFigure"><h2 class="fig-label">Figure 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-5/jm4012643/production/images/medium/jm-2013-012643_0003.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-5/jm4012643/production/images/large/jm-2013-012643_0003.jpeg" id="gr7" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 2. HTS hit compound (<b>2a</b>) and its inactive isomer (<b>2b</b>).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-5/jm4012643/production/images/large/jm-2013-012643_0003.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm4012643&amp;id=fig2"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p last">Because <b>2a</b> did not inhibit HCV polymerase (data not shown), resistant replicons were generated in an effort to determine the viral target for this class of compounds. The generation of a resistant replicon resulted in the identification of a replicon with decreased sensitivity to <b>2a</b>. Genotypic and phenotypic analyses suggested that the NS4B protein (NS4B) was the target for <b>2a</b>. When known inhibitors of NS3/4A and NS5A were tested against the compound <b>2a</b>-resistant replicon, no significant shift in HCV EC<sub>50</sub> values was observed. Three separate rounds of resistance selection generated high frequency mutations at residues 90 and 98 of NS4B. High frequency mutations found in NS4B were constructed in the GT-1b ET:PVI replicon by site-directed mutagenesis, and the sensitivity was determined using the luciferase reporter assay. Compound <b>2a</b> and <b>95</b> showed a 17-fold reduction and >20-fold reduction in activity against these mutant replicons, respectively, thus indicating that NS4B was the target for this class of molecules. The known NS4B inhibitor anguizole showed ∼10-fold reduction in activity against residue 94 and 98 mutant replicons. Despite submicromolar potency of <b>2a</b> and <b>95</b> against GT-1a and GT-1b replicons, no appreciable activity was observed using a GT-2a replicon. JFH-1 GT-2a WT naturally contains a Leu at position 98. When GT-2a L98 was mutated to Phe, some inhibition was recovered for compound <b>2a</b> and <b>95</b>.</div></div><div id="sec2" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i2">Synthesis of HCV NS4B Inhibitors</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_32825" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_32825" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">The general synthesis of piperazinone core <b>7</b> (Scheme <a class="ref internalNav" href="#sch1" aria-label="1">1</a>) was achieved by employing a modified literature procedure.<a onclick="showRef(event, 'ref13'); return false;" href="javascript:void(0);" class="ref ref13">(13)</a> The aldehyde <b>5</b> was prepared via Weinreb amide intermediate <b>4</b>, which was in turn synthesized from commercially available Fmoc-<span class="smallcaps smallerCapital">l</span>-leucine <b>3</b>. Reductive amination of methyl ester of <span class="smallcaps smallerCapital">l</span>-leucine with aldehyde <b>5</b> furnished <b>6</b>, which on subsequent internal cyclization afforded the core 3,6-disiobutylpiperazinone <b>7</b>. Compound <b>7</b> was coupled to commercially available (±)-(<i>R</i>,<i>R</i>)-phenyl-cyclopropane carboxylic acid followed by chiral column (SFC) separation to furnish active inhibitor <b>2a</b> and its inactive isomer <b>2b</b> (Scheme <a class="ref internalNav" href="#sch1" aria-label="1">1</a>). TBTU mediated coupling of <b>7</b> with 5-(4-fluorophenyl)isoxazole-3-carboxylic acid furnished inhibitor <b>67</b> (Scheme <a class="ref internalNav" href="#sch1" aria-label="1">1</a>).</div><figure id="sch1" data-index="3" class="article__inlineFigure"><h2 class="fig-label">Scheme 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-5/jm4012643/production/images/medium/jm-2013-012643_0004.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-5/jm4012643/production/images/large/jm-2013-012643_0004.jpeg" id="gr1" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 1. Synthesis of Piperazinone Core <b>7</b> and Compounds <b>2a</b>, <b>2b</b>, and <b>67</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-5/jm4012643/production/images/large/jm-2013-012643_0004.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm4012643&amp;id=sch1"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>Reagents and conditions: (a) MeNHOMe·HCl, TBTU, DIPEA, CH<sub>3</sub>CN, 0 °C to RT (98%); (b) LiAlH4, THF, −78 °C (98%); (c) NH<sub>2</sub>-Leu-OMe, NaBH(OAc)<sub>3</sub>, DCE (90%); (d) 20% Et<sub>2</sub>NH in DCM, DCM (95%); (e) (±)-(1<i>R</i>,2<i>R</i>)-2-phenylcyclopropanecarboxylic acid, TBTU, DIPEA, DCM (90%); (f) 5-(4-fluorophenyl)isoxazole-3-carboxylic acid, TBTU, DIPEA, DCM (91%).</p></p></figure><div class="NLM_p">Synthesis of core <b>12</b> bearing a furanyl moiety began by treating furanyl-2-boronic acid (<b>8</b>) with glyoxylic acid monohydrate and bis(4-methoxyphenyl)methanamine in dichloromethane using the Petasis<a onclick="showRef(event, 'ref14'); return false;" href="javascript:void(0);" class="ref ref14">(14)</a> multicomponent coupling reaction to afford the acid <b>9</b> (Scheme <a class="ref internalNav" href="#sch2" aria-label="2">2</a>). The acid compound <b>9</b> was converted to the corresponding Weinreb amide compound <b>10</b>. Weinreb amide <b>10</b> was reduced with LiAlH<sub>4</sub> and then underwent a reductive amination with the methyl ester of <span class="smallcaps smallerCapital">l</span>-leucine to furnish the corresponding ester <b>11</b>. Ester <b>11</b> was cyclized using aqueous acetic acid followed by SFC (chiral) separation providing the cores <b>12</b> and <b>13</b>. Compound <b>12</b> was then coupled to the 5-(4-fluorophenyl)isoxazole-3-carboxylic acid to furnish the inhibitor <b>107</b>.</div><figure id="sch2" data-index="4" class="article__inlineFigure"><h2 class="fig-label">Scheme 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-5/jm4012643/production/images/medium/jm-2013-012643_0005.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-5/jm4012643/production/images/large/jm-2013-012643_0005.jpeg" id="gr2" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 2. Synthesis of Furanyl Derivative <b>107</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-5/jm4012643/production/images/large/jm-2013-012643_0005.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm4012643&amp;id=sch2"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>Reagents and conditions: (a) glyoxylic acid monohydrate, bis(4-methoxyphenyl)methanamine, DCM (94%); (b) MeNHOMe·HCl, TBTU, DIPEA, CH<sub>3</sub>CN (93%); (c) LiAlH<sub>4</sub>,THF, −78 °C, then NH<sub>2</sub>-Leu-OMe, NaBH(OAc)<sub>3</sub>, DCM (49%); (d) 70% aqueous AcOH, reflux (75%); (e) 5-(4-fluorophenyl)-isoxazole-3-carboxylic acid, TBTU, DIPEA, DCM (50%).</p></p></figure><div class="NLM_p">Synthesis of oxazole core <b>16</b> began with coupling of commercially available FMOC-<span class="smallcaps smallerCapital">l</span>-Ser-O<sup>t</sup>Bu and the hydrochloride salt of <span class="smallcaps smallerCapital">l</span>-leucine methyl ester by the method described for compound <b>7</b> (Scheme <a class="ref internalNav" href="#sch1" aria-label="1">1</a>) to afford intermediate <b>14</b> (Scheme <a class="ref internalNav" href="#sch3" aria-label="3">3</a>). Acid hydrolysis followed by the nitrogen protection with a Boc group furnished alcohol <b>15</b>. Oxidation of hydroxy group in <b>15</b> with Dess–Martin’s reagent followed by treatment with tosylmethyl isocyanide and SFC (chiral) separation furnished the desired oxazole core <b>16</b>. Oxazole core <b>16</b> was subsequently treated with HCl to deprotect the Boc group and coupled with 5-(4-fluorophenyl)isoxazole-3-carboxylic acid to furnish inhibitor <b>108</b>.</div><figure id="sch3" data-index="5" class="article__inlineFigure"><h2 class="fig-label">Scheme 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-5/jm4012643/production/images/medium/jm-2013-012643_0006.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-5/jm4012643/production/images/large/jm-2013-012643_0006.jpeg" id="gr3" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 3. Synthesis of Oxazole Derivative <b>108</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-5/jm4012643/production/images/large/jm-2013-012643_0006.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm4012643&amp;id=sch3"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>Reagents and conditions: (a) HCl in dioxane, 70 °C; (b) (BOC)<sub>2</sub>O, DIPEA, DCM, DMF (2 steps 87%); (c) DMP, DCM, 0 °C to RT; (d) tosylmethyl isocyanide, K<sub>2</sub>CO<sub>3</sub>, MeOH, 70 °C (2 steps 15%); (e) HCl in dioxane, DCM, 0 °C to RT; (f) HATU, DIPEA, DMF at RT (2 steps, 70%).</p></p></figure><figure id="sch4" data-index="6" class="article__inlineFigure"><h2 class="fig-label">Scheme 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-5/jm4012643/production/images/medium/jm-2013-012643_0007.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-5/jm4012643/production/images/large/jm-2013-012643_0007.jpeg" id="gr4" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 4. Syntheses of Inhibitors <b>21</b>, <b>22</b>, and <b>109</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-5/jm4012643/production/images/large/jm-2013-012643_0007.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm4012643&amp;id=sch4"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>Reagents and conditions: (a) Fmoc-Cl, aq dioxane, 0 °C to RT (quantitative); (b) DMP, DCM; (c) (<i>S</i>)-2-amino-4-methylpentanoic acid methyl ester HCl salt, NaBH(OAc)<sub>3</sub>, THF (2 steps 42%); (d) 40% Et<sub>2</sub>NH in EtOH, 60 °C (42%); (e) 5-(4-fluorophenyl)isoxazole-3-carboxylic acid, HOBT hydrate, EDC, DIPEA, CH<sub>3</sub>CN (30%); (f) OsO<sub>4</sub>, oxone, DMF (60%); (g) 2,2-dimethoxy-ethylamine, HOBT hydrate, EDC, DIPEA, CH<sub>3</sub>CN (50%); (h), TFA, DCM (75%).</p></p></figure><div class="NLM_p">Synthesis of piperazinone core derivative <b>109</b> bearing a oxazole moiety began with Fmoc protection of (<i>S</i>)-2-amino-but-3-en-1-ol (<b>17</b>) to give Fmoc protected alcohol <b>18</b> (Scheme <a class="ref internalNav" href="#sch4" aria-label="4">4</a>). Oxidation of <b>18</b> with Dess–Martin’s reagent followed by reductive amination with (<i>S</i>)-2-amino-4-methylpentanoic acid methyl ester furnished <b>19</b>. Compound <b>19</b> was converted to the piperazinone core <b>20</b> via the reaction sequence outlined in Scheme <a class="ref internalNav" href="#sch1" aria-label="1">1</a>. Piperazinone <b>20</b> was coupled with 5-(4-fluorophenyl)-isoxazole-3-carboxylic acid giving <b>21</b>, and subsequent oxidation of the vinyl goup with OsO<sub>4</sub> afforded the acid <b>22</b>. Acid <b>22</b> was treated with 2,2-dimethoxy-ethylamine to give the acetal product <b>23</b>, which was cyclized to furnish the inhibitor <b>109</b>.</div><figure id="sch5" data-index="7" class="article__inlineFigure"><h2 class="fig-label">Scheme 5</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-5/jm4012643/production/images/medium/jm-2013-012643_0008.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-5/jm4012643/production/images/large/jm-2013-012643_0008.jpeg" id="gr5" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 5. Synthesis of Pyrrolidine Derivative <b>111</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-5/jm4012643/production/images/large/jm-2013-012643_0008.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm4012643&amp;id=sch5"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>Reagents and conditions: (a) glyoxylic acid monohydrate, bis(4-methoxyphenyl)methanamine, DCM; (b) MeNHOMe·HCl, TBTU, DIPEA, CH<sub>3</sub>CN (2 steps 98%); (c) LiAlH<sub>4</sub>,THF, −78 °C, then NH<sub>2</sub>-Leu-OMe, NaBH(OAc)<sub>3</sub>, DCM, (67%); (d) 5-(4-fluorophenyl)-isoxazole-3-carboxylic acid, TBTU, DIPEA, CH<sub>3</sub>CN; (e) 70% aq AcOH, reflux (2 steps 12%).</p></p></figure><div class="NLM_p last">Synthesis of pyrrolidine <b>26</b> began with a Petasis<a onclick="showRef(event, 'ref14'); return false;" href="javascript:void(0);" class="ref ref14">(14)</a> multicomponent coupling reaction utilizing (1-(<i>tert</i>-butoxycarbonyl)-1<i>H</i>-pyrrol-2-yl)boronic acid (<b>24</b>) followed by treatment with <i>N</i>-methylmethoxyamine to afford the corresponding Weinreb amide derivative <b>25</b> (Scheme <a class="ref internalNav" href="#sch5" aria-label="5">5</a>). Amide <b>25</b> was subjected to reductive amination, deprotection, and acylation as described for compound <b>107</b> (Scheme <a class="ref internalNav" href="#sch2" aria-label="2">2</a>) to furnish inhibitor <b>111</b> (trans diastereomers).</div></div><div id="sec3" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i8">Results and Discussion</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_72363" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_72363" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_table-wrap" id="tbl1"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 1. SAR of Piperazinone Core</div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-5/jm4012643/production/images/medium/jm-2013-012643_0009.gif" alt="" id="fx1" /></img><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-5/jm4012643/production/images/medium/jm-2013-012643_0010.gif" alt="" id="fx2" /></img><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t1fn1"><div class="footnote" id="t1fn1"><sup>Table a</sup><p class="last">For description of the assays, see ref <a onclick="showRef(event, 'ref15'); return false;" href="javascript:void(0);" class="ref ref15">15</a>. Replicon data is the average of <i>n</i> = 2 with ±0.2 mM SD.</p></div></div><div></div></div><div class="NLM_p">A study was first undertaken to understand which structural elements of the piperazinone core were critical to its HCV inhibitory activity. This was accomplished by preparing analogues of key structural motifs found in <b>2a</b> (Table <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">1</a>). Compounds derived from combination of core <b>2a</b> with <i>trans</i>-<i>S</i>,<i>S</i>, side chain or core <b>2b</b> with <i>trans</i>-<i>R</i>,<i>R</i> side chain were shown to be inactive, indicating that the stereochemistry of the core as well as the side chain were essential for activity. Alkylation of the <i>N</i>-1 amide nitrogen (<b>27</b>) resulted in a 10-fold loss in GT-1b potency. Removal of the core carbonyl group was also shown to be detrimental to GT-1b activity as exemplified by compound <b>28</b>. Together, these results seemed to imply that the piperazinone <i>N</i>-1 nitrogen and <i>C</i>-2 carbonyl groups might be providing an important hydrogen bond donor and acceptor interaction with the NS4B protein. The cis stereochemical relationship between <i>C</i>-3 and <i>C</i>-6 of the piperazinone core was also shown to be important because changing the stereochemistry at <i>C</i>-3 or <i>C</i>-6 to the <i>R</i>-stereochemistry as shown in compound <b>29</b> and <b>30</b> resulted in complete loss of activity. Molecular modeling of <b>2a</b> indicated that the lowest energy conformers of <b>2a</b> have the <i>i</i>-Bu at <i>C</i>-3 above plane and the <i>i</i>-Bu at <i>C</i>-6 in plane with the piperazinone ring. In the case of <b>29</b> and <b>30</b>, the <i>i</i>-Bu substituents at <i>C</i>-3 and <i>C</i>-6 are in opposite orientation to each other and also out of plane to the piperazinone ring. On the basis of these molecular modeling and activity results, we concluded that the cis stereochemical relationship between <i>C</i>-3 and <i>C</i>-6 substituents of the piperazinone core confers the preferred orientation for tight binding.</div><div class="NLM_p">Futher investigation of the <i>C</i>-3 and <i>C</i>-6 core substitutents showed that substituting an ethyl moiety for the <i>i</i>-Bu at <i>C</i>-3 (<b>31</b>) or <i>C</i>-6 (<b>32</b>) resulted in substantial loss of activity. Replacing the <i>i</i>-Bu moiety with a <i>sec</i>-Bu (<b>33</b>) group at <i>C</i>-6 also led to a loss of GT-1b potency. The only modification to <b>2a</b> that maintained GT-1b activity was replacement of <i>n</i>-Pr (<b>34</b>) for <i>i</i>-Bu at <i>C</i>-6. The observed results for modifications at <i>C</i>-3 and <i>C</i>-6 suggest that these positions are sensitive to the nature of the hydrophobic groups. On the basis of the piperazinone core SAR, it is apparent that the amide function and the cis stereochemistry (<i>S</i>,<i>S</i>) of the piperazinone core are essential for GT1b activity.</div><div class="NLM_table-wrap" id="tbl2"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 2. SAR of Cyclopropyl Amide Side Chain Replacements</div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-5/jm4012643/production/images/medium/jm-2013-012643_0011.gif" alt="" id="fx3" /></img><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-5/jm4012643/production/images/medium/jm-2013-012643_0012.gif" alt="" id="fx4" /></img><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t2fn1"><div class="footnote" id="t2fn1"><sup>Table a</sup><p class="last">For description of the assay, see ref <a onclick="showRef(event, 'ref15'); return false;" href="javascript:void(0);" class="ref ref15">15</a>. Replicon data is the average of <i>n</i> = 2 with ±0.2 μM SD.</p></div></div><div></div></div><div class="NLM_p">A series of replacements for the cyclopropyl moiety were investigated (Table <a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">2</a>). Replacement of the cyclopropyl amide moiety of <b>2a</b> with propiolamide (<b>35</b>) produced a 3-fold loss in activity. Cinnamide (<i>trans</i>-<i>E</i>) <b>36</b> showed 2-fold loss in activity, while the <i>cis</i>-(<i>Z</i>)-cinnamide (<b>37</b>) showed a complete loss of activity. These findings indicated that the trans geometry of the side chain is important for potency. Further analysis indicated that the side chain carbonyl group may not be required for potency as shown by the <i>N</i>-alkylated analogue <b>38</b>. Removal of side chain phenyl group (<b>39</b>) led to complete loss of activity, indicating that the phenyl group is essential and might be involved in π–π interactions with the target protein. Replacement of cyclopropyl moiety with a bulky pheny moiety (<b>40</b>) led to significant loss in GT-1b activity. On the basis of the observed SAR, we decided to utilize the <i>trans</i>-cinnamide side chain for further SAR studies.</div><div class="NLM_table-wrap" id="tbl3"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 3. SAR of the <i>trans</i>-Cinnamide Side Chain Analogues</div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-5/jm4012643/production/images/medium/jm-2013-012643_0013.gif" alt="" id="fx5" /></img><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-5/jm4012643/production/images/medium/jm-2013-012643_0014.gif" alt="" id="fx6" /></img><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t3fn1"><div class="footnote" id="t3fn1"><sup>Table a</sup><p class="last">For description of the assay, see ref <a onclick="showRef(event, 'ref15'); return false;" href="javascript:void(0);" class="ref ref15">15</a>. Replicon data is the average of <i>n</i> = 2 determinations with ±0.2 μM SD.</p></div></div><div></div></div><div class="NLM_p">In an effort to improve the potency of the nonchiral cinnamide side chain, investigation of phenyl group substituent effects was undertaken. Several analogues<a onclick="showRef(event, 'ref16'); return false;" href="javascript:void(0);" class="ref ref16">(16)</a> were prepared by coupling the piperazinone core (<b>7</b>) with commercially available cinnamic acid derivatives (Scheme <a class="ref internalNav" href="#sch1" aria-label="1">1</a>). For selected compounds, GT1b inhibitory activity is shown in Table <a class="ref showTableEvent internalNav" data-ID="tbl3" href="#tbl3">3</a>. Methyl (<b>41</b>), trifluoromethyl (<b>42</b>), and methoxy (<b>43</b>) phenyl substituents were not tolerated, as indicated by the significant decrease in GT1b activity. Loss of activity was also observed for compounds having a nitro (<b>44</b>), dimethylamino (<b>45</b>), methyl sulfone (<b>46</b>), or carboxylate (<b>47</b>) phenyl substituent. These results indicate that strong electron withdrawing and polar functionalities were not tolerated on the phenyl moiety of the cinnamide side chain. Improvement in potency was seen for <i>p</i>-chloro (<b>49</b>) and <i>p</i>-fluoro (<b>52</b>) phenyl-substituted cinnamide derivatives, however, these derivatives only showed comparable potency to <b>2a</b>. The <i>p</i>-Br, <i>m</i>-Cl, and <i>o</i>-Cl analogues <b>48</b>, <b>50</b>, and <b>51</b> showed 4-fold loss in activity. Interestingly, the disubstituted compounds <b>53</b> and <b>54</b> did demonstrate GT-1b potency similar to the mono substituted analogue <b>52</b>. For the cinnamide series, the SAR showed that substituents at the <i>para</i>-position consistently produced compounds with improved potency relative to compounds having a <i>meta</i>- or <i>ortho</i>-substituted phenyl moiety and that fluoro and chloro are optimal substituents. The replicon potency of compounds <b>49</b>, <b>52</b>, and <b>53</b> which lack the chiral cyclopropyl unit was shown to be comparable to that observed for compound <b>2a</b> and, consequently, served as the basis for further lead optimization by exploring cinnamide double-bond replacements.</div><div class="NLM_table-wrap" id="tbl4"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 4. HCV Replicon Activity of Heterocyclic Amide Side Chain</div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-5/jm4012643/production/images/medium/jm-2013-012643_0015.gif" alt="" id="fx7" /></img><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-5/jm4012643/production/images/medium/jm-2013-012643_0016.gif" alt="" id="fx8" /></img><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t4fn1"><div class="footnote" id="t4fn1"><sup>Table a</sup><p class="last">For description of the assay, see ref <a onclick="showRef(event, 'ref15'); return false;" href="javascript:void(0);" class="ref ref15">15</a>. Replicon data is the average of <i>n</i> = 2 determinations with ±0.2 μM SD.</p></div></div><div></div></div><div class="NLM_p">To further improve the potency relative to compounds having the cinnamide side chain (<b>52</b>), we investigated amide side chains having 5-membered heterocyclic ring systems in place of the cinnamide double bond. The hope was that such a replacement might provide additional electrostatic interactions while still maintaining a favorable geometry. A commercially available diverse set of heterocyclic acid derivatives capable of forming H-bond acceptor and/or donor interactions were coupled to the piperazinone core<a onclick="showRef(event, 'ref16'); return false;" href="javascript:void(0);" class="ref ref16">(16)</a> by the method shown in Scheme <a class="ref internalNav" href="#sch1" aria-label="1">1</a>, and the activity of selected compounds is shown in Table <a class="ref showTableEvent internalNav" data-ID="tbl4" href="#tbl4">4</a>. Compound <b>56</b> exhibiting H-acceptor characteristics led to a several-fold decrease in GT-1b activity. Similarly, the oxazole <b>57</b> and imidazole <b>60</b> did not show GT-1b activity up to 10 μM. Pyrazole <b>61</b> and imidazole <b>62</b> having H-donor ability were also shown to be inactive up to 10 μM. However, the isoxazole <b>58</b> and oxadiazole <b>59</b> showed a 2-fold increase in GT-1b activity. We surmise that both <b>67</b> and <b>68</b> provide favorable substituent orientation and electronic character to result in the observed 2-fold increase in GT-1b potency when compared to the corresponding cinnamide <b>36</b>. Replacing the side chain phenyl group of <b>58</b> with other heterocyclic moieties that can provide similar π–π interaction with protein did not pan out. Isoxazole <b>58</b> became the basis for further lead optimization by studying substituent effects on the phenyl moiety.</div><div class="NLM_table-wrap" id="tbl5"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 5. Effect of Phenyl Ring Substitution on the GT-1b Potency of Isoxazole Derivatives</div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-5/jm4012643/production/images/medium/jm-2013-012643_0017.gif" alt="" id="fx9" /></img><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-5/jm4012643/production/images/medium/jm-2013-012643_0018.gif" alt="" id="fx10" /></img><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t5fn1"><div class="footnote" id="t5fn1"><sup>Table a</sup><p class="last">For description of the assay, see ref <a onclick="showRef(event, 'ref15'); return false;" href="javascript:void(0);" class="ref ref15">15</a>. Replicon data is the average of <i>n</i> = 2 determinations with ±0.20 μM SD.</p></div></div><div></div></div><div class="NLM_p">The next step in our attempt to improve the GT-1b potency beyond that of <b>58</b> investigated the effect of substituents on the phenyl moiety while maintaining intact the piperazinone core and isoxazole amide side chain (Table <a class="ref showTableEvent internalNav" data-ID="tbl5" href="#tbl5">5</a>). Synthesis of these compounds was achieved by the method in Scheme <a class="ref internalNav" href="#sch1" aria-label="1">1</a>. As expected (see Table <a class="ref showTableEvent internalNav" data-ID="tbl3" href="#tbl3">3</a>), the <i>para</i>-substituted methyl (<b>63</b>), methoxy (<b>64</b>), cyano (<b>70</b>), and nitro (<b>72</b>) derivatives showed no improvement in GT-1b activity, while the GT-1b potency of <i>para</i>-F (<b>67</b>), <i>para</i>-Cl (<b>65</b>), and <i>para</i>-Br (<b>66</b>) derivatives increased by 8-fold, 4-fold, and 2-fold, respectively. The 3,4- and 2,4-disubstituted compounds (<b>68</b> and <b>69</b>) showed a 5-fold decrease in potency when compared to the <i>para</i>-F substituted compound (<b>67</b>). After optimizing the GT-1b potency of the piperazinone side chain, we decided to focus on modification of the core in an attempt to further improve the GT-1b potency.</div><div class="NLM_table-wrap" id="tbl6"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 6. Piperazinone <i>C</i>-6 Substituent SAR</div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-5/jm4012643/production/images/medium/jm-2013-012643_0019.gif" alt="" id="fx11" /></img><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-5/jm4012643/production/images/medium/jm-2013-012643_0020.gif" alt="" id="fx12" /></img><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t6fn1"><div class="footnote" id="t6fn1"><sup>Table a</sup><p class="last">For description of the assay, see ref <a onclick="showRef(event, 'ref15'); return false;" href="javascript:void(0);" class="ref ref15">15</a>. Replicon data is the average of <i>n</i> = 2 determinations with ±0.20 μM SD and for <b>95</b> it was ±0.02 μM SD.</p></div></div><div></div></div><div class="NLM_p">Piperazinone core <i>C</i>-6 substituent effects were probed using hydrophobic moieties (acyclic, branched, and cyclic) to study space constraints and substituents having H-acceptor and/or H-donor moieties to evaluate potential electrostatic interactions (Table <a class="ref showTableEvent internalNav" data-ID="tbl6" href="#tbl6">6</a>).<a onclick="showRef(event, 'ref16'); return false;" href="javascript:void(0);" class="ref ref16">(16)</a> The neopentyl (<b>75</b>), <i>sec</i>-butyl (<b>76</b>), and <i>tert</i>-butyl (<b>84</b>) derivatives produced a significant reduction in GT-1b activity compared to <b>67</b>. The <i>n</i>-propyl analogue <b>73</b> retained potency, while the ethyl analogue <b>82</b> and <i>n</i>-Bu analogue <b>80</b> showed a 6–4-fold decrease in potency, respectively. The propenyl compound <b>74</b> exhibited 2-fold improvement in GT-1b potency, yet the allyl moiety (<b>77</b>) and vinyl moiety (<b>21</b>) containing compounds showed 3-fold and 8-fold decrease in GT-1b potency, respectively. The cyclopropyl methyl compound <b>78</b> showed 3-fold decrease in potency, and the cyclopropyl analogue <b>85</b> showed 8-fold loss of potency. The <i>i</i>-propyl analogue <b>83</b> retains the GT-1b potency of parent compound <b>67</b>. The thio-ether analogues <b>79</b> and <b>81</b> showed 2- and 3-fold decrease in GT-1b potency, respectively. Among the cycloalkyl analogues, cyclobutyl derivative <b>86</b> showed 6-fold loss of potency, but the cyclopentyl analogue <b>87</b> proved to be a slightly more potent inhibitor than <b>67</b>. Among the 6-membered cycloalkyl analogues, cyclohexyl compound <b>88</b> proved to be slightly less potent, while the tetrahydropyran analogue <b>93</b> showed a 4-fold loss of potency, and thio-pyran <b>94</b> showed 8-fold decrease in potency. The phenyl analogue <b>95</b> showed potency similar to that seen for <b>74</b> and <b>87</b> but demonstrated better metabolic stability<a onclick="showRef(event, 'ref17'); return false;" href="javascript:void(0);" class="ref ref17">(17)</a> and was chosen for further SAR optimization.</div><div class="NLM_table-wrap" id="tbl7"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 7. Substitution Effects on the GT-1b Potency of Piperazinone <i>C</i>-6 Phenyl Analogues</div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-5/jm4012643/production/images/medium/jm-2013-012643_0021.gif" alt="" id="fx13" /></img><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-5/jm4012643/production/images/medium/jm-2013-012643_0022.gif" alt="" id="fx14" /></img><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t7fn1"><div class="footnote" id="t7fn1"><sup>Table a</sup><p class="last">For description of the assay, see ref <a onclick="showRef(event, 'ref15'); return false;" href="javascript:void(0);" class="ref ref15">15</a>. Replicon data is the average of <i>n</i> = 2 determinations with ±0.20 μM SD.</p></div></div><div></div></div><div class="NLM_p">The substituent effects on the <i>C</i>-6 phenyl group of <b>95</b> were investigated but did not lead to any improvement in potency (Table <a class="ref showTableEvent internalNav" data-ID="tbl7" href="#tbl7">7</a>). A nearly 10-fold decrease in GT-1b potency was observed when a methyl (<b>96</b>) or fluoro (<b>99</b>) substituent was introduced at the 4-position of the phenyl moiety. Significant loss of potency also occurred with introduction of chloro (<b>98</b>) and trifluoromethyl (<b>102</b>) substitution, indicating that the substitution at the 4-position of the phenyl moiety was not well tolerated. In the case of fluoro substituted compounds, substitution at the <i>meta</i> position (<b>100</b>) resulted in 4-fold loss of potency, while the <i>ortho</i>-F compound (<b>101</b>) showed only a modest loss of potency. Because we were not able to improve the GT-1b potency of inhibitor <b>95</b> through the addition of substituents on the phenyl moiety, our next step was to investigate heterocyclic moieties as replacements for the <i>C</i>-6 phenyl group.</div><div class="NLM_table-wrap" id="tbl8"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 8. Optimization of GT-1b Potency with <i>C</i>-6 Heterocyclic Moieties</div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-5/jm4012643/production/images/medium/jm-2013-012643_0023.gif" alt="" id="fx15" /></img><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-5/jm4012643/production/images/medium/jm-2013-012643_0024.gif" alt="" id="fx16" /></img><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t8fn1"><div class="footnote" id="t8fn1"><sup>Table a</sup><p class="last">For description of the assay, see ref <a onclick="showRef(event, 'ref15'); return false;" href="javascript:void(0);" class="ref ref15">15</a>. Replicon data is the average of <i>n</i> = 2 determinations with ±0.025 μM SD, and for <b>113</b> it was ±0.002 μM SD.</p></div></div><div></div></div><div class="NLM_p">We envisioned that introduction of a heterocyclic moiety at the C-6 position of the piperazinone ring should result in retention of any favorable (π–π) interactions provided by a <i>C</i>-6 phenyl group and may introduce additional interactions that could further improve the GT1 potency. Consequently, we synthesized a series of <i>C</i>-6 heterocyclic derivatives (<b>103</b>–<b>113</b>) using synthetic methods depicted in Schemes <a class="ref internalNav" href="#sch2" aria-label="2">2</a>–<a class="ref internalNav" href="#sch5" aria-label="5">5</a> (Table <a class="ref showTableEvent internalNav" data-ID="tbl8" href="#tbl8">8</a>). The 2-thiophene compound <b>103</b> showed a dramatic 10-fold increase in potency, while the 3-thiophene compound <b>104</b> showed a less dramatic 3-fold increase the GT1b potency when compared to the corresponding phenyl analogue <b>95</b>. The 3-methyl-thiophene compound <b>105</b> was 110-fold less active, and 5-methyl-thiophene <b>106</b> was 30-fold less active than the unsubstituted 2-thiophene analogue <b>103</b>. The furan derivative <b>107</b> was 3-fold less active than <b>95</b> and 30-fold less active than the 2-thiophene derivative <b>103</b>. The 2-oxazole <b>109</b> and 2-thiazole <b>110</b> were inactive, but the 4-oxazole <b>108</b> retained the activity of the phenyl derivative <b>95</b>. The results for the oxazoles <b>108</b> and <b>109</b> suggested that the position of the nitrogen atom in the heterocyclic ring was critical to the GT-1b potency. The unsubstituted 2-pyrrole compound <b>111</b> showed a 11-fold loss of activity, but the 3-pyrrole compound <b>112</b> showed similar potency to the phenyl analogue <b>98</b>.</div><div class="NLM_p">An attempt to further optimize the potency of 3-thiophene compound (<b>104</b>) led to the 2-chloro thiophene derivative (<b>113</b>) that showed a 6-fold improvement in the GT-1b potency (Table <a class="ref showTableEvent internalNav" data-ID="tbl8" href="#tbl8">8</a>). Further evaluation of inhibitors <b>103</b> and <b>108</b> in both GT-1a and 1b replicons showed that the GT-1b potency was superior to GT-1a potency (Table <a class="ref showTableEvent internalNav" data-ID="tbl9" href="#tbl9">9</a>). The thiophene derivative <b>103</b> exhibited a preferable metabolic stability, yet the oxazole <b>108</b> had superior solubility characteristics and none of these compounds showed any CYP (1A2, 2C9, 2D6, and 3A4) inhibition up to 10 μM. Neither <b>103</b> nor <b>108</b> demonstrated any appreciable GT-2 activity when tested in a replicon assay. Unfortunately, due to their lack of broad genotype coverage, the piperazinone class of NS4B inhibitors did not progress further into preclinical development.</div><div class="NLM_table-wrap" id="tbl9"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 9. Lead Compounds Profiling Data<a class="ref internalNav" href="#t9fn1" aria-label="a">a</a></div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-5/jm4012643/production/images/medium/jm-2013-012643_0025.gif" alt="" id="fx17" /></img><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t9fn1"><div class="footnote" id="t9fn1"><sup>Table a</sup><p class="last">For description of the assays, see ref <a onclick="showRef(event, 'ref15'); return false;" href="javascript:void(0);" class="ref ref15">15</a>. GT 1a Replicon data is the average of <i>n</i> = 2 determinations with ±0.010 μM SD.</p></div></div><div></div></div></div><div id="sec4" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i18">Conclusion</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_58638" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_58638" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">HCV infection is a disease that afflicts a large patient population with negative long-term consequences. Research has shown that the combination of potent direct acting antivirals can provide a cure for this debilitating and often fatal disease. Therefore, novel direct acting antiviral agents acting by new mechanisms of action have the potential to become part of future therapeutic regimens. With this desire in mind, an HTS campaign was undertaken that led to the identification of piperazinone <b>2a</b> as a novel and specific HCV inhibitor. Compound <b>2a</b> was shown to be an effective inhibitor of HCV genotype 1b and 1a replicons, with a 50-fold activity/toxicity window in whole cells and excellent selectivity over other viruses. Resistance mapping studies aimed at determining which HCV nonstructural protein was the target for piperazinone <b>2a</b> revealed that mutations at residues 90 and 98 in the TM1 domain of NS4B resulted in a significant reduction in the HCV inhibitory activity of compound <b>2a</b>, thus supporting NS4B was the primary target. An extensive chemistry-driven SAR development effort looking at multiple positions of the piperazinone core and amide side chain was performed on compound <b>2a</b>. Although we did not have structural information to guide the inhibitor design, we were able to effectively develop a robust SAR picture that led to potent HCV GT1 inhibitors. Initial studies kept the piperazinone core constant, explored the side chain cyclopropyl replacements as well as the substituents on the side chain phenyl moiety to optimize compound <b>2a</b> potency. These studies resulted in the <i>p</i>-fluorophenylisoxazole amide as the optimized side chain as shown in compound <b>67</b>. The core <i>C</i>-6 SAR investigation demonstrated that the <i>i</i>-Bu moiety could be replaced with a phenyl moiety and resulted in molecule <b>95</b> with double-digit nanomolar GT-1b potency. Further optimization of the lead compounds GT-1b potency led to the single-digit nanomolar GT-1b and low double-digit nanomolar GT-1a HCV inhibitors <b>103</b> and <b>108</b> having acceptable metabolic stability and solubility parameters. Through this effort, we have discovered a useful novel prototype inhibitor of HCV NS4B that has good genotype 1b and 1a potency with suitable stability, solubility parameters, and no CYP liabilities but lacked broad genotype coverage suitable for further development.</div><div class="NLM_p last">The identification and optimization of the piperazinone class of NS4B inhibitors did however introduce a new structural class of NS4B inhibitors into the repertoire of HCV replication inhibitors. Each of the previously identified NS4B inhibitors <b>1a</b>–<b>d</b> incorporates a critical 6,5-bicyclic ring system containing similar patterns of substitution. In fact, compounds <b>1b</b> and <b>1c</b> are based on the original anguizole motif where each are substituted similarly and include an essential amide side chain. Even though indole inhibitor <b>1d</b> does not display an amide side chain directly attached to the 5-membered ring of the bicycle, it shares with <b>1b</b> and <b>1c</b> a common amide-type functionality on its side chain at a similar distance from the 5-membered ring point of attachment. The clear structural similarities among inhibitors <b>1a</b>–<b>d</b> and the existence of identical resistance profiles supports the hypothesis that they all share a common binding site on the NS4B protein. In stark contrast to the known NS4B inhibitors <b>1a</b>–<b>d</b>, the piperazinone class of inhibitors exemplified by lead <b>2a</b> and optimized compound <b>103</b> do not incorporate a bicyclic nucleus, however, this class does incorporate an amide side chain. Any attempts to incorporate structural features, such as bicyclic systems, similar to those noted in <b>1a</b>–<b>d</b>, resulted in loss of activity. In addition, efforts to draw structural comparisons between the piperazinones <b>2a</b> and <b>103</b> with inhibitors <b>1a</b>–<b>d</b> did not lead to any understanding of common topographical motifs. However, irrespective of the apparent lack of significant structural similarity between the piperazinone class of NS4B inhibitors and the previously reported inhibitors <b>1a</b>–<b>d</b>, they all share a F98L resistant phenotype and lose substantial activity when assayed against the GT2a replicon where the wild-type phenotype is L98. It can therefore be surmised that because of this common resistant amino acid substitution and activity loss against the GT2a replicon, there must be some overlap in binding sites between the structurally similar inhibitors <b>1a</b>–<b>d</b> and the piperazinone class of NS4B inhibitors. Therefore, it may be reasonable to speculate that overlapping binding sites occur in the region of the NS4B protein where the amide side chains of <b>1a</b>–<b>d</b> and that of the piperazinones bind. However, definitive proof of this common binding site will only occur when cocrytal structures of these different inhibitors with the NS4B protein are obtained. The possibility exists that with the identification of the structurally novel and potent piperazinone class of NS4B inhibitors in conjunction with the information reported for the other classes of NS4B inhibitors, further work may lead to the identification of NS4B inhibitors that can overcome the genotype coverage limitations that currently plague the search for clinically viable NS4B inhibitors.</div></div><div id="sec5" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i19">Experimental Section</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_81068" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_81068" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div id="sec5_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i20" class="anchor-spacer"></div><h3 class="article-section__title" id="_i20"> General Methods</h3><div class="NLM_p last">Unless specified otherwise, starting materials were available from commercial sources. Dry solvents and reagents were of commercial quality and were used as purchased. Nuclear magnetic resonance (NMR) spectra were recorded on Bruker Advance II 400 MHz and Varian AS 400 MHz spectrometers at room temperature with tetramethylsilane as an internal standard. Chemical shifts (δ) are reported in parts per million (ppm), and peak multiplicity are reported as s (singlet), d (doublet), t (triplet), q (quartet), m (multiplet), or br s (broad singlet). Purities of the final compounds were determined by HPLC and UPLC-MS and were ≥95% purity. HPLC conditions to assess ≥95% purity of final compounds were as follows: Shimadzu HPLC 20AB Sepax HP-C18 4.6 mm × 50 mm (5 μm); flow rate, 3.0 mL/min; acquisition time, 6 min; wavelength, UV 230 nm; oven temperature, 40 °C. UPLC-MS conditions to assess ≥95% purity for final compounds were as follows: Waters Acquity UPLCMS UPLC BEH C18 2.1 mm × 50 mm (1.7 μm); flow rate, 0.8 mL/min; wavelength, UV 254 nm; oven temperature, 50 °C. Chiral HPLC was conducted on Shimadzu HPLC 20A. The preparative HPLC system includes two sets of Gilson 306 pumps, a Gilson 156 UV/vis detector, and a Gilson 215 injector and fraction collector, with Unipoint control software. A YMC 25 mm × 30 mm × 2 mm column was used. The mobile phase was HPLC grade water (A) and HPLC grade acetonitrile (B) system. SFC separation conditions were as follows: Berger Multi-Gram SFC from Mettler Toledo Co, Ltd.; column, AD 250 mm × 30 mm (5 μm), 38 °C; mobile phase, supercritical CO<sub>2</sub> (A), MeOH (B), A/B = 75/25 at 60 mL/min; nozzle pressure (100 Bar), nozzle temperature (60 °C); evaporator temperature (20 °C); trimmer temperature (25 °C); wavelength (220 nm). LC/MS was conducted on Shimadzu LCMS 2010EV using electrospray positive [ES + ve to give MH<sup>+</sup>] equipped with a Shim-pack XR-ODS 2.2 μm column (3.0 mm × 30 mm, 3.0 mm i.d.), eluting with 0.0375% TFA in water (solvent A) and 0.01875% TFA in acetonitrile (solvent B). Unless specified otherwise, Column chromatography was performed on Intelli Flash 280 (AnaLogix) using silica flash columns.</div></div><div id="sec5_1_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i21" class="anchor-spacer"></div><h3 class="article-section__title" id="_i21"> General Procedures for the Synthesis of Piperazinone Core</h3><div id="sec5_1_1_1" class="NLM_sec NLM_sec_level_3"><div id="ac_i22" class="anchor-spacer"></div><h4 class="article-section__title" id="_i22"> (3<i>S</i>,6<i>S</i>)-3,6-Diisobutylpiperazin-2-one (<b>7</b>)</h4><div id="sec5_1_1_1_1" class="NLM_sec NLM_sec_level_4"><div id="ac_i23" class="anchor-spacer"></div><h5 class="article-section__title" id="_i23">A (<i>S</i>)-(9<i>H</i>-Fluoren-9-yl)methyl-(1-methoxy-(methyl)-amino)-4-methyl-1-oxopentan-2-yl)carbamate (<b>4</b>)</h5><div class="NLM_p last">A mixture of FMOC-Leu-OH (<b>3</b>, 0.5 g, 1.41 mmol), TBTU (0.68 g, 2.12 mmol), and <i>N</i>,<i>O</i>-dimethylhydroxylamine hydrochloride (0.207 mg, 2.12 mmol) in MeCN (5 mL) were stirred at 0 °C under nitrogen for 10 min. DIPEA (0.736 mL, 4.23 mmol) was added dropwise (5 min) and stirred for 30 min. The reaction mixture was allowed to warm to rt and stirred for 2.5 h. The reaction mixture concentrated in vacuo, and the residue was dissolved in EtOAc (100 mL) and washed sequentially with 1 M aqueous HCl (15 mL × 2), 1 M aqueous NaHCO<sub>3</sub> (15 mL × 2), and brine (20 mL). The solution was dried over Na<sub>2</sub>SO<sub>4</sub> and concentrated in vacuo to dryness to afford <b>4</b> (574 mg, 98% yield), which was used for the next step without further purification. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 7.76–7.58 (m, 4 H), 7.41–7.29 (m, 4 H), 5.42 (d, <i>J</i> = 9.2 Hz, 1 H), 4.82–4.80 (m, 1 H), 4.37–4.32 (m, 2 H), 4.23–4.20 (t, <i>J</i> = 14.0 Hz, 1 H), 3.79 (s, 3 H), 3.21 (s, 3 H), 1.74–1.70 (m, 1 H), 1.52–1.48 (m, 1 H), 0.99–0.94 (m, 6 H). MS (ESI): <i>m</i>/<i>z</i> 413.2 (M + 1).</div></div><div id="sec5_1_1_1_2" class="NLM_sec NLM_sec_level_4"><div id="ac_i24" class="anchor-spacer"></div><h5 class="article-section__title" id="_i24">B (<i>S</i>)-(9<i>H</i>-Fluoren-9-yl)methyl (4-methyl-1-oxopentan-2-yl)carbamate (<b>5</b>)</h5><div class="NLM_p last">To a solution of <b>4</b> (0.4 g, 0.97 mmol) in dry THF (10 mL) at −78 °C was added LiAlH<sub>4</sub> (80 mg, 1.94 mmol), and the reaction was stirred under argon for 30 min. The reaction was quenched with 6% aqueous HCl (10 mL, pH 4–5) at −78 °C, and the solution was allowed to warm to 0 °C and stirred for 5 min. This mixture was partitioned between EtOAc/brine (1:2, 100 mL) and extracted with EtOAc (50 mL). The organic layer was washed with brine, dried over Na<sub>2</sub>SO<sub>4</sub>, and concentrated in vacuo to afford <b>5</b> (320 mg, 98% yield), which was used for the next step without further purification. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 9.58 (s, 1 H), 7.77–7.59 (m, 4 H), 7.42–7.30 (m, 4 H), 5.18 (d, <i>J</i> = 7.2 Hz, 1 H), 4.45 (d, <i>J</i> = 6.8 Hz, 2 H), 4.34–4.32 (m, 1 H), 4.24–4.21 (t, <i>J</i> = 6.8 Hz, 1 H), 1.75–1.68 (m, 2 H), 1.48–1.39 (m, 1 H), 0.98–0.96 (m, 6 H). MS (ESI): <i>m</i>/<i>z</i> 438.1 (M + 1).</div></div><div id="sec5_1_1_1_3" class="NLM_sec NLM_sec_level_4"><div id="ac_i25" class="anchor-spacer"></div><h5 class="article-section__title" id="_i25">C (<i>S</i>)-Methyl 2-(((<i>S</i>)-2-((((9<i>H</i>-Fluoren-9-yl)methoxy)carbonyl)amino)-4-methylpentyl)-amino)-4-methylpentanoate (<b>6</b>)</h5><div class="NLM_p last">To a well dried mixture of aldehyde <b>5</b> (290 mg, 0.86 mmol) and Leu-OMe hydrochloride (160 mg, 0.86 mmol) were added DCM (3 mL) and NaBH(OAc)<sub>3</sub> (260 mg, 1.2 mmol) and stirred at rt under nitrogen for 6 h. The reaction was quenched with saturated aqueous NaHCO<sub>3</sub> (50 mL) and was extracted with EtOAc (50 mL) and dried over Na<sub>2</sub>SO<sub>4</sub>. The solvent was concentrated in vacuo and the crude product purified by column chromatography (0–25% EtOAc in hexanes) to afford <b>6</b> (360 mg, 90% yield) as a white solid. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 7.77–7.59 (m, 4 H), 7.41–7.29 (m, 4 H), 4.82 (d, <i>J</i> = 5.6 Hz, 1 H), 4.40 (d, <i>J</i> = 7.2 Hz, 2 H), 4.24 (t, <i>J</i> = 6.8 Hz, 1 H), 3.71 (s, 3 H), 3.27–3.24 (m, 1 H), 2.71–2.42 (m, 2 H), 1.76–1.60 (m, 2 H), 1.46–1.30 (m, 4 H), 0.92–0.87 (m, 12 H). MS (ESI): <i>m</i>/<i>z</i> 467.2 (M + 1).</div></div><div id="sec5_1_1_1_4" class="NLM_sec NLM_sec_level_4"><div id="ac_i26" class="anchor-spacer"></div><h5 class="article-section__title" id="_i26">D (3<i>S</i>,6<i>S</i>)-3,6-Diisobutylpiperazin-2-one (<b>7</b>)</h5><div class="NLM_p last">To a solution of <b>6</b> (120 mg, 0.26 mmol) in DCM (1.6 mL) was added diethyl amine (0.4 mL, 3.86 mmol 20% in DCM) at rt under nitrogen and stirred overnight. The reaction mixture was concentrated in vacuo, and the crude product was purified by column chromatography (0–25% EtOAc in hexanes) to afford <b>7</b> (52 mg, 95% yield) as a white solid. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 5.83 (s, 1 H), 3.47–3.39 (m, 2 H), 3.02–2.98 (m, 1 H), 2.79–2.74 (m, 1 H), 1.80–1.54 (m, 4 H), 1.45–1.31 (m, 2 H), 0.96–0.90 (m, 12 H). MS (ESI): <i>m</i>/<i>z</i> 213.1 (M + 1).</div></div></div><div id="sec5_1_1_2" class="NLM_sec NLM_sec_level_3"><div id="ac_i27" class="anchor-spacer"></div><h4 class="article-section__title" id="_i27"> (3<i>S</i>,6<i>S</i>)-3,6-Diisobutyl-4-((1<i>R</i>,2<i>R</i>)-2-phenylcyclopropanecarbonyl)piperazin-2-one (<b>2a</b>) and (3<i>S</i>,6<i>S</i>)-3,6-Diisobutyl-4-((1<i>S</i>,2<i>S</i>)-2-phenylcyclopropanecarbonyl)piperazin-2-one (<b>2b</b>)</h4><div class="NLM_p last">To a well dried (±)-(1<i>R</i>,2<i>R</i>)-2-phenylcyclopropanecarboxylic acid (53.5 mg, 0.33 mmol), TBTU (127.5 mg, 0.396 mmol), and <b>7</b> (70 mg, 0.33 mmol) was added MeCN (3 mL) followed by DIPEA (0.17 mL, 0.99 mmol) dropwise (5 min) and stirred at rt for 3 h. The reaction mixture was concentrated in vacuo, and the crude residue was dissolved in EtOAc (25 mL) and washed sequentially with 1 M aqueous HCl (15 mL × 2), 1 M aqueous NaHCO<sub>3</sub> (15 mL × 2), and brine (20 mL). The solution was dried over Na<sub>2</sub>SO<sub>4</sub> and concentrated in vacuo, and the crude product was purified by column chromatography (0–60% EtOAc in hexanes) to afford a mixture of products <b>2a</b> and <b>2b</b> (105.8 mg, 90% yield). The product mixture (<b>2a</b> and <b>2b</b>) was separated by SFC (chiral) column to furnish <b>2a</b> (30 mg, 25% yield) as a white solid. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 7.50 (s, 1 H), 3.23–3.26 (m, 1 H), 3.07 (dd, <i>J</i> = 9.6 Hz, 3.6 Hz,1 H), 2.80 (dd, <i>J</i> = 12.8 Hz, 4.4 Hz, 1 H), 2.58 (dd, <i>J</i> = 13.2 Hz, 5.2 Hz, 1 H), 2.36 (s, 1 H), 1.74–1.78 (m, 1 H), 1.59–1.65 (m, 1 H),1.28–1.48 (m, 4 H), 0.80–0.89 (m, 12 H). MS (ESI): <i>m</i>/<i>z</i> 213.1 (M + 1). Compound <b>2b</b> (29 mg, 25% yield, white solid): <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 7.50 (s, 1 H), 3.23–3.26 (m, 1 H), 3.07 (dd, <i>J</i> = 9.6 Hz, 3.6 Hz,1 H), 2.80 (dd, <i>J</i> = 12.8 Hz, 4.4 Hz, 1 H), 2.58 (dd, <i>J</i> = 13.2 Hz, 5.2 Hz, 1 H), 2.36 (s, 1 H), 1.74–1.78 (m, 1 H), 1.59–1.65(m, 1 H),1.28–1.48 (m, 4 H), 0.80–0.89 (m, 12 H). MS (ESI): <i>m</i>/<i>z</i> 213.1 (M + 1).</div></div><div id="sec5_1_1_3" class="NLM_sec NLM_sec_level_3"><div id="ac_i28" class="anchor-spacer"></div><h4 class="article-section__title" id="_i28"> (3<i>S</i>,6<i>R</i>)-6-(Furan-2-yl)-3-isobutylpiperazin-2-one (<b>12</b>) and (3<i>S</i>,6<i>S</i>)-6-(Furan-2-yl)-3-isobutylpipera-zin-2-one (<b>13</b>)</h4><div id="sec5_1_1_3_1" class="NLM_sec NLM_sec_level_4"><div id="ac_i29" class="anchor-spacer"></div><h5 class="article-section__title" id="_i29">A 2-((Bis(4-methoxyphenyl)methyl)amino)-2-(furan-2-yl)acetic Acid (<b>9</b>)</h5><div class="NLM_p last">To a stirred solution of glyoxylic acid monohydrate (920 mg, 10.11 mmol) in DCM (70 mL) were added bis(4-methoxyphenyl)methanamine (2.46 g, 10.11 mmol) and 2-furanboronic acid (1.13 g, 10.11 mmol), and the reaction mixture was stirred at rt for 2 min to form clear solution. The solution was purged with argon (2 min), and the sealed reaction mixture was stirred for overnight. The reaction mixture was concentrated in vacuo to afford compound <b>9</b> (3.5 g, 94% yield) as pale-yellow foam. The crude product was used for the next step without further purification. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 7.31 (s, 1 H), 7.27–7.24 (m, 4 H), 6.81–6.79 (m, 4 H), 6.28 (br s, 1 H), 6.24 (br s, 1 H), 4.80 (s, 1 H), 4.44 (s, 1 H) 3.76 (s, 3 H), 3.75 (s, 3 H) 3.70 (s, 1 H). MS (ESI): <i>m</i>/<i>z</i> 368.0 (M + 1).</div></div><div id="sec5_1_1_3_2" class="NLM_sec NLM_sec_level_4"><div id="ac_i30" class="anchor-spacer"></div><h5 class="article-section__title" id="_i30">B 2-((Bis(4-methoxyphenyl)methyl)amino)-2-(furan-2-yl)-<i>N</i>-methoxy-<i>N</i>-methyl-acetamide (<b>10</b>)</h5><div class="NLM_p last">To a mixture of <b>9</b> (0.5 g, 1.36 mmol), TBTU (0.66 g, 2.04 mmol), and <i>N</i>,<i>O</i>-dimethylhydroxylamine hydrochloride (0.2 g, 2.04 mmol) in dry MeCN (6 mL), DIPEA (710 uL, 4.08 mmol) was added and stirred at rt for 4 h. The reaction mixture was concentrated in vacuo, and the crude product was purified by column chromatography (0–40% EtOAc in hexanes) to afford compound <b>10</b> (520 mg, 93% yield) as a white foam. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 7.37 (s, 1 H), 7.34–7.25 (m, 4 H), 6.85–6.79 (m, 4 H), 6.33–6.32 (m, 1 H), 6.22 (d, <i>J</i> = 3.2 Hz, 1 H), 4.83 (s, 1 H), 4.68 (s, 1 H) 3.77 (s, 3 H), 3.75 (s, 3 H) 3.28 (s, 3 H), 3.20 (s, 3 H). MS (ESI): <i>m</i>/<i>z</i> 411.1 (M +1).</div></div><div id="sec5_1_1_3_3" class="NLM_sec NLM_sec_level_4"><div id="ac_i31" class="anchor-spacer"></div><h5 class="article-section__title" id="_i31">C (2<i>S</i>)-Methyl 2-((2-((Bis(4-methoxyphenyl)methyl)amino)-2-(furan-2-yl)ethyl)amino)-4-methyl-pentanoate (<b>11</b>)</h5><div class="NLM_p last">To a solution of compound <b>10</b> (0.2 g, 1.22 mmol) in dry THF (3 mL) at −78 °C, LiAlH<sub>4</sub> (40 mg, 0.97 mmol) was added and stirred at −78 °C under argon for 3 h. The reaction mixture was quenched with saturated aqueous NH<sub>4</sub>Cl solution (2 mL) by dropwise addition. This mixture was partitioned between EtOAc and brine (1:1, 50 mL) and extracted with EtOAc (50 mL). The organic layers were combined and washed with brine, dried over MgSO<sub>4</sub>, and concentrated in vacuo. The crude aldehyde intermediate was used for the next step without further purification. To a solution of aldehyde (0.4 g, 1.14 mmol) and HCl salt of Leu-OMe (210 mg, 1.14 mmol) in DCM (8 mL), NaBH(OAc)<sub>3</sub> (340 mg, 1.59 mmol) was added and the mixture was stirred at rt under argon for 6 h. The reaction mixture was quenched with saturated aqueous NaHCO<sub>3</sub> solution (30 mL), and the aqueous solution was extracted with EtOAc (30 mL), dried over Na<sub>2</sub>SO<sub>4</sub>, and concentrated in vacuo. The crude product was purified by column chromatography (0–40% EtOAc in hexanes) to afford compound <b>11</b> (0.27 g, 49% yield) as a pale-yellow oil. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 7.37–7.36 (m, 1 H), 7.30–7.17 (m, 4 H), 6.85–6.76 (m, 4 H), 6.32–6.31 (m, 1 H), 6.16–6.11 (m, 1 H), 4.64 (d, <i>J</i> = 5.2 Hz, 1 H), 3.78–3.67 (m, 7 H) 3.28–3.20 (m, 1 H), 2.94–2.88 (m, 1 H) 2.75–2.66 (m, 1 H), 1.96 (s, 1 H), 1.70–1.64 (m, 1 H), 1.48–1.40 (m, 2 H), 0.94–0.86 (m, 6 H). MS (ESI): <i>m</i>/<i>z</i> 481.1 (M + 1).</div></div><div id="sec5_1_1_3_4" class="NLM_sec NLM_sec_level_4"><div id="ac_i32" class="anchor-spacer"></div><h5 class="article-section__title" id="_i32">D (3<i>S</i>,6<i>R</i>)-6-(Furan-2-yl)-3-isobutylpiperazin-2-one (<b>12</b>) and (3<i>S</i>,6<i>S</i>)-6-(Furan-2-yl)-3-isobutylpiperazin-2-one (<b>13</b>)</h5><div class="NLM_p last">Compound <b>11</b> (0.4 g, 0.84 mmol) was dissolved in 70% aqueous AcOH (5 mL) and heated under reflux for 3 h. The reaction mixture was concentrated in vacuo, and the crude product was purified by column chromatography (20–60% EtOAc in hexanes) to afford compounds <b>12</b> (85 mg, 40% yield) and <b>13</b> (75 mg, 35% yield). Compound <b>12</b>: <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 7.39–7.38 (m, 1H), 6.40 (s, 1H), 6.45–6.34 (m, 1H), 6.26–6.25 (m, 1H), 4.63–4.61 (m, 1H), 3.46–3.43 (m, 1H), 3.24–3.23 (m, 2H), 1.91 (s, 1H), 1.89–1.79 (m, 2H), 1.53–1.47 (m, 1H) 0.95–0.82 (m, 6H). MS (ESI): <i>m</i>/<i>z</i> 223.0 (M + 1). Compound <b>13</b>: <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 7.38–7.37 (m, 1H), 6.34–6.33 (m, 1H), 6.26–6.25 (m, 1H), 6.07 (s, 1H), 4.68 (m, 1H), 3.75 (d, <i>J</i> = 7.2 Hz, 1H), 3.47–3.43 (m, 1H), 3.40–3.35 (m, 2H), 3.06–3.01 (m, 1H), 1.89–1.78 (m, 2H), 1.60–1.54 (m, 1H) 0.97–0.92 (m, 6H). MS (ESI): <i>m</i>/<i>z</i> 223.0 (M + 1).</div></div></div><div id="sec5_1_1_4" class="NLM_sec NLM_sec_level_3"><div id="ac_i33" class="anchor-spacer"></div><h4 class="article-section__title" id="_i33"> (3<i>S</i>,6<i>R</i>)-6-(<i>tert</i>-Butoxymethyl)-3-isobutylpiperazin-2-one (<b>14</b>)</h4><div class="NLM_p last">Synthesized from FMOC-<span class="smallcaps smallerCapital">l</span>-Ser-O<sup>t</sup>Bu (42.0 g, 0.114 mol) and HCl salt of Leu-OMe (21.0 g, 0.115 mol) by the method described for the compound <b>7</b> (Scheme <a class="ref internalNav" href="#sch1" aria-label="1">1</a>) to afford <b>14</b> (4.2 g, 5.7% yield) as a colorless gum. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 7.38–7.37 (m, 1 H), 3.35–3.39 (m, 1 H), 3.21–3.32 (m, 2 H), 3.03–3.06 (m, 1 H), 2.77–2.84 (m, 2 H), 1.72–174 (m, 1 H), 1.56 −1.57 (m, 1 H), 1.34–1.33 (m, 1 H), 1.121–1.126 (m, 9 H) and 0.82–0.88 (m, 6 H). MS (ESI): <i>m</i>/<i>z</i> 243.2 (M + 1).</div></div><div id="sec5_1_1_5" class="NLM_sec NLM_sec_level_3"><div id="ac_i34" class="anchor-spacer"></div><h4 class="article-section__title" id="_i34"> (2<i>S</i>,5<i>R</i>)-<i>tert</i>-Butyl 5-(Hydroxymethyl)-2-isobutyl-3-oxopiperazine-1-carboxylate (<b>15</b>)</h4><div class="NLM_p last">Compound <b>14</b> (2.00 g, 8.25 mmol) and HCl in dioxane (4 N, 20 mL) were stirred at 70 °C for 1.5 h. The reaction mixture was concentrated in vacuo, and the crude compound was dissolved in DMF/DCM (2:1, 30 mL) and DIPEA (3.5 mL) was added followed by BOC-anhydride (1.60 mL, 6.96 mmol) in DCM (5 mL). After 5 h stirring, the reaction mixture was concentrated in vacuo, and the oily residue was partioned in EtOAc (15 mL) and water (15 mL). The organic layer was separated and washed with brine, dried (MgSO<sub>4</sub>), concentrated in vacuo, and purified by column chromatography (0–90% EtOAc in hexanes) to give <b>15</b> (2.06 g, 87% yield) as a white solid. <sup>1</sup>H NMR (DMSO-<i>d</i><sub>6</sub>) δ 7.69 (s, 1 H), 4.88 (t, <i>J</i> = 5.6 Hz, 1 H), 4.40–4.22 (m, 1 H), 4.11–3.90 (m, 1 H), 3.44–3.24 (m, 2 H), 2.90–2.76 (m, 2 H), 1.65–1.56 (m, 2 H), 1.51–1.46 (m, 1 H), 1.41 (s, 9 H), 0.91 (m, 6 H). MS (ESI): <i>m</i>/<i>z</i> 287.2 (M + 1).</div></div><div id="sec5_1_1_6" class="NLM_sec NLM_sec_level_3"><div id="ac_i35" class="anchor-spacer"></div><h4 class="article-section__title" id="_i35"> (2<i>S</i>,5<i>R</i>)-<i>tert</i>-Butyl 2-Isobutyl-5-(oxazol-5-yl)-3-oxopiperazine-1-carboxylate (<b>16</b>)</h4><div class="NLM_p last">To a solution of the alcohol <b>15</b> (0.50 g, 1.75 mmol) in DCM (25 mL) at 0 °C was added Dess–Martin reagent (0.965 g, 4.55 mmol) and water (0.5 mL). Reaction mixture was warmed to rt and stirred for 6 h. Then, <i>i</i>-PrOH (0.3 mL) was added and the mixture was stirred for 15 min followed by saturated aqueous sodium thiosulfate (10 mL) and saturated aqueous NaHCO3 (10 mL) were added. Organic layer was separated, and the aqueous layer was extracted with EtOAc (2 × 5 mL). Combined organic layers were washed with brine, dried (MgSO<sub>4</sub>), and concentrated to give the aldehyde product. To the crude aldehyde in MeOH (20 mL) was added tosylmethyl isocyanide (480 mg, 2.46 mmol) and K<sub>2</sub>CO<sub>3</sub> (483 mg, 3.50 mmol) and was stirred at 70 °C for 1 h. The reaction mixture was concentrated in vacuo, and EtOAc (30 mL) and water (20 mL) were added. Organic layer was separated, and the aqueous layer was extracted with EtOAc (20 mL × 2). Combined organic layers were washed with brine, dried (MgSO<sub>4</sub>), concentrated in vacuo, and purified by column chromatography (0–95% EtOAc in hexanes) to give <b>16</b> (78 mg, 14% yield) as a white solid. <sup>1</sup>H NMR (CDCl<sub>3</sub>) δ 7.90 (s, 1 H), 7.08 (s, 1 H), 5.93 (br s, 1 H), 4.88–4.84 (m, 1 H), 4.69–4.64 (m, 1 H), 4.50–4.44 (m, 1 H), 3.18 (t, <i>J</i> = 12.4 Hz, 1 H), 1.78–1.62 (m, 3 H), 1.02 (d, <i>J</i> = 5.6 Hz, 3 H), 0.97 (d, <i>J</i> = 6.0 Hz, 3 H). MS (ESI): <i>m</i>/<i>z</i> 324.1 (M + 1).</div></div><div id="sec5_1_1_7" class="NLM_sec NLM_sec_level_3"><div id="ac_i36" class="anchor-spacer"></div><h4 class="article-section__title" id="_i36"> (2<i>R</i>,5<i>S</i>)-<i>N</i>-(2,2-Dimethoxyethyl)-4-(5-(4-fluorophenyl)isoxazole-3-carbonyl)-5-isobutyl-6-oxopiperazine-2-carboxamide (<b>23</b>)</h4><div id="sec5_1_1_7_1" class="NLM_sec NLM_sec_level_4"><div id="ac_i37" class="anchor-spacer"></div><h5 class="article-section__title" id="_i37">A (<i>S</i>)-(9<i>H</i>-Fluoren-9-yl)methyl (1-Hydroxybut-3-en-2-yl)carbamate (<b>18</b>)</h5><div class="NLM_p last">To a mixture of <b>17</b> (HCl salt, 1g, 8.1 mmol) and a solution of K<sub>2</sub>CO<sub>3</sub> (3.4 g, 24.3 mmol) in water (50 mL) was added a solution of Fmoc-Cl (2.3g, 8.91 mmol) in dioxane (50 mL) at 0 °C and stirred at rt for 3 h. The reaction mixture was extracted with DCM (100 mL × 3) and washed with saturated aqueous NH<sub>4</sub>Cl (50 mL) and brine (50 mL). The organic layer was dried over Na<sub>2</sub>SO<sub>4</sub> and concentrated in vacuo, and the residue was purified by column chromatography (0–30% EtOAC in hexanes) to give <b>18</b> (2.5 g, quantitative) as a white solid. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 7.77 (d, <i>J</i> = 7.6 Hz, 2 H), 7.60 (d, <i>J</i> = 7.6 Hz, 2 H), 7.41 (t, <i>J</i> = 7.6 Hz, 2 H), 7.32 (t, <i>J</i> = 7.6 Hz, 2 H), 5.89–5.74 (m, 1 H), 5.25 (d, <i>J</i> = 12.4 Hz, 2 H), 5.12 (s, 1 H), 4.45 (d, <i>J</i> = 6.8 Hz, 2 H), 4.40–4.26 (m, 1 H), 4.22 (t, <i>J</i> = 6.8 Hz, 1 H), 3.78–3.61(m, 2 H), 1.93(s, 1 H). MS (ESI): <i>m</i>/<i>z</i> 310.0 (M + 1).</div></div><div id="sec5_1_1_7_2" class="NLM_sec NLM_sec_level_4"><div id="ac_i38" class="anchor-spacer"></div><h5 class="article-section__title" id="_i38">B (<i>S</i>)-Methyl 2-(((<i>S</i>)-2-((((9<i>H</i>-Fluoren-9-yl)methoxy)carbonyl)amino)but-3-en-1-yl)amino)-4-methyl-pentanoate (<b>19</b>)</h5><div class="NLM_p last">To a solution of <b>18</b> (1.85 g, 6 mmol) in anhydrous DCM (30 mL) was added Dess–Martin’s reagent (5.33 g, 12.6 mmol) and stirred at rt for 1 h. The reaction mixture was diluted with ether (21 mL), and a solution of sodium thiosulfate (10.43 g, 66 mmol) in saturated aqueous NaHCO<sub>3</sub> (20 mL) was added. The reaction mixture was stirred for 10 min, the layers were separated, and the aqueous layer was extracted with ether (50 mL × 3). The combined organic layers were washed with saturated aqueous NaHCO<sub>3</sub> (10 mL), water (10 mL), and brine (10 mL) and then dried over Na<sub>2</sub>SO<sub>4</sub> and concentrated in vacuo to furnish the crude aldehyde (1.8g, quantitative), which was used for the next step without further purification. MS (ESI): <i>m</i>/<i>z</i> 308.0 (M + 1). To a solution of the crude aldehyde (1.842 g, 6 mmol) in THF (20 mL) was added HCl salt of Leu-OMe (1.2 g, 6.6 mmol) and NaBH(OAc)<sub>3</sub> (1.9 g, 9 mmol) and stirred at rt overnight. The reaction mixture was quenched with saturated aqueous NaHCO<sub>3</sub> (20 mL) and extracted with EtOAc (100 mL × 3). The combined organic layers were dried over anhydrous Na<sub>2</sub>SO<sub>4</sub> and concentrated in vacuo, and the residue was purified by column chromatography (10–50% EtOAC in hexanes) to give <b>19</b> (1.1 g, 42% yield) as a pale-brown solid. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 9.25(s, 1 H), 7.78–7.75 (m, 2 H), 7.62–7.60 (m, 2 H), 7.41(t, <i>J</i> = 7.6 Hz, 2 H), 7.43–7.38 (m, 2 H), 7.34–7.29 (m, 2 H), 5.81–5.74 (m, 1 H), 5.24–5.17 (m, 2 H), 4.46–4.39 (m, 3 H), 4.27–4.21 (m, 2 H), 3.71 (s, 3 H), 3.30 (t, <i>J</i> = 7 Hz, 1 H), 1.87–1.67 (m, 3 H), 0.98–0.87 (m, 6 H). MS (ESI): <i>m</i>/<i>z</i> 437.3 (M + 1).</div></div><div id="sec5_1_1_7_3" class="NLM_sec NLM_sec_level_4"><div id="ac_i39" class="anchor-spacer"></div><h5 class="article-section__title" id="_i39">C (3<i>S</i>,6<i>S</i>)-3-Isobutyl-6-vinylpiperazin-2-one (<b>20</b>)</h5><div class="NLM_p last">To a solution of <b>19</b> (0.55 g, 1.26 mmol) in EtOH (6 mL) was added diethylamine (4 mL) at rt and heated at 60 °C overnight. The reaction mixture concentrated in vacuo, and the residue was purified by column chromatography (10–40% EtOAC in hexanes) to give <b>20</b> (92 mg, 42% yield) as a colorless solid. <sup>1</sup>H NMR (400 MHz, CD<sub>3</sub>OD) δ 5.93–5.85 (m, 1 H), 5.26–5.21 (m, 2 H), 4.03–3.95 (m, 1 H), 3.34–3.29 (m, 1 H), 3.02 (dd, <i>J</i> = 13.4 Hz, 4.8 Hz, 1 H), 2.85 (dd, <i>J</i> = 13.4 Hz, 4.8 Hz, 1 H), 1.88–1.80 (m, 1 H), 1.72–1.64 (m, 1 H), 1.55–1.48 (m, 1 H), 0.95(d, <i>J</i> = 6.4 Hz, 3 H), 0.92 (d, <i>J</i> = 6.4 Hz, 3 H). MS (ESI): <i>m</i>/<i>z</i> 183.0 (M + 1).</div></div><div id="sec5_1_1_7_4" class="NLM_sec NLM_sec_level_4"><div id="ac_i40" class="anchor-spacer"></div><h5 class="article-section__title" id="_i40">D (3<i>S</i>,6<i>S</i>)-4-(5-(4-Fluorophenyl)isoxazole-3-carbonyl)-3-isobutyl-6-vinylpiperazin-2-one (<b>21</b>)</h5><div class="NLM_p last">A mixture of <b>20</b> (61.9 mg, 0.34 mmol), 5-(4-fluorophenyl)-isoxazole-3-carboxylic acid (84.4 mg, 0.41 mmol), HOBT hydrate (65.1 mg, 0.425 mmol), EDC (78.2 mg, 0.41 mmol), and DIPEA (0.12 mL, 0.68 mmol) in MeCN (5 mL) were stirred at rt overnight. The reaction mixture was concentrated in vacuo, and the residue was purified by column chromatography (0–60% EtOAC in hexanes) to give <b>21</b> (37.5 mg, 30% yield) as a brown solid. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 7.80–7.77 (m, 2 H), 7.21–7.15 (m, 2 H), 6.87 (s, 1 H), 6.20 (s, 1 H), 5.76–5.68 (m, 1 H), 5.43 (d, <i>J</i> = 17.2 Hz, 1 H), 5.32 (d, <i>J</i> = 10.0 Hz, 1 H), 5.36–5.27 (m, 1 H), 4.88–4.82 (m, 1 H), 4.28–4.21 (m, 1 H), 3.21(dd, <i>J</i> = 14.0 Hz, 11.0 Hz, 1H), 1.92–1.67 (m, 3 H), 1.07 (d, <i>J</i> = 6.4 Hz, 3 H), 0.98 (d, <i>J</i> = 6.4 Hz, 3 H). MS (ESI): <i>m</i>/<i>z</i> 372.1 (M + 1).</div></div><div id="sec5_1_1_7_5" class="NLM_sec NLM_sec_level_4"><div id="ac_i41" class="anchor-spacer"></div><h5 class="article-section__title" id="_i41">E (2<i>R</i>,5<i>S</i>)-4-(5-(4-Fluorophenyl)isoxazole-3-carbonyl)-5-isobutyl-6-oxopipera-zine-2-carboxylic Acid (<b>22</b>)</h5><div class="NLM_p last">To a solution of <b>21</b> (92.9 mg, 0.25 mmol) in DMF (5 mL) was added OsO<sub>4</sub> (2.5% in <i>t</i>-BuOH, 0.03 mL, 0.0025 mmol) and stirred at rt for 5 min ,and then oxone (614.8 mg, 1 mmol) was added and stirred at rt for 3 h. Na<sub>2</sub>SO<sub>3</sub> (189 mg, 1.5 mmol) was added to the reaction mixture and stirred for 1 h, and then EtOAc (20 mL) and 1N aqueous HCl (20 mL) were added. The organic layer was separated, washed with 1N aqueous HCl (10 mL × 2) and brine (20 mL), dried over Na<sub>2</sub>SO<sub>4</sub>, and concentrated in vacuo. The residue was purified by column chromatography (0–10% MeOH in DCM) to give <b>22</b> (58.4 mg, 60% yield) as a brown solid. <sup>1</sup>H NMR (400 MHz, CD<sub>3</sub>OD) δ 7.95–7.91 (m, 2 H), 7.30–7.25 (m, 2 H), 7.05(s, 1 H), 5.16 (dd, <i>J</i> = 10.0 Hz, 4.0 Hz, 1 H), 4.78–4.70 (m, 1 H), 4.18–4.10 (m, 1 H), 3.49–3.43 (m, 1 H), 1.89–1.68 (m, 3 H), 1.06 (d, <i>J</i> = 6.0 Hz, 3 H), 0.99 (d, <i>J</i> = 6.0 Hz, 3 H). MS (ESI): <i>m</i>/<i>z</i> 390.0 (M + 1).</div></div><div id="sec5_1_1_7_6" class="NLM_sec NLM_sec_level_4"><div id="ac_i42" class="anchor-spacer"></div><h5 class="article-section__title" id="_i42">F (2<i>R</i>,5<i>S</i>)-<i>N</i>-(2,2-Dimethoxyethyl)-4-(5-(4-fluorophenyl)isoxazole-3-carbonyl)-5-isobutyl-6-oxopiperazine-2-carboxamide (<b>23</b>)</h5><div class="NLM_p last">Compound <b>22</b> (96 mg, 0.25 mmol) and 2,2-dimethoxy-ethylamine (0.03 mL, 0.3 mmol) were coupled (96 mg, 0.25 mmol) according to the method described for the preparation of compound <b>21</b> to give <b>23</b> (60 mg, 50% yield) as a pale-yellow gum. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 7.81–7.77 (m, 2 H), 7.22–7.17 (m, 2 H), 6.91 (s, 1 H), 6.60 (s, 1 H), 6.32 (t, <i>J</i> = 5.6 Hz, 1 H), 5.29–5.26 (m, 1 H), 5.11 (dd, <i>J</i> = 14.0 Hz, 4.0 Hz, 1 H), 4.43–4.38 (m, 3 H), 3.50–3.36 (m, 8 H), 1.93–1.65 (m, 3 H), 1.08 (d, <i>J</i> = 6.4 Hz, 3 H), 0.98 (d, <i>J</i> = 6.4 Hz, 3 H). MS (ESI): <i>m</i>/<i>z</i> 477.1 (M + 1).</div></div></div><div id="sec5_1_1_8" class="NLM_sec NLM_sec_level_3"><div id="ac_i43" class="anchor-spacer"></div><h4 class="article-section__title" id="_i43"> (3<i>S</i>,6<i>S</i>)-3,6-Diisobutyl-1-methyl-4-((1<i>R</i>,2<i>R</i>)-2-phenylcyclopropanecarbonyl)piperazin-2-one (<b>27</b>)</h4><div class="NLM_p last">To a mixture of <b>2a</b> (100 mg, 0.281 mmol) and BMAP (0.5 mL, 1.800 mmol) in DCM (25 mL) were added iodomethane (2700 mg, 19.005 mmol) stirred at rt for 36 h. The reaction mixture was washed with water (15 mL × 2) and dried over MgSO<sub>4</sub>, and the organic layers were concentrated in vacuo. The residue was purified by pre-HPLC under basic conditions to afford <b>27</b> (12 mg, 12% yield) as a white solid. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 7.09 −7.21 (m, 3 H), 6.96–7.00 (m, 2 H), 4.50–4.77 (m, 2 H), 3.00–3.50 (m, 1 H), 2.63–2.80 (m, 1 H), 2.30–2.43 (m, 1 H), 1.81–1.96 (m, 1 H), 1.07–1.75 (m, 10 H), 0.70–0.97 (m, 9 H), 0.47–0.55 (m, 3 H). MS (ESI): <i>m</i>/<i>z</i> 371.2 (M + 1).</div></div><div id="sec5_1_1_9" class="NLM_sec NLM_sec_level_3"><div id="ac_i44" class="anchor-spacer"></div><h4 class="article-section__title" id="_i44"> ((2<i>S</i>,5<i>S</i>)-2,5-Diisobutylpiperazin-1-yl)((1<i>R</i>,2<i>R</i>)-2-phenylcyclopropyl)methanone (<b>28</b>)</h4><div class="NLM_p last">To a solution of compound <b>7</b> (300 mg, 1.41 mmol) in THF (30 mL) was added LiAlH<sub>4</sub> (107 mg, 2.82 mmol) at −40 °C and the mixture was stirred for 6 h. The reaction mixture was quenched with water, filtered, extracted withed EtOAc (50 mL), dried over Na<sub>2</sub>SO<sub>4</sub>, and concentrated in vacuo to give the decarbonylated compound (200 mg, 72% yield), which was used for the next reaction without further purification. The decarbonylated compound (200 mg, 1.01 mmol) was coupled to (1<i>R</i>,2<i>R</i>)-2-phenylcyclopropanecarboxylic acid (164 mg, 1.01 mmol) according to the method described for compound <b>2a</b> to give compound <b>28</b> (110 mg, 28% yield) as a white solid. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 7.24–7.30 (m, 2 H), 7.16–7.22 (m, 1 H), 7.06–7.10 (m, 2 H), 4.54–4.58 (m, 1 H), 3.84–3.88 (m, 1 H), 3.03–3.14 (m, 3 H), 2.78–2.86 (m, 1 H), 2.36–2.45 (m, 1 H), 1.87–1.95 (m, 1 H), 1.71–1.74 (m, 2 H), 1.27–1.51 (m, 6 H), 0.91–0.96 (m, 6 H), 0.63–0.82 (m, 6 H). MS (ESI): <i>m</i>/<i>z</i> 343.1 (M + 1).</div></div><div id="sec5_1_1_10" class="NLM_sec NLM_sec_level_3"><div id="ac_i45" class="anchor-spacer"></div><h4 class="article-section__title" id="_i45"> (3<i>R</i>,6<i>S</i>)-3,6-Diisobutyl-4-((1<i>R</i>,2<i>R</i>)-2-phenylcyclopropanecarbonyl)piperazin-2-one (<b>29</b>)</h4><div class="NLM_p last">Compound <b>29</b> was synthesized from Fmoc-Leu and <span class="smallcaps smallerCapital">d</span>-Leu-OMe according to the reaction sequence outlined in Scheme <a class="ref internalNav" href="#sch1" aria-label="1">1</a> for compound <b>2a</b>. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 7.25–7.29 (m, 2 H), 7.19–7.21 (m, 1 H), 7.05–7.08 (m, 2 H), 6.48–6.63 (m, 1 H), 5.17–5.21 (m, 0.5 H), 4.54–4.57 (m, 0.5 H), 4.39–4.42 (m, 0.5 H), 3.79–3.82 (m, 0.5 H), 3.65–3.69 (m, 0.5 H), 3.41–3.50 (m, 1 H), 3.22–3.27 (m, 0.5 H), 2.43–2.50 (m, 3 H), 1.89–1.92 (m, 1 H), 1.63–1.75 (m, 4 H), 1.33–1.49 (m, 3 H), 0.90–1.02 (m, 6 H), 0.58–0.80 (m, 6 H). MS (ESI): <i>m</i>/<i>z</i> 357.1 (M + 1).</div></div><div id="sec5_1_1_11" class="NLM_sec NLM_sec_level_3"><div id="ac_i46" class="anchor-spacer"></div><h4 class="article-section__title" id="_i46"> (3<i>S</i>,6<i>R</i>)-3,6-Diisobutyl-4-((1<i>R</i>,2<i>R</i>)-2-phenylcyclopropanecarbonyl)piperazin-2-one (<b>30</b>)</h4><div class="NLM_p last">Compound <b>30</b> was synthesized from Fmoc-<span class="smallcaps smallerCapital">d</span>-leu and Leu-OMe according to the reaction sequence outlined in Scheme <a class="ref internalNav" href="#sch1" aria-label="1">1</a> for compound <b>2a</b>. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 7.26–7.30 (m, 2 H), 7.20–7.23 (m, 1 H), 7.06–7.12 (m, 2 H), 6.44–6.60 (m, 0.5 H), 5.13–5.17 (m, 0.5 H), 4.53–4.56 (m, 0.5 H), 4.39–4.42 (m, 0.5 H), 3.82–3.85 (m, 0.5 H), 3.61–3.66 (m, 0.5 H), 3.48–3.49 (m, 1 H), 3.19–3.23 (m, 0.5 H), 2.55–2.57 (m, 1 H), 1.94–1.97 (m, 0.5 H), 1.83–1.91 (m, 2.5 H), 1.63–1.71 (m, 4 H), 1.30–1.52 (m, 3 H), 0.92–1.01 (m, 12 H). MS (ESI): <i>m</i>/<i>z</i> 357.1 (M + 1).</div></div><div id="sec5_1_1_12" class="NLM_sec NLM_sec_level_3"><div id="ac_i47" class="anchor-spacer"></div><h4 class="article-section__title" id="_i47"> (3<i>S</i>,6<i>S</i>)-6-Ethyl-3-isobutyl-4-((1<i>R</i>,2<i>R</i>)-2-phenylcyclopropanecarbonyl)piperazin-2-one (<b>31</b>)</h4><div class="NLM_p last">Compound <b>31</b> was synthesized from Fmoc-Ala and Leu-OMe according to the reaction sequence outlined in Scheme <a class="ref internalNav" href="#sch1" aria-label="1">1</a> for compound <b>2a</b>. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 7.32–7.05 (m, 5 H), 5.97 (s, 1 H), 5.22–4.71 (m, 1 H), 4.58–4.06 (m, 1 H), 3.50–3.39 (m, 1 H), 3.12–2.60 (m, 1 H), 2.56–2.51 (m, 1 H), 1.95–1.91 (m, 1 H), 1.86–1.72 (m, 2 H), 1.70–1.58 9m, 2 H), 1.56–1.45 (m, 2 H), 1.33–1.28 (m, 1 H), 1.02–0.93 (m, 9 H). MS (ESI): <i>m</i>/<i>z</i> 329.20 (M – 1).</div></div><div id="sec5_1_1_13" class="NLM_sec NLM_sec_level_3"><div id="ac_i48" class="anchor-spacer"></div><h4 class="article-section__title" id="_i48"> (3<i>S</i>,6<i>S</i>)-3-Ethyl-6-isobutyl-4-((1<i>R</i>,2<i>R</i>)-2-phenylcyclopropanecarbonyl)piperazin-2-one (<b>32</b>)</h4><div class="NLM_p last">Compound <b>32</b> was synthesized from Leu-OMe and Fmoc-Ala according to the reaction sequence outlined in Scheme <a class="ref internalNav" href="#sch1" aria-label="1">1</a> for compound <b>2a</b>. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 7.10–7.40 (m, 5 H), 5.90 (s, 1 H), 5.05–5.15 (m, 0.3 H), 4.70–4.80 (m, 0.7 H), 4.45–4.55 (m, 0.7 H), 4.05–4.15 (m, 0.3 H), 3.50–3.65 (m, 1 H), 2.45–2.55 (m, 2 H), 0.90–2.20 (m, 17 H). MS(ESI): <i>m</i>/<i>z</i> 328.9 (M + 1)].</div></div><div id="sec5_1_1_14" class="NLM_sec NLM_sec_level_3"><div id="ac_i49" class="anchor-spacer"></div><h4 class="article-section__title" id="_i49"> (3<i>S</i>,6<i>S</i>)-6-((<i>S</i>)-<i>sec</i>-Butyl)-3-isobutyl-4-((1<i>R</i>,2<i>R</i>)-2-phenylcyclopropanecarbonyl)piperazin-2-one (<b>33</b>)</h4><div class="NLM_p last">Compound <b>33</b> was synthesized from (2<i>S</i>,3<i>R</i>)-2((((9<i>H</i>-fluoren-9-yl)methoxy)carbonyl)amino)-3-methylpentanoic acid and Leu-OMe according to the reaction sequence outlined in Scheme <a class="ref internalNav" href="#sch1" aria-label="1">1</a> for compound <b>2a</b>. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 7.05–7.30 (m, 5 H), 5.90–6.05 (m, 1H), 4.40–4.65 (m, 1 H), 4.05–4.15 (m, 0.5 H), 3.55–3.65 (m, 0.5 H), 3.15–3.25 (m, 2 H), 2.50–2.65 (m, 1 H), 0.85–1.95 (m, 20 H). MS (ESI): <i>m</i>/<i>z</i> 357.1 (M + 1).</div></div><div id="sec5_1_1_15" class="NLM_sec NLM_sec_level_3"><div id="ac_i50" class="anchor-spacer"></div><h4 class="article-section__title" id="_i50"> (3<i>S</i>,6<i>S</i>)-3-Isobutyl-4-((1<i>R</i>,2<i>R</i>)-2-phenylcyclopropanecarbonyl)-6-propylpiperazin-2-one (<b>34</b>)</h4><div class="NLM_p last">Compound <b>34</b> was synthesized from (<i>S</i>)-2-((((9<i>H</i>-fluoren-9-yl)methoxy)carbonyl)amino)pentanoic acid and Leu-OMe according to the reaction sequence outlined in Scheme <a class="ref internalNav" href="#sch1" aria-label="1">1</a> for compound <b>2a</b>. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 7.32–7.05 (m, 5 H), 6.29 (m, 1 H), 5.21–4.70 (m, 1 H), 4.57–4.04 (m, 1 H), 3.56–3.48 (m, 1 H), 3.12–2.60 (m, 1 H), 2.56–2.51 (m, 1 H), 2.12–2.05 (m, 1 H), 1.94–1.58 (m, 5 H), 1.49–1.28 (m, 4 H), 1.01–0.92 (m, 9 H). MS (ESI): <i>m</i>/<i>z</i> 343.1 (M + 1).</div></div><div id="sec5_1_1_16" class="NLM_sec NLM_sec_level_3"><div id="ac_i51" class="anchor-spacer"></div><h4 class="article-section__title" id="_i51"> (3<i>S</i>,6<i>S</i>)-3,6-Diisobutyl-4-(3-phenylpropioloyl)piperazin-2-one (<b>35</b>)</h4><div class="NLM_p last">Compound <b>7</b> (400 mg, 1.88 mmol) was coupled with 3-phenylpropiolic acid (275 mg, 1.88 mmol) according to the procedure described for the preparation of compound <b>2a</b> (Scheme <a class="ref internalNav" href="#sch1" aria-label="1">1</a>) to give <b>35</b> (195 mg, 30% yield) as a white solid. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 7.51–7.55 (m, 2 H), 7.34–7.45 (m, 3 H), 6.10–6.14 (m, 1 H), 5.08–5.18 (m, 0.5 H), 4.92–5.15 (m, 0.5 H), 4.47–4.70 (m, 1 H), 3.59–3.67 (m, 1 H), 3.11–3.14 (m, 0.5 H), 2.67–2.73 (m, 0.5 H), 1.78–1.86 (m, 2 H), 1.65–1.73 (m, 2 H), 1.34–1.40 (m, 2 H), 0.90–1.06 (m, 12 H). MS (ESI): <i>m</i>/<i>z</i> 341.1 (M + 1).</div></div><div id="sec5_1_1_17" class="NLM_sec NLM_sec_level_3"><div id="ac_i52" class="anchor-spacer"></div><h4 class="article-section__title" id="_i52"> (3<i>S</i>,6<i>S</i>)-4-Cinnamoyl-3,6-diisobutylpiperazin-2-one (<b>36</b>)</h4><div class="NLM_p last">Compound <b>7</b> (200 mg, 0.941 mmol) was coupled with cinnamic acid (139 mg, 0.939 mmol) according to the procedure described for the preparation of compound <b>2a</b> (Scheme <a class="ref internalNav" href="#sch1" aria-label="1">1</a>) to give <b>36</b> (39 mg, 13% yield) as a white solid. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 7.72–7.76 (m, 1 H), 7.46–7.53 (m, 2 H), 7.35–7.42 (m, 3 H), 6.81–6.87 (m, 1 H), 5.82 (s, 1 H), 4.57–4.82 (m, 2 H), 3.59–3.64 (m, 1 H), 2.66–3.16 (m, 1 H), 1.69–1.89 (m, 4 H), 1.32–1.42 (m, 2 H), 1.05–1.10 (m, 3 H), 0.90–1.03 (m, 9H). MS (ESI): <i>m</i>/<i>z</i> 343.1 (M + 1) and 365.1 (M + 23).</div></div><div id="sec5_1_1_18" class="NLM_sec NLM_sec_level_3"><div id="ac_i53" class="anchor-spacer"></div><h4 class="article-section__title" id="_i53"> (3<i>S</i>,6<i>S</i>)-3,6-Diisobutyl-4-((<i>Z</i>)-3-phenylacryloyl)piperazin-2-one (<b>37</b>)</h4><div class="NLM_p last">Compound <b>35</b> (140 mg, 0.41 mmol) in MeOH (15 mL) was added Lindlar-Pd (30 mg), and the mixture was stirred at rt under H<sub>2</sub> (40 psi) for 24 h. The reaction mixture was filtered, concentrated in vacuo, and purified by prep HPLC under basic conditions to afford <b>37</b> (41 mg, 29% yield) as a white solid. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 7.23–7.36 (m, 5 H), 6.67–6.74 (m, 1 H), 6.02(d, <i>J</i> = 2.4 Hz, 1 H), 5.46–5.72 (m, 1 H), 4.65–5.19 (m, 1 H), 3.85–4.26 (m, 1 H), 2.85–3.41 (m, 1 H), 2.50–2.80 (m, 1 H), 1.45–1.72 (m, 4 H), 1.21–1.25 (m, 1 H), 1.05–1.11 (m, 1 H), 0.81–0.90 (m, 9 H), 0.70–0.78 (m, 3 H). MS (ESI): <i>m</i>/<i>z</i> 343.3 (M + 1).</div></div><div id="sec5_1_1_19" class="NLM_sec NLM_sec_level_3"><div id="ac_i54" class="anchor-spacer"></div><h4 class="article-section__title" id="_i54"> (3<i>S</i>,6<i>S</i>)-3,6-Diisobutyl-4-((<i>E</i>)-3-phenylallyl)piperazin-2-one(<b>38</b>)</h4><div class="NLM_p last">To a solution of compound <b>7</b> (150 mg, 0.706 mmol) in DMF (10 mL) was added (<i>E</i>)-(3-chloroprop-en-1-yl)benzene (210 mg, 0.85 mmol) and K<sub>2</sub>CO<sub>3</sub> (97 mg, 0.706 mmol) and stirred at 80 °C for 12 h. The reaction mixture was diluted with water (10 mL) and extracted with EtOAc (15 mL × 3), and the combined organic layers were washed with brine, dried over Na<sub>2</sub>SO<sub>4</sub>, and concentrated in vacuo. The residue was purified by prep HPLC under acidic conditions to give <b>38</b> (63 mg, 27% yield) as a white solid. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 7.58 (s, 1 H), 7.37–7.39 (m, 2 H), 7.27–7.30 (m, 2 H), 7.20–7.21 (m, 1 H), 6.51–6.55 (m, 1 H), 6.22 (m, 1 H), 3.45–3.49 (m, 1 H), 2.87 (m, 1 H), 2.65–2.67 (m, 2 H), 1.80–1.78 (m, 1 H), 1.58–1.60 (m, 2 H), 1.34–1.37 (m, 2 H), 1.19 (s, 3 H) 0.78–0.84 (m, 12 H). MS (ESI): <i>m</i>/<i>z</i> 329.3 (M + 1).</div></div><div id="sec5_1_1_20" class="NLM_sec NLM_sec_level_3"><div id="ac_i55" class="anchor-spacer"></div><h4 class="article-section__title" id="_i55"> (3<i>S</i>,6<i>S</i>)-4-(Cyclopropanecarbonyl)-3,6-diisobutylpiperazin-2-one (<b>39</b>)</h4><div class="NLM_p last">Compound <b>7</b> (200 mg, 0.941 mmol), cyclopropanecarboxylic acid (86 mg, 1.0 mmol), HATU (360 mg, 0.947 mmol), and DIPEA (129 mg, 1.000 mmol) in DCM (15 mL) were stirred at rt for 2 h. The reaction mixture was washed with water (15 mL × 2), dried over MgSO<sub>4</sub>, and concentrated in vacuo. The residue was purified by prep HPLC under basic conditions to afford <b>39</b> (128 mg, 49% yield) as a colorless syrup. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 6.63–6.91 (m, 1 H), 4.17–5.21 (m, 2 H), 3.52–3.65 (m, 1 H), 2.57–3.15 (m, 1 H), 1.59–1.89 (m, 5 H), 1.32–1.41 (m, 2 H), 0.91–1.06 (m, 14 H), 0.82–0.88 (m, 2 H). MS (ESI): <i>m</i>/<i>z</i> 281.2 (M + 1).</div></div><div id="sec5_1_1_21" class="NLM_sec NLM_sec_level_3"><div id="ac_i56" class="anchor-spacer"></div><h4 class="article-section__title" id="_i56"> (3<i>S</i>,6<i>S</i>)-4-([1,1′-Biphenyl]-3-carbonyl)-3,6-diisobutylpiperazin-2-one (<b>40</b>)</h4><div class="NLM_p last">Compound <b>7</b> (100 mg, 0.47 mmol) was coupled with [1,1′-biphenyl]-3-carboxylic acid (112 mg, 0.564 mmol) according to the procedure described for the preparation of compound <b>2a</b> (Scheme <a class="ref internalNav" href="#sch1" aria-label="1">1</a>) to give <b>40</b> (37 mg, 20% yield) as a white solid. <sup>1</sup>H NMR (400 MHz, CD<sub>3</sub>OD) δ 7.77 (d, <i>J</i> = 8.0 Hz, 1 H), 7.67–7.56 (m, 4 H), 7.45–7.36 (m, 4 H), 5.20 (d, <i>J</i> = 8.4 Hz, 1 H), 3.79–3.73 (m, 1 H), 3.62–3.52 (m, 1 H), 3.20–3.14 (m, 1 H), 1.92–1.70 (m, 3 H), 1.45–1.19 (m, 4 H), 1.10–0.96 (m, 6 H), 0.79–0.65 (m, 5 H). MS (ESI): <i>m</i>/<i>z</i> 393.2 (M + 1).</div></div><div id="sec5_1_1_22" class="NLM_sec NLM_sec_level_3"><div id="ac_i57" class="anchor-spacer"></div><h4 class="article-section__title" id="_i57"> (3<i>S</i>,6<i>S</i>)-3,6-Diisobutyl-4-((<i>E</i>)-3-(<i>p</i>-tolyl)acryloyl)piperazin-2-one (<b>41</b>)</h4><div class="NLM_p last">Compound <b>7</b> (60 mg, 0.29 mmol) and 4-methylcinnamic acid (50 mg, 0.3 mmol) were coupled according to the procedure described for the preparation of compound <b>2a</b> to furnish <b>41</b> (95 mg, 95% yield) as a white solid. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 7.72 (dd, <i>J</i> = 14.0 Hz, 4.5 Hz, 1 H), 7.41 (t, <i>J</i> = 6.5 Hz, 1 H), 7.19 (d, <i>J</i> = 8.0 Hz, 1 H), 6.82–6.76 (dd, <i>J</i> = 15.0 Hz, 7.2 Hz, 1 H) (s, 1H), 5.93 (br s, 1 H), 5.35 (br s, 1 H), 4.81 (dd, <i>J</i> = 12.5 Hz, 6.5 Hz, 1 H), 4.57 (br s, 1 H), 3.60 (m, 1 H), 3.14 (m, 1 H), 2.67 (m, 1 H), 2.37 (m, 1 H), 1.75 (m, 4 H), 1.36 (m, 2 H), 1.06–0 (m, 12 H). MS (ESI): <i>m</i>/<i>z</i> 357.2 (M + 1).</div></div><div id="sec5_1_1_23" class="NLM_sec NLM_sec_level_3"><div id="ac_i58" class="anchor-spacer"></div><h4 class="article-section__title" id="_i58"> (3<i>S</i>,6<i>S</i>)-3,6-Diisobutyl-4-((<i>E</i>)-3-(4-(trifluoromethyl)phenyl)acryloyl)piperazin-2-one (<b>42</b>)</h4><div class="NLM_p last">Compound <b>7</b> (60 mg, 0.29 mmol) and 4-trifluorocinnamic acid (65 mg, 0.3 mmol) were coupled according to the procedure described for the preparation of compound <b>2a</b> to furnish <b>42</b> (44 mg, 38% yield) as a white solid. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 7.77–7.58 (m, 5 H), 6.91 (dd, <i>J</i> = 8.0 Hz, 7.2 Hz, 1 H), 5.87 (s, 1 H), 5.33 (d, <i>J</i> = 9.6 Hz, 1 H), 4.81 (d, <i>J</i> = 13.6 Hz, 1 H), 4.56–4.53 (m, 1 H), 4.00 (d, <i>J</i> = 12.4 Hz, 1 H), 3.62 (m, 2 H), 2.70 (m, 1 H), 1.90–1.69 (m, 2 H), 1.44–0.93 (m, 14 H). MS (ESI): <i>m</i>/<i>z</i> 411.2 (M + 1).</div></div><div id="sec5_1_1_24" class="NLM_sec NLM_sec_level_3"><div id="ac_i59" class="anchor-spacer"></div><h4 class="article-section__title" id="_i59"> (3<i>S</i>,6<i>S</i>)-3,6-Diisobutyl-4-((<i>E</i>)-3-(4-methoxyphenyl)acryloyl)piperazin-2-one (<b>43</b>)</h4><div class="NLM_p last">Compound <b>7</b> (60 mg, 0.29 mmol) and (<i>E</i>)-3-(4-methoxyphenyl) acrylic acid (60 mg, 0.34 mmol) were coupled according to the procedure described for the preparation of compound <b>2a</b> to give <b>43</b> (84 mg, 96% yield) as a white solid. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 7.71 (m, 1 H), 7.46–7.43 (br s, 2 H), 6.92–6.90 (br s, 2 H), 6.69 (m, 1 H), 5.93 (br s, 1 H), 4.79 (m, 1 H), 4.56 (m, 1 H), 3.83 (s, 3 H) 3.66–3.52 (m, 1 H), 2.67 (m, 1 H), 1.87–1.60 (m, 5 H), 1.38–1.28 (m, 2 H), 1.05–0.93 (m, 12 H). MS (ESI): <i>m</i>/<i>z</i> 373.2 (M + 1).</div></div><div id="sec5_1_1_25" class="NLM_sec NLM_sec_level_3"><div id="ac_i60" class="anchor-spacer"></div><h4 class="article-section__title" id="_i60"> (3<i>S</i>,6<i>S</i>)-3,6-Diisobutyl-4-((<i>E</i>)-3-(4-nitrophenyl)acryloyl)piperazin-2-one (<b>44</b>)</h4><div class="NLM_p last">Compound <b>7</b> (99.8 mg, 0.47 mmol) and (<i>E</i>)-3-(4-nitrophenyl) acrylic acid (109 mg, 0.564 mmol) were coupled according to the procedure described for the preparation of compound <b>2a</b> to give <b>44</b> (82 mg, 45% yield) as a white solid. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 8.21 (d, <i>J</i> = 8.4 Hz, 2 H), 7.73 (d, <i>J</i> = 15.2 Hz, 1 H), 7.63 (d, <i>J</i> = 8.4 Hz, 2 H), 6.95 (d, <i>J</i> = 15.2 Hz, 1 H), 6.50 (s, 1 H), 4.77 (d, <i>J</i> = 13.2 Hz, 1 H), 4.55–4.49 (m, 1 H), 3.64–3.52 (m, 1 H), 2.72–2.66 (m, 1 H), 1.91–1.58 (m, 4 H), 1.42–1.32 (m, 2 H), 1.04–0.89 (m, 12 H). MS (ESI): <i>m</i>/<i>z</i> 388.1 (M + 1).</div></div><div id="sec5_1_1_26" class="NLM_sec NLM_sec_level_3"><div id="ac_i61" class="anchor-spacer"></div><h4 class="article-section__title" id="_i61"> (3<i>S</i>,6<i>S</i>)-4-((<i>E</i>)-3-(4-(Dimethylamino)phenyl)acryloyl)-3,6-diisobutylpiperazin-2-one (<b>45</b>)</h4><div class="NLM_p last">Compound <b>7</b> (60 mg, 0.28 mmol) and (<i>E</i>)-3-[4-(dimethylamino)phenyl]acrylic acid (60 mg, 0.3 mmol) were coupled according to the procedure described for the preparation of compound <b>2a</b> to give the product <b>45</b> (100 mg, 96% yield) as an yellow syrup. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 7.69 (d, <i>J</i> = 16.0 Hz, 1 H), 7.41–7.39 (br s, 2 H), 6.68–6.66 (br s, 2 H), 6.64–6.58 (m, 1 H), 5.83 (br s, 1 H), 4.83–4.80 (m, 1 H), 4.61–4.59 (m,1 H), 3.66–3.57 (m, 1 H), 3.01 (s, 6 H); 2.68–2.62 (m,1 H), 1.86–1.66 (m, 4 H), 1.38–1.32 (m, 2 H), 1.05–0.92 (m, 12 H). MS (ESI): <i>m</i>/<i>z</i> 387.4 (M + 1).</div></div><div id="sec5_1_1_27" class="NLM_sec NLM_sec_level_3"><div id="ac_i62" class="anchor-spacer"></div><h4 class="article-section__title" id="_i62"> (3<i>S</i>,6<i>S</i>)-3,6-Diisobutyl-4-((<i>E</i>)-3-(4-(methylsulfonyl)phenyl)acryloyl)piperazin-2-one (<b>46</b>)</h4><div class="NLM_p last">Compound <b>7</b> (99.8 mg, 0.47 mmol) and (<i>E</i>)-3-(4-(methylsulfonyl)phenyl)acrylic acid (127.6 mg, 0.564 mmol) were coupled according to the procedure described for the preparation of compound <b>2a</b> to give the product <b>46</b> (151 mg, 76% yield) as a white solid. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 7.94 (d, <i>J</i> = 8.4 Hz, 2 H), 7.73 (d, <i>J</i> = 15.6 Hz, 1 H), 7.66 (d, <i>J</i> = 8.4 Hz, 2 H), 6.94 (d, <i>J</i> = 15.6 Hz, 1 H), 6.33 (s, 1 H), 4.78 (d, <i>J</i> = 13.2 Hz, 3.8 Hz, 1 H), 4.55–4.51 (m, 1 H), 3.65–3.52 (m, 1 H), 3.06 (s, 3 H), 2.69 (d, <i>J</i> = 13.2 Hz, 11.2 Hz, 1 H), 1.91–1.62 (m, 4 H), 1.43–1.33 (m, 2 H), 1.06–0.91 (m, 12 H). MS (ESI): <i>m</i>/<i>z</i> 421.4 (M + 1).</div></div><div id="sec5_1_1_28" class="NLM_sec NLM_sec_level_3"><div id="ac_i63" class="anchor-spacer"></div><h4 class="article-section__title" id="_i63"> Methyl 4-((<i>E</i>)-3-((2<i>S</i>,5<i>S</i>)-2,5-Diisobutyl-3-oxopiperazin-1-yl)-3-oxoprop-1-en-1-yl)benzoate (<b>47</b>)</h4><div class="NLM_p last">Compound <b>7</b> (55 mg, 0.26 mmol) and (<i>E</i>)-3-[4-(methoxycarbonyl)phenyl] acrylic acid (60 mg, 0.29 mmol) were coupled according to the procedure described for the preparation of compound <b>2a</b> to furnish <b>47</b> (94 mg, 90% yield) as a white solid. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 8.03 (d, <i>J</i> = 8.0 Hz, 2 H), 7.72 (dd, <i>J</i> = 15.2 Hz, 8.0 Hz, 1 H), 7.55 (t, <i>J</i> = 8.0 Hz, 2 H), 6.91 (dd, <i>J</i> = 15.2 Hz, 8.0 Hz, 1 H), 6.30 (brs, 1 H), 5.30 (dd, <i>J</i> = 8.0 Hz, 4.0 Hz, 1 H), 4.78 (dd, <i>J</i> = 13.2 Hz, 4.0 Hz, 1 H), 4.53 (t, <i>J</i> = 8.0 Hz, 1 H), 3.91 (s, 1 H), 3.65–3.55 (m, 1 H), 2.67 (t, <i>J</i> = 12.0 Hz,1 H), 1.89–1.63 (m, 4 H), 1.38–1.34 (m, 2 H), 1.04–0.93 (m, 12 H). MS (ESI): <i>m</i>/<i>z</i> 401.5 (M + 1).</div></div><div id="sec5_1_1_29" class="NLM_sec NLM_sec_level_3"><div id="ac_i64" class="anchor-spacer"></div><h4 class="article-section__title" id="_i64"> (3<i>S</i>,6<i>S</i>)-4-((<i>E</i>)-3-(4-Bromophenyl)acryloyl)-3,6-diisobutylpiperazin-2-one (<b>48</b>)</h4><div class="NLM_p last">Compound <b>7</b> (60 mg, 0.29 mmol) and 4-bromocinnamic acid (55 mg, 0.3 mmol) were coupled according to the procedure described for the preparation of compound <b>2a</b> to furnish <b>48</b> (70 mg, 65% yield) as a white solid. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 8.80–8.60 (m, 2 H), 7.85–7.70 (m, 2 H), 7.4 (br s, 1 H), 6.95 (br s, 1 H), 5.95 (s, 1 H), 5.38 (br s, 1 H), 5.06–4.99 (m, 1 H), 4.80 (br s, 1 H), 4.55 (br s, 1 H), 4.05 (m, 1 H), 3.10 (m, 1 H), 2.70 (m, 1 H), 1.90–1.10 (m, 5 H), 1.05–0.85 (m, 12 H). MS (ESI): <i>m</i>/<i>z</i> 377.2 (M + 1).</div></div><div id="sec5_1_1_30" class="NLM_sec NLM_sec_level_3"><div id="ac_i65" class="anchor-spacer"></div><h4 class="article-section__title" id="_i65"> (3<i>S</i>,6<i>S</i>)-4-((<i>E</i>)-3-(4-Chlorophenyl)acryloyl)-3,6-diisobutylpiperazin-2-one (<b>49</b>)</h4><div class="NLM_p last">Compound <b>7</b> (60 mg, 0.29 mmol) and 4-chlorocinnamic acid (55 mg, 0.3 mmol) were coupled according to the procedure described for the preparation of compound <b>2a</b> to furnish <b>49</b> (70 mg, 65% yield) as a white solid. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 8.80–8.60 (m, 2 H), 7.85–7.70 (m, 2 H), 7.4 (br s, 1 H), 6.95 (br s, 1 H), 5.95 (s, 1 H), 5.38 (br s, 1 H), 5.06–4.99 (m, 1 H), 4.80 (d, 1 H), 4.55 (br s, 1 H), 4.05 (m, 1 H), 3.10 (m, 1 H), 2.70 (m, 1 H), 1.90–1.10 (m, 5 H), 1.05–0.85 (m, 12 H). MS (ESI): <i>m</i>/<i>z</i> 377.2 (M + 1).</div></div><div id="sec5_1_1_31" class="NLM_sec NLM_sec_level_3"><div id="ac_i66" class="anchor-spacer"></div><h4 class="article-section__title" id="_i66"> (3<i>S</i>,6<i>S</i>)-4-((<i>E</i>)-3-(3-Chlorophenyl)acryloyl)-3,6-diisobutylpiperazin-2-one (<b>50</b>)</h4><div class="NLM_p last">Compound <b>7</b> (60 mg, 0.29 mmol) and 3-chlorocinnamic acid (60 mg, 0.33 mmol) were coupled according to the procedure described for the preparation of compound <b>2a</b> to furnish <b>50</b> (88 mg, 98% yield) as a white solid. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 7.67 (dd, <i>J</i> = 15.6 Hz, 5.6 Hz, 1 H), 7.50 (d, <i>J</i> = 15.6 Hz, 1 H); 7.38–7.29 (m, 2 H), 6. 83 (dd, <i>J</i> = 15.6 Hz, 5.6 Hz, 1 H), 5.95 (br s, 1 H), 5.33 (dd, <i>J</i> = 9.6 Hz, 4.0 Hz, 1 H), 4.79 (dd, <i>J</i> = 13.2 Hz, 4.0 Hz, 1H), 4.56–4.53 (m, 1 H), 3.65–3.56 (m, 2 H), 2.68 (dd, <i>J</i> = 13.2 Hz, 11.2 Hz, 1 H), 1.88–1.63 (m, 4 H), 1.39–1.34 (m, 2 H), 1.05–0.93 (m, 12 H). MS (ESI): <i>m</i>/<i>z</i> 379 (M + 1).</div></div><div id="sec5_1_1_32" class="NLM_sec NLM_sec_level_3"><div id="ac_i67" class="anchor-spacer"></div><h4 class="article-section__title" id="_i67"> (3<i>S</i>,6<i>S</i>)-4-((<i>E</i>)-3-(2-Chlorophenyl)acryloyl)-3,6-diisobutylpiperazin-2-one (<b>51</b>)</h4><div class="NLM_p last">Compound <b>7</b> (60 mg, 0.29 mmol) and 2-chlorocinnamic acid (60 mg, 0.33 mmol) were coupled according to the procedure described for the preparation of compound <b>2a</b> to furnish <b>51</b> (50 mg, 56% yield) as a white solid. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 7.84 (d, <i>J</i> = 15.6 Hz, 1 H), 7.50 (d, <i>J</i> = 15.6 Hz, 1 H); 7.35 (dd, <i>J</i> = 8.4 Hz, 2.0 Hz, 1 H), 7.20–7.16 (m, 1 H), 6.99 (d, <i>J</i> = 15.6 Hz, 1 H), 5.89 (br s, 1 H), 5.33 (dd, <i>J</i> = 8.0 Hz, 4.0 Hz, 1 H), 4.79 (dd, <i>J</i> = 13.2 Hz, 4.0 Hz, 1 H), 4.46 (dd, <i>J</i> = 8.0 Hz, 4.0 Hz, 1 H), 3.69–3.56 (m, 2 H), 2.71 (dd, <i>J</i> = 13.2 Hz, 11.2 Hz, 1 H), 1.84–1.64 (m, 4 H), 1.39–1.32 (m, 2 H), 1.07–0.92 (m, 12 H). MS (ESI): <i>m</i>/<i>z</i> 379 (M + 1).</div></div><div id="sec5_1_1_33" class="NLM_sec NLM_sec_level_3"><div id="ac_i68" class="anchor-spacer"></div><h4 class="article-section__title" id="_i68"> (3<i>S</i>,6<i>S</i>)-4-((<i>E</i>)-3-(4-Fluorophenyl)acryloyl)-3,6-diisobutylpiperazin-2-one (<b>52</b>)</h4><div class="NLM_p last">Compound <b>7</b> (53 mg, 0.25 mmol) and 4-fluorocinnamic acid (50 mg, 0.3 mmol) were coupled according to the procedure described for the preparation of compound <b>2a</b> to furnish <b>52</b> (80 mg, 94% yield) as a white solid. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 7.71–7.57 (m, 3 H), 7.19–7.11 (m, 3 H), 5.19 (dd, <i>J</i> = 10.5 Hz, 3.2 Hz, 1 H) 4.72 (m, 1 H), 4.36 (dd, <i>J</i> = 14.4 Hz, 3.2 Hz, 1 H), 3.58–3.52 (m, 1 H), 3.19 (dd, <i>J</i> = 12.0 Hz, 10.8 Hz, 1 H), 2.79–2.74 (m, 1 H), 2.37 (m, 1 H), 1.85–1.60 (m, 4 H), 1.41 (t, <i>J</i> = 7.2 Hz, 2 H), 1.03–0.94 (m, 12 H). MS (ESI): <i>m</i>/<i>z</i> 361.5 (M + 1).</div></div><div id="sec5_1_1_34" class="NLM_sec NLM_sec_level_3"><div id="ac_i69" class="anchor-spacer"></div><h4 class="article-section__title" id="_i69"> (3<i>S</i>,6<i>S</i>)-4-((<i>E</i>)-3-(3,4-Difluorophenyl)acryloyl)-3,6-diisobutylpiperazin-2-one (<b>53</b>)</h4><div class="NLM_p last">Compound <b>7</b> (53 mg, 0.25 mmol) and 3,4-difluorocinnamic acid (60 mg, 0.33 mmol) were coupled according to the procedure described for the preparation of compound <b>2a</b> to furnish <b>53</b> (90 mg, 97% yield) as a white solid. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 7.66–7.60 (m, 1 H), 7.35–7.13 (m, 3 H), 6. 73 (dd, <i>J</i> = 15.2 Hz, 4.8 Hz, 1 H), 6.23 (d, <i>J</i> = 15.2, 1 H), 5.31 (dd, <i>J</i> = 9.6 Hz, 3.6 Hz, 1 H), 4.78 (dd, <i>J</i> = 13.2 Hz, 4.0 Hz, 1 H), 4.53 (dd, <i>J</i> = 8.8 Hz, 4 Hz, 1 H), 3.64–3.55 (m, 1 H), 3.59 (m, 1 H), 3.15 (dd, <i>J</i> = 14.0 Hz, 11.2 Hz, 1 H), 2.68 (dd, <i>J</i> = 14.0 Hz, 10.8 Hz, 1 H), 1.87–1.65 (m, 4 H), 1.38–1.34 (m, 2 H), 1.04–0.92 (m, 12 H). MS (ESI): <i>m</i>/<i>z</i> 379.1 (M + 1).</div></div><div id="sec5_1_1_35" class="NLM_sec NLM_sec_level_3"><div id="ac_i70" class="anchor-spacer"></div><h4 class="article-section__title" id="_i70"> (3<i>S</i>,6<i>S</i>)-4-((<i>E</i>)-3-(2,4-Difluorophenyl)acryloyl)-3,6-diisobutylpiperazin-2-one (<b>54</b>)</h4><div class="NLM_p last">Compound <b>7</b> (60 mg, 0.29 mmol) and 2,4-difluorocinnamic acid (60 mg, 0.33 mmol) were coupled according to the procedure described for the preparation of compound <b>2a</b> to furnish <b>54</b> (104 mg, 95% yield) as a white solid. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 7.66–7.73 (m, 1 H), 7.41–7.47 (m, 1 H), 6.81–6.97 (m, 3 H), 6.43 (d, <i>J</i> = 13.8 Hz, 1 H), 5.29 (dd, <i>J</i> = 10.0 Hz, 4.0 Hz, 1 H), 4.01 (d, <i>J</i> = 11.2 Hz, 1 H), 3.57–3.60 (m, 1 H), 3.08–3.14 (m, 1 H), 1.72–1.86 (m, 4 H), 1.34–1.38 (m, 2 H), 0.91–1.02 (m, 12 H). MS (ESI): <i>m</i>/<i>z</i> 379.1 (M + 1).</div></div><div id="sec5_1_1_36" class="NLM_sec NLM_sec_level_3"><div id="ac_i71" class="anchor-spacer"></div><h4 class="article-section__title" id="_i71"> (3<i>S</i>,6<i>S</i>)-3,6-Diisobutyl-4-(5-phenylfuran-2-carbonyl)piperazin-2-one (<b>55</b>)</h4><div class="NLM_p last">Compound <b>7</b> (100 mg, 0.47 mmol) and 5-phenylfuran-2-carboxylic acid (106 mg, 0.564 mmol) were coupled according to the procedure described for the preparation of compound <b>2a</b> to give <b>55</b> (52 mg, 29% yield) as a white solid. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 7.67 (d, <i>J</i> = 7.6 Hz, 2 H), 7.44–7.39 (m, 2 H), 7.36–7.33 (m, 1 H), 7.21(d, <i>J</i> = 3.6 Hz, 1 H), 6.75 (d, <i>J</i> = 3.6 Hz, 1 H), 6.04 (br s, 1 H), 5.35–5.26 (s, 1 H), 4.77 (dd, <i>J</i> = 20.0 Hz, 4 Hz, 1H), 3.82–3.73 (m, 1 H), 3.25–3.12 (m, 1 H), 1.92–1.65 (m, 4 H), 1.41–1.37 (m, 2 H), 1.00–0.89 (m, 12 H). MS (ESI): <i>m</i>/<i>z</i> 383.1 (M + 1).</div></div><div id="sec5_1_1_37" class="NLM_sec NLM_sec_level_3"><div id="ac_i72" class="anchor-spacer"></div><h4 class="article-section__title" id="_i72"> (3<i>S</i>,6<i>S</i>)-3,6-Diisobutyl-4-(2-phenylthiazole-4-carbonyl)piperazin-2-one (<b>56</b>)</h4><div class="NLM_p last">Compound <b>7</b> (100 mg, 0.47 mmol) and 2-phenylthiazole-4-carboxylic acid (116 mg, 0.564 mmol) were coupled according to the procedure described for the preparation of compound <b>2a</b> to give <b>56</b> (58 mg, 31% yield) as a colorless solid. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 8.07 (s, 1 H), 7.94–7.89 (m, 2 H), 7.45–7.43 (m, 3 H), 6.48 (s, 1 H), 5.31–5.29 (m, 1 H), 5.13 (d, <i>J</i> = 14.0 Hz, 1 H), 3.92–3.84 (m, 1 H), 3.08 (dd, <i>J</i> = 14.0 Hz, 10.8 Hz, 1 H), 1.90–1.66 (m, 4 H), 1.41–1.24 (m, 2 H), 1.09–0.82 (m, 12 H). MS (ESI): <i>m</i>/<i>z</i> 400.1 (M + 1).</div></div><div id="sec5_1_1_38" class="NLM_sec NLM_sec_level_3"><div id="ac_i73" class="anchor-spacer"></div><h4 class="article-section__title" id="_i73"> (3<i>S</i>,6<i>S</i>)-3,6-Diisobutyl-4-(2-phenyloxazole-4-carbonyl)piperazin-2-one (<b>57</b>)</h4><div class="NLM_p last">Compound <b>7</b> (99.8 mg, 0.47 mmol) and 2-phenyloxazole-4-carboxylic acid (106.7 mg, 0.564 mmol) were coupled according to the procedure described for the preparation of compound <b>2a</b> to give <b>57</b> (55 mg, 30% yield) as a white solid. <sup>1</sup>H NMR (400 MHz, CD<sub>3</sub>OD) δ 8.47 (s, 1 H), 8.08–8.03 (m, 2 H), 7.56–7.50 (m, 3 H), 5.39 (dd, <i>J</i> = 14.2 Hz, 3.6 Hz, 1 H), 5.16–5.13 (m, 1 H), 3.84–3.74 (m, 1 H), 3.18 (dd, <i>J</i> = 14.0 Hz, 11.2 Hz, 1 H), 1.92–1.66 (m, 4 H), 1.50–1.38 (m, 2 H), 1.08–0.92 (m, 12 H). MS (ESI): <i>m</i>/<i>z</i> 384.4 (M + 1).</div></div><div id="sec5_1_1_39" class="NLM_sec NLM_sec_level_3"><div id="ac_i74" class="anchor-spacer"></div><h4 class="article-section__title" id="_i74"> (3<i>S</i>,6<i>S</i>)-3,6-Diisobutyl-4-(5-phenylisoxazole-3-carbonyl)piperazin-2-one (<b>58</b>)</h4><div class="NLM_p last">Compound <b>7</b> (100 mg, 0.47 mmol) and 5-phenylisoxazole-3-carboxylic acid (107 mg, 0.56 mmol) were coupled according to the procedure described for the preparation of compound <b>2a</b> to give <b>58</b> (120 mg, 67% yield) as a white solid. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 7.82–7.78 (m, 2 H), 7.51–7.45 (m, 3 H), 6.92 (s, 1 H), 6.36 (s, 1 H), 5.29–5.26 (m, 1 H), 4.87 (dd, <i>J</i> = 14.2 Hz, 4.0 Hz, 1 H), 3.78–3.67 (m, 1 H), 3.11 (dd, <i>J</i> = 14.0 Hz, 10.8 Hz, 1 H), 1.92–1.82 (m, 1 H), 1.81–1.67 (m, 3 H), 1.42–1.34 (m, 2 H), 1.08 (d, <i>J</i> = 6.4 Hz, 3 H), 0.99–0.93 (m, 9 H). MS (ESI): <i>m</i>/<i>z</i> 384.2 (M + 1).</div></div><div id="sec5_1_1_40" class="NLM_sec NLM_sec_level_3"><div id="ac_i75" class="anchor-spacer"></div><h4 class="article-section__title" id="_i75"> (3<i>S</i>,6<i>S</i>)-3,6-Diisobutyl-4-(5-phenyl-1,2,4-oxadiazole-3-carbonyl)piperazin-2-one (<b>59</b>)</h4><div class="NLM_p last">Compound <b>7</b> (50 mg, 0.24 mmol) and 5-phenyl-1,2,4-oxadiazole-3-carboxylic acid (54 mg, 0.28 mmol) were coupled according to the procedure described for the preparation of compound <b>2a</b> to give <b>59</b> (30 mg, 33% yield) as a colorless gum. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 8.21–8.18 (m, 2 H), 7.67–7.54 (m, 3 H), 5.93 (s, 1 H), 5.32–5.29 (m, 1 H), 4.89–4.82 (m, 1 H), 3.87–3.74 (m, 1 H), 3.14 (dd, <i>J</i> = 13.8 Hz, 11.0 Hz, 1 H), 1.94–1.63 (m, 4 H), 1.43–1.32 (m, 2 H), 1.11–0.89 (m, 12 H). MS (ESI): <i>m</i>/<i>z</i> 385.2 (M + 1).</div></div><div id="sec5_1_1_41" class="NLM_sec NLM_sec_level_3"><div id="ac_i76" class="anchor-spacer"></div><h4 class="article-section__title" id="_i76"> (3<i>S</i>,6<i>S</i>)-3,6-Diisobutyl-4-(1-phenyl-1<i>H</i>-imidazole-4-carbonyl)piperazin-2-one (<b>60</b>)</h4><div class="NLM_p last">Compound <b>7</b> (100 mg, 0.47 mmol) and 1-phenyl-1<i>H</i>-imidazole-4-carboxylic acid (106 mg, 0.56 mmol) were coupled according to the procedure described for the preparation of compound <b>2a</b> to give <b>60</b> (83 mg, 46% yield) as a colorless oil. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 7.99 (s, 1 H), 7.77 (s, 1 H), 7.53–7.49 (m, 2 H), 7.43–7.39 (m, 3 H), 5.94 (s, 1 H), 5.84–5.76 (m, 1 H), 5.36–5.32 (m, 1 H), 3.76–3.64 (m, 1 H), 3.10–3.04 (m, 1 H), 1.87–1.71 (m, 4 H), 1.42–1.27 (m, 2 H), 1.08–0.93 (m, 12 H). MS (ESI): <i>m</i>/<i>z</i> 383.3 (M + 1).</div></div><div id="sec5_1_1_42" class="NLM_sec NLM_sec_level_3"><div id="ac_i77" class="anchor-spacer"></div><h4 class="article-section__title" id="_i77"> (3<i>S</i>,6<i>S</i>)-3,6-Diisobutyl-4-(5-phenyl-1<i>H</i>-pyrazole-3-carbonyl)piperazin-2-one (<b>61</b>)</h4><div class="NLM_p last">Compound <b>7</b> (100 mg, 0.47 mmol) and 5-phenyl-1<i>H</i>-pyrazole-3-carboxylic acid (106 mg, 0.56 mmol) were coupled according to the procedure described for the preparation of compound <b>2a</b> to give <b>61</b> (33 mg, 18% yield) as a white solid. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 11.7 (br s, 1 H), 7.69–7.64 (m, 2 H), 7.45–7.35 (m, 3 H), 6.94 (s, 1 H), 6.05 (s, 1 H), 5.38–5.31 (m, 1 H), 4.88–4.79 (m, 1 H), 3.76–3.63 (m, 1 H), 3.15–3.05 (m, 1 H), 1.92–1.55 (m, 4 H), 1.43–1.28 (m, 2 H), 1.12–0.78 (m, 12 H). MS (ESI): <i>m</i>/<i>z</i> 383.4 (M + 1).</div></div><div id="sec5_1_1_43" class="NLM_sec NLM_sec_level_3"><div id="ac_i78" class="anchor-spacer"></div><h4 class="article-section__title" id="_i78"> (3<i>S</i>,6<i>S</i>)-3,6-Diisobutyl-4-(2-phenyl-1<i>H</i>-imidazole-4-carbonyl)piperazin-2-one (<b>62</b>)</h4><div class="NLM_p last">Compound <b>7</b> (100 mg, 0.47 mmol) and 2-phenyl-1<i>H</i>-imidazole-4-carboxylic acid (106 mg, 0.56 mmol) were coupled according to the procedure described for the preparation of compound <b>2a</b> to give <b>62</b> (45 mg, 25% yield) as a white solid. <sup>1</sup>H NMR (400 MHz, CD<sub>3</sub>OD) δ 7.91 (d, <i>J</i> = 6.8 Hz, 2 H), 7.74 (s, 1 H), 7.48–7.39 (m, 3 H), 5.86 (d, <i>J</i> = 12.0 Hz, 1 H), 5.20 (d, <i>J</i> = 9.2 Hz, 1 H), 3.78–3.62 (m, 1 H), 3.17–3.11 (m, 1 H), 1.89–1.73 (m, 4 H), 1.44–1.39 (m, 2 H), 1.07–0.91 (m, 12 H). MS (ESI): <i>m</i>/<i>z</i> 383.2 (M + 1).</div></div><div id="sec5_1_1_44" class="NLM_sec NLM_sec_level_3"><div id="ac_i79" class="anchor-spacer"></div><h4 class="article-section__title" id="_i79"> (3<i>S</i>,6<i>S</i>)-3,6-Diisobutyl-4-(5-(<i>p</i>-tolyl)isoxazole-3-carbonyl)piperazin-2-one (<b>63</b>)</h4><div class="NLM_p last">Compound <b>7</b> (100 mg, 0.47 mmol) and 5-(<i>p</i>-tolyl)isoxazole-3-carboxylic acid (114 mg, 0.56 mmol) were coupled according to the procedure described for the preparation of compound <b>2a</b> to give <b>63</b> (107 mg, 57% yield) as a white solid. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 7.67 (d, <i>J</i> = 8.0 Hz, 2 H), 7.27 (d, <i>J</i> = 8.0 Hz, 2 H), 6.85 (s, 1 H), 6.51 (s, 1H), 5.26 (dd, <i>J</i> = 9.4 Hz, 4 Hz, 1 H), 4.86 (dd, <i>J</i> = 14.2 Hz, 4.0 Hz, 1 H), 3.77–3.67 (m, 1 H), 3.10 (dd, <i>J</i> = 14.2 Hz, 11.0 Hz, 1 H), 2.40 (s, 3 H), 1.91–1.67 (m, 4 H), 1.41–1.33 (m, 2 H), 1.08–0.91 (m, 12 H). MS (ESI): <i>m</i>/<i>z</i> 398.2 (M + 1).</div></div><div id="sec5_1_1_45" class="NLM_sec NLM_sec_level_3"><div id="ac_i80" class="anchor-spacer"></div><h4 class="article-section__title" id="_i80"> (3<i>S</i>,6<i>S</i>)-3,6-Diisobutyl-4-(5-(4-methoxyphenyl)isoxazole-3-carbonyl)piperazin-2-one (<b>64</b>)</h4><div class="NLM_p last">Compound <b>7</b> (100 mg, 0.47 mmol) and 5-(4-methoxyphenyl)isoxazole-3-carboxylic acid (123 mg, 0.56 mmol) were coupled according to the procedure described for the preparation of compound <b>2a</b> to give <b>64</b> (106 mg, 55% yield) as a white solid. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 7.72 (d, <i>J</i> = 8.8 Hz, 2 H), 6.98 (d, <i>J</i> = 8.8 Hz, 2 H), 6.78 (s, 1 H), 6.51 (s, 1 H), 5.26 (dd, <i>J</i> = 9.4 Hz, 4.4 Hz, 1 H), 4.85 (dd, <i>J</i> = 14.0 Hz, 4.4 Hz, 1 H), 3.85 (s, 3 H), 3.77–3.66 (m, 1 H), 3.09 (dd, <i>J</i> = 13.8 Hz, 10.8 Hz, 1 H), 1.91–1.67 (m, 4 H), 1.41–1.33 (m, 2 H), 1.07–0.90 (m, 12 H). MS (ESI): <i>m</i>/<i>z</i> 414.1 (M + 1).</div></div><div id="sec5_1_1_46" class="NLM_sec NLM_sec_level_3"><div id="ac_i81" class="anchor-spacer"></div><h4 class="article-section__title" id="_i81"> (3<i>S</i>,6<i>S</i>)-4-(5-(4-Chlorophenyl)isoxazole-3-carbonyl)-3,6-diisobutylpiperazin-2-one (<b>65</b>)</h4><div class="NLM_p last">Compound <b>7</b> (100 mg, 0.47 mmol) and 5-(4-chlorophenyl)isoxazole-3-carboxylic acid (126 mg, 0.56 mmol) were coupled according to the procedure described for the preparation of compound <b>2a</b> to give <b>65</b> (109 mg, 56% yield) as a white solid. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 7.72 (d, <i>J</i> = 8.4 Hz, 2 H), 7.46 (d, <i>J</i> = 8.4 Hz, 2 H), 6.91 (s, 1 H), 6.49 (s, 1 H), 5.26 (dd, <i>J</i> = 9.4 Hz, 4.0 Hz, 1 H), 4.85 (dd, <i>J</i> = 14.2 Hz, 4.0 Hz, 1 H), 3.77–3.67 (m, 1 H), 3.10 (dd, <i>J</i> = 14.2 Hz, 11.0 Hz, 1 H), 1.91–1.67 (m, 4 H), 1.41–1.34 (m, 2 H), 1.07–0.91 (m, 12 H). MS (ESI): <i>m</i>/<i>z</i> 418.4 (M + 1).</div></div><div id="sec5_1_1_47" class="NLM_sec NLM_sec_level_3"><div id="ac_i82" class="anchor-spacer"></div><h4 class="article-section__title" id="_i82"> (3<i>S</i>,6<i>S</i>)-4-(5-(4-Bromophenyl)isoxazole-3-carbonyl)-3,6-diisobutylpiperazin-2-one (<b>66</b>)</h4><div class="NLM_p last">Compound <b>7</b> (100 mg, 0.47 mmol) and 5-(4-bromophenyl)isoxazole-3-carboxylic acid (151 mg, 0.56 mmol) were coupled according to the procedure described for the preparation of compound <b>2a</b> to give <b>66</b> (130 mg, 60% yield) as a white solid. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 7.66–7.60 (m, 4 H), 6.92 (s, 1 H), 6.54 (s, 1 H), 5.27–5.24 (m, 1 H), 4.86–4.76 (m, 1 H), 3.77–3.66 (m, 1 H), 3.10 (dd, <i>J</i> = 13.6 Hz, 11.2 Hz, 1 H), 1.91–1.69 (m, 4 H), 1.41–1.34 (m, 2 H), 1.07–0.91 (m, 12 H). MS (ESI): <i>m</i>/<i>z</i> 462.1 (M + 1).</div></div><div id="sec5_1_1_48" class="NLM_sec NLM_sec_level_3"><div id="ac_i83" class="anchor-spacer"></div><h4 class="article-section__title" id="_i83"> (3<i>S</i>,6<i>S</i>)-4-(5-(4-Fluorophenyl)isoxazole-3-carbonyl)-3,6-diisobutylpiperazin-2-one (<b>67</b>)</h4><div class="NLM_p last">Compound <b>7</b> (100 mg, 0.47 mmol) and 5-(4-fluorophenyl)isoxazole-3-carboxylic acid (117 mg, 0.564 mmol) were coupled according to the procedure described for the preparation of compound <b>2a</b> to give <b>67</b> (172 mg, 91% yield) as a white solid. <sup>1</sup>H NMR (400 MHz, CD<sub>3</sub>OD) δ 7.96–7.92 (m, 2 H), 7.30–7.26 (m, 2 H), 7.06 (s, 1 H), 5.16–5.12 (m, 1 H), 4.53 (dd, <i>J</i> = 14.2 Hz, 4.4 Hz, 1 H), 3.79–3.71 (m, 1 H), 3.21 (dd, <i>J</i> = 14.2 Hz, 11.0 Hz, 1 H), 1.92–1.62 (m, 4 H), 1.48–1.32 (m, 2 H), 1.12–0.88 (m, 12 H). MS (ESI): <i>m</i>/<i>z</i> 402.2 (M + 1).</div></div><div id="sec5_1_1_49" class="NLM_sec NLM_sec_level_3"><div id="ac_i84" class="anchor-spacer"></div><h4 class="article-section__title" id="_i84"> (3<i>S</i>,6<i>S</i>)-4-(5-(3,4-Difluorophenyl)isoxazole-3-carbonyl)-3,6-diisobutylpiperazin-2-one (<b>68</b>)</h4><div class="NLM_p last">Compound <b>7</b> (45 mg, 0.21 mmol) and 5-(3,4-difluorophenyl)isoxazole-3-carboxylic acid (56 mg, 0.25 mmol) were coupled according to the procedure described for the preparation of compound <b>2a</b> to give <b>68</b> (57 mg, 65% yield) as a white solid. <sup>1</sup>H NMR (400 MHz, CD<sub>3</sub>OD) δ 7.65–7.60 (m, 1 H), 7.55–7.53 (m, 1 H), 7.33–7.26 (m, 1 H), 6.89 (s, 1 H), 5.93 (s, 1 H), 5.28 (dd, <i>J</i> = 9.8 Hz, 3.8 Hz, 1H), 4.86 (dd, <i>J</i> = 14.0 Hz, 3.8 Hz, 1 H), 3.79–3.69 (m, 1 H), 3.12 (dd, <i>J</i> = 14.0 Hz, 10.8 Hz, 1 H), 1.92–1.85 (m, 1 H), 1.79–1.65 (m, 3 H), 1.42–1.32 (m, 2 H), 1.08–0.92 (m, 12 H). MS (ESI): <i>m</i>/<i>z</i> 420.2 (M + 1).</div></div><div id="sec5_1_1_50" class="NLM_sec NLM_sec_level_3"><div id="ac_i85" class="anchor-spacer"></div><h4 class="article-section__title" id="_i85"> (3<i>S</i>,6<i>S</i>)-4-(5-(2,4-Difluorophenyl)isoxazole-3-carbonyl)-3,6-diisobutylpiperazin-2-one (<b>69</b>)</h4><div class="NLM_p last">Compound <b>7</b> (50 mg, 0.24 mmol) and 5-(2,4-difluorophenyl)isoxazole-3-carboxylic acid (53 mg, 0.24 mmol) were coupled according to the procedure described for the preparation of compound <b>2a</b> to furnish <b>69</b> (72 mg, 73% yield) as a white solid. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 8.00–7.93 (m, 1 H), 7.07–6.95 (m, 3 H), 5.88 (s, 1 H), 5.30–5.22 (m, 1 H), 4.81–4.76 (m, 1 H), 3.78–3.70 (m, 1 H), 3.15–2.79 (m, 1 H), 1.89–1.61 (m, 4 H), 1.42–1.31 (m, 2 H) 1.09–0.76 (m, 12 H). MS (ESI): <i>m</i>/<i>z</i> 420.1 (M + 1).</div></div><div id="sec5_1_1_51" class="NLM_sec NLM_sec_level_3"><div id="ac_i86" class="anchor-spacer"></div><h4 class="article-section__title" id="_i86"> 4-(3-((2<i>S</i>,5<i>S</i>)-2,5-Diisobutyl-3-oxopiperazine-1-carbonyl)isoxazol-5-yl)benzonitrile (<b>70</b>)</h4><div class="NLM_p last">Compound <b>7</b> (100 mg, 0.47 mmol) and 5-(4-cyanophenyl)isoxazole-3-carboxylic acid (121 mg, 0.56 mmol) were coupled according to the procedure described for the preparation of compound <b>2a</b> to give <b>70</b> (61 mg, 32% yield) as a white solid. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 7.91 (d, <i>J</i> = 8.4 Hz, 2 H), 7.79 (d, <i>J</i> = 8.4 Hz, 2 H), 7.07 (s, 1 H), 6.32 (s, 1 H), 5.30–5.24 (m, 1 H), 4.87–4.83 (m, 1 H), 3.79–3.67 (m, 1 H), 3.12 (dd, <i>J</i> = 13.6 Hz, 11.2 Hz, 1 H), 1.92–1.67 (m, 4 H), 1.42–1.35 (m, 2 H), 1.08–0.90 (m, 12 H). MS (ESI): <i>m</i>/<i>z</i> 409.2 (M + 1).</div></div><div id="sec5_1_1_52" class="NLM_sec NLM_sec_level_3"><div id="ac_i87" class="anchor-spacer"></div><h4 class="article-section__title" id="_i87"> (3<i>S</i>,6<i>S</i>)-4-(5-(4-(Dimethylamino)phenyl)isoxazole-3-carbonyl)-3,6-diisobutylpiperazin-2-one (<b>71</b>)</h4><div class="NLM_p last">Compound <b>7</b> (100 mg, 0.47 mmol) and 5-(4-(dimethylamino)phenyl)isoxazole-3-carboxylic acid (131 mg, 0.56 mmol) were coupled according to the procedure described for the preparation of compound <b>2a</b> to give <b>71</b> (52 mg, 26% yield) as white solid. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 7.64 (d, <i>J</i> = 8.8 Hz, 2 H), 6.72 (d, <i>J</i> = 8.8 Hz, 2 H), 6.67 (s, 1 H), 6.43 (s, 1 H), 5.29–5.25 (m, 1 H), 4.87–4.81 (m, 1 H), 3.78–3.65 (m, 1 H), 3.08 (dd, <i>J</i> = 13.6 Hz, 10.8 Hz, 1 H), 3.03 (s, 6 H), 1.90–1.67 (m, 4 H), 1.41–1.32 (m, 2 H), 1.08–0.90 (m, 12 H). MS (ESI): <i>m</i>/<i>z</i> 427.2 (M + 1).</div></div><div id="sec5_1_1_53" class="NLM_sec NLM_sec_level_3"><div id="ac_i88" class="anchor-spacer"></div><h4 class="article-section__title" id="_i88"> (3<i>S</i>,6<i>S</i>)-3,6-Diisobutyl-4-(5-(4-nitrophenyl)isoxazole-3-carbonyl)piperazin-2-one (<b>72</b>)</h4><div class="NLM_p last">Compound <b>7</b> (60 mg, 0.28 mmol) and 5-(4-nitrophenyl)-isoxazole-3-carboxylic acid (60 mg, 0.28 mmol) were coupled according to the procedure described for the preparation of compound <b>2a</b> to furnish <b>72</b> (90 mg, 74% yield) as a pale-yellow solid. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 8.37–7.34 (m, 2 H), 7.99–7.96 (m, 2 H), 7.12 (s, 1 H), 6.20 (s, 1 H), 5.29–5.25 (m, 1 H), 4.88–4.76 (m, 1 H), 3.79–3.69 (m, 1 H), 3.18 (dd, <i>J</i> = 14.0 Hz, 10.8 Hz, 1 H), 1.91–1.69 (m, 4 H), 1.42–1.35 (m, 2 H) and 1.08–0.92 (m, 12 H). MS (ESI): <i>m</i>/<i>z</i> 429.1 (M + 1).</div></div><div id="sec5_1_1_54" class="NLM_sec NLM_sec_level_3"><div id="ac_i89" class="anchor-spacer"></div><h4 class="article-section__title" id="_i89"> (3<i>S</i>,6<i>S</i>)-4-(5-(4-Fluorophenyl)isoxazole-3-carbonyl)-3-isobutyl-6-propylpiperazin-2-one (<b>73</b>)</h4><div id="sec5_1_1_54_1" class="NLM_sec NLM_sec_level_4"><div id="ac_i90" class="anchor-spacer"></div><h5 class="article-section__title" id="_i90">A (3<i>S</i>,6<i>S</i>)-3-Isobutyl-6-propyl-piperazin-2-one</h5><div class="NLM_p last">Synthesized from Fmoc-<span class="smallcaps smallerCapital">l</span>-norvaline (19.82 g, 58 mmol) and HCl salt of Leu-OMe (4.7 g, 26.25 mmol) by the method described for the preparation of compound <b>7</b> (Scheme <a class="ref internalNav" href="#sch1" aria-label="1">1</a>) to afford (3<i>S</i>,6<i>S</i>)-3-isobutyl-6-propyl-piperazin-2-one (3.4 g, 25% yield) as a white solid. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 7.53 (s, 1 H), 3.06 (dd, <i>J</i> = 14.0 Hz, 4.0 Hz, 1 H), 2.78 (dd, <i>J</i> = 12.8 Hz, 4.0 Hz, 1 H), 2.59 (dd, <i>J</i> = 12.8 Hz, 5.2 Hz, 1 H), 2.49 (dd, <i>J</i> = 3.6 Hz, 2.0 Hz, 1 H), 2.35 (s, 1 H), 1.73–1.80 (m, 1 H), 1.36–1.51 (m, 6 H), 0.80–0.90 (m, 9 H). MS (ESI): <i>m</i>/<i>z</i> 198.9 (M + 1).</div></div><div id="sec5_1_1_54_2" class="NLM_sec NLM_sec_level_4"><div id="ac_i91" class="anchor-spacer"></div><h5 class="article-section__title" id="_i91">B (3<i>S</i>,6<i>S</i>)-4-(5-(4-Fluorophenyl)isoxazole-3-carbonyl)-3-isobutyl-6-propylpiperazin-2-one (<b>73</b>)</h5><div class="NLM_p last">(3<i>S</i>,6<i>S</i>)-3-Isobutyl-6-propylpiperazin-2-one (50 mg, 0.25 mmol) and 5-(4-fluorophenyl)isoxazole-3-carboxylic acid (53 mg, 0.25 mmol) were coupled according to the procedure described for the preparation of compound <b>2a</b> to furnish <b>73</b> (93 mg, 95% yield) as a white solid. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 7.80–7.77 (m, 2 H), 7.21–7.17 (m, 2 H), 6.86 (s, 1 H), 6.08 (s, 1 H), 5.29–5.28 (m, 1 H), 4.89–4.78 (m, 1 H), 3.71–3.63 (m, 1 H), 3.17–2.83 (m, 1 H), 1.921.65 (m, 3 H), 1.58–1.37 (m, 4 H), 1.08–0.77 (m, 9 H). MS (ESI): <i>m</i>/<i>z</i> 388.1 (M + 1).</div></div></div><div id="sec5_1_1_55" class="NLM_sec NLM_sec_level_3"><div id="ac_i92" class="anchor-spacer"></div><h4 class="article-section__title" id="_i92"> (3<i>S</i>,6<i>S</i>)-4-(5-(4-Fluorophenyl)isoxazole-3-carbonyl)-3-isobutyl-6-((<i>E</i>)-prop-1-en-1-yl)pipe-razin-2-one (<b>74</b>)</h4><div id="sec5_1_1_55_1" class="NLM_sec NLM_sec_level_4"><div id="ac_i93" class="anchor-spacer"></div><h5 class="article-section__title" id="_i93">A (3<i>S</i>,6<i>S</i>)-3-Isobutyl-6-propenyl-piperazin-2-one</h5><div class="NLM_p last">Synthesized from 2-amino-pent-3-enoic acid (11.93 g, 104 mmol) and HCl salt of Leu-OMe (7.8 g, 42.95 mmol) by the method described for the preparation of compound <b>7</b> (Scheme <a class="ref internalNav" href="#sch1" aria-label="1">1</a>) to afford (3<i>S</i>,6<i>S</i>)-3-Isobutyl-6-propenyl-piperazin-2-one (1.623 g, 8% yield) as a white solid. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 7.56 (s, 1 H), 5.43–5.57(m, 2 H), 3.74 (s, 1 H), 3.07 (dd, <i>J</i> = 10.8 Hz, 3.2 Hz, 1 H), 2.82 (dd, <i>J</i> = 12.8 Hz, 4.8 Hz, 1 H), 2.63 (dd, <i>J</i> = 12.8 Hz, 5.6 Hz, 1 H), 1.74–1.82 (m, 1 H), 1.64 (d, <i>J</i> = 7.2 Hz, 3 H), 1.47–1.54 (m, 1 H), 1.35–1.42 (m, 1 H), 0.82–0.88 (m, 7 H). MS (ESI): <i>m</i>/<i>z</i> 197.2 (M + 1).</div></div><div id="sec5_1_1_55_2" class="NLM_sec NLM_sec_level_4"><div id="ac_i94" class="anchor-spacer"></div><h5 class="article-section__title" id="_i94">B (3<i>S</i>,6<i>S</i>)-4-(5-(4-Fluorophenyl)isoxazole-3-carbonyl)-3-isobutyl-6-((<i>E</i>)-prop-1-en-1-yl)pipera-zin-2-one (<b>74</b>)</h5><div class="NLM_p last">(3<i>S</i>,6<i>S</i>)-3-Isobutyl-6-propenyl-piperazin-2-one (40 mg, 0.20 mmol) and 5-(4-fluorophenyl)isoxazole-3-carboxylic acid (45 mg, 0.22 mmol) were coupled according to the procedure described for the preparation of compound <b>2a</b> to furnish <b>74</b> (32 mg, 41% yield) as a white solid. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 7.80–7.76 (m, 2 H), 7.20–7.15 (m, 2 H), 6.86 (s, 1 H), 5.92–5.81 (m, 2 H), 5,34–5.25 (m, 2 H), 4.80–4.72 (m, 1 H), 4.20–4.13 (m, 1 H), 3.19 (dd, <i>J</i> = 14.0 Hz, 11.2 Hz, 1 H), 1.92–1.68 (m, 6 H) and 1.08–0.77 (m, 6 H). MS (ESI): <i>m</i>/<i>z</i> 386.2 (M + 1).</div></div></div><div id="sec5_1_1_56" class="NLM_sec NLM_sec_level_3"><div id="ac_i95" class="anchor-spacer"></div><h4 class="article-section__title" id="_i95"> (3<i>S</i>,6<i>S</i>)-4-(5-(4-Fluorophenyl)isoxazole-3-carbonyl)-3-isobutyl-6-neopentylpiperazin-2-one (<b>75</b>)</h4><div id="sec5_1_1_56_1" class="NLM_sec NLM_sec_level_4"><div id="ac_i96" class="anchor-spacer"></div><h5 class="article-section__title" id="_i96">A (3<i>S</i>,6<i>S</i>)-6-(2,2-Dimethyl-propyl)-3-isobutyl-piperazin-2-one</h5><div class="NLM_p last">Synthesized from (<i>S</i>)-2-((((9<i>H</i>-fluoren-9-yl)methoxy)carbonyl)amino)-4,4-dimethylpentanoic acid (15.0 g, 40 mmol) and HCl salt of Leu-OMe (3.5 g, 19.35 mmol) by the method described for the preparation of compound <b>7</b> (Scheme <a class="ref internalNav" href="#sch1" aria-label="1">1</a>) to afford (3<i>S</i>,6<i>S</i>)-6-(2,2-dimethyl-propyl)-3-isobutyl-piperazin-2-one (1.6 g, 35% yield) as a white solid. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 7.37 (s, 1 H), 3.30 (dd, <i>J</i> = 5.6 Hz, 4.0 Hz, 1 H), 3.07 (dd, <i>J</i> = 9.6 Hz, 4.0 Hz, 1 H), 2.83 (dd, <i>J</i> = 12.8 Hz, 4.0 Hz, 1 H), 2.56 (dd, <i>J</i> = 13.2 Hz, 6.0 Hz, 1 H), 1.90 (s, 1 H), 1.74–1.79 (m, 1 H), 1.33–1.49 (m, 4 H), 0.80–0.90 (m, 15 H). MS (ESI): <i>m</i>/<i>z</i> 227.0 (M + 1).</div></div><div id="sec5_1_1_56_2" class="NLM_sec NLM_sec_level_4"><div id="ac_i97" class="anchor-spacer"></div><h5 class="article-section__title" id="_i97">B (3<i>S</i>,6<i>S</i>)-4-(5-(4-Fluorophenyl)isoxazole-3-carbonyl)-3-isobutyl-6-neopentylpiperazin-2-one (<b>75</b>)</h5><div class="NLM_p last">(3<i>S</i>,6<i>S</i>)-6-(2,2-Dimethyl-propyl)-3-isobutyl-piperazin-2-one (56 mg, 0.25 mmol) and 5-(4-fluorophenyl)isoxazole-3-carboxylic acid (53 mg, 0.25 mmol) were coupled according to the procedure described for the preparation of compound <b>2a</b> to give <b>75</b> (94 mg, 90% yield) as a white solid. <sup>1</sup>H NMR (400 MHz, CD<sub>3</sub>OD) δ 7.86–7.82 (m, 2 H), 7.29–7.26 (m, 2 H), 7.06 (s, 1 H), 5.16–5.12 (m, 1 H), 4.53 (dd, <i>J</i> = 14.2 Hz, 4.4 Hz, 1 H), 3.79–3.71 (m, 1 H), 3.21 (dd, <i>J</i> = 14.2 Hz, 11.0 Hz, 1 H), 1.92–1.62 (m, 4 H), 1.48–1.32 (m, 2 H), 1.12–0.88 (m, 15 H). MS (ESI): <i>m</i>/<i>z</i> 416.1 (M + 1).</div></div></div><div id="sec5_1_1_57" class="NLM_sec NLM_sec_level_3"><div id="ac_i98" class="anchor-spacer"></div><h4 class="article-section__title" id="_i98"> (3<i>S</i>,6<i>S</i>)-6-((<i>R</i>)-<i>sec</i>-Butyl)-4-(5-(4-fluorophenyl)isoxazole-3-carbonyl)-3-isobutylpiperazin-2-one (<b>76</b>)</h4><div id="sec5_1_1_57_1" class="NLM_sec NLM_sec_level_4"><div id="ac_i99" class="anchor-spacer"></div><h5 class="article-section__title" id="_i99">A (3<i>S</i>,6<i>S</i>)-6-((<i>R</i>)-<i>sec</i>-Butyl)-3-isobutylpiperazin-2-one</h5><div class="NLM_p last">Synthesized from (2<i>S</i>,3<i>R</i>)-2-(Fmoc)amino-3-methylpentanoic acid (14.5 g, 40 mmol) and HCl salt of Leu-OMe (7.8 g, 42.95 mmol) by the method described for the preparation of compound <b>7</b> (Scheme <a class="ref internalNav" href="#sch1" aria-label="1">1</a>) to afford (3<i>S</i>,6<i>S</i>)-6-((<i>R</i>)-<i>sec</i>-butyl)-3-isobutylpiperazin-2-one (4.26 g, 50% yield) as a white solid. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 5.64 (s, 1 H), 3.10–3.43 (m, 3 H), 2.68–2.94 (m, 1 H), 1.05–1.94 (m, 6 H), 0.89–0.96 (m, 12 H). MS (ESI): <i>m</i>/<i>z</i> 213.1 (M + 1).</div></div><div id="sec5_1_1_57_2" class="NLM_sec NLM_sec_level_4"><div id="ac_i100" class="anchor-spacer"></div><h5 class="article-section__title" id="_i100">B (3<i>S</i>,6<i>S</i>)-6-((<i>R</i>)-<i>sec</i>-Butyl)-4-(5-(4-fluorophenyl)isoxazole-3-carbonyl)-3-isobutylpiperazin-2-one (<b>76</b>)</h5><div class="NLM_p last">(3<i>S</i>,6<i>S</i>)-6-((<i>R</i>)-<i>sec</i>-Butyl)-3-isobutylpiperazin-2-one (50 mg, 0.24 mmol) and 5-(4-fluorophenyl)isoxazole-3-carboxylic acid (53 mg, 0.25 mmol) were coupled according to the procedure described for the preparation of compound <b>2a</b> to furnish <b>76 (</b>79 mg, 83% yield) as a colorless solid. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 7.83–7.76 (m, 2 H), 7.22–7.16 (m, 2 H), 6.86 (s, 1 H), 6.24 (s, 1 H), 5.33–5.25 (m, 1 H), 5.00–4.70 (m, 1 H), 3.76–3.36 (m, 1 H), 3.34–3.11 (m, 1H), 1.91–1.71 (m, 3 H), 1.48–1.16 (m, 2 H), 1.05–0.71 (m, 12 H). MS (ESI): <i>m</i>/<i>z</i> 402.20 (M + 1).</div></div></div><div id="sec5_1_1_58" class="NLM_sec NLM_sec_level_3"><div id="ac_i101" class="anchor-spacer"></div><h4 class="article-section__title" id="_i101"> (3<i>S</i>,6<i>S</i>)-6-Allyl-4-(5-(4-fluorophenyl)isoxazole-3-carbonyl)-3-isobutylpiperazin-2-one (<b>77</b>)</h4><div id="sec5_1_1_58_1" class="NLM_sec NLM_sec_level_4"><div id="ac_i102" class="anchor-spacer"></div><h5 class="article-section__title" id="_i102">A (3<i>S</i>,6<i>S</i>)-6-Allyl-3-isobutylpiperazin-2-one</h5><div class="NLM_p last">Synthesized from (<i>S</i>)-2-((((9<i>H</i>-fluoren-9-yl)methoxy)-carbonyl)amino)pent-4-enoic acid (12.5 g, 37 mmmol) and HCl salt of Leu-OMe (7.8 g, 42.95 mmol) by the method described for the preparation of compound <b>7</b> (Scheme <a class="ref internalNav" href="#sch1" aria-label="1">1</a>) to afford (3<i>S</i>,6<i>S</i>)-6-allyl-3-isobutylpiperazin-2-one (2.6 g, 36% yield) as a white solid. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 6.01 (s, 1 H), 5.66–5.74 (m, 1 H), 5.15–5.17 (m, 1 H), 5.12–5.15 (m, 1 H), 3.38–3.43 (m, 2 H), 2.97–3.01 (m, 1 H), 2.79–2.84 (m, 1 H), 2.28–2.33 (m, 1 H), 2.16–2.20 (m, 1 H), 1.70–1.79 (m, 2 H), 1.66–1.69 (m, 1 H), 1.53–1.59 (m, 1 H), 0.90–0.96 (m, 6 H). MS (ESI): <i>m</i>/<i>z</i> 197.2 (M + 1).</div></div><div id="sec5_1_1_58_2" class="NLM_sec NLM_sec_level_4"><div id="ac_i103" class="anchor-spacer"></div><h5 class="article-section__title" id="_i103">B (3<i>S</i>,6<i>S</i>)-6-Allyl-4-(5-(4-fluorophenyl)isoxazole-3-carbonyl)-3-isobutylpiperazin-2-one (<b>77</b>)</h5><div class="NLM_p last">(3<i>S</i>,6<i>S</i>)-6-Allyl-3-isobutylpiperazin-2-one (40 mg, 0.20 mmol) and 5-(4-fluorophenyl)isoxazole-3-carboxylic acid (45 mg, 0.22 mmol) were coupled according to the procedure described for the preparation of compound <b>2a</b> to furnish <b>77</b> (60 mg, 79% yield) as a white solid. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 7.81–7.76 (m, 2 H), 7.22–7.16 (m, 2 H), 6.86 (m, 1 H), 5.99 (br s, 1 H), 5.76–5.67 (m, 1 H), 5.32–5.20 (m, 2 H), 4.88–4.78 (m, 1 H), 3.76–3.65 (m, 1 H), 3.18 (dd, <i>J</i> = 14.0 Hz, 11.2 Hz, 0.5 H), 2.89 (dd, <i>J</i> = 14.0 Hz, 11.2 Hz, 0.5 H), 2.42–2.36 (m, 1 H), 2.16–2.05 (m, 1 H), 1.92–1.63 (m, 4 H), 1.08–0.77 (m, 6 H). MS (ESI): <i>m</i>/<i>z</i> 386.1 (M + 1).</div></div></div><div id="sec5_1_1_59" class="NLM_sec NLM_sec_level_3"><div id="ac_i104" class="anchor-spacer"></div><h4 class="article-section__title" id="_i104"> (3<i>S</i>,6<i>S</i>)-6-(Cyclopropylmethyl)-4-(5-(4-fluorophenyl)isoxazole-3-carbonyl)-3-isobutyl-pipe-razin-2-one (<b>78</b>)</h4><div id="sec5_1_1_59_1" class="NLM_sec NLM_sec_level_4"><div id="ac_i105" class="anchor-spacer"></div><h5 class="article-section__title" id="_i105">A (3<i>S</i>,6<i>S</i>)-6-(Cyclopropylmethyl)-3-isobutylpiperazin-2-one</h5><div class="NLM_p last">Synthesized from Fmoc-cyclopropylalanine (23.6 g, 67.3 mmol) and HCl salt of Leu-OMe (6.6 g, 37.0 mmol) by the method described for the preparation of compound <b>7</b> (Scheme <a class="ref internalNav" href="#sch1" aria-label="1">1</a>) to afford (3<i>S</i>,6<i>S</i>)-6-(cyclopropylmethyl)-3-isobutylpiperazin-2-one (1.6 g, 11.5% yield) as a white solid. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 7.49 (s, 1 H), 3.24–3.27 (m, 1 H), 3.05–3.08 (dd, <i>J</i> = 9.6 Hz, 4.0 Hz, 1 H), 2.82–2.86 (dd, <i>J</i> = 13.2 Hz, 4.4 Hz, 1 H), 2.69–2.74 (dd, <i>J</i> = 12.8 Hz, 5.2 Hz, 1 H), 1.72–1.78 (m, 1 H), 1.39–1.49 (m, 2 H), 1.31–1.36 (m, 2 H), 0.81–0.89 (m, 6 H), 0.62–0.67 (m, 1 H), 0.38–0.40 (m, 2 H), 0.01–0.08 (m, 2 H). MS (ESI): <i>m</i>/<i>z</i> 210.9 (M + 1).</div></div><div id="sec5_1_1_59_2" class="NLM_sec NLM_sec_level_4"><div id="ac_i106" class="anchor-spacer"></div><h5 class="article-section__title" id="_i106">B (3<i>S</i>,6<i>S</i>)-6-(Cyclopropylmethyl)-4-(5-(4-fluorophenyl)isoxazole-3-carbonyl)-3-isobutylpipera-zin-2-one (<b>78</b>)</h5><div class="NLM_p last">(3<i>S</i>,6<i>S</i>)-6-(Cyclopropylmethyl)-3-isobutylpiperazin-2-one (50 mg, 0.24 mmol) and 5-(4-fluorophenyl)isoxazole-3-carboxylic acid (53 mg, 0.25 mmol) were coupled according to the procedure described for the preparation of compound <b>2a</b> to furnish <b>78</b> (53 mg, 54% yield) as a white solid. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 7.79–7.61 (m, 2 H), 7.19–7.15 (m, 2 H), 6.86 (s, 1 H), 6.47 (s, 1 H), 5.29–5.25 (m, 1 H), 4.93–4.88 (m, 1 H), 3.78–3.74 (m, 1 H), 3.21 (dd, <i>J</i> = 14.0 Hz, 11.0 Hz, 1 H), 1.88–1.52 (m, 4 H), 1.30–1.22 (m, 1 H), 1.08–0.96 (m, 6 H), 0.74–0.52 (m, 3 H), 0.21–0.08 (m, 2 H). MS (ESI): <i>m</i>/<i>z</i> 400.1 (M + 1).</div></div></div><div id="sec5_1_1_60" class="NLM_sec NLM_sec_level_3"><div id="ac_i107" class="anchor-spacer"></div><h4 class="article-section__title" id="_i107"> (3<i>S</i>,6<i>R</i>)-4-(5-(4-Fluorophenyl)isoxazole-3-carbonyl)-3-isobutyl-6-((methylthio)methyl)-piperazin-2-one (<b>79</b>)</h4><div id="sec5_1_1_60_1" class="NLM_sec NLM_sec_level_4"><div id="ac_i108" class="anchor-spacer"></div><h5 class="article-section__title" id="_i108">A (3<i>S</i>,6<i>R</i>)-3-Isobutyl-6-((methylthio)methyl)piperazin-2-one</h5><div class="NLM_p last">Synthesized from (<i>R</i>)-2-(Fmoc)amino-3-(methylthio)propanoic acid (23.9 g, 67 mmol) and HCl salt of Leu-OMe (6.6 g, 37.0 mmol) by the method described for the preparation of compound <b>7</b> to afford (3<i>S</i>,6<i>R</i>)-3-isobutyl-6-((methylthio)methyl)piperazin-2-one (1.7 g, 12% yield). <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 7.49 (s, 1 H), 3.31–3.33 (m, 1 H), 3.06–3.09 (m, 1 H), 2.84–2.89 (m, 2 H), 2.68–2.71 (m, 1 H), 2.53–2.54 (m,1 H), 2.05–2.06 (m, 3 H), 1.74–1.78 (m, 1 H), 1.51–1.54 (m, 1 H), 1.36–1.39 (m, 1 H), 0.82–0.88 (m, 6 H). MS (ESI): <i>m</i>/<i>z</i> 217.14 (M +1).</div></div><div id="sec5_1_1_60_2" class="NLM_sec NLM_sec_level_4"><div id="ac_i109" class="anchor-spacer"></div><h5 class="article-section__title" id="_i109">B (3<i>S</i>,6<i>R</i>)-4-(5-(4-Fluorophenyl)isoxazole-3-carbonyl)-3-isobutyl-6-((methylthio)methyl)-piperazin-2-one (<b>78</b>)</h5><div class="NLM_p last">(3<i>S</i>,6<i>R</i>)-3-Isobutyl-6-((methylthio)methyl)piperazin-2-one (50 mg, 0.23 mmol) and 5-(4-fluorophenyl)isoxazole-3-carboxylic acid (50 mg, 0.24 mmol) were coupled according to the procedure described for the preparation of compound <b>2a</b> to furnish <b>79</b> (30 mg, 30% yield) as a white solid. <sup>1</sup>H NMR (CDCl<sub>3</sub>) δ 7.82–7.77 (m, 2 H), 7.25–7.17 (m, 2 H), 6.88 (s, 0.5 H), 6.78 (s, 0.5 H), 6.52 (br s, 1 H), 5.39–5.28 (m, 1 H), 5.04–4.82 (m, 1 H), 4.50–4.39 (m, 1 H), 3.85- 3.74 (m, 1 H), 3.42–2.36 (m, 2 H), 2.15 (s, 2 H), 2.13 (s, 1 H), 1.94–1.86 (m, 1 H), 1.81–1.72 (m, 2 H), 1.10–0.78 (m, 6 H). MS (ESI): <i>m</i>/<i>z</i> 406.2 (M + 1).</div></div></div><div id="sec5_1_1_61" class="NLM_sec NLM_sec_level_3"><div id="ac_i110" class="anchor-spacer"></div><h4 class="article-section__title" id="_i110"> (3<i>S</i>,6<i>S</i>)-6-Butyl-4-(5-(4-fluorophenyl)isoxazole-3-carbonyl)-3-isobutylpiperazin-2-one (<b>80</b>)</h4><div id="sec5_1_1_61_1" class="NLM_sec NLM_sec_level_4"><div id="ac_i111" class="anchor-spacer"></div><h5 class="article-section__title" id="_i111">A (3<i>S</i>,6<i>S</i>)-3-Isobutyl-6-butyl-piperazin-2-one</h5><div class="NLM_p last">Synthesized from Fmoc-(<i>S</i>)-2-aminohexanoic acid (9.91 g, 28.5 mmol) and HCl salt of Leu-OMe (4.7 g, 26.25 mmol) by the method described for the preparation of compound <b>7</b> (Scheme <a class="ref internalNav" href="#sch1" aria-label="1">1</a>) to afford (3<i>S</i>,6<i>S</i>)-3-isobutyl-6-butyl-piperazin-2-one (3.4 g, 25% yield) as a white solid. MS (ESI): <i>m</i>/<i>z</i> 213.3 (M + 1).</div></div><div id="sec5_1_1_61_2" class="NLM_sec NLM_sec_level_4"><div id="ac_i112" class="anchor-spacer"></div><h5 class="article-section__title" id="_i112">B (3<i>S</i>,6<i>S</i>)-6-Butyl-4-(5-(4-fluorophenyl)isoxazole-3-carbonyl)-3-isobutylpiperazin-2-one (<b>80</b>)</h5><div class="NLM_p last">(3<i>S</i>,6<i>S</i>)-3-Isobutyl-6-butyl-piperazin-2-one (40 mg, 0.19 mmol) and 5-(4-fluorophenyl)isoxazole-3-carboxylic acid (50 mg, 0.24 mmol) were coupled according to the procedure described for the preparation of compound <b>2a</b> to furnish <b>80</b> (60 mg, 79% yield) as a white solid. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 7.80–7.76 (m, 2 H), 7.20–7.15 (m, 2 H), 6.86 (s, 1 H), 6.43 (br s, 1 H), 5.28–5.25 (m, 1 H), 4.87–4.77 (m, 1 H), 3.69–3.59 (m, 1 H), 3.13 (dd, <i>J</i> = 14.0 Hz, 11.2 Hz, 0.5H), 2.84 (dd, <i>J</i> = 14.0 Hz, 11.2 Hz, 0.5H), 2.80–2.74 (m, 2 H), 1.92–1.68 (m, 4 H), 1.58–1.24 (m, 7 H), 1.07–0.76 (m, 9 H). MS (ESI): <i>m</i>/<i>z</i> 402.2 (M + 1).</div></div></div><div id="sec5_1_1_62" class="NLM_sec NLM_sec_level_3"><div id="ac_i113" class="anchor-spacer"></div><h4 class="article-section__title" id="_i113"> (3<i>S</i>,6<i>S</i>)-4-(5-(4-Fluorophenyl)isoxazole-3-carbonyl)-3-isobutyl-6-(2-(methylthio)ethyl)-piperazin-2-one (<b>81</b>)</h4><div id="sec5_1_1_62_1" class="NLM_sec NLM_sec_level_4"><div id="ac_i114" class="anchor-spacer"></div><h5 class="article-section__title" id="_i114">A (3<i>S</i>,6<i>S</i>)-3-Isobutyl-6-(2-(methylthio)ethyl)piperazin-2-one</h5><div class="NLM_p last">Synthesized from (<i>S</i>)-2-(Fmoc)amino-4-(methylthio)butanoic acid (24.9 g, 67 mmol) and HCl salt of Leu-OMe (6.6 g, 37.0 mmol) by the method described for the preparation of compound <b>7</b> to afford (3<i>S</i>,6<i>S</i>)-3-isobutyl-6-(2-(methylthio)ethyl)piperazin-2-one (5.0 g, 49% yield). <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 6.14 (s, 1 H), 3.54 (s, 1 H), 3.39–3.42 (m, 1 H), 3.03–3.07 (m, 1 H), 2.83–2.87 (m, 1 H), 2.78 (s, 1 H), 2.53–2.58 (m, 2 H), 2.09–2.15 (m, 3 H), 1.86–1.90 (m, 1 H), 1.71–1.82 (m, 2 H), 1.54–1.57 (m, 1 H), 0.90–0.96 (m, 6 H). MS (ESI): <i>m</i>/<i>z</i> 231.1 (M + 1).</div></div><div id="sec5_1_1_62_2" class="NLM_sec NLM_sec_level_4"><div id="ac_i115" class="anchor-spacer"></div><h5 class="article-section__title" id="_i115">B (3<i>S</i>,6<i>S</i>)-4-(5-(4-Fluorophenyl)isoxazole-3-carbonyl)-3-isobutyl-6-(2-(methylthio)ethyl)-piperazin-2-one (<b>81</b>)</h5><div class="NLM_p last">(3<i>S</i>,6<i>S</i>)-3-Isobutyl-6-(2-(methylthio)ethyl)piperazin-2-one (50 mg, 0.22 mmol) and 5-(4-fluorophenyl)isoxazole-3-carboxylic acid (45 mg, 0.22 mmol) were coupled according to the procedure described for the preparation of compound <b>2a</b> to furnish <b>81</b> (71 mg, 78% yield) as a colorless solid. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 7.81–7.76 (m, 2 H), 7.22–7.16 (m, 2 H), 6.87 (s, 1 H), 6.41 (s, 1 H), 5.33–5.26 (m, 1 H), 4.93–4.79 (m, 1 H), 3.86–3.77 (m, 1 H), 3.20–2.91 (m, 1 H), 2.63–2.58 (m, 2 H), 2.13 (s, 3 H), 1.92–1.70 (m, 5 H), 1.08–0.78 (m, 6 H). MS (ESI): <i>m</i>/<i>z</i> 420.10 (M + 1).</div></div></div><div id="sec5_1_1_63" class="NLM_sec NLM_sec_level_3"><div id="ac_i116" class="anchor-spacer"></div><h4 class="article-section__title" id="_i116"> (3<i>S</i>,6<i>S</i>)-6-Ethyl-4-(5-(4-fluorophenyl)isoxazole-3-carbonyl)-3-isobutylpiperazin-2-one (<b>82</b>)</h4><div id="sec5_1_1_63_1" class="NLM_sec NLM_sec_level_4"><div id="ac_i117" class="anchor-spacer"></div><h5 class="article-section__title" id="_i117">A (3<i>S</i>,6<i>S</i>)-3-Isobutyl-6-ethylpiperazin-2-one</h5><div class="NLM_p last">Synthesized from (<i>S</i>)-2-(Fmoc)amino-butanoic acid (21.8 g, 67 mmol) and HCl salt of Leu-OMe (6.6 g, 37.0 mmol) by the method described for the compound <b>7</b> to afford (3<i>S</i>,6<i>S</i>)-3-isobutyl-6-ethylpiperazin-2-one (2.1 g, 65% yield). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 6.03 (s, 1 H), 3.21–3.37 (m, 2 H), 2.91–2.97 (m, 1 H), 2.72–2.76 (m, 1 H), 1.63–1.67 (m, 1 H), 1.44–1.52 (m, 3 H), 0.85–0.91 (m, 9 H). MS (ESI): <i>m</i>/<i>z</i> 185.1 (M + 1).</div></div><div id="sec5_1_1_63_2" class="NLM_sec NLM_sec_level_4"><div id="ac_i118" class="anchor-spacer"></div><h5 class="article-section__title" id="_i118">B (3<i>S</i>,6<i>S</i>)-6-Ethyl-4-(5-(4-fluorophenyl)isoxazole-3-carbonyl)-3-isobutylpiperazin-2-one (<b>82</b>)</h5><div class="NLM_p last">(3<i>S</i>,6<i>S</i>)-3-Isobutyl-6-ethylpiperazin-2-one (50 mg, 0.27 mmol) and 5-(4-fluorophenyl)isoxazole-3-carboxylic acid (56 mg, 0.27 mmol) were coupled according to the procedure described for the preparation of compound <b>2a</b> to furnish <b>82</b> (50 mg, 50% yield) as a colorless solid. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 7.80–7.76 (m, 2 H), 7.26–7.16 (m, 2 H), 6.86 (s, 1 H), 5.97 (s, 1 H), 5.32–5.27 (m, 1 H), 4.91–4.80 (m, 1 H), 3.64–3.55 (m, 1 H), 3.18–2.83 (m, 1 H), 1.92–1.69 (m, 2 H), 1.63–1.48 (m, 3 H), 1.09–0.77 (m, 9 H). MS (ESI): <i>m</i>/<i>z</i> 374.10 (M + 1).</div></div></div><div id="sec5_1_1_64" class="NLM_sec NLM_sec_level_3"><div id="ac_i119" class="anchor-spacer"></div><h4 class="article-section__title" id="_i119"> (3<i>S</i>,6<i>S</i>)-4-(5-(4-Fluorophenyl)isoxazole-3-carbonyl)-3-isobutyl-6-isopropylpiperazin-2-one (<b>83</b>)</h4><div id="sec5_1_1_64_1" class="NLM_sec NLM_sec_level_4"><div id="ac_i120" class="anchor-spacer"></div><h5 class="article-section__title" id="_i120">A (3<i>S</i>,6<i>S</i>)-3-Isobutyl-6-isopropylpiperazin-2-one</h5><div class="NLM_p last">Synthesized from Fmoc-<span class="smallcaps smallerCapital">l</span>-valine (27.4 g, 80 mmol) and HCL salt of Leu-OMe (3.4 g, 23 mmol) by the method described for the preparation of compound <b>7</b> (Scheme <a class="ref internalNav" href="#sch1" aria-label="1">1</a>) to afford the (3<i>S</i>,6<i>S</i>)-3-isobutyl-6-isopropylpiperazin-2-one (2.5 g, 22% yield) as a white solid. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 5.88 (s, 1 H), 3.40 (dd, <i>J</i> = 10.4 Hz, 4.0 Hz, 1H), 3.09–3.06 (m, 1 H), 2.94–2.86 (m, 2 H), 1.77–1.72 (m, 2 H), 1.59–1.55 (dd, <i>J</i> = 10.4 Hz, 4.4 Hz, 1 H), 1.31–1.23 (m, 1 H), 0.95–0.90 (m, 12 H). MS (ESI): <i>m</i>/<i>z</i> 199.0 (M + 1).</div></div><div id="sec5_1_1_64_2" class="NLM_sec NLM_sec_level_4"><div id="ac_i121" class="anchor-spacer"></div><h5 class="article-section__title" id="_i121">B (3<i>S</i>,6<i>S</i>)-4-(5-(4-Fluorophenyl)isoxazole-3-carbonyl)-3-isobutyl-6-isopropylpiperazin-2-one (<b>83</b>)</h5><div class="NLM_p last">(3<i>S</i>,6<i>S</i>)-3-Isobutyl-6-isopropylpiperazin-2-one (50 mg, 0.25 mmol) and 5-(4-fluorophenyl)isoxazole-3-carboxylic acid (52 mg, 0.25 mmol) were coupled according to the procedure described for the preparation of compound <b>2a</b> to furnish <b>83</b> (43 mg, 44% yield) as a white solid. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 7.80–7.76 (m, 2 H), 7.21–7.16 (m, 2 H), 6.87 (s, 1 H), 5.97 (s, 1 H), 5.31–5.27 (m, 1 H), 4.92–4.77 (m, 1 H), 3.53–3.44 (m, 1 H), 3.23–2.90 (m, 1 H), 1.90–1.69 (m, 4 H), 1.08–0.77 (m, 12 H). MS (ESI): <i>m</i>/<i>z</i> 388.1 (M + 1).</div></div></div><div id="sec5_1_1_65" class="NLM_sec NLM_sec_level_3"><div id="ac_i122" class="anchor-spacer"></div><h4 class="article-section__title" id="_i122"> (3<i>S</i>,6<i>S</i>)-6-(<i>tert</i>-Butyl)-4-(5-(4-fluorophenyl)isoxazole-3-carbonyl)-3-isobutylpiperazin-2-one (<b>84</b>)</h4><div id="sec5_1_1_65_1" class="NLM_sec NLM_sec_level_4"><div id="ac_i123" class="anchor-spacer"></div><h5 class="article-section__title" id="_i123">A (3<i>S</i>,6<i>S</i>)-6-(<i>tert</i>-Butyl)-3-isobutylpiperazin-2-one</h5><div class="NLM_p last">Synthesized from Fmoc-<span class="smallcaps smallerCapital">l</span>-<i>tert</i>-leucine (23.0 g, 16 mmol) and HCL salt of Leu-OMe (5.0 g, 27.0 mmol) by the method described for the preparation of compound <b>7</b> (Scheme <a class="ref internalNav" href="#sch1" aria-label="1">1</a>) to afford (3<i>S</i>,6<i>S</i>)-6-(<i>tert</i>-butyl)-3-isobutylpiperazin-2-one (1.0 g, 16% yield) as a white solid. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 7.18 (s, 1 H), 3.05–3.09 (m, 2 H), 2.97–2.99 (m, 1 H), 2.66–2.69 (m, 1 H), 2.60–2.64 (m, 1 H), 1.76–1.89 (m, 1 H), 1.38–1.44 (m, 2 H), 0.86–0.89 (m, 15 H). MS (ESI): <i>m</i>/<i>z</i> 213.0 (M + 1).</div></div><div id="sec5_1_1_65_2" class="NLM_sec NLM_sec_level_4"><div id="ac_i124" class="anchor-spacer"></div><h5 class="article-section__title" id="_i124">B (3<i>S</i>,6<i>S</i>)-6-(<i>tert</i>-Butyl)-4-(5-(4-fluorophenyl)isoxazole-3-carbonyl)-3-isobutylpiperazin-2-one (<b>84</b>)</h5><div class="NLM_p last">(3<i>S</i>,6<i>S</i>)-3-Isobutyl-6-isopropylpiperazin-2-one (50 mg, 0.24 mmol) and 5-(4-fluorophenyl)-isoxazole-3-carboxylic acid (50 mg, 0.24 mmol) were coupled according to the procedure described for the preparation of compound <b>2a</b> to furnish <b>84</b> (78 mg, 82% yield) as a colorless solid. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 7.80–7.77 (m, 2 H), 7.21–7.16 (m, 2 H), 6.87 (s, 1 H), 5.85 (s, 1 H), 5.30–5.27 (m, 1 H), 4.95–4.79 (m, 1 H), 3.48–3.37 (m, 1 H), 3.25–2.92 (m, 1 H), 1.90–1.81 (m, 1 H), 1.77–1.71 (m, 2 H), 1.09–0.79 (m, 15 H). MS (ESI): <i>m</i>/<i>z</i> 402.10 (M – 1).</div></div></div><div id="sec5_1_1_66" class="NLM_sec NLM_sec_level_3"><div id="ac_i125" class="anchor-spacer"></div><h4 class="article-section__title" id="_i125"> (3<i>S</i>,6<i>S</i>)-6-Cyclopropyl-4-(5-(4-fluorophenyl)isoxazole-3-carbonyl)-3-isobutylpiperazin-2-one (<b>85</b>)</h4><div id="sec5_1_1_66_1" class="NLM_sec NLM_sec_level_4"><div id="ac_i126" class="anchor-spacer"></div><h5 class="article-section__title" id="_i126">A (3<i>S</i>,6<i>S</i>)-6-Cyclopropyl-3-isobutylpiperazin-2-one</h5><div class="NLM_p last">Synthesized from Fmoc-<span class="smallcaps smallerCapital">l</span>-cyclopropylglycine (13.78 g, 43 mmol) and HCl salt of Leu-OMe (6.0 g, 32.9 mmol) by the method described for the compound <b>7</b> (Scheme <a class="ref internalNav" href="#sch1" aria-label="1">1</a>) to afford (3<i>S</i>,6<i>S</i>)-6-cyclopropyl-3-isobutylpiperazin-2-one (1.7 g, 20% yield) as a white solid. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 7.575 (s, 1 H), 3.43 (t, <i>J</i> = 4.0 Hz, 1 H), 2.81–2.82 (m, 1 H), 2.78–2.79 (m, 2 H), 2.38–2.39 (m, 2 H), 1.72–1.80 (m, 1 H), 1.49–1.52 (m, 1 H), 1.45–1.47 (m, 1 H), 0.95–1.05 (m, 1 H), 0.87 (d, <i>J</i> = 3.2 Hz, 3 H), 0.82 (d, <i>J</i> = 3.2 Hz, 3 H), 0.42–0.45 (m, 1 H), 0.32–0.36 (m, 1 H), 0.24–0.26 (m, 1 H), 0.08–0.12 (m, 1 H). MS (ESI): <i>m</i>/<i>z</i> 197.1 (M + 1).</div></div><div id="sec5_1_1_66_2" class="NLM_sec NLM_sec_level_4"><div id="ac_i127" class="anchor-spacer"></div><h5 class="article-section__title" id="_i127">B (3<i>S</i>,6<i>S</i>)-6-Cyclopropyl-4-(5-(4-fluorophenyl)isoxazole-3-carbonyl)-3-isobutylpiperazin-2-one (<b>85</b>)</h5><div class="NLM_p last">(3<i>S</i>,6<i>S</i>)-6-Cyclopropyl-3-isobutylpiperazin-2-one (50 mg, 0.25 mmol) and 5-(4-fluorophenyl)-isoxazole-3-carboxylic acid (52 mg, 0.25 mmol) were coupled according to the procedure described for the preparation of compound <b>2a</b> to furnish <b>85</b> (78 mg, 79% yield) as a white solid. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 7.80–7.77 (m, 2 H), 7.20–7.16 (m, 2 H), 6.85 (s, 1 H), 6.05 (s, 1 H), 5.29–5.24 (m, 1 H), 4.94–4.86 (m, 1 H), 3.35–3.02 (m, 1 H), 2.88–2.77 (m, 1 H), 1.92–1.88 (m, 1 H), 1.83–1.71 (m, 2 H), 1.09–0.92 (m, 6 H), 0.79–0.75 (m, 2 H), 0.64–0.60 (m, 2 H), 0.43–0.27 (m, 1 H). MS (ESI): <i>m</i>/<i>z</i> 386.1 (M + 1).</div></div></div><div id="sec5_1_1_67" class="NLM_sec NLM_sec_level_3"><div id="ac_i128" class="anchor-spacer"></div><h4 class="article-section__title" id="_i128"> (3<i>S</i>,6<i>S</i>)-6-Cyclobutyl-4-(5-(4-fluorophenyl)isoxazole-3-carbonyl)-3-isobutylpiperazin-2-one (<b>86</b>)</h4><div id="sec5_1_1_67_1" class="NLM_sec NLM_sec_level_4"><div id="ac_i129" class="anchor-spacer"></div><h5 class="article-section__title" id="_i129">A (3<i>S</i>,6<i>S</i>)-6-Cyclobutyl-3-isobutylpiperazin-2-one</h5><div class="NLM_p last">Synthesized from Fmoc-(<i>S</i>)-amino-cyclobutyl-acetic acid (11.3 g, 32.19 mmol) and HCl salt of Leu-OMe (3.67 g, 20.3 mmol) by the method described for the compound <b>7</b> (Scheme <a class="ref internalNav" href="#sch1" aria-label="1">1</a>) to afford (3<i>S</i>,6<i>S</i>)-6-cyclobutyl-3-isobutylpiperazin-2-one (1.55 g, 26% yield) as a white solid. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 5.74 (s, 1 H), 3.35–3.38 (m, 1 H), 3.24–3.26 (m, 1 H), 2.89–2.94 (dd, <i>J</i> = 13.2 Hz, 4.4 Hz, 1 H), 2.68–2.73 (m, 1 H), 2.41–2.45 (m, 1 H), 1.90–2.04 (m, 3 H), 1.63–1.81 (m, 5 H), 1.51–1.54 (m, 2 H), 0.85–0.94 (m, 6 H). MS (ESI): <i>m</i>/<i>z</i> 211.1 (M + 1).</div></div><div id="sec5_1_1_67_2" class="NLM_sec NLM_sec_level_4"><div id="ac_i130" class="anchor-spacer"></div><h5 class="article-section__title" id="_i130">B (3<i>S</i>,6<i>S</i>)-6-Cyclobutyl-4-(5-(4-fluorophenyl)isoxazole-3-carbonyl)-3-isobutylpiperazin-2-one (<b>86</b>)</h5><div class="NLM_p last">(3<i>S</i>,6<i>S</i>)-6-Cyclobutyl-3-isobutylpiperazin-2-one (42 mg, 0.20 mmol) and 5-(4-fluorophenyl)isoxa-zole-3-carboxylic acid (42 mg, 0.20 mmol) were coupled according to the procedure described for the preparation of compound <b>2a</b> to furnish <b>98</b> (55 mg, 69% yield) as a white solid. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 7.80–7.77 (m, 2 H), 7.26–7.16 (m, 2 H), 6.87 (s, 1 H), 5.91 (s, 1 H), 5.30–5.25 (m, 1 H), 4.84–5.73 (m, 1 H), 3.69–3.55 (m, 1 H), 3.09 (dd, <i>J</i> = 14.0 Hz, 11.2 Hz, 0.5 H), 2.73 (dd, <i>J</i> = 14.0 Hz, 11.2 Hz, 0.5 H), 2.38–2.29 (m, 1 H), 2.14–1.66 (m, 9 H), 1.08–0.76 (m, 6 H). MS (ESI): <i>m</i>/<i>z</i> 400.0 (M + 1).</div></div></div><div id="sec5_1_1_68" class="NLM_sec NLM_sec_level_3"><div id="ac_i131" class="anchor-spacer"></div><h4 class="article-section__title" id="_i131"> (3<i>S</i>,6<i>S</i>)-6-Cyclopentyl-4-(5-(4-fluorophenyl)isoxazole-3-carbonyl)-3-isobutylpiperazin-2-one (<b>87</b>)</h4><div id="sec5_1_1_68_1" class="NLM_sec NLM_sec_level_4"><div id="ac_i132" class="anchor-spacer"></div><h5 class="article-section__title" id="_i132">A (3<i>S</i>,6<i>S</i>)-6-Cyclopentyl-3-isobutylpiperazin-2-one</h5><div class="NLM_p last">Synthesized from Fmoc-<span class="smallcaps smallerCapital">l</span>-cyclopentyl-glycine (10.23 g, 28 mmol) and HCl salt of Leu-OMe (6.7 g, 36.8 mmol) by the method described for the preparation of compound <b>7</b> (Scheme <a class="ref internalNav" href="#sch1" aria-label="1">1</a>) to afford (3<i>S</i>,6<i>S</i>)-6-cyclopentyl-3-isobutyl-piperazin-2-one (1.1 g, 16% yield) as a white solid. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 7.51 (s, 1 H), 3.08 (dd, <i>J</i> = 10.0 Hz, 3.6 Hz, 1 H), 2.93 (dd, <i>J</i> = 7.6 Hz, 3.6 Hz, 1 H), 2.77 (dd, <i>J</i> = 12.8 Hz, 4.0 Hz, 1 H), 2.68 (dd, <i>J</i> = 12.8 Hz, 4.8 Hz, 1 H), 1.97 (s, 1 H), 1.38–1.55 (m, 9 H), 1.08–1.22 (m, 3 H), 0.80–0.90 (m, 6 H). MS (ESI): <i>m</i>/<i>z</i> 225.1 (M + 1).</div></div><div id="sec5_1_1_68_2" class="NLM_sec NLM_sec_level_4"><div id="ac_i133" class="anchor-spacer"></div><h5 class="article-section__title" id="_i133">B (3<i>S</i>,6<i>S</i>)-6-Cyclopentyl-4-(5-(4-fluorophenyl)isoxazole-3-carbonyl)-3-isobutylpiperazin-2-one (<b>87</b>)</h5><div class="NLM_p last">(3<i>S</i>,6<i>S</i>)-6-Cyclopentyl-3-isobutylpiperazin-2-one (50 mg, 0.22 mmol) and 5-(4-fluorophenyl)-isoxazole-3-carboxylic acid (46 mg, 0.22 mmol) were coupled according to the procedure described for the preparation of compound <b>2a</b> to furnish <b>87</b> (56 mg, 61% yield) as a white solid. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 7.81–7.76 (m, 2 H), 7.21–7.16 (m, 2 H), 6.87 (s, 1 H), 5.94 (s, 1 H), 5.29–5.26 (m, 1 H), 4.93–4.79 (m, 1 H), 3.53–3.41 (m, 1 H), 3.19–2.86 (m, 1 H), 1.91–1.58 (m, 10 H), 1.32–1.23 (m, 2 H), 1.09–0.77 (m, 6 H). MS (ESI): <i>m</i>/<i>z</i> 414.1 (M + 1).</div></div></div><div id="sec5_1_1_69" class="NLM_sec NLM_sec_level_3"><div id="ac_i134" class="anchor-spacer"></div><h4 class="article-section__title" id="_i134"> (3<i>S</i>,6<i>S</i>)-6-Cyclohexyl-4-(5-(4-fluorophenyl)isoxazole-3-carbonyl)-3-isobutylpiperazin-2-one (<b>88</b>)</h4><div id="sec5_1_1_69_1" class="NLM_sec NLM_sec_level_4"><div id="ac_i135" class="anchor-spacer"></div><h5 class="article-section__title" id="_i135">A (3<i>S</i>,6<i>S</i>)-6-Cyclohexyl-3-isobutylpiperazin-2-one</h5><div class="NLM_p last">Synthesized from Fmoc-<span class="smallcaps smallerCapital">l</span>-cyclohexylglycine (22.78 g, 60 mmol) and HCl salt of Leu-OMe (6.0 g, 32.8 mmol) by the method described for the preparation of compound <b>7</b> (Scheme <a class="ref internalNav" href="#sch1" aria-label="1">1</a>) to afford the product (3<i>S</i>,6<i>S</i>)-6-cyclohexyl-3-isobutylpiperazin-2-one (1.2 g, 8% yield) as a white solid. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 7.45 (s, 1 H), 3.08 (dd, <i>J</i> = 10.0 Hz, 4.4 Hz, 1 H), 2.95 (d, <i>J</i> = 5.6 Hz, 1 H), 2.76 (dd, <i>J</i> = 13.6 Hz, 6.0 Hz, 1 H), 2.68 (dd, <i>J</i> = 13.2 Hz, 4.4 Hz, 1 H), 1.59–1.77 (m, 6 H), 1.38–1.45 (m, 3 H), 1.09–1.16 (m, 3 H), 0.89–0.95 (m, 5 H), 0.72–0.88 (m, 3 H). MS (ESI): <i>m</i>/<i>z</i> 239.0 (M + 1).</div></div><div id="sec5_1_1_69_2" class="NLM_sec NLM_sec_level_4"><div id="ac_i136" class="anchor-spacer"></div><h5 class="article-section__title" id="_i136">B (3<i>S</i>,6<i>S</i>)-6-Cyclohexyl-4-(5-(4-fluorophenyl)isoxazole-3-carbonyl)-3-isobutylpiperazin-2-one (<b>88</b>)</h5><div class="NLM_p last">(3<i>S</i>,6<i>S</i>)-6-Cyclohexyl-3-isobutylpiperazin-2-one (50 mg, 0.24 mmol) and 5-(4-fluorophenyl)-isoxazole-3-carboxylic acid (43 mg, 0.21 mmol) were coupled according to the procedure described for the preparation of compound <b>2a</b> to furnish <b>88</b> (46 mg, 51% yield) as a white solid. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 7.81–7.76 (m, 2 H), 7.21–7.16 (m, 2 H), 6.86 (s, 1 H), 5.86 (s, 1 H), 5.30–5.27 (m, 1 H), 4.92–4.78 (m, 1 H), 3.53–3.44 (m, 1 H), 3.26–2.93 (m, 1 H), 1.88–1.70 (m, 8 H), 1.45–1.37 (m, 1 H), 1.29–1.11 (m, 5 H), 1.09–0.77 (m, 6 H). MS (ESI): <i>m</i>/<i>z</i> 428.1 (M + 1).</div></div></div><div id="sec5_1_1_70" class="NLM_sec NLM_sec_level_3"><div id="ac_i137" class="anchor-spacer"></div><h4 class="article-section__title" id="_i137"> (3<i>S</i>,6<i>S</i>)-4-(5-(4-Fluorophenyl)isoxazole-3-carbonyl)-3-isobutyl-6-(3,3,3-trifluoro-2-(trifluoromethyl)propyl)piperazin-2-one (<b>89</b>)</h4><div id="sec5_1_1_70_1" class="NLM_sec NLM_sec_level_4"><div id="ac_i138" class="anchor-spacer"></div><h5 class="article-section__title" id="_i138">A (3<i>S</i>,6<i>S</i>)-3-Isobutyl-6-(3,3,3-trifluoro-2-(trifluoromethyl)-propyl)piperazin-2-one</h5><div class="NLM_p last">Synthesized from (<i>S</i>)-2-((((9<i>H</i>-fluoren-9-yl)methoxy)carbonyl)amino)-5,5,5-trifluoro-4-(trifluoro-methyl)pentanoic acid (9.22 g, 20 mmol) and HCl salt of Leu-OMe (3.0 g, 16.4 mmol) by the method described for the compound 7 (Scheme <a class="ref internalNav" href="#sch1" aria-label="1">1</a>) to afford (3<i>S</i>,6<i>S</i>)-3-isobutyl-6-(3,3,3-trifluoro-2-(trifluoromethyl)propyl)piperazin-2-one (321 mg, 5% yield). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 6.83 (s, 1 H), 3.87–3.89 (m, 0.5 H), 3.72–3.75 (m, 0.5 H), 3.52–3.56 (m, 1 H), 2.89–2.92 (m, 1 H), 3.11–3.15 (m, 1 H), 2.86–2.90 (m, 1 H), 2.28–2.35 (m, 1 H), 1.97–2.01 (m, 1 H), 1.66–1.80 (m, 2 H), 1.49–1.52 (m, 1 H), 0.85–0.89 (m, 6 H). MS (ESI): <i>m</i>/<i>z</i> 321.1 (M + 1).</div></div><div id="sec5_1_1_70_2" class="NLM_sec NLM_sec_level_4"><div id="ac_i139" class="anchor-spacer"></div><h5 class="article-section__title" id="_i139">B (3<i>S</i>,6<i>S</i>)-4-(5-(4-Fluorophenyl)isoxazole-3-carbonyl)-3-isobutyl-6-(3,3,3-trifluoro-2-(trifluoromethyl)propyl)piperazin-2-one (<b>89</b>)</h5><div class="NLM_p last">(3<i>S</i>,6<i>S</i>)-3-Isobutyl-6-(3,3,3-trifluoro-2-(trifluoromethyl)propyl)-piperazin-2-one (40 m g, 0.14 mmol) and 5-(4-fluorophenyl)-isoxazole-3-carboxylic acid (30 mg, 0.14 mmol) were coupled according to the procedure described for the preparation of compound <b>2a</b> to furnish compound <b>89</b> (40 mg, 48% yield) as a white solid. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 7.82–7.79 (m, 2 H), 7.22–7.17 (m, 2 H), 6.91 (s, 1 H), 5.39 (t, <i>J</i> = 6.0 Hz, 0.5 H), 5.28 (dd, <i>J</i> = 7.2 Hz, 4.0 Hz, 1 H), 5.06 (d, <i>J</i> = 13.2 Hz, 1 H), 4.89 (d, <i>J</i> = 7.2 Hz, 0.5 H), 3.99–3.85 (m, 1 H), 3.40–3.34 (m, 1 H), 3.17 (dd, <i>J</i> = 14.8 Hz, 10.2 Hz, 1 H), 2.07–1.83 (m, 3 H), 1.77–1.71 (m, 2 H), 1.08 (d, <i>J</i> = 6.4 Hz, 2 H), 0.99 (d, <i>J</i> = 6.4 Hz, 2 H), 0.94 (d, <i>J</i> = 6.0 Hz, 1 H), 0.81 (d, <i>J</i> = 6.0 Hz, 1 H). MS (ESI): <i>m</i>/<i>z</i> 510.2 (M + 1).</div></div></div><div id="sec5_1_1_71" class="NLM_sec NLM_sec_level_3"><div id="ac_i140" class="anchor-spacer"></div><h4 class="article-section__title" id="_i140"> (3<i>S</i>,6<i>R</i>)-4-(5-(4-Fluorophenyl)isoxazole-3-carbonyl)-6-(hydroxymethyl)-3-isobutylpipera-zin-2-one (<b>90</b>)</h4><div class="NLM_p last">Compound <b>14</b> (2.00 g, 8.25 mmol) and HCl in dioxane (4 N, 20 mL) were stirred at 70 °C for 1.5 h and then concentrated under vacuo to give the crude (3<i>S</i>,6<i>R</i>)-6-(hydroxymethyl)-3-isobutylpiperazin-2-one, which was used for the next step without further purification. Crude compound of (3<i>S</i>,6<i>R</i>)-6-(hydroxymethyl)-3-isobutylpiperazin-2-one (0.20 g, 0.90 mmol) and 5-(4-fluorophenyl)-isoxazole-3-carboxylic acid (0.19 g, 0.90 mmol) were coupled according to the procedure described for the preparation of compound <b>2a</b> to furnish <b>90</b> (0.294 g, 87% yield) as a white solid. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 8.03–7.99 (m, 2 H), 7.93 (s, 0.3 H), 7.90 (s, 0.7 H), 7.45–7.41 (m, 2 H), 7.37 (s, 1 H), 5.01 (m, 0.3 H), 4.92–4.89 (m, 1.7 H), 4.69–4.60 (m, 0.3 H), 4.21 (dd, <i>J</i> = 14.4 Hz, 4.4 Hz, 0.7 H), 3.53–3.48 (m, 1 H), 3.46–3.41 (m, 1 H), 3.31–3.27 (m, 1.7 H), 3.05 (m, 0.3 H), 1.81 (t, <i>J</i> = 9.6 Hz, 1 H), 1.68–1.61 (m, 2 H), 0.98 (d, <i>J</i> = 6.0 Hz, 2.4 H), 0.94 (d, <i>J</i> = 6.0 Hz, 2.4 H), 0.81 (d, <i>J</i> = 6.4 Hz, 0.6 H), 0.61 (d, <i>J</i> = 6.4 Hz, 0.6 H). MS (ESI): <i>m</i>/<i>z</i> 376.2 (M + 1).</div></div><div id="sec5_1_1_72" class="NLM_sec NLM_sec_level_3"><div id="ac_i141" class="anchor-spacer"></div><h4 class="article-section__title" id="_i141"> (3<i>S</i>,6<i>R</i>)-4-(5-(4-Fluorophenyl)isoxazole-3-carbonyl)-3-isobutyl-6-(methoxymethyl)pipera-zin-2-one (<b>91</b>)</h4><div class="NLM_p last">To a soluton of alcohol <b>90</b> (50 mg, 0.13 mmol) in MeCN (3 mL) under argon was added MeI (83 uL, 1.33 mmol) and Ag<sub>2</sub>O (154 mg, 0.66 mmol) and stirred at rt for 3 days. The reaction mixture was filtered through a short pad of Celite, concentrated in vacuo, and purified by column chromatography (0–80% EtOAc in hexanes) to give <b>91</b> (19 mg, 37% yield) as a colorless solid. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 8.06–8.00 (m, 3 H), 7.45–7.40 (m, 2 H), 7.38 (s, 1 H), 4.90 (m, 1 H), 4.70–4.56 (m, 1 H), 4.21 (m, 1 H), 3.68 (m, 1 H), 3.44–3.37 (m, 1 H), 3.23 (s, 2 H), 3.18–3.05 (m, 1 H), 2.69 (s, 1 H), 1.81 (t, <i>J</i> = 10.0 Hz, 1 H), 1.69–1.59 (m, 2 H), 0.98 (d, <i>J</i> = 5.6 Hz, 3 H), 0.94 (d, <i>J</i> = 6.0 Hz, 3 H). MS (ESI): <i>m</i>/<i>z</i> 390.2 (M +1).</div></div><div id="sec5_1_1_73" class="NLM_sec NLM_sec_level_3"><div id="ac_i142" class="anchor-spacer"></div><h4 class="article-section__title" id="_i142"> (3<i>S</i>,6<i>S</i>)-6-((Dimethylamino)methyl)-4-(5-(4-fluorophenyl)isoxazole-3-carbonyl)-3-isobutyl-piperazin-2-one (<b>92</b>)</h4><div class="NLM_p last">To a solution of the alcohol <b>90</b> (0.20 g, 0.53 mmol) in DMF (3 mL) was added Et<sub>3</sub>N (0.23 mL, 1.65 mmol) and MsCl (70 uL, 0.90 mmol) and stirred at rt for 16 h and then concentrated in vacuo. The residue was purified by column chromatography (0–75% EtOAc in hexanes) to give the crude mesylate product (0.132 g, 55% yield), which was used for the next step without further purification. MS (ESI): <i>m</i>/<i>z</i> 454.2 (M + 1). To a solution of the mesylate (30 mg, 0.07 mmol) in DMF (2 mL) was added dimethyamine in THF (2 M, 0.17 mL, 0.34 mmol) and heated at 60 °C for 16 h. The reaction mixture was concentrated in vacuo and purified by column chromatography (0–90% EtOAc in hexanes) to give <b>92</b> (19 mg, 71% yield) as a white solid. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 8.01 (m, 2 H), 7.76 (s, 1 H), 7.68 (s, 3 H), 7.45–7.38 (m, 3 H), 4.91–4.89 (m, 1 H), 4.70–4.64 (m, 1 H), 4.25–4.18 (m, 1 H), 3.74–3.64 (m, 1 H), 3.22 (m, 1 H), 2.36–2.25 (m, 2 H), 2.09 (s, 6 H), 1.84 (t, <i>J</i> = 10.8 Hz, 1 H), 1.67–1.63 (m, 1 H), 0.98 (d, <i>J</i> = 5.6 Hz, 2.5 H), 0.94 (d, <i>J</i> = 6.0 Hz, 2.5 H), 0.81 (d, <i>J</i> = 6.4 Hz, 0.5 H), 0.61 (d, <i>J</i> = 6.4 Hz, 0.5 H). MS (ESI): <i>m</i>/<i>z</i> 403.2 (M + 1).</div></div><div id="sec5_1_1_74" class="NLM_sec NLM_sec_level_3"><div id="ac_i143" class="anchor-spacer"></div><h4 class="article-section__title" id="_i143"> (3<i>S</i>)-4-(5-(4-Fluorophenyl)isoxazole-3-carbonyl)-3-isobutyl-6-(tetrahydro-2<i>H</i>-pyran-4-yl)-piperazin-2-one (<b>93</b>)</h4><div id="sec5_1_1_74_1" class="NLM_sec NLM_sec_level_4"><div id="ac_i144" class="anchor-spacer"></div><h5 class="article-section__title" id="_i144">A (3<i>S</i>)-3-Isobutyl-6-(tetrahydro-2<i>H</i>-pyran-4-yl)piperazin-2-one</h5><div class="NLM_p last">Synthesized from Fmoc-2-amino-2-(tetrahydro-2<i>H</i>-pyran-4-yl)acetic acid (11.98 g, 31.4 mmol) and hydrochloride salt of Leu-OMe (3.0 g, 16.4 mmol) by the method described for the compound <b>7</b> to afford (3<i>S</i>)-3-isobutyl-6-(tetrahydro-2<i>H</i>-pyran-4-yl)piperazin-2-one (0.50 g, 6.70% yield) as a white solid. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 6.12–6.35 (m, 1 H), 3.94–4.09 (m, 2 H), 2.94–3.38 (m, 5 H), 2.00–2.01 (m, 1 H), 1.20–1.86 (m, 9 H), 0.87–0.93 (m, 6 H). MS (ESI): <i>m</i>/<i>z</i> 241.17 (M + 1).</div></div><div id="sec5_1_1_74_2" class="NLM_sec NLM_sec_level_4"><div id="ac_i145" class="anchor-spacer"></div><h5 class="article-section__title" id="_i145">B (3<i>S</i>)-4-(5-(4-Fluorophenyl)isoxazole-3-carbonyl)-3-isobutyl-6-(tetrahydro-2<i>H</i>-pyran-4-yl)-piperazin-2-one (<b>93</b>)</h5><div class="NLM_p last">(3<i>S</i>)-3-Isobutyl-6-(tetrahydro-2<i>H</i>-pyran-4-yl)piperazin-2-one (36 mg, 0.15 mmol) and 5-(4-fluorophenyl)isoxazole-3-carboxylic acid (35 mg, 0.17 mmol) were coupled according to the procedure described for the preparation of compound <b>2a</b> to furnish <b>93</b> (10 mg, 15% yield) as a white solid. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 7.80–7.77 (m, 2 H), 7.21–7.10 (m, 2 H), 6.88 (s, 1 H), 6.17 (br s, 1 H), 5.34–5.27 (m, 1 H), 4.99 and 4.82 (dd, <i>J</i> = 13.2 Hz, 4.4 Hz, 1 H), 4.06–4.00 (m, 2 H), 3.59–3.47 (m, 1 H), 3.43–3.34 (m, 2 H), 3.23 and 2.95 (dd, <i>J</i> = 13.6 Hz, 11.2 Hz, 1 H), 1.90–1.42 (m, 8 H) and 1.08–0.78 (m, 6 H). MS (ESI): <i>m</i>/<i>z</i> 430.1 (M + 1).</div></div></div><div id="sec5_1_1_75" class="NLM_sec NLM_sec_level_3"><div id="ac_i146" class="anchor-spacer"></div><h4 class="article-section__title" id="_i146"> (3<i>S</i>,6<i>S</i>)-4-(5-(4-Fluorophenyl)isoxazole-3-carbonyl)-3-isobutyl-6-(tetrahydro-2<i>H</i>-thiopyran-4-yl)piperazin-2-one (<b>94</b>)</h4><div id="sec5_1_1_75_1" class="NLM_sec NLM_sec_level_4"><div id="ac_i147" class="anchor-spacer"></div><h5 class="article-section__title" id="_i147">A (3<i>S</i>,6<i>S</i>)-3-Isobutyl-6-(tetrahydro-2<i>H</i>-thiopyran-4-yl)piperazin-2-one</h5><div class="NLM_p last">Synthesized from Fmoc-2-amino-2-(tetrahydro-2<i>H</i>-thiopyran-4-yl)acetic acid (12 g, 31 mmol) and HCl salt of Leu-OMe (3.0 g, 16.4 mmol) by the method described for the preparation of compound <b>7</b> to afford (3<i>S</i>,6<i>S</i>)-3-isobutyl-6-(tetrahydro-2<i>H</i>-thiopyran-4-yl)piperazin-2-one (0.77 g, 37% yield) as a brown solid. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 6.09 (s, 1 H), 3.31–3.37 (m, 2 H), 3.10–3.14 (m, 1 H), 2.62–2.74 (m, 5 H), 1.90–2.03 (m, 3 H), 1.84–1.88 (m, 1 H), 1.71–1.80 (m, 1 H), 1.37–1.54 (m, 4 H), 0.87–0.95 (m, 6 H). MS (ESI): <i>m</i>/<i>z</i> 257.17 (M + 1).</div></div><div id="sec5_1_1_75_2" class="NLM_sec NLM_sec_level_4"><div id="ac_i148" class="anchor-spacer"></div><h5 class="article-section__title" id="_i148">B (3<i>S</i>,6<i>S</i>)-4-(5-(4-Fluorophenyl)isoxazole-3-carbonyl)-3-isobutyl-6-(tetrahydro-2<i>H</i>-thiopyran-4-yl)piperazin-2-one (<b>94</b>)</h5><div class="NLM_p last">(3<i>S</i>,6<i>S</i>)-3-Isobutyl-6-(tetrahydro-2<i>H</i>-thiopyran-4-yl)piperazin-2-one (50 mg, 0.27 mmol) and 5-(4-fluorophenyl)isoxazole-3-carboxylic acid (44 mg, 0.27 mmol) were coupled according to the procedure described for the preparation of compound <b>2a</b> to furnish compound <b>94</b> (37 mg, 42% yield) as a colorless gum. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 7.81–7.77 (m, 2 H), 7.22–7.16 (m, 2 H), 6.87 (s, 1 H), 6.32 (s, 1 H), 5.32–5.26 (m, 1 H), 4.92–4.71 (m, 1 H), 3.65–3.54 (m, 1 H), 3.29–2.95 (m, 1 H), 2.73–2.66 (m, 4 H), 2.09–2.06 (m, 2 H), 1.90–1.82 (m, 1 H), 1.76–1.66 (m, 2 H), 1.60–1.54 (m, 2 H), 1.08–0.0.78 (m, 6 H). MS (ESI): <i>m</i>/<i>z</i> 445.97 (M + 1).</div></div></div><div id="sec5_1_1_76" class="NLM_sec NLM_sec_level_3"><div id="ac_i149" class="anchor-spacer"></div><h4 class="article-section__title" id="_i149"> (3<i>S</i>,6<i>S</i>)-4-(5-(4-Fluorophenyl)isoxazole-3-carbonyl)-3-isobutyl-6-phenylpiperazin-2-one (<b>95</b>)</h4><div id="sec5_1_1_76_1" class="NLM_sec NLM_sec_level_4"><div id="ac_i150" class="anchor-spacer"></div><h5 class="article-section__title" id="_i150">A (3<i>S</i>,6<i>S</i>)-3-Isobutyl-6-phenylpiperazin-2-one</h5><div class="NLM_p last">Synthesized from Fmoc-<span class="smallcaps smallerCapital">l</span>-2-phenylglycine (23.41 g, 63 mmol) and HCl salt of Leu-OMe (8 g, 56 mmol) by the method described for the compound <b>7</b> (Scheme <a class="ref internalNav" href="#sch1" aria-label="1">1</a>) to afford the (3<i>S</i>,6<i>S</i>)-3-isobutyl-6-phenylpiperazin-2-one (2.0 g, 9% yield) as a white solid. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 7.35–7.40 (m, 2 H), 7.24–7.32 (m, 2 H), δ 6.12 (s, 1 H), 4.62 (q, <i>J</i> = 7.2 Hz, 1 H), 3.49 (dd, <i>J</i> = 10.4 Hz, 3.2 Hz, 1 H), 3.22–3.27 (m, 1 H), 2.98 (dd, <i>J</i> = 13.6 Hz, 5.2 Hz, 1 H), 1.68–1.87 (m, 2 H), 1.54–1.61 (m, 1 H), 0.94 (d, <i>J</i> = 3.2 Hz, 3 H), 0.91 (d, <i>J</i> = 3.2 Hz, 3 H). MS (ESI): <i>m</i>/<i>z</i> 233.2 (M + 1).</div></div><div id="sec5_1_1_76_2" class="NLM_sec NLM_sec_level_4"><div id="ac_i151" class="anchor-spacer"></div><h5 class="article-section__title" id="_i151">B (3<i>S</i>,6<i>S</i>)-4-(5-(4-Fluorophenyl)isoxazole-3-carbonyl)-3-isobutyl-6-phenylpiperazin-2-one (<b>95</b>)</h5><div class="NLM_p last">(3<i>S</i>,6<i>S</i>)-3-Isobutyl-6-phenylpiperazin-2-one (50 mg, 0.22 mmol) and 5-(4-fluorophenyl)isoxazole-3-carboxylic acid (45 mg, 0.22 mmol) were coupled according to the procedure described for the preparation of compound <b>2a</b> to furnish <b>95</b> (69 mg, 76% yield) as a white solid. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 7.82–7.78 (m, 2 H), 7.44–7.36 (m, 5 H), 7.22–7.16 (m, 2 H), 6.89 (s, 1 H), 6.04 (s, 1 H), 5.43–5.36 (m, 1 H), 4.97–4.88 (m, 2 H), 3.37–3.06 (m, 1 H), 2.04–1.94 (m, 1 H), 1.93–1.84 (m, 1 H), 1.80–1.70 (m, 1 H), 1.11–0.81 (m, 6 H). MS (ESI): <i>m</i>/<i>z</i> 422.1 (M +1).</div></div></div><div id="sec5_1_1_77" class="NLM_sec NLM_sec_level_3"><div id="ac_i152" class="anchor-spacer"></div><h4 class="article-section__title" id="_i152"> (3<i>S</i>,6<i>S</i>)-4-(5-(4-Fluorophenyl)isoxazole-3-carbonyl)-3-isobutyl-6-(<i>p</i>-tolyl)piperazin-2-one (<b>96</b>)</h4><div id="sec5_1_1_77_1" class="NLM_sec NLM_sec_level_4"><div id="ac_i153" class="anchor-spacer"></div><h5 class="article-section__title" id="_i153">A (3<i>S</i>,6<i>S</i>)-3-Isobutyl-6-<i>p</i>-tolyl-piperazin-2-one</h5><div class="NLM_p last">Synthesized from (<i>S</i>)-2-amino-2-(<i>p</i>-tolyl)acetic acid (5.0g, 30 mmol) and HCl salt of Leu-OMe (4.37 g, 24.3 mmol) by the method described for the preparation of compound <b>7</b> (Scheme <a class="ref internalNav" href="#sch1" aria-label="1">1</a>) to afford (3<i>S</i>,6<i>S</i>)-3-Isobutyl-6-<i>p</i>-tolyl-piperazin-2-one (1.44 g, 19% yield) as a white solid. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 7.87 (s, 1 H), 7.15 (s, 4 H), 4.41–4.44 (m, 1 H), 3.17–3.20 (m, 1 H), 3.00–3.03 (m, 1 H), 2.68–2.72 (m, 1 H), 2.31 (s, 1 H), 2.28 (s, 3 H), 1.72–1.80 (m, 1 H), 1.51–1.62 (m, 1 H), 1.44–1.49 (m, 1 H), 0.89 (d, <i>J</i> = 5.6 Hz, 3 H), 0.85 (d, <i>J</i> = 6.4 Hz, 3 H). MS (ESI): <i>m</i>/<i>z</i> 247.1 (M + 1).</div></div><div id="sec5_1_1_77_2" class="NLM_sec NLM_sec_level_4"><div id="ac_i154" class="anchor-spacer"></div><h5 class="article-section__title" id="_i154">B (3<i>S</i>,6<i>S</i>)-4-(5-(4-Fluorophenyl)isoxazole-3-carbonyl)-3-isobutyl-6-(<i>p</i>-tolyl)piperazin-2-one (<b>96</b>)</h5><div class="NLM_p last">(3<i>S</i>,6<i>S</i>)-3-Isobutyl-6-<i>p</i>-tolyl-piperazin-2-one (50 mg, 0.20 mmol) and 5-(4-fluorophenyl)-isoxazole-3-carboxylic acid (41 mg, 0.20 mmol) were coupled according to the procedure described for the preparation of compound <b>2a</b> to furnish <b>96</b> (77 mg, 88% yield) as a white solid. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 7.82–7.78 (m, 2 H), 7.28–7.18 (m, 6 H), 6.89 (s, 0.7 H), 6.81 (s, 0.3 H), 6.01 (br s, 0.7 H), 5.97 (br s, 0.3 H), 5.45–5.36 (m, 1 H), 4.94–4.73 (m, 2 H), 3.33 (dd, <i>J</i> = 14.0 Hz, 10.4 Hz, 1 H), 2.38 (s, 1 H), 2.37 (s, 2 H), 2.05–1.68 (m, 3 H), 1.17–0.81 (m, 6 H). MS (ESI): <i>m</i>/<i>z</i> 436.2 (M + 1).</div></div></div><div id="sec5_1_1_78" class="NLM_sec NLM_sec_level_3"><div id="ac_i155" class="anchor-spacer"></div><h4 class="article-section__title" id="_i155"> (3<i>S</i>,6<i>S</i>)-4-(5-(4-Fluorophenyl)isoxazole-3-carbonyl)-3-isobutyl-6-(<i>o</i>-tolyl)piperazin-2-one (<b>97</b>)</h4><div id="sec5_1_1_78_1" class="NLM_sec NLM_sec_level_4"><div id="ac_i156" class="anchor-spacer"></div><h5 class="article-section__title" id="_i156">A (3<i>S</i>,6<i>S</i>)-3-Isobutyl-6-<i>o</i>-tolyl-piperazin-2-one</h5><div class="NLM_p last">Synthesized from (<i>S</i>)-amino-<i>o</i>-tolyl-acetic acid (4 g, 24.2 mmol) and HCl salt of Leu-OMe (3.3 g, 22.9 mmol) by the method described for the preparation of compound <b>7</b> (Scheme <a class="ref internalNav" href="#sch1" aria-label="1">1</a>) to afford (3<i>S</i>,6<i>S</i>)-3-Isobutyl-6-<i>o</i>-tolyl-piperazin-2-one (1.2 g, 20% yield) as a white solid. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 7.67 (s, 1 H), 7.18 (dd, <i>J</i> = 4.0 Hz, 2.0 Hz, 2 H), 7.11 (dd, <i>J</i> = 4.8 Hz, 3.2 Hz, 2 H), 4.66 (m, 1 H), 3.17 (dd, <i>J</i> = 10.0 Hz, 3.6 Hz, 1 H), 3.01 (dd, <i>J</i> = 13.2 Hz, 4.4 Hz, 1 H), 2.63 (dd, <i>J</i> = 13.2 Hz, 5.6 Hz, 1 H), 2.29–2.31 (m, 1 H), 2.24 (s, 3 H), 1.71–1.77 (m, 1 H), 1.43–1.62 (m, 2 H), 0.86 (d, <i>J</i> = 6.8 Hz, 3 H), 0.82 (d, <i>J</i> = 6.8 Hz, 3 H). MS (ESI): <i>m</i>/<i>z</i> 247.1 (M + 1).</div></div><div id="sec5_1_1_78_2" class="NLM_sec NLM_sec_level_4"><div id="ac_i157" class="anchor-spacer"></div><h5 class="article-section__title" id="_i157">B (3<i>S</i>,6<i>S</i>)-4-(5-(4-Fluorophenyl)isoxazole-3-carbonyl)-3-isobutyl-6-(<i>o</i>-tolyl)piperazin-2-one (<b>97</b>)</h5><div class="NLM_p last">(3<i>S</i>,6<i>S</i>)-3-Isobutyl-6-(<i>o</i>-tolyl)piperazin-2-one (50 mg, 0.2 mmol) and 5-(4-fluorophenyl)isoxazole-3-carboxylic acid (41 mg, 0.2 mmol) were coupled according to the procedure described for the preparation of compound <b>2a</b> to furnish <b>97</b> (77 mg, 87% yield) as a colorless solid. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 7.82–7.77 (m, 2 H), 7.42–7.39 (m, 1 H), 7.30–7.17 (m, 5 H), 6.89 (s, 1 H), 5.90 (s, 1 H), 5.46–5.37 (m, 1 H), 5.17–5.02 (m, 1 H), 4.98–4.87 (m, 1 H), 3.30–2.96 (m, 1 H), 2.45 (s, 3 H), 2.04–1.71 (m, 3 H), 1.12–0.83 (m, 6 H). MS (ESI): <i>m</i>/<i>z</i> 436.1 (M + 1).</div></div></div><div id="sec5_1_1_79" class="NLM_sec NLM_sec_level_3"><div id="ac_i158" class="anchor-spacer"></div><h4 class="article-section__title" id="_i158"> (3<i>S</i>,6<i>S</i>)-6-(4-Chlorophenyl)-4-(5-(4-fluorophenyl)isoxazole-3-carbonyl)-3-isobutyl-piperazin-2-one (<b>98</b>)</h4><div id="sec5_1_1_79_1" class="NLM_sec NLM_sec_level_4"><div id="ac_i159" class="anchor-spacer"></div><h5 class="article-section__title" id="_i159">A (3<i>S</i>,6<i>S</i>)-6-(4-Chloro-phenyl)-3-isobutyl-piperazin-2-one</h5><div class="NLM_p last">Synthesized from (<i>S</i>)-2-amino-2-(4-chlorophenyl)acetic acid (10.0 g, 53.88 mmol) and HCl salt of Leu-OMe (13.9 g, 76.51 mmol) by the method described for the preparation of compound <b>7</b> (Scheme <a class="ref internalNav" href="#sch1" aria-label="1">1</a>) to afford (3<i>S</i>,6<i>S</i>)-6-(4-chlorophenyl)-3-isobutyl-piperazin-2-one (445 mg, 3% yield) as a white solid. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 7.34–7.37 (m, 2 H), 7.20–7.25 (m, 2 H), 5.94 (s, 1 H), 4.60 (dd, <i>J</i> = 7.8 Hz, 4.8 Hz, 1 H), 3.51(dd, <i>J</i> = 10.4 Hz, 3.2 Hz, 1 H), 3.26 (dd, <i>J</i> = 13.6 Hz, 4.8 Hz,1 H), 2.94–2.99 (m, 1 H), 1.75–1.88 (m, 3 H), 1.55–1.61 (m, 1 H), 0.94 (dd, <i>J</i> = 12.8 Hz, 6.4 Hz, 6H). MS (ESI): <i>m</i>/<i>z</i> 267.0 (M + 1).</div></div><div id="sec5_1_1_79_2" class="NLM_sec NLM_sec_level_4"><div id="ac_i160" class="anchor-spacer"></div><h5 class="article-section__title" id="_i160">B (3<i>S</i>,6<i>S</i>)-6-(4-Chlorophenyl)-4-(5-(4-fluorophenyl)isoxazole-3-carbonyl)-3-isobutyl-piperazin-2-one (<b>98</b>)</h5><div class="NLM_p last">(3<i>S</i>,6<i>S</i>)-6-(4-Chloro-phenyl)-3-isobutyl-piperazin-2-one (53 mg, 0.20 mmol) and 5-(4-fluorophenyl)-isoxazole-3-carboxylic acid (41 mg, 0.20 mmol) were coupled according to the procedure described for the preparation of compound <b>2a</b> to furnish <b>98</b> (73 mg, 85% yield) as a white solid. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 7.82–7.78 (m, 2 H), 7.42–7.34 (m, 4 H), 7.20 (m, 2 H), 6.90 (s, 1 H), 5.93 (br s, 1 H), 5.39 (dd, <i>J</i> = 14.4 Hz, 4.4 Hz, 1 H), 4.99–4.76 (m, 2 H), 3.30 (dd, <i>J</i> = 14.0 Hz, 10.8 Hz, 1 H), 2.01–1.70 (m, 3 H), 1.02 (d, <i>J</i> = 6.4 Hz, 2 H), 1.00 (d, <i>J</i> = 6.8 Hz, 2 H), 0.97–0.82 (m, 2 H). MS (ESI): <i>m</i>/<i>z</i> 456.2 (M + 1).</div></div></div><div id="sec5_1_1_80" class="NLM_sec NLM_sec_level_3"><div id="ac_i161" class="anchor-spacer"></div><h4 class="article-section__title" id="_i161"> (3<i>S</i>,6<i>S</i>)-6-(4-Fluorophenyl)-4-(5-(4-fluorophenyl)isoxazole-3-carbonyl)-3-isobutyl-piperazin-2-one (<b>99</b>)</h4><div id="sec5_1_1_80_1" class="NLM_sec NLM_sec_level_4"><div id="ac_i162" class="anchor-spacer"></div><h5 class="article-section__title" id="_i162">A (3<i>S</i>,6<i>S</i>)-6-(4-Fluorophenyl)-3-isobutyl-piperazin-2-one</h5><div class="NLM_p last">Synthesized from (<i>S</i>)-amino-(4-fluorophenyl)-acetic acid (10 g, 60 mmol) and HCl salt of Leu-OMe (1.56 g, 10.67 mmol) by the method described for the preparation of compound <b>7</b> (Scheme <a class="ref internalNav" href="#sch1" aria-label="1">1</a>) to afford (3<i>S</i>,6<i>S</i>)-6-(4-fluorophenyl)-3-isobutyl-piperazin-2-one (420 mg, 3% yield) as a white solid. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 7.96 (s, 1 H), 7.37 (dd, <i>J</i> = 6.4 Hz, 2.8 Hz, 2 H),7.23 (dd, <i>J</i> = 11.2 Hz, 9.2 Hz, 2 H), 4.54 (d, <i>J</i> = 2.4 Hz, 1 H), 3.26 (dd, <i>J</i> = 10 Hz, 3.6 Hz, 1 H), 3.10 (dd, <i>J</i> = 13.2 Hz, 4.4 Hz, 1 H), 2.79 (dd, <i>J</i> = 12.8 Hz, 4.8 Hz, 1 H), 2.45 (s, 1 H), 1.80–1.84 (m, 1 H), 1.53–1.70 (m, 2 H), 0.95 (d, <i>J</i> = 6.8 Hz, 3 H), 0.91 (d, <i>J</i> = 6.4 Hz, 3 H). MS (ESI): <i>m</i>/<i>z</i> 251.1 (M +1).</div></div><div id="sec5_1_1_80_2" class="NLM_sec NLM_sec_level_4"><div id="ac_i163" class="anchor-spacer"></div><h5 class="article-section__title" id="_i163">B (3<i>S</i>,6<i>S</i>)-6-(4-Fluorophenyl)-4-(5-(4-fluorophenyl)isoxazole-3-carbonyl)-3-isobutyl-piperazin-2-one (<b>99</b>)</h5><div class="NLM_p last">(3<i>S</i>,6<i>S</i>)-6-(4-Fluorophenyl)-3-isobutyl-piperazin-2-one (50 mg, 0.20 mmol) and 5-(4-fluorophenyl)-isoxazole-3-carboxylic acid (41 mg, 0.20 mmol) were coupled according to the procedure described for the preparation of compound <b>2a</b> to furnish <b>99</b> (68 mg, 78% yield) as a white solid. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 7.82–7.78 (m, 2 H), 7.40–7.37 (m, 2 H), 7.22–7.18 (m, 2 H), 7.14–7.10 (m, 2 H), 6.90 (s, 1 H), 6.06 (br s, 1 H), 5.39–5.36 (m, 1 H), 4.98–4.76 (m, 2 H), 3.31 (dd, <i>J</i> = 13.6 Hz, 10.0 Hz, 1 H), 2.01–1.92 (m, 1 H), 1.89–1.73 (m, 2 H), 1.11 (d, <i>J</i> = 6.4 Hz, 2 H), 1.00 (d, <i>J</i> = 6.8 Hz, 2 H), 0.96–0.82 (m, 2 H). MS (ESI): <i>m</i>/<i>z</i> 440.2 (M +1).</div></div></div><div id="sec5_1_1_81" class="NLM_sec NLM_sec_level_3"><div id="ac_i164" class="anchor-spacer"></div><h4 class="article-section__title" id="_i164"> (3<i>S</i>,6<i>S</i>)-6-(3-Fluorophenyl)-4-(5-(4-fluorophenyl)isoxazole-3-carbonyl)-3-isobutylpiperazin-2-one (<b>100</b>)</h4><div id="sec5_1_1_81_1" class="NLM_sec NLM_sec_level_4"><div id="ac_i165" class="anchor-spacer"></div><h5 class="article-section__title" id="_i165">A (3<i>S</i>,6<i>S</i>)-6-(3-Fluorophenyl)-3-isobutyl-piperazin-2-one</h5><div class="NLM_p last">Synthesized from (<i>S</i>)-amino-(3-fluorophenyl)-acetic acid (9 g, 53 mmol) and HCl salt of Leu-OMe (6.9 g, 38 mmol) by the method described for the preparation of compound <b>7</b> (Scheme <a class="ref internalNav" href="#sch1" aria-label="1">1</a>) to afford (3<i>S</i>,6<i>S</i>)-6-(3-fluorophenyl)-3-isobutyl-piperazin-2-one (478 mg, 4% yield) as a white solid. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 7.32–7.38 (m, 1 H), 6.99–7.07 (m, 2 H), 6.10 (s, 1 H), 4.62 (dd, <i>J</i> = 7.6 Hz, 4.4 Hz, 1 H), 3.50 (dd, <i>J</i> = 13.2 Hz, 4.4 Hz, 1 H), 3.00 (dd, <i>J</i> = 13.2 Hz, 4.8 Hz, 1 H), 1.76–1.88 (m, 2 H), 1.55–1.60 (m, 2 H), 0.95 (dd, <i>J</i> = 12.8 Hz, 6.4 Hz, 6 H). MS (ESI): <i>m</i>/<i>z</i> 251.0 (M + 1).</div></div><div id="sec5_1_1_81_2" class="NLM_sec NLM_sec_level_4"><div id="ac_i166" class="anchor-spacer"></div><h5 class="article-section__title" id="_i166">B (3<i>S</i>,6<i>S</i>)-6-(3-Fluorophenyl)-4-(5-(4-fluorophenyl)isoxazole-3-carbonyl)-3-isobutyl-piperazin-2-one (<b>100</b>)</h5><div class="NLM_p last">(3<i>S</i>,6<i>S</i>)-6-(3-Fluorophenyl)-3-isobutyl-piperazin-2-one (50 mg, 0.2 mmol) and 5-(4-fluorophenyl)isoxazole-3-carboxylic acid (41 mg, 0.2 mmol) were coupled according to the procedure described for the preparation of compound <b>2a</b> to furnish <b>100</b> (67 mg, 76% yield) as a colorless solid. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 7.82–7.78 (m, 2 H), 7.44–7.37 (m, 1 H), 7.26–7.18 (m, 3 H), 7.13–7.05 (m, 2 H), 6.90–6.81 (m, 1 H), 6.12–6.10 (m, 1 H), 5.45–5.35 (m, 1 H), 5.01–4.77 (m, 2 H), 3.35–3.04 (m, 1 H), 1.99–1.92 (m, 1 H), 1.89–1.08 (m, 1 H), 1.78–1.71 (m, 1 H), 1.11–0.81 (m, 6 H). MS (ESI): <i>m</i>/<i>z</i> 440.0 (M + 1).</div></div></div><div id="sec5_1_1_82" class="NLM_sec NLM_sec_level_3"><div id="ac_i167" class="anchor-spacer"></div><h4 class="article-section__title" id="_i167"> (3<i>S</i>,6<i>S</i>)-6-(2-Fluorophenyl)-4-(5-(4-fluorophenyl)isoxazole-3-carbonyl)-3-isobutyl-piperazin-2-one (<b>101</b>)</h4><div id="sec5_1_1_82_1" class="NLM_sec NLM_sec_level_4"><div id="ac_i168" class="anchor-spacer"></div><h5 class="article-section__title" id="_i168">A (3<i>S</i>,6<i>S</i>)-6-(3-Fluorophenyl)-3-isobutyl-piperazin-2-one</h5><div class="NLM_p last">Synthesized from (<i>S</i>)-amino-(2-fluorophenyl)-acetic acid (5.0 g, 29.58 mmol) and HCl salt of Leu-OMe (7.8 g, 42.95 mmol) by the method described for the preparation of compound <b>7</b> (Scheme <a class="ref internalNav" href="#sch1" aria-label="1">1</a>) to afford (3<i>S</i>,6<i>S</i>)-6-(2-fluorophenyl)-3-isobutyl-piperazin-2-one (660 mg, 9% yield). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 7.28–7.36 (m, 2 H), 7.17–7.21 (m, 1 H), 7.04–7.09 (m, 1 H), 6.14 (s, 1 H), 4.96 (dd, <i>J</i> = 7.8 Hz, 4.0 Hz, 1 H), 3.50 (dd, <i>J</i> = 10.8 Hz, 3.6 Hz, 1 H), 3.32 (dd, <i>J</i> = 10.8 Hz, 3.6 Hz, 1 H), 3.07 (dd, <i>J</i> = 13.2 Hz, 3.6 Hz, 1 H), 1.85–1.91 (m, 1 H), 1.75–1.81 (m, 1 H), 1.51–1.58 (m, 2 H), 0.91–0.96 (m, 6 H). MS (ESI): <i>m</i>/<i>z</i> 251.1 (M + 1).</div></div><div id="sec5_1_1_82_2" class="NLM_sec NLM_sec_level_4"><div id="ac_i169" class="anchor-spacer"></div><h5 class="article-section__title" id="_i169">B (3<i>S</i>,6<i>S</i>)-6-(2-Fluorophenyl)-4-(5-(4-fluorophenyl)isoxazole-3-carbonyl)-3-isobutyl-piperazin-2-one (<b>101</b>)</h5><div class="NLM_p last">(3<i>S</i>,6<i>S</i>)-6-(2-Fluorophenyl)-3-isobutyl-piperazin-2-one (50 mg, 0.20 mmol) and 5-(4-fluorophenyl)-isoxazole-3-carboxylic acid (41 mg, 0.20 mmol) were coupled according to the procedure described for the preparation of compound <b>2a</b> to furnish <b>101</b> (69 mg, 86% yield) as a white solid. <sup>1</sup>H NMR (CDCl<sub>3</sub>) δ 7.83–7.78 (m, 2 H), 7.43–7.34 (m, 2 H), 7.25–7.09 (m, 4 H), 6.89 (s, 1 H), 5.90 (br s, 1 H), 5.41 (dd, <i>J</i> = 10.0 Hz, 4.8 Hz, 1 H), 5.17–5.02 (m, 2 H), 3.49 (dd, <i>J</i> = 14.4 Hz, 11.2 Hz, 1 H), 2.01–1.86 (m, 2 H), 1.82–1.70 (m, 1 H), 1.11 (d, <i>J</i> = 6.4 Hz, 3 H), 1.01 (d, <i>J</i> = 6.8 Hz, 3 H). MS (ESI): <i>m</i>/<i>z</i> 440.2 (M + 1).</div></div></div><div id="sec5_1_1_83" class="NLM_sec NLM_sec_level_3"><div id="ac_i170" class="anchor-spacer"></div><h4 class="article-section__title" id="_i170"> (3<i>S</i>,6<i>S</i>)-4-(5-(4-Fluorophenyl)isoxazole-3-carbonyl)-3-isobutyl-6-(4-(trifluoromethyl)-phenyl)piperazin-2-one (<b>102</b>)</h4><div id="sec5_1_1_83_1" class="NLM_sec NLM_sec_level_4"><div id="ac_i171" class="anchor-spacer"></div><h5 class="article-section__title" id="_i171">A (3<i>S</i>,6<i>S</i>)-3-Isobutyl-6-(4-trifluoromethyl-phenyl)-piperazin-2-one</h5><div class="NLM_p last">Synthesized from (<i>S</i>)-amino-(4-trifluoromethyl-phenyl)-acetic acid (3.0 g, 13.70 mmol) and HCl salt of Leu-OMe (3.5 g, 19.20 mmol) by the method described for the preparation of compound <b>7</b> (Scheme <a class="ref internalNav" href="#sch1" aria-label="1">1</a>) to afford (3<i>S</i>,6<i>S</i>)-3-isobutyl-6-(4-trifluoromethyl-phenyl)-piperazin-2-one (217 mg, 5% yield) as a white solid. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 7.65 (d, <i>J</i> = 8.0 Hz, 2 H), 7.42 (d, <i>J</i> = 8.0 Hz, 2 H), 6.07 (s, 1 H), 4.70–4.71 (m, 1 H), 3.54 (dd, <i>J</i> = 10.4 Hz, 3.6 Hz, 1 H), 3.33 (dd, <i>J</i> = 13.2 Hz, 4.8 Hz, 1 H), 3.02 (dd, <i>J</i> = 13.2 Hz, 4.4 Hz, 1 H), 1.75–1.88 (m, 3 H), 1.58–1.62 (m, 1 H), 0.97 (d, <i>J</i> = 6.4 Hz, 3 H), 0.94 (d, <i>J</i> = 6.4 Hz, 3 H). MS (ESI): <i>m</i>/<i>z</i> 301.0 (M + 1).</div></div><div id="sec5_1_1_83_2" class="NLM_sec NLM_sec_level_4"><div id="ac_i172" class="anchor-spacer"></div><h5 class="article-section__title" id="_i172">B (3<i>S</i>,6<i>S</i>)-4-(5-(4-Fluorophenyl)isoxazole-3-carbonyl)-3-isobutyl-6-(4-(trifluoromethyl)-phenyl)piperazin-2-one (<b>102</b>)</h5><div class="NLM_p last">(3<i>S</i>,6<i>S</i>)-3-Isobutyl-6-(4-trifluoromethyl-phenyl)-piperazin-2-one (50 mg, 0.17 mmol) and 5-(4-fluorophenyl)isoxazole-3-carboxylic acid (35 mg, 0.17 mmol) were coupled according to the procedure described for the preparation of compound <b>2a</b> to furnish compound <b>102</b> (43 mg, 53% yield) as a colorless solid. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 7.69–7.67 (m, 2 H), 7.51–7.47 (m, 2 H), 7.32–7.20 (m, 3 H), 7.12–7.08 (m, 1 H), 6.03 (s, 1 H), 5.35–4.80 (m, 1 H), 4.78–4.72 (m, 1 H), 4.69–4.17 (m, 1 H), 3.37–2.81 (m, 1 H), 2.60–2.55 (m, 1 H), 1.98–1.91 (m, 2 H), 1.88–1.82 (m, 1 H) 1.79–1.60 (m, 2 H), 1.40–1.33 (m, 1 H), 1.04–0.91 (m, 6 H). MS (ESI): <i>m</i>/<i>z</i> 445.1 (M + 1).</div></div></div><div id="sec5_1_1_84" class="NLM_sec NLM_sec_level_3"><div id="ac_i173" class="anchor-spacer"></div><h4 class="article-section__title" id="_i173"> (3<i>S</i>,6<i>R</i>)-4-(5-(4-Fluorophenyl)isoxazole-3-carbonyl)-3-isobutyl-6-(thiophen-2-yl)piperazin-2-one (<b>103</b>)</h4><div id="sec5_1_1_84_1" class="NLM_sec NLM_sec_level_4"><div id="ac_i174" class="anchor-spacer"></div><h5 class="article-section__title" id="_i174">A (3<i>S</i>,6<i>R</i>)-3-Isobutyl-6-thiophen-2-yl-piperazin-2-one</h5><div class="NLM_p last">Synthesized from (<i>R</i>)-amino-(thiophen-2-yl)-acetic acid (5.0 g, 31.85 mmol) and HCl salt of Leu-OMe (38.6 g, 47.78 mmol) by the method described for the preparation of compound <b>7</b> (Scheme <a class="ref internalNav" href="#sch1" aria-label="1">1</a>) to afford (3<i>S</i>,6<i>R</i>)-3-isobutyl-6-thiophen-2-yl-piperazin-2-one (610 mg, 8.0% yield) as a white solid. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 7.26–7.28 (m, 1 H), 6.97–7.01 (m, 2 H), 5.96 (s, 1 H), 4.88 (dd, <i>J</i> = 9.2 Hz, 4.4 Hz, 1 H), 3.49 (dd, <i>J</i> = 10.0 Hz, 3.6 Hz, 1 H), 3.36–3.41 (m, 1 H), 2.93–2.99 (m, 1 H), 1.88–1.94 (m, 1 H), 1.75–1.84 (m, 1 H), 1.63–1.71 (m, 1 H), 1.54–1.60 (m, 1 H), 0.94–0.99 (m, 6 H). MS (ESI): <i>m</i>/<i>z</i> 239.1 (M + 1).</div></div><div id="sec5_1_1_84_2" class="NLM_sec NLM_sec_level_4"><div id="ac_i175" class="anchor-spacer"></div><h5 class="article-section__title" id="_i175">B (3<i>S</i>,6<i>R</i>)-4-(5-(4-Fluorophenyl)isoxazole-3-carbonyl)-3-isobutyl-6-(thiophen-2-yl)piperazin-2-one (<b>103</b>)</h5><div class="NLM_p last">(3<i>S</i>,6<i>R</i>)-3-Isobutyl-6-thiophen-2-yl-piperazin-2-one (112 mg, 0.46 mmol) and 5-(4-fluorophenyl)-isoxazole-3-carboxylic acid (117.2 mg, 0.57 mmol) were coupled according to the method described for the preparation of compound <b>2a</b> to give <b>103</b> (100 mg, 50% yield) as an yellow solid. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 7.81–7.77 (m, 2 H), 7.35–7.32 (m, 1 H), 7.21–7.12 (m, 3 H), 7.04–7.00 (m, 1 H), 6.89 (s, 1 H), 6.45(s, 1 H), 5.35–5.31 (m, 1 H), 5.18–5.15 (m, 1 H), 5.04–4.99 (m, 1 H), 3.51–3.45 (m, 1 H), 1.95–1.71 (m, 3 H), 1.09 (d, <i>J</i> = 6.4 Hz, 3 H), 1.00 (d, <i>J</i> = 6.4 Hz, 3 H). MS (ESI): <i>m</i>/<i>z</i> 428.0 (M + 1).</div></div></div><div id="sec5_1_1_85" class="NLM_sec NLM_sec_level_3"><div id="ac_i176" class="anchor-spacer"></div><h4 class="article-section__title" id="_i176"> (3<i>S</i>,6<i>S</i>)-4-(5-(4-Fluorophenyl)isoxazole-3-carbonyl)-3-isobutyl-6-(thiophen-3-yl)piperazin-2-one (<b>104</b>)</h4><div id="sec5_1_1_85_1" class="NLM_sec NLM_sec_level_4"><div id="ac_i177" class="anchor-spacer"></div><h5 class="article-section__title" id="_i177">A (3<i>S</i>,6<i>S</i>)-3-Isobutyl-6-thiophen-3-yl-piperazin-2-one</h5><div class="NLM_p last">Synthesized from (<i>S</i>)-2-amino-2-(thiophen-3-yl)acetic acid (4 g, 25 mmol) and HCl salt of Leu-OMe (3.73 g, 20.6 mmol) by the method described for the preparation of compound <b>7</b> (Scheme <a class="ref internalNav" href="#sch1" aria-label="1">1</a>) to afford (3<i>S</i>,6<i>S</i>)-3-isobutyl-6-thiophen-3-yl-piperazin-2-one (1.1 g, 18% yield) as a white solid. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 7.35–7.37 (m, 1 H), 7.17–7.18 (m, 1 H), 6.99–7.00 (m, 1 H), 6.12 (s, 1 H), 4.71–4.74 (m, 1 H), 3.48–3.51 (m, 1 H), 3.23–3.27 (m, 1 H), 3.03–3.07 (m, 1 H), 1.77–1.90 (m, 3 H), 1.52–1.59 (m, 1 H), 0.94–0.99 (m, 6 H). MS (ESI): <i>m</i>/<i>z</i> 239.1 (M + 1).</div></div><div id="sec5_1_1_85_2" class="NLM_sec NLM_sec_level_4"><div id="ac_i178" class="anchor-spacer"></div><h5 class="article-section__title" id="_i178">B (3<i>S</i>,6<i>S</i>)-4-(5-(4-Fluorophenyl)isoxazole-3-carbonyl)-3-isobutyl-6-(thiophen-3-yl)piperazin-2-one (<b>104</b>)</h5><div class="NLM_p last">(3<i>S</i>,6<i>S</i>)-3-Isobutyl-6-thiophen-3-yl-piperazin-2-one (48 mg, 0.20 mmol) and 5-(4-fluorophenyl)-isoxazole-3-carboxylic acid (45 mg, 0.22 mmol) were coupled according to the method described for the preparation of compound <b>2a</b> to furnish <b>104</b> (45 mg, 52% yield) as a white solid. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 7.82–7.77 (m, 2 H), 7.42–7.10 (m, 5 H), 6.89 (br s, 1 H), 6.04 (br s, 1 H), 5.44–5.34 (m, 1 H), 5.02–4.89 (m, 2 H), 3.41 (dd, <i>J</i> = 15.2 Hz, 12.0 Hz, 0.5 H), 3.13 (dd, <i>J</i> = 15.2 Hz, 12.0 Hz, 0.5 H), 2.02–1.72 (m, 3 H) and 1.11–0.80 (m, 6 H). MS (ESI): <i>m</i>/<i>z</i> 428.0 (M + 1).</div></div></div><div id="sec5_1_1_86" class="NLM_sec NLM_sec_level_3"><div id="ac_i179" class="anchor-spacer"></div><h4 class="article-section__title" id="_i179"> (3<i>S</i>,6<i>R</i>)-4-(5-(4-Fluorophenyl)isoxazole-3-carbonyl)-3-isobutyl-6-(5-methylthiophen-2-yl)piperazin-2-one (<b>105</b>)</h4><div id="sec5_1_1_86_1" class="NLM_sec NLM_sec_level_4"><div id="ac_i180" class="anchor-spacer"></div><h5 class="article-section__title" id="_i180">A (3<i>S</i>,6<i>R</i>)-3-Isobutyl-6-(5-methyl-thiophen-2-yl)-piperazin-2-one</h5><div class="NLM_p last">Synthesized from (<i>R</i>)-2-amino-(5-methyl-thiophen-2-yl)-acetic acid (9 g, 52.6 mmol) and HCl salt of Leu-OMe (6.37 g, 35.2 mmol) by the method described for the preparation of compound <b>7</b> (Scheme <a class="ref internalNav" href="#sch1" aria-label="1">1</a>) to afford (3<i>S</i>,6<i>R</i>)-3-isobutyl-6-(5-methyl-thiophen-2-yl)-piperazin-2-one (0.57 g, 4% yield) as a white solid. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 7.34–7.35 (m, 1 H), 6.77–6.78 (m, 1 H), 6.73–6.74 (m, 1 H), 6.60–6.61 (s, 1 H), 6.02 (s, 1 H), 5.79 (s, 2 H), 4.76–4.79 (m, 1 H), 3.45–3.48 (m, 1 H), 3.33–3.37 (m, 1 H), 2.90–2.95 (m, 1 H), 2.51 (s, 3 H), 2.45 (s, 3 H), 1.78–1.90 (m, 4 H), 1.52–1.58(m, 1 H), 0.94–0.99 (m, 6 H). MS (ESI): <i>m</i>/<i>z</i> 253.15 (M + 1).</div></div><div id="sec5_1_1_86_2" class="NLM_sec NLM_sec_level_4"><div id="ac_i181" class="anchor-spacer"></div><h5 class="article-section__title" id="_i181">B (3<i>S</i>,6<i>R</i>)-4-(5-(4-Fluorophenyl)isoxazole-3-carbonyl)-3-isobutyl-6-(5-methylthiophen-2-yl)-piperazin-2-one (<b>105</b>)</h5><div class="NLM_p last">(3<i>S</i>,6<i>R</i>)-3-Isobutyl-6-(5-methyl-thiophen-2-yl)-piperazin-2-one (50 mg, 0.20 mmol) and 5-(4-fluorophenyl)-isoxazole-3-carboxylic acid (45 mg, 0.22 mmol) were coupled according to the method described for the preparation of compound <b>2a</b> to furnish <b>105</b> (40 mg, 46% yield) as a white solid. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 7.81–7.77 (m, 2 H), 7.21–7.16 (m, 2 H), 6.90–6.87 (m, 2 H), 6.66–6.64 (m, 1 H), 6.08 (br s, 1 H), 5.41–5.29 (m, 1 H), 5.06–4.91 (m, 2 H), 3.46 (dd, <i>J</i> = 14.0 Hz, 9.8 Hz, 1 H), 2.47 (s, 3 H), 1.98–1.70 (m, 3 H) and 1.10–0.80 (m, 6 H). MS (ESI): <i>m</i>/<i>z</i> 442.2 (M + 1).</div></div></div><div id="sec5_1_1_87" class="NLM_sec NLM_sec_level_3"><div id="ac_i182" class="anchor-spacer"></div><h4 class="article-section__title" id="_i182"> (3<i>S</i>,6<i>R</i>)-4-(5-(4-Fluorophenyl)isoxazole-3-carbonyl)-3-isobutyl-6-(3-methylthiophen-2-yl)-piperazin-2-one (<b>106</b>)</h4><div id="sec5_1_1_87_1" class="NLM_sec NLM_sec_level_4"><div id="ac_i183" class="anchor-spacer"></div><h5 class="article-section__title" id="_i183">A (3<i>S</i>,6<i>R</i>)-3-Isobutyl-6-(3-methyl-thiophen-2-yl)-piperazin-2-one</h5><div class="NLM_p last">Synthesized from (<i>R</i>)-2-amino-(3-methyl-thiophen-2-yl)acetic acid (9 g, 52.6 mmol) and HCl salt of Leu-OMe (3.6 g, 19.6 mmol) by the method described for the preparation of compound <b>7</b> (Scheme <a class="ref internalNav" href="#sch1" aria-label="1">1</a>) to afford (3<i>S</i>,6<i>R</i>)-3-isobutyl-6-(3-methyl-thiophen-2-yl)-piperazin-2-one (268 mg, 2% yield). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 7.17–7.18 (m, 1 H), 6.81–6.82 (m, 1 H), 5.86 (s, 1 H), 4.93–4.97 (m, 1 H), 3.35–3.52 (m, 1 H), 3.30–3.34 (m, 1 H), 2.92–2.98 (m, 1 H), 2.22 (s, 3 H), 1.92–1.98 (m, 1 H), 1.68–1.84 (m, 1 H), 1.53–1.59 (m, 1 H), 0.95–1.01 (m, 6 H). MS (ESI): <i>m</i>/<i>z</i> 253.1 (M + 1).</div></div><div id="sec5_1_1_87_2" class="NLM_sec NLM_sec_level_4"><div id="ac_i184" class="anchor-spacer"></div><h5 class="article-section__title" id="_i184">B (3<i>S</i>,6<i>R</i>)-4-(5-(4-Fluorophenyl)isoxazole-3-carbonyl)-3-isobutyl-6-(3-methylthiophen-2-yl)-piperazin-2-one (<b>106</b>)</h5><div class="NLM_p last">(3<i>S</i>,6<i>R</i>)-3-Isobutyl-6-(3-methyl-thiophen-2-yl)-piperazin-2-one (50 mg, 0.20 mmol) and 5-(4-fluorophenyl)-isoxazole-3-carboxylic acid (45 mg, 0.22 mmol) were coupled according to the method described for the preparation of compound <b>2a</b> to furnish product <b>106</b> (40 mg, 46% yield) as a white solid. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>): δ 8.21–8.07 (m, 2 H), 7.26–7.19 (m, 2 H), 7.13–7.08 (m, 1 H), 6.89–6.79 (m, 1 H), 6.64–6.52 (m, 1 H), 6.08 (br s, 1 H), 5.50–5.14 (m, 1 H), 5.06–4.91 (m, 1 H), 4.80–4.74 (m, 1 H), 4.00–3.46 (m, 1 H), 1.95 (s, 3 H), 1.93–1.71 (m, 3 H), 1.16–0.66 (m, 6 H). MS (ESI): <i>m</i>/<i>z</i> 442.1 (M + 1).</div></div></div><div id="sec5_1_1_88" class="NLM_sec NLM_sec_level_3"><div id="ac_i185" class="anchor-spacer"></div><h4 class="article-section__title" id="_i185"> (3<i>S</i>,6<i>R</i>)-4-(5-(4-Fluorophenyl)isoxazole-3-carbonyl)-6-(furan-2-yl)-3-isobutylpiperazin-2-one (<b>107</b>)</h4><div class="NLM_p last">Compound <b>12</b> (40 mg, 0.18 mmol) and 5-(4-fluorophenyl)isoxazole-3-carboxylic acid (55 mg, 0.3 mmol) were coupled according to the procedure described for the preparation of compound <b>2a</b> to afford <b>107</b> (17 mg, 24% yield) as a colorless gum. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 7.72–7.69 (m, 2 H), 7.19–7.15 (m, 2 H), 7.11–7.10 (m, 1 H), 6.71–6.60 (m, 1 H), 6.30 (s, 1 H), 6.26–6.22 (m, 2 H), 5.45–5.40 (m, 1 H), 5.01–4.95 (m, 1 H), 4.76–4.64 (m, 1 H), 3.93–3.54 (m, 1 H), 1.90–1.86 (m, 2 H), 1.75–1.69 (m, 1 H) 1.05–0.74 (m, 6 H). MS (ESI): <i>m</i>/<i>z</i> 412.1 (M + 1).</div></div><div id="sec5_1_1_89" class="NLM_sec NLM_sec_level_3"><div id="ac_i186" class="anchor-spacer"></div><h4 class="article-section__title" id="_i186"> (3<i>S</i>,6<i>R</i>)-4-(5-(4-Fluorophenyl)isoxazole-3-carbonyl)-3-isobutyl-6-(oxazol-5-yl)piperazin-2-one (<b>108</b>)</h4><div class="NLM_p last">To a solution <b>16</b> (26 mg, 0.078 mmol) in DCM (1.5 mL) at 0 °C was added 4 N HCl in dioxane (0.5 mL) and then stirred at rt for 1 h. The reaction mixture was concentrated in vacuo to give the Boc deprotected compound, which was used for the next step without further purification. To a stirred solution of 5-(4-fluorophenyl)-isoxazole-3-carboxylic acid (16 mg, 0.078 mmol) and HATU (22.9 mg, 0.079 mmol) in DMF (1.5 mL), BOC deprotected compound in DMF (0.5 mL) and DIPEA (0.1 mL) was added and stirred for 1 h. The reaction mixture was concentrated in vacuo, and the crude product was purified by column chromatography (0–95% EtOAc in hexanes) to furnish <b>108</b> (24.6 mg, 71% yield) as a white solid. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 8.01 (s, 1 H), 7.80–7.77 (m, 2 H), 7.21–7.16 (m, 2 H), 7.02 (br s, 1 H), 6.90 (s, 1 H), 6.86 (s, 0.5 H), 6.83 (s, 0.5 H), 5.52–5.44 (m, 0.5 H), 5.37–5.29 (m, 0.5 H), 5.18–4.88 (m, 2 H), 3.65–3.56 (m, 0.5 H), 3.38–3.29 (m, 0.5 H), 1.93–1.86 (m, 1 H), 1.76–1.71 (m, 1 H), 1.10–0.80 (m, 6 H). MS (ESI): <i>m</i>/<i>z</i> 413.2 (M + 1).</div></div><div id="sec5_1_1_90" class="NLM_sec NLM_sec_level_3"><div id="ac_i187" class="anchor-spacer"></div><h4 class="article-section__title" id="_i187"> (3<i>S</i>,6<i>R</i>)-4-(5-(4-Fluorophenyl)isoxazole-3-carbonyl)-3-isobutyl-6-(oxazol-2-yl)piperazin-2-one (<b>109</b>)</h4><div class="NLM_p last">To a solution of <b>23</b> (11.2 mg, 0.0235 mmol) in DCM (2 mL) was added TFA (0.6 mL) and stirred at rt for 5 h. The reaction mixture was concentrated in vacuo, and the residue was purified by column chromatography (10–60% EtOAC in hexanes) to give <b>109</b> (7.3 mg, 75% yield) as a colorless solid. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 7.80–7.77 (m, 2 H), 7.21–7.17 (m, 2 H), 6.92 (s, 1 H), 6.83 (s, 1 H), 6.69 (d, <i>J</i> = 5.6 Hz, 1 H), 5.92 (d, <i>J</i> = 5.6 Hz, 1 H), 5.42–5.38 (m, 1 H), 5.34–5.28 (m, 1 H), 4.51 (dd, <i>J</i> = 11.0 Hz, 4.6 Hz, 1 H), 3.73 (dd, <i>J</i> = 15.0 Hz, 11.0 Hz, 1 H), 1.91–1.68 (m, 3 H), 1.09 (d, <i>J</i> = 6.4 Hz, 3 H), 1.00 (d, <i>J</i> = 6.4 Hz, 3 H). MS (ESI): <i>m</i>/<i>z</i> 413.0 (M + 1).</div></div><div id="sec5_1_1_91" class="NLM_sec NLM_sec_level_3"><div id="ac_i188" class="anchor-spacer"></div><h4 class="article-section__title" id="_i188"> (3<i>S</i>,6<i>R</i>)-4-(5-(4-Fluorophenyl)isoxazole-3-carbonyl)-3-isobutyl-6-(thiazol-2-yl)piperazin-2-one (<b>110</b>)</h4><div class="NLM_p last">To a solution of the alcohol <b>90</b> (0.30 g, 0.80 mmol) in DCM (10 mL) at 0 °C was added Dess–Martin’s reagent (441 mg, 1.04 mmol) and water (0.05 mL). The reaction mixture was stirred at rt for 6 h and then <i>i</i>-PrOH (0.2 mL), saturated aqueous sodium thiosulfate (5 mL), and saturated aqueous NaCO<sub>3</sub> (5 mL) were added. The aqueous layer was extracted with EtOAc (5 mL × 3), the combined organic layers were dried over MgSO<sub>4</sub> and concentrated in vacuo, and the crude aldehyde product was used for the next step without further purification. To a solution of crude aldehyde (0.20 g, 0.53 mmol) in EtOH (5 mL) was added HCl salt of 2-aminoethanethiol (60.5 mg, 0.533 mmol) and KOAc (62.8 mg, 0.640 mmol) and stirred at rt for 2 h. The reaction mixture was concentrated in vacuo, and EtOAc (4 mL) and water (3 mL) were added. The aqueous layer was extracted with EtOAc (5 mL × 3). The combined organic layers were dried over MgSO<sub>4</sub> and concentrated in vacuo, and the crude thiazolidine product was used for the next step without further purification. To a solution of the thiazolidine (60 mg, 0.14 mmol) in dioxane (2 mL) was added activated MnO<sub>2</sub> (100 mg) and stirred at 55 °C for 6 h. The reaction mixture was filtered, and the filtrate was concentrated and purified by column chromatopraphy (0–80% EtOAc in hexanes) to give the product <b>110</b> (14 mg, 24% yield). <sup>1</sup>H NMR (DMSO-<i>d</i><sub>6</sub>) δ 9.91 (s, 1 H), 8.06 (m, 2 H), 7.53–7.37 (m, 4 H), 4.95 (t, <i>J</i> = 7.6 Hz, 1 H), 4.33–4.27 (m, 2 H), 3.83 (m, 1 H), 1.63 (m, 1 H), 1.52–1.48 (m, 2 H), 0.95 (d, <i>J</i> = 6.4 Hz, 6 H). MS (ESI): <i>m</i>/<i>z</i> 429.2 (M + 1).</div></div><div id="sec5_1_1_92" class="NLM_sec NLM_sec_level_3"><div id="ac_i189" class="anchor-spacer"></div><h4 class="article-section__title" id="_i189"> (3<i>S</i>,6<i>R</i>)-4-(5-(4-Fluorophenyl)isoxazole-3-carbonyl)-3-isobutyl-6-(1<i>H</i>-pyrrol-2-yl)piperazin-2-one (<b>111</b>)</h4><div id="sec5_1_1_92_1" class="NLM_sec NLM_sec_level_4"><div id="ac_i190" class="anchor-spacer"></div><h5 class="article-section__title" id="_i190">A <i>tert</i>-Butyl 2-(1-((Bis(4-methoxyphenyl)methyl)amino)-2-(methoxy-(methyl)-amino)-2-oxo-ethyl)-1<i>H</i>-pyrrole-1-carboxylate (<b>25</b>)</h5><div class="NLM_p last">To a stirred solution of glyoxylic acid monohydrate (0.92 g, 10.11 mmol) in DCM (70 mL), bis(4-methoxyphenyl)methanamine (2.46 g, 10.11 mmol) and <b>24</b> (2.13 g, 10.11 mmol) were added and stirred at rt for 2 min to form a clear solution. The solution was purged with argon (2 min), and the sealed reaction mixture was stirred overnight. Reaction mixture was concentrated in vacuo to yield crude acid product (4.5 g, 95% yield) as pale-yellow foam. Crude acid product (4.5 g, 10 mmol), TBTU (4.87 g, 15 mmol), and <i>N</i>,<i>O</i>-dimethylhydroxylamine hydrochloride (1.47 g, 15 mmol) were dissolved in dry MeCN (50 mL), and DIPEA (5.3 mL, 30.22 mmol) was added and stirred at rt for 12 h. The reaction mixture was concentrated in vacuo, and the crude product was purified by column chromatography (5 to 40% EtOAc in hexanes) to afford <b>25</b> (5.1 g, 98% yield) as a pale-yellow foam. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 7.36–7.25 (m, 4 H), 7.15–7.14 (m, 1 H), 6.82–6.76 (m, 4 H), 6.18 (s, 1 H), 6.07 (t, <i>J</i> = 3.2 Hz, 1 H), 5.72 (br s, 1 H), 4.82 (s, 1 H) 3.76 (s, 3 H), 3.74 (s, 3 H) 3.24 (s, 3 H), 3.13 (s, 3 H). 2.58 (br s, 1 H), 1.53 (s, 9 H). MS (ESI): <i>m</i>/<i>z</i> 510.1 (M + 1).</div></div><div id="sec5_1_1_92_2" class="NLM_sec NLM_sec_level_4"><div id="ac_i191" class="anchor-spacer"></div><h5 class="article-section__title" id="_i191">B <i>tert</i>-Butyl 2-(1-((Bis(4-methoxyphenyl)methyl)amino)-2-(((<i>S</i>)-1-methoxy-4-methyl-1-oxo-pentan-2-yl)amino)ethyl)-1<i>H</i>-pyrrole-1-carboxylate (<b>26</b>)</h5><div class="NLM_p last">To a solution of <b>25</b> (1.5 g, 2.94 mmol) in dry THF (30 mL) at −78 °C, LiAlH<sub>4</sub> (220 mg, 5.89 mmol) was added and stirred under argon for 3 h. The reaction mixture was quenched with saturated aqueous NH<sub>4</sub>Cl solution (5 mL) by dropwise addition. The reaction mixture was partitioned between EtOAc and brine and extracted with EtOAc (20 mL × 2). The organic layers were combined, washed with brine, and dried over MgSO<sub>4</sub> and concentrated in vacuo to afford the crude aldehyde (unstable, slowly decomposes at rt), which was used for the next step without further purification. To a mixture of aldehyde compound (1.2 g, 2.66 mmol) and HCl salt of Leu-OMe (0.58 g, 2.66 mmol) in DCM (24 mL), NaBH(OAc)<sub>3</sub> (790 mg, 3.73 mmol) was added and stirred at rt under argon for 6 h. The reaction mixture was quenched with saturated aqueous NaHCO<sub>3</sub> solution (25 mL), extracted with EtOAc (30 mL), dried over Na<sub>2</sub>SO<sub>4</sub>, and concentrated in vacuo. The crude product was purified by column chromatography (0–40% EtOAc in hexanes) to afford <b>26</b> (1.54 g, 67% yield) as a pale-yellow foam. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 7.24–7.21 (m, 4 H), 6.80–6.78 (m, 5 H), 6.15–6.14 (m, 2 H), 4.72 (s, 1 H), 4.30 (br s, 1 H), 3.79–3.75 (m, 4 H), 3.64 (s, 3 H) 3.26–3.90 (m, 2 H), 2.68–2.65 (m, 1 H) 2.05 (br s, 1 H), 1.70–1.65 (m, 1 H), 1.48–1.41 (m, 11 H), 0.91–0.85 (m, 6 H). MS (ESI): <i>m</i>/<i>z</i> 580.1 (M + 1).</div></div><div id="sec5_1_1_92_3" class="NLM_sec NLM_sec_level_4"><div id="ac_i192" class="anchor-spacer"></div><h5 class="article-section__title" id="_i192">C (3<i>S</i>,6<i>R</i>)-4-(5-(4-Fluorophenyl)isoxazole-3-carbonyl)-3-isobutyl-6-(1<i>H</i>-pyrrol-2-yl)pipera-zin-2-one (<b>111</b>)</h5><div class="NLM_p last">To a stirred solution of <b>26</b> (225 mg, 0.39 mmol), TBTU (161 mg, 0.5 mmol), and 5-(4-fluorophenyl)-isoxazole-3-carboxylic acid (116 mg, 0.56 mmol) in anhydrous MeCN (6 mL), DIPEA (0.41 mL, 2.33 mmol) was added and stirred at rt for 24 h. The reaction mixture was concentrated in vacuo, and the crude product was purified by column chromatography (0–50% EtOAc in hexanes) to afford crude amide compound (250 mg, 83% yield) as pale-yellow foam. The crude amide compound (250 mg, 0.32 mmol) was dissolved in 70% aqueous AcOH (6 mL) and heated under reflux (80 °C) for 24 h. The reaction mixture was concentrated under vacuo, and the crude product was purified by column chromatography (0–4% MeOH in CH<sub>2</sub>Cl<sub>2</sub>) to afford <b>111</b> (13 mg, 15% yield) and it is trans core isomer (3<i>S</i>,6<i>S</i>)-4-(5-(4-fluorophenyl)isoxazole-3-carbonyl)-3-isobutyl-6-(1<i>H</i>-pyrrol-2-yl)piperazin-2-one (12 mg, 14% yield). Compound <b>111</b> (brown solid): <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 9.23–9.09 (d, <i>J</i> = 53 Hz, 1 H), 7.81–7.76 (m, 2 H), 7.21–7.16 (m, 2 H), 6.94–6.79 (m, 3 H), 6.18–6.16 (m, 1 H), 5.43–5.29 (m, 1 H), 4.97–4.85 (m, 1 H), 3.77 (br s, 1 H), 3.51–3.16 (m, 1 H), 1.90–1.84 (m, 2 H), 1.74–1.60 (m, 1 H), 1.09–0.77 (m, 6 H). MS (ESI): <i>m</i>/<i>z</i> 411.1 (M + 1). (3<i>S</i>,6<i>S</i>)-4-(5-(4-Fluorophenyl)isoxazole-3-carbonyl)-3-isobutyl-6-(1<i>H</i>-pyrrol-2-yl)piperazin-2-one (brown solid): <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 9.05–8.81 (m, 1 H), 7.79–7.65 (m, 2 H), 7.19–7.08 (m, 2 H), 7.08–6.61 (m, 3 H), 6.05–5.91 (m, 1 H), 5.45–5.29 (m, 1 H), 4.83–4.58 (m, 1 H), 3.93–3.48 (m, 2 H), 1.96–1.81 (m, 2 H), 1.78–1.67 (m, 1 H), 1.04–0.75 (m, 6 H). MS (ESI): <i>m</i>/<i>z</i> 411.1 (M + 1).</div></div></div><div id="sec5_1_1_93" class="NLM_sec NLM_sec_level_3"><div id="ac_i193" class="anchor-spacer"></div><h4 class="article-section__title" id="_i193"> (3<i>S</i>,6<i>S</i>)-4-(5-(4-Fluorophenyl)isoxazole-3-carbonyl)-3-isobutyl-6-(1<i>H</i>-pyrrol-3-yl)piperazin-2-one (<b>112</b>)</h4><div class="NLM_p last">Synthesized from (1-(<i>tert</i>-butoxycarbonyl)-1<i>H</i>-pyrrol-2-yl)boronic acid (2.13 g, 10.11 mmol) by the procedures described for the preparation of <b>26</b> (Scheme <a class="ref internalNav" href="#sch5" aria-label="5">5</a>) to furnish <b>112</b> (15 mg, 17% yield) as a brown solid. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 8.42 (br s, 1 H), 7.81–7.76 (m, 2 H), 7.20–7.16 (m, 2 H), 6.86–6.79 (m, 3 H), 6.24–6.21 (m, 1 H), 5.97 (br s, 1 H), 5.35–5.32 (m, 1 H), 4.89–4.75 (m, 2 H), 3.45–3.11 (m, 1 H), 1.99–1.71 (m, 3 H), 1.10–0.0.78 (m, 6 H). MS (ESI): <i>m</i>/<i>z</i> 409.07 (M – 1).</div></div><div id="sec5_1_1_94" class="NLM_sec NLM_sec_level_3"><div id="ac_i194" class="anchor-spacer"></div><h4 class="article-section__title" id="_i194"> (3<i>S</i>,6<i>S</i>)-6-(2-Chlorothiophen-3-yl)-4-(5-(4-fluorophenyl)isoxazole-3-carbonyl)-3-isobutyl-piperazin-2-one (<b>113</b>)</h4><div id="sec5_1_1_94_1" class="NLM_sec NLM_sec_level_4"><div id="ac_i195" class="anchor-spacer"></div><h5 class="article-section__title" id="_i195">A (3<i>S</i>,6<i>S</i>)-6-(2-Chlorothiophen-3-yl)-3-isobutylpiperazin-2-one and (3<i>S</i>,6<i>R</i>)-6-(2-Chlorothiophen-3-yl)-3-isobutylpiperazin-2-one</h5><div class="NLM_p last">Synthesized from 2-chlorothiophen-3-ylboronic acid (4.15 g, 56.12 mmol) and (<i>S</i>)-methyl 2-amino-4-methylpentanoate hydrochloride (3.15 g, 17.39 mmol) by the method described for the preparation of compound <b>12</b> (Scheme <a class="ref internalNav" href="#sch2" aria-label="2">2</a>) to afford (3<i>S</i>,6<i>S</i>)-6-(2-chlorothiophen-3-yl)-3-isobutylpiperazin-2-one (237 mg, 1.6% yield) and (3<i>S</i>,6<i>R</i>)-6-(2-chlorothiophen-3-yl)-3-isobutylpiperazin-2-one (385 mg, 2.6% yield). (3<i>S</i>,6<i>S</i>)-6-(2-Chlorothiophen-3-yl)-3-isobutylpiperazin-2-one (white solid): <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 7.13 (d, <i>J</i> = 6.0 Hz, 1 H), 6.99 (d, <i>J</i> = 6.0 Hz, 1 H), 5.91 (s, 1 H), 4.78–4.75 (m, 1 H), 3.82–3.74 (m, 1 H), 3.54–3.50 (m, 1 H), 3.26–3.21 (m, 1 H), 3.10–3.06 (m, 1 H), 1.88–1.80 (m, 2 H), 1.64–1.54 (m, 1 H), 0.99–0.94 (m, 6 H). MS (ESI): <i>m</i>/<i>z</i> 272.83 (M + 1). (3<i>S</i>,6<i>R</i>)-6-(2-Chlorothiophen-3-yl)-3-isobutylpiperazin-2-one (white solid): <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 7.14 (d, <i>J</i> = 4.8 Hz, 1 H), 6.96 (d, <i>J</i> = 4.8 Hz, 1 H), 5.82 (s, 1 H), 4.86–4.82 (m, 1 H), 3.77–3.75 (m, 1 H), 3.52–3.48 (m, 1 H), 3.34–3.30 (m, 1 H), 2.89–2.84 (m, 1 H), 1.99–1.92 (m, 1 H), 1.86–1.78 (m, 1 H), 1.62–1.53 (m, 1 H), 1.00–0.94 (m, 6 H). MS (ESI): <i>m</i>/<i>z</i> 272.84 (M + 1).</div></div><div id="sec5_1_1_94_2" class="NLM_sec NLM_sec_level_4"><div id="ac_i196" class="anchor-spacer"></div><h5 class="article-section__title" id="_i196">B (3<i>S</i>,6<i>S</i>)-6-(2-Chlorothiophen-3-yl)-4-(5-(4-fluorophenyl)isoxazole-3-carbonyl)-3-isobutyl-piperazin-2-one (<b>113</b>)</h5><div class="NLM_p last">(3<i>S</i>,6<i>S</i>)-6-(2-Chlorothiophen-3-yl)-3-isobutylpiperazin-2-one (55 mg, 0.20 mmol) and 5-(4-fluorophenyl)-isoxazole-3-carboxylic acid (45 mg, 0.22 mmol) were coupled according to the method described for the preparation of compound <b>2a</b> to furnish <b>113</b> (42 mg, 45% yield) as a white solid. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 7.85–7.77 (m, 2 H), 7.21–7.16 (m, 3 H), 6.99–6.95 (m, 1 H), 6.88 (s, 1 H), 6.03 (br s, 1 H), 5.46 and 5.36 (dd, <i>J</i> = 10.0 Hz, 4.4 Hz, 1 H), 5.07–4.89 (m, 2 H), 3.43 and 3.16 (dd, <i>J</i> = 14.4 Hz, 11.2 Hz, 1 H), 1.99–1.70 (m, 3 H) and 1.10–0.81 (m, 6 H). MS (ESI): <i>m</i>/<i>z</i> 463.92 (M + 2).</div></div></div></div></div><div class="NLM_back"><div class="article_supporting-info" id=""></div><div class="testing" data-doi="10.1021/jm4012643" data-url="https://widgets.figshare.com/static/figshare.js" id="figshare-widget"></div><div class="authorInformationSection"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="authorInformationSection">Author Information</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_27656" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_27656" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><ul><li><span class="author-information-subsection-header">Corresponding Author</span><ul><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Ramesh Kakarla</span> - <span class="hlFld-Affiliation affiliation">Pharmasset,
Inc. 303A College Road
East, Princeton, New Jersey 08540, United States</span>; 
    <span class="author-email">
                Email: <a href="/cdn-cgi/l/email-protection#e694878b83958e8d878d87948a87a69f878e8989c885898b"><span class="__cf_email__" data-cfemail="a3d1c2cec6d0cbc8c2c8c2d1cfc2e3dac2cbcccc8dc0ccce">[email protected]</span></a></span></div></li></ul></li><li><span class="author-information-subsection-header">Authors</span><ul><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Jian Liu</span> - <span class="hlFld-Affiliation affiliation">Pharmasset,
Inc. 303A College Road
East, Princeton, New Jersey 08540, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Devan Naduthambi</span> - <span class="hlFld-Affiliation affiliation">Pharmasset,
Inc. 303A College Road
East, Princeton, New Jersey 08540, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Wonsuk Chang</span> - <span class="hlFld-Affiliation affiliation">Pharmasset,
Inc. 303A College Road
East, Princeton, New Jersey 08540, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Ralph T. Mosley</span> - <span class="hlFld-Affiliation affiliation">Pharmasset,
Inc. 303A College Road
East, Princeton, New Jersey 08540, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Donghui Bao</span> - <span class="hlFld-Affiliation affiliation">Pharmasset,
Inc. 303A College Road
East, Princeton, New Jersey 08540, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Holly M. Micolochick Steuer</span> - <span class="hlFld-Affiliation affiliation">Pharmasset,
Inc. 303A College Road
East, Princeton, New Jersey 08540, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Meg Keilman</span> - <span class="hlFld-Affiliation affiliation">Pharmasset,
Inc. 303A College Road
East, Princeton, New Jersey 08540, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Shalini Bansal</span> - <span class="hlFld-Affiliation affiliation">Pharmasset,
Inc. 303A College Road
East, Princeton, New Jersey 08540, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Angela M. Lam</span> - <span class="hlFld-Affiliation affiliation">Pharmasset,
Inc. 303A College Road
East, Princeton, New Jersey 08540, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">William Seibel</span> - <span class="hlFld-Affiliation affiliation">Pharmasset,
Inc. 303A College Road
East, Princeton, New Jersey 08540, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Sandra Neilson</span> - <span class="hlFld-Affiliation affiliation">Pharmasset,
Inc. 303A College Road
East, Princeton, New Jersey 08540, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Phillip A. Furman</span> - <span class="hlFld-Affiliation affiliation">Pharmasset,
Inc. 303A College Road
East, Princeton, New Jersey 08540, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Michael J. Sofia</span> - <span class="hlFld-Affiliation affiliation">Pharmasset,
Inc. 303A College Road
East, Princeton, New Jersey 08540, United States</span></div></li></ul></li><li></li><li></li><li><span class="author-information-subsection-header">Notes</span><div class="authorInformation_notesSection">The authors declare the following competing financial interest(s): All of the authors except W.S. and S.N. were employees of Pharmasset where this work was completed. Gilead Sciences acquired Pharmasset in January 2012.<br /></br></div></li></ul></div><div class="ack" id="ACK-d144e9591-autogenerated"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i209">Acknowledgment</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_20261" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_20261" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><p class="last">We are grateful to the scientists at Wuxi-Aptec for synthesizing valuable intermediates involved in the synthesis of HCV inhibitors and providing SFC (Chiral) separation service for some of the compounds.</p></div><div id="" class="NLM_sec NLM_sec_level_1"><div id="ac_i210" class="anchor-spacer"></div><h2 class="article-section__title section__title" id="_i210"> </h2><div class="NLM_p last"><table summary="" class="NLM_def-list" id="dl1"><div id="ac_i211" class="anchor-spacer"></div><h2 class="article-section__title section__title" id="_i211"> Abbreviations Used</h2><tr><td class="NLM_term">AcOH</td><td class="NLM_def"><p class="first last">acetic acid</p></td></tr><tr><td class="NLM_term">BuOH</td><td class="NLM_def"><p class="first last">butanol</p></td></tr><tr><td class="NLM_term">Boc</td><td class="NLM_def"><p class="first last"><i>tert</i>-butyloxycarbonyl</p></td></tr><tr><td class="NLM_term">CyP</td><td class="NLM_def"><p class="first last">cytochrome P450</p></td></tr><tr><td class="NLM_term">DCM</td><td class="NLM_def"><p class="first last">dichloromethane</p></td></tr><tr><td class="NLM_term">DIPEA</td><td class="NLM_def"><p class="first last"><i>N</i>,<i>N</i>-diisopropylethylamine</p></td></tr><tr><td class="NLM_term">DMAP</td><td class="NLM_def"><p class="first last">4-(dimethylamino)pyridine</p></td></tr><tr><td class="NLM_term">DMF</td><td class="NLM_def"><p class="first last">dimethylformamide</p></td></tr><tr><td class="NLM_term">EDC</td><td class="NLM_def"><p class="first last"><i>N</i>-(3-dimethylaminopropyl)-<i>N</i>′-ethylcarbodiimide hydrochloride</p></td></tr><tr><td class="NLM_term">EtOAc</td><td class="NLM_def"><p class="first last">ethyl acetate</p></td></tr><tr><td class="NLM_term">Fmoc</td><td class="NLM_def"><p class="first last">9-fluorenylmethyloxycarbonyl</p></td></tr><tr><td class="NLM_term">HATU</td><td class="NLM_def"><p class="first last">(<i>O</i>-(7-azabenzotriazol-1-yl)-<i>N</i>,<i>N</i>,<i>N</i>′,<i>N</i>′-tetramethyluronium hexa-fluorophosphate)</p></td></tr><tr><td class="NLM_term">HLM</td><td class="NLM_def"><p class="first last">human liver microsomal</p></td></tr><tr><td class="NLM_term">HOBt</td><td class="NLM_def"><p class="first last"><i>N</i>-hydroxybenzotriazole</p></td></tr><tr><td class="NLM_term">Leu</td><td class="NLM_def"><p class="first last"><span class="smallcaps smallerCapital">l</span>-leucine</p></td></tr><tr><td class="NLM_term">LiAlH<sub>4</sub></td><td class="NLM_def"><p class="first last">lithium aluminum hydride</p></td></tr><tr><td class="NLM_term">MeCN</td><td class="NLM_def"><p class="first last">acetonitrile</p></td></tr><tr><td class="NLM_term">MeOH</td><td class="NLM_def"><p class="first last">methanol</p></td></tr><tr><td class="NLM_term">Phe</td><td class="NLM_def"><p class="first last">phenylalanine</p></td></tr><tr><td class="NLM_term"><i>i</i>-PrOH</td><td class="NLM_def"><p class="first last">2-propanol</p></td></tr><tr><td class="NLM_term">SFC</td><td class="NLM_def"><p class="first last">supercritical fluid chromatography</p></td></tr><tr><td class="NLM_term">TBTU</td><td class="NLM_def"><p class="first last">2-(1<i>H</i>-benzotriazole-1-yl)-1,1,3,3-tetramethyluronium tetrafluoroborate</p></td></tr><tr><td class="NLM_term">TFA</td><td class="NLM_def"><p class="first last">trifluoroacetic acid</p></td></tr><tr><td class="NLM_term">THF</td><td class="NLM_def"><p class="first last">tetrahydrofuran</p></td></tr><tr><td class="NLM_term">WT</td><td class="NLM_def"><p class="first last">wild type</p></td></tr></table></div></div><div class="refs-header-label"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i212">References</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_64637" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_64637" class="dropBlock__holder"></div></div></div></div></div><hr /></hr></div><p class="references-count">
            This article references 17 other publications.
        </p><ol id="references" class="useLabel"><li id="ref1"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref1'); return false;" data-citation="" class="refNumLink">1</a></strong><div class="NLM_citation" id="cit1a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Te, H. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jensen, D. M.</span><span> </span><span class="NLM_article-title">Epidemiology of hepatitis B and C viruses: a global overview</span> <span class="citation_source-journal">Clin. Liver Dis.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">14</span><span class="NLM_x">, </span> <span class="NLM_fpage">1</span><span class="NLM_x">–</span> <span class="NLM_lpage">21</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref1/cit1a&amp;dbid=16&amp;doi=10.1021%2Fjm4012643&amp;key=10.1016%2Fj.cld.2009.11.009" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref1/cit1a&amp;dbid=8&amp;doi=10.1021%2Fjm4012643&amp;key=20123436" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref1/cit1a&amp;dbid=32&amp;doi=10.1021%2Fjm4012643&amp;key=1%3ACAS%3A280%3ADC%252BC3c7gslClsQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=14&publication_year=2010&pages=1-21&author=H.+S.+Teauthor=D.+M.+Jensen&title=Epidemiology+of+hepatitis+B+and+C+viruses%3A+a+global+overview"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit1aR"><div class="casContent"><span class="casTitleNuber">1a</span><div class="casTitle"><span class="NLM_cas:atitle">Epidemiology of hepatitis B and C viruses: a global overview</span></div><div class="casAuthors">Te Helen S; Jensen Donald M</div><div class="citationInfo"><span class="NLM_cas:title">Clinics in liver disease</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">14</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">1-21, vii</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">This article reviews the prevalence, disease burden, genotype distribution, and transmission patterns of hepatitis B virus (HBV) and hepatitis C virus in the 6 World Health Organization regions.  The global epidemiology of hepatitis B and C demonstrates a predominantly declining prevalence of the diseases.  Improvement in the control of hepatitis B has been largely achieved with implementation of a more universal HBV vaccine program, although a large gap still remains in the effort toward global prevention of hepatitis B.  The transmission of hepatitis C has been greatly impacted by mandatory screening of blood donors in most countries in the world, although intravenous drug use continues to be a major source of infection.  Public education regarding the risks of exposure to infected paraphernalia as well as household items such as razors is necessary in the continuing effort to curb this disease.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRbiYsvs7SIbxKDYG3bNImrfW6udTcc2eYI4t7NuVHHfLntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC3c7gslClsQ%253D%253D&md5=116f0f2ecd8b141a4ce57311af520589</span></div><a href="/servlet/linkout?suffix=cit1a&amp;dbid=16384&amp;doi=10.1016%2Fj.cld.2009.11.009&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.cld.2009.11.009%26sid%3Dliteratum%253Aachs%26aulast%3DTe%26aufirst%3DH.%2BS.%26aulast%3DJensen%26aufirst%3DD.%2BM.%26atitle%3DEpidemiology%2520of%2520hepatitis%2520B%2520and%2520C%2520viruses%253A%2520a%2520global%2520overview%26jtitle%3DClin.%2520Liver%2520Dis.%26date%3D2010%26volume%3D14%26spage%3D1%26epage%3D21" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit1b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Shepard, C. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Finelli, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Alter, M. J.</span><span> </span><span class="NLM_article-title">Global epidemiology of hepatitis C virus infection</span> <span class="citation_source-journal">Lancet Infect. Dis.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">5</span><span class="NLM_x">, </span> <span class="NLM_fpage">558</span><span class="NLM_x">–</span> <span class="NLM_lpage">567</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref1/cit1b&amp;dbid=16&amp;doi=10.1021%2Fjm4012643&amp;key=10.1016%2FS1473-3099%2805%2970216-4" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref1/cit1b&amp;dbid=8&amp;doi=10.1021%2Fjm4012643&amp;key=16122679" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref1/cit1b&amp;dbid=32&amp;doi=10.1021%2Fjm4012643&amp;key=1%3ACAS%3A280%3ADC%252BD2Mvls1Wlsg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=2005&pages=558-567&author=C.+W.+Shepardauthor=L.+Finelliauthor=M.+J.+Alter&title=Global+epidemiology+of+hepatitis+C+virus+infection"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit1bR"><div class="casContent"><span class="casTitleNuber">1b</span><div class="casTitle"><span class="NLM_cas:atitle">Global epidemiology of hepatitis C virus infection</span></div><div class="casAuthors">Shepard Colin W; Finelli Lyn; Alter Miriam J</div><div class="citationInfo"><span class="NLM_cas:title">The Lancet. Infectious diseases</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">5</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">558-67</span>
        ISSN:<span class="NLM_cas:issn">1473-3099</span>.
    </div><div class="casAbstract">Hepatitis C virus (HCV) is a major cause of liver disease worldwide and a potential cause of substantial morbidity and mortality in the future.  The complexity and uncertainty related to the geographic distribution of HCV infection and chronic hepatitis C, determination of its associated risk factors, and evaluation of cofactors that accelerate its progression, underscore the difficulties in global prevention and control of HCV.  Because there is no vaccine and no post-exposure prophylaxis for HCV, the focus of primary prevention efforts should be safer blood supply in the developing world, safe injection practices in health care and other settings, and decreasing the number of people who initiate injection drug use.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQyQ65qEM2alVm8bhe6roZYfW6udTcc2eYI4t7NuVHHfLntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD2Mvls1Wlsg%253D%253D&md5=4d5f81fa0c2191b8c32b328e39933fad</span></div><a href="/servlet/linkout?suffix=cit1b&amp;dbid=16384&amp;doi=10.1016%2FS1473-3099%2805%2970216-4&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS1473-3099%252805%252970216-4%26sid%3Dliteratum%253Aachs%26aulast%3DShepard%26aufirst%3DC.%2BW.%26aulast%3DFinelli%26aufirst%3DL.%26aulast%3DAlter%26aufirst%3DM.%2BJ.%26atitle%3DGlobal%2520epidemiology%2520of%2520hepatitis%2520C%2520virus%2520infection%26jtitle%3DLancet%2520Infect.%2520Dis.%26date%3D2005%26volume%3D5%26spage%3D558%26epage%3D567" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref2"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref2'); return false;" data-citation="" class="refNumLink">2</a></strong><div class="NLM_citation" id="cit2a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">El-Serag, H. B.</span><span> </span><span class="NLM_article-title">Epidemiology of viral hepatitis and hepatocellular carcinoma</span> <span class="citation_source-journal">Gastroenterology</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">142</span><span class="NLM_x">, </span> <span class="NLM_fpage">1264</span><span class="NLM_x">–</span> <span class="NLM_lpage">1273</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref2/cit2a&amp;dbid=16&amp;doi=10.1021%2Fjm4012643&amp;key=10.1053%2Fj.gastro.2011.12.061" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref2/cit2a&amp;dbid=8&amp;doi=10.1021%2Fjm4012643&amp;key=22537432" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref2/cit2a&amp;dbid=32&amp;doi=10.1021%2Fjm4012643&amp;key=1%3ACAS%3A280%3ADC%252BC38rotl2gsA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=142&publication_year=2012&pages=1264-1273&author=H.+B.+El-Serag&title=Epidemiology+of+viral+hepatitis+and+hepatocellular+carcinoma"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit2aR"><div class="casContent"><span class="casTitleNuber">2a</span><div class="casTitle"><span class="NLM_cas:atitle">Epidemiology of viral hepatitis and hepatocellular carcinoma</span></div><div class="casAuthors">El-Serag Hashem B</div><div class="citationInfo"><span class="NLM_cas:title">Gastroenterology</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">142</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">1264-1273.e1</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Most cases of hepatocellular carcinoma (HCC) are associated with cirrhosis related to chronic hepatitis B virus (HBV) or hepatitis C virus (HCV) infection.  Changes in the time trends of HCC and most variations in its age-, sex-, and race-specific rates among different regions are likely to be related to differences in hepatitis viruses that are most prevalent in a population, the timing of their spread, and the ages of the individuals the viruses infect.  Environmental, host genetic, and viral factors can affect the risk of HCC in individuals with HBV or HCV infection.  This review summarizes the risk factors for HCC among HBV- or HCV-infected individuals, based on findings from epidemiologic studies and meta-analyses, as well as determinants of patient outcome and the HCC disease burden, globally and in the United States.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcR-sKKtlOWgPI2y4bB4mnvYfW6udTcc2eYd84IQdFQmK7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC38rotl2gsA%253D%253D&md5=b80f1cb68dc9622140918028775e248c</span></div><a href="/servlet/linkout?suffix=cit2a&amp;dbid=16384&amp;doi=10.1053%2Fj.gastro.2011.12.061&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1053%252Fj.gastro.2011.12.061%26sid%3Dliteratum%253Aachs%26aulast%3DEl-Serag%26aufirst%3DH.%2BB.%26atitle%3DEpidemiology%2520of%2520viral%2520hepatitis%2520and%2520hepatocellular%2520carcinoma%26jtitle%3DGastroenterology%26date%3D2012%26volume%3D142%26spage%3D1264%26epage%3D1273" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit2b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Perz, J. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Armstrong, G. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Farrington, L. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hutin, Y. J. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bell, B. P.</span><span> </span><span class="NLM_article-title">The contributions of hepatitis B virus and hepatitis C virus infections to cirrhosis and primary liver cancer worldwide</span> <span class="citation_source-journal">J. Hepatol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">45</span><span class="NLM_x">, </span> <span class="NLM_fpage">529</span><span class="NLM_x">–</span> <span class="NLM_lpage">538</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref2/cit2b&amp;dbid=16&amp;doi=10.1021%2Fjm4012643&amp;key=10.1016%2Fj.jhep.2006.05.013" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref2/cit2b&amp;dbid=8&amp;doi=10.1021%2Fjm4012643&amp;key=16879891" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref2/cit2b&amp;dbid=32&amp;doi=10.1021%2Fjm4012643&amp;key=1%3ACAS%3A280%3ADC%252BD28rivVCmsA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=45&publication_year=2006&pages=529-538&author=J.+F.+Perzauthor=G.+L.+Armstrongauthor=L.+A.+Farringtonauthor=Y.+J.+F.+Hutinauthor=B.+P.+Bell&title=The+contributions+of+hepatitis+B+virus+and+hepatitis+C+virus+infections+to+cirrhosis+and+primary+liver+cancer+worldwide"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit2bR"><div class="casContent"><span class="casTitleNuber">2b</span><div class="casTitle"><span class="NLM_cas:atitle">The contributions of hepatitis B virus and hepatitis C virus infections to cirrhosis and primary liver cancer worldwide</span></div><div class="casAuthors">Perz Joseph F; Armstrong Gregory L; Farrington Leigh A; Hutin Yvan J F; Bell Beth P</div><div class="citationInfo"><span class="NLM_cas:title">Journal of hepatology</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">45</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">529-38</span>
        ISSN:<span class="NLM_cas:issn">0168-8278</span>.
    </div><div class="casAbstract">BACKGROUND/AIMS:  End-stage liver disease accounts for one in forty deaths worldwide.  Chronic infections with hepatitis B virus (HBV) and hepatitis C virus (HCV) are well-recognized risk factors for cirrhosis and liver cancer, but estimates of their contributions to worldwide disease burden have been lacking.  METHODS:  The prevalence of serologic markers of HBV and HCV infections among patients diagnosed with cirrhosis or hepatocellular carcinoma (HCC) was obtained from representative samples of published reports.  Attributable fractions of cirrhosis and HCC due to these infections were estimated for 11 WHO-based regions.  RESULTS:  Globally, 57% of cirrhosis was attributable to either HBV (30%) or HCV (27%) and 78% of HCC was attributable to HBV (53%) or HCV (25%).  Regionally, these infections usually accounted for >50% of HCC and cirrhosis.  Applied to 2002 worldwide mortality estimates, these fractions represent 929,000 deaths due to chronic HBV and HCV infections, including 446,000 cirrhosis deaths (HBV: n=235,000; HCV: n=211,000) and 483,000 liver cancer deaths (HBV: n=328,000; HCV: n=155,000).  CONCLUSIONS:  HBV and HCV infections account for the majority of cirrhosis and primary liver cancer throughout most of the world, highlighting the need for programs to prevent new infections and provide medical management and treatment for those already infected.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcSJG9SyjOebU3y-c-E1v-fmfW6udTcc2eYd84IQdFQmK7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD28rivVCmsA%253D%253D&md5=c388e797f694130776fdba6d336cbd45</span></div><a href="/servlet/linkout?suffix=cit2b&amp;dbid=16384&amp;doi=10.1016%2Fj.jhep.2006.05.013&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.jhep.2006.05.013%26sid%3Dliteratum%253Aachs%26aulast%3DPerz%26aufirst%3DJ.%2BF.%26aulast%3DArmstrong%26aufirst%3DG.%2BL.%26aulast%3DFarrington%26aufirst%3DL.%2BA.%26aulast%3DHutin%26aufirst%3DY.%2BJ.%2BF.%26aulast%3DBell%26aufirst%3DB.%2BP.%26atitle%3DThe%2520contributions%2520of%2520hepatitis%2520B%2520virus%2520and%2520hepatitis%2520C%2520virus%2520infections%2520to%2520cirrhosis%2520and%2520primary%2520liver%2520cancer%2520worldwide%26jtitle%3DJ.%2520Hepatol.%26date%3D2006%26volume%3D45%26spage%3D529%26epage%3D538" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref3"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref3'); return false;" data-citation="" class="refNumLink">3</a></strong><div class="NLM_citation" id="cit3a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Kwong, A. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kauffman, R. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hurter, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mueller, P.</span><span> </span><span class="NLM_article-title">Discovery and development of telaprevir: an NS3-4A protease inhibitor for treating genotype 1 chronic hepatitis C virus</span> <span class="citation_source-journal">Nature Biotechnol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">29</span><span class="NLM_x">, </span> <span class="NLM_fpage">993</span><span class="NLM_x">–</span> <span class="NLM_lpage">1003</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref3/cit3a&amp;dbid=16&amp;doi=10.1021%2Fjm4012643&amp;key=10.1038%2Fnbt.2020" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref3/cit3a&amp;dbid=8&amp;doi=10.1021%2Fjm4012643&amp;key=22068541" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref3/cit3a&amp;dbid=32&amp;doi=10.1021%2Fjm4012643&amp;key=1%3ACAS%3A528%3ADC%252BC3MXhsVCntLvJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=29&publication_year=2011&pages=993-1003&author=A.+D.+Kwongauthor=R.+S.+Kauffmanauthor=P.+Hurterauthor=P.+Mueller&title=Discovery+and+development+of+telaprevir%3A+an+NS3-4A+protease+inhibitor+for+treating+genotype+1+chronic+hepatitis+C+virus"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit3aR"><div class="casContent"><span class="casTitleNuber">3a</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery and development of telaprevir: an NS3-4A protease inhibitor for treating genotype 1 chronic hepatitis C virus</span></div><div class="casAuthors">Kwong, Ann D.; Kauffman, Robert S.; Hurter, Patricia; Mueller, Peter</div><div class="citationInfo"><span class="NLM_cas:title">Nature Biotechnology</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">29</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">993-1003</span>CODEN:
                <span class="NLM_cas:coden">NABIF9</span>;
        ISSN:<span class="NLM_cas:issn">1087-0156</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  Infection with hepatitis C virus (HCV) is a major medical problem with over 170 million people infected worldwide.  Substantial morbidity and mortality are assocd. with hepatic manifestations (cirrhosis and hepatocellular carcinoma), which develop with increasing frequency in people infected with HCV for more than 20 years.  Less well known is the burden of HCV disease assocd. with extrahepatic manifestations (diabetes, B-cell proliferative disorders, depression, cognitive disorders, arthritis and Sjoegren's syndrome).  For patients infected with genotype 1 HCV, treatment with polyethylene glycol decorated interferon (peginterferon) α and ribavirin (PR) is assocd. with a low (40-50%) success rate, substantial treatment-limiting side effects and a long (48-wk) duration of treatment.  In the past 15 years, major scientific advances have enabled the development of new classes of HCV therapy, the direct-acting antiviral agents, also known as specifically targeted antiviral therapy for hepatitis C (STAT-C).  In combination with PR, the HCV NS3-4A protease inhibitor telaprevir has recently been approved for treatment of genotype 1 chronic HCV in the United States, Canada, European Union and Japan.  Compared with PR, telaprevir combination therapy offers significantly improved viral cure rates and the possibility of shortened treatment duration for diverse patient populations.  Developers of innovative drugs have to blaze a new path with few validated sign posts to guide the way.  Indeed, telaprevir's development was once put on hold because of its performance in a std. IC50 assay.  Data from new hypotheses and novel expts. were required to justify further investment and reduce risk that the drug might fail in the clinic.  In addn., the poor drug-like properties of telaprevir were a formidable hurdle, which the manufg. and formulation teams had to overcome to make the drug.  Finally, novel clin. trial designs were developed to improve efficacy and shorten treatment in parallel instead of sequentially.  Lessons learned from the development of telaprevir suggest that makers of innovative medicines cannot rely solely on traditional drug discovery metrics, but must develop innovative, scientifically guided pathways for success.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGodUEHshXTAvbVg90H21EOLACvtfcHk0liI_sw0st_UOg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXhsVCntLvJ&md5=952966419a2e72107550d0a63c337ae4</span></div><a href="/servlet/linkout?suffix=cit3a&amp;dbid=16384&amp;doi=10.1038%2Fnbt.2020&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnbt.2020%26sid%3Dliteratum%253Aachs%26aulast%3DKwong%26aufirst%3DA.%2BD.%26aulast%3DKauffman%26aufirst%3DR.%2BS.%26aulast%3DHurter%26aufirst%3DP.%26aulast%3DMueller%26aufirst%3DP.%26atitle%3DDiscovery%2520and%2520development%2520of%2520telaprevir%253A%2520an%2520NS3-4A%2520protease%2520inhibitor%2520for%2520treating%2520genotype%25201%2520chronic%2520hepatitis%2520C%2520virus%26jtitle%3DNature%2520Biotechnol.%26date%3D2011%26volume%3D29%26spage%3D993%26epage%3D1003" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit3b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Venkatraman, S.</span><span> </span><span class="NLM_article-title">Discovery of boceprevir, a direct-acting NS3/4A protease inhibitor for treatment of chronic hepatitis C infections</span> <span class="citation_source-journal">Trends Pharmacol. Sci.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">33</span><span class="NLM_x">, </span> <span class="NLM_fpage">289</span><span class="NLM_x">–</span> <span class="NLM_lpage">294</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=33&publication_year=2012&pages=289-294&author=S.+Venkatraman&title=Discovery+of+boceprevir%2C+a+direct-acting+NS3%2F4A+protease+inhibitor+for+treatment+of+chronic+hepatitis+C+infections"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit3b&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DVenkatraman%26aufirst%3DS.%26atitle%3DDiscovery%2520of%2520boceprevir%252C%2520a%2520direct-acting%2520NS3%252F4A%2520protease%2520inhibitor%2520for%2520treatment%2520of%2520chronic%2520hepatitis%2520C%2520infections%26jtitle%3DTrends%2520Pharmacol.%2520Sci.%26date%3D2012%26volume%3D33%26spage%3D289%26epage%3D294" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit3c"><span><span class="NLM_label">(c) </span><span class="NLM_contrib-group">Chen, K. X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Njoroge, F. G.</span><span> </span><span class="NLM_article-title">The journey to the discovery of boceprevir: an NS3-NS4 HCV protease inhibitor for the treatment of chronic hepatitis C</span> <span class="citation_source-journal">Prog. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">49</span><span class="NLM_x">, </span> <span class="NLM_fpage">1</span><span class="NLM_x">–</span> <span class="NLM_lpage">36</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref3/cit3c&amp;dbid=16&amp;doi=10.1021%2Fjm4012643&amp;key=10.1016%2FS0079-6468%2810%2949001-3" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref3/cit3c&amp;dbid=8&amp;doi=10.1021%2Fjm4012643&amp;key=20855037" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref3/cit3c&amp;dbid=32&amp;doi=10.1021%2Fjm4012643&amp;key=1%3ACAS%3A528%3ADC%252BC3MXitlSqtg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=49&publication_year=2010&pages=1-36&author=K.+X.+Chenauthor=F.+G.+Njoroge&title=The+journey+to+the+discovery+of+boceprevir%3A+an+NS3-NS4+HCV+protease+inhibitor+for+the+treatment+of+chronic+hepatitis+C"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit3cR"><div class="casContent"><span class="casTitleNuber">3c</span><div class="casTitle"><span class="NLM_cas:atitle">The journey to the discovery of boceprevir: an NS3-NS4 HCV protease inhibitor for the treatment of chronic hepatitis C</span></div><div class="casAuthors">Chen, Kevin X.; Njoroge, F. George</div><div class="citationInfo"><span class="NLM_cas:title">Progress in Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">49</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">1-36</span>CODEN:
                <span class="NLM_cas:coden">PMDCAY</span>;
        ISSN:<span class="NLM_cas:issn">0079-6468</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A review.  The hepatitis C virus (HCV) NS3 protease as a target for HCV therapy, mechanism of inhibition, biol. assays, and substrate-based drug design are discussed.  The depeptization efforts, macrocyclic inhibitors, selectivity, structure-activity relationship development at P2, P1, P3 and P3 capping, synergistic effects among different residues, profile of boceprevir, and synthesis of inhibitors are also reported.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqnlwuGjHIdCLVg90H21EOLACvtfcHk0lgd_ZFxfIJdRA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXitlSqtg%253D%253D&md5=a68d8faba8276f2949de52b6c86e84a1</span></div><a href="/servlet/linkout?suffix=cit3c&amp;dbid=16384&amp;doi=10.1016%2FS0079-6468%2810%2949001-3&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0079-6468%252810%252949001-3%26sid%3Dliteratum%253Aachs%26aulast%3DChen%26aufirst%3DK.%2BX.%26aulast%3DNjoroge%26aufirst%3DF.%2BG.%26atitle%3DThe%2520journey%2520to%2520the%2520discovery%2520of%2520boceprevir%253A%2520an%2520NS3-NS4%2520HCV%2520protease%2520inhibitor%2520for%2520the%2520treatment%2520of%2520chronic%2520hepatitis%2520C%26jtitle%3DProg.%2520Med.%2520Chem.%26date%3D2010%26volume%3D49%26spage%3D1%26epage%3D36" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref4"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref4'); return false;" data-citation="" class="refNumLink">4</a></strong><div class="NLM_citation" id="cit4a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Sheridan, C. W.</span><span> </span><span class="NLM_article-title">New Merck and Vertex drugs raise standard of care in hepatitis C</span> <span class="citation_source-journal">Nature Biotechnol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">29</span><span class="NLM_x">, </span> <span class="NLM_fpage">553</span><span class="NLM_x">–</span> <span class="NLM_lpage">554</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref4/cit4a&amp;dbid=16&amp;doi=10.1021%2Fjm4012643&amp;key=10.1038%2Fnbt0711-553" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref4/cit4a&amp;dbid=8&amp;doi=10.1021%2Fjm4012643&amp;key=21747363" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref4/cit4a&amp;dbid=32&amp;doi=10.1021%2Fjm4012643&amp;key=1%3ACAS%3A528%3ADC%252BC3MXoslymtrw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=29&publication_year=2011&pages=553-554&author=C.+W.+Sheridan&title=New+Merck+and+Vertex+drugs+raise+standard+of+care+in+hepatitis+C"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit4aR"><div class="casContent"><span class="casTitleNuber">4a</span><div class="casTitle"><span class="NLM_cas:atitle">New Merck and Vertex drugs raise standard of care in hepatitis C</span></div><div class="casAuthors">Sheridan, Cormac</div><div class="citationInfo"><span class="NLM_cas:title">Nature Biotechnology</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">29</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">553-554</span>CODEN:
                <span class="NLM_cas:coden">NABIF9</span>;
        ISSN:<span class="NLM_cas:issn">1087-0156</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">
                There is no expanded citation for this reference.
            </div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqDRNfcMR5e4rVg90H21EOLACvtfcHk0lgVS6Row49rsg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXoslymtrw%253D&md5=35734099c95a7a35dfd35d90f5820641</span></div><a href="/servlet/linkout?suffix=cit4a&amp;dbid=16384&amp;doi=10.1038%2Fnbt0711-553&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnbt0711-553%26sid%3Dliteratum%253Aachs%26aulast%3DSheridan%26aufirst%3DC.%2BW.%26atitle%3DNew%2520Merck%2520and%2520Vertex%2520drugs%2520raise%2520standard%2520of%2520care%2520in%2520hepatitis%2520C%26jtitle%3DNature%2520Biotechnol.%26date%3D2011%26volume%3D29%26spage%3D553%26epage%3D554" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit4b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Fried, M. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Russo, M. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fried, M. W.</span><span> </span><span class="NLM_article-title">Side effects of therapy for chronic hepatitis C</span> <span class="citation_source-journal">Gastroenterology</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2003</span><span class="NLM_x">, </span> <span class="NLM_volume">124</span><span class="NLM_x">, </span> <span class="NLM_fpage">1711</span><span class="NLM_x">–</span> <span class="NLM_lpage">1719</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=124&publication_year=2003&pages=1711-1719&author=M.+W.+Friedauthor=M.+W.+Russoauthor=M.+W.+Fried&title=Side+effects+of+therapy+for+chronic+hepatitis+C"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit4b&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DFried%26aufirst%3DM.%2BW.%26aulast%3DRusso%26aufirst%3DM.%2BW.%26aulast%3DFried%26aufirst%3DM.%2BW.%26atitle%3DSide%2520effects%2520of%2520therapy%2520for%2520chronic%2520hepatitis%2520C%26jtitle%3DGastroenterology%26date%3D2003%26volume%3D124%26spage%3D1711%26epage%3D1719" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit4c"><span><span class="NLM_label">(c) </span><span class="NLM_contrib-group">Manns, M. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wedemeyer, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cornberg, M.</span><span> </span><span class="NLM_article-title">Treating viral hepatitis C: efficacy, side effects, and complications</span> <span class="citation_source-journal">Gut</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">55</span><span class="NLM_x">, </span> <span class="NLM_fpage">1350</span><span class="NLM_x">–</span> <span class="NLM_lpage">1359</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=55&publication_year=2006&pages=1350-1359&author=M.+P.+Mannsauthor=H.+Wedemeyerauthor=M.+Cornberg&title=Treating+viral+hepatitis+C%3A+efficacy%2C+side+effects%2C+and+complications"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit4c&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DManns%26aufirst%3DM.%2BP.%26aulast%3DWedemeyer%26aufirst%3DH.%26aulast%3DCornberg%26aufirst%3DM.%26atitle%3DTreating%2520viral%2520hepatitis%2520C%253A%2520efficacy%252C%2520side%2520effects%252C%2520and%2520complications%26jtitle%3DGut%26date%3D2006%26volume%3D55%26spage%3D1350%26epage%3D1359" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref5"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref5'); return false;" data-citation="" class="refNumLink">5</a></strong><div class="NLM_citation" id="cit5a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Kato, N.</span><span> </span><span class="NLM_article-title">Genome of human hepatitis C virus (HCV): gene organization, sequence diversity, and variation</span> <span class="citation_source-journal">Microb. Comp. Genomics</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2000</span><span class="NLM_x">, </span> <span class="NLM_volume">5</span><span class="NLM_x"> (</span><span class="NLM_issue">3</span><span class="NLM_x">) </span> <span class="NLM_fpage">129</span><span class="NLM_x">–</span> <span class="NLM_lpage">151</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref5/cit5a&amp;dbid=16&amp;doi=10.1021%2Fjm4012643&amp;key=10.1089%2Fomi.1.2000.5.129" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref5/cit5a&amp;dbid=8&amp;doi=10.1021%2Fjm4012643&amp;key=11252351" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref5/cit5a&amp;dbid=32&amp;doi=10.1021%2Fjm4012643&amp;key=1%3ACAS%3A528%3ADC%252BD3MXitFaqurk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=2000&pages=129-151&issue=3&author=N.+Kato&title=Genome+of+human+hepatitis+C+virus+%28HCV%29%3A+gene+organization%2C+sequence+diversity%2C+and+variation"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit5aR"><div class="casContent"><span class="casTitleNuber">5a</span><div class="casTitle"><span class="NLM_cas:atitle">Genome of human hepatitis C virus (HCV): Gene organization, sequence diversity, and variation</span></div><div class="casAuthors">Kato, Nobuyuki</div><div class="citationInfo"><span class="NLM_cas:title">Microbial & Comparative Genomics</span>
        (<span class="NLM_cas:date">2000</span>),
    <span class="NLM_cas:volume">5</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">129-151</span>CODEN:
                <span class="NLM_cas:coden">MCGEFP</span>;
        ISSN:<span class="NLM_cas:issn">1090-6592</span>.
    
            (<span class="NLM_cas:orgname">Mary Ann Liebert, Inc.</span>)
        </div><div class="casAbstract">A review with refs.  Hepatitis C virus (HCV) is the major etiol. agent of non-A, non-B hepatitis.  HCV infection frequently causes chronic hepatitis, which progresses to liver cirrhosis and hepatocellular carcinoma.  Since the discovery of HCV in 1989, a large no. of genetic analyses of HCV have been reported, and the viral genome structure has been elucidated.  An enveloped virus, HCV belongs to the family Flaviviridae, whose genome consists of a pos.-stranded RNA mol. of about 9.6 kilobases and encodes a large polyprotein precursor (about 3000 amino acids).  This precursor protein is cleaved by the host and viral proteinase to generate at least 10 proteins: the core, envelope 1 (E1), E2, p7, nonstructural (NS) 2, NS3, NS4A, NS4B, NS5A, and NS5B.  These HCV proteins not only function in viral replication but also affect a variety of cellular functions.  HCV has been found to have remarkable genetic heterogeneity.  To date, more than 30 HCV genotypes have been identified worldwide.  Furthermore, HCV may show quasispecies distribution in an infected individual.  These findings may have important implications in diagnosis, pathogenesis, treatment, and vaccine development.  The hypervariable region 1 found within the envelope E2 protein was shown to be a major site for the genetic evolution of HCV after the onset of hepatitis, and might be involved in escape from the host immunesurveillance system.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqtYgXE3VZ8YLVg90H21EOLACvtfcHk0lgVS6Row49rsg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3MXitFaqurk%253D&md5=9cb2f80fe202cf58547f35ec16018397</span></div><a href="/servlet/linkout?suffix=cit5a&amp;dbid=16384&amp;doi=10.1089%2Fomi.1.2000.5.129&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1089%252Fomi.1.2000.5.129%26sid%3Dliteratum%253Aachs%26aulast%3DKato%26aufirst%3DN.%26atitle%3DGenome%2520of%2520human%2520hepatitis%2520C%2520virus%2520%2528HCV%2529%253A%2520gene%2520organization%252C%2520sequence%2520diversity%252C%2520and%2520variation%26jtitle%3DMicrob.%2520Comp.%2520Genomics%26date%3D2000%26volume%3D5%26issue%3D3%26spage%3D129%26epage%3D151" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit5b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Dubuisson, J.</span><span> </span><span class="NLM_article-title">Hepatitis C virus proteins</span> <span class="citation_source-journal">World J. Gastroenterol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">13</span><span class="NLM_x"> (</span><span class="NLM_issue">17</span><span class="NLM_x">) </span> <span class="NLM_fpage">2406</span><span class="NLM_x">–</span> <span class="NLM_lpage">2415</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref5/cit5b&amp;dbid=16&amp;doi=10.1021%2Fjm4012643&amp;key=10.3748%2Fwjg.v13.i17.2406" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref5/cit5b&amp;dbid=8&amp;doi=10.1021%2Fjm4012643&amp;key=17552023" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref5/cit5b&amp;dbid=32&amp;doi=10.1021%2Fjm4012643&amp;key=1%3ACAS%3A528%3ADC%252BD2sXotl2ltL8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=2007&pages=2406-2415&issue=17&author=J.+Dubuisson&title=Hepatitis+C+virus+proteins"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit5bR"><div class="casContent"><span class="casTitleNuber">5b</span><div class="casTitle"><span class="NLM_cas:atitle">Hepatitis C virus proteins</span></div><div class="casAuthors">Dubuisson, Jean</div><div class="citationInfo"><span class="NLM_cas:title">World Journal of Gastroenterology</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">13</span>
        (<span class="NLM_cas:issue">17</span>),
    <span class="NLM_cas:pages">2406-2415</span>CODEN:
                <span class="NLM_cas:coden">WJGAF2</span>;
        ISSN:<span class="NLM_cas:issn">1007-9327</span>.
    
            (<span class="NLM_cas:orgname">World Journal of Gastroenterology</span>)
        </div><div class="casAbstract">A review.  Hepatitis C virus (HCV) encodes a single polyprotein, which is processed by cellular and viral proteases to generate 10 polypeptides.  The HCV genome also contains an overlapping +1 reading frame that may lead to the synthesis of an addnl. protein.  Until recently, studies of HCV have been hampered by the lack of a productive cell culture system.  Since the identification of HCV genome approx. 17 years ago, structural, biochem. and biol. information on HCV proteins has mainly been obtained with proteins produced by heterologous expression systems.  In addn., some functional studies have also been confirmed with replicon systems or with retroviral particles pseudotyped with HCV envelope glycoproteins.  The data that have accumulated on HCV proteins begin to provide a framework for understanding the mol. mechanisms involved in the major steps of HCV life cycle.  Moreover, the knowledge accumulated on HCV proteins is also leading to the development of antiviral drugs among which some are showing promising results in early-phase clin. trials.  This review summarizes the current knowledge on the functions and biochem. features of HCV proteins.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpezIkAF0sydLVg90H21EOLACvtfcHk0lhy47KbDnYoBw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXotl2ltL8%253D&md5=e99a88ec6a8102fd7611c376f6a78d80</span></div><a href="/servlet/linkout?suffix=cit5b&amp;dbid=16384&amp;doi=10.3748%2Fwjg.v13.i17.2406&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3748%252Fwjg.v13.i17.2406%26sid%3Dliteratum%253Aachs%26aulast%3DDubuisson%26aufirst%3DJ.%26atitle%3DHepatitis%2520C%2520virus%2520proteins%26jtitle%3DWorld%2520J.%2520Gastroenterol.%26date%3D2007%26volume%3D13%26issue%3D17%26spage%3D2406%26epage%3D2415" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref6"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref6'); return false;" data-citation="" class="refNumLink">6</a></strong><div class="NLM_citation" id="cit6a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Asselah, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Marcellin, P.</span><span> </span><span class="NLM_article-title">Direct acting antivirals for the treatment of chronic hepatitis C: One pill a day for tomorrow</span> <span class="citation_source-journal">Liver Int.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">32</span><span class="NLM_x"> (</span><span class="NLM_issue">Suppl 1</span><span class="NLM_x">) </span> <span class="NLM_fpage">88</span><span class="NLM_x">–</span> <span class="NLM_lpage">102</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=32&publication_year=2012&pages=88-102&issue=Suppl+1&author=T.+Asselahauthor=P.+Marcellin&title=Direct+acting+antivirals+for+the+treatment+of+chronic+hepatitis+C%3A+One+pill+a+day+for+tomorrow"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit6a&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DAsselah%26aufirst%3DT.%26aulast%3DMarcellin%26aufirst%3DP.%26atitle%3DDirect%2520acting%2520antivirals%2520for%2520the%2520treatment%2520of%2520chronic%2520hepatitis%2520C%253A%2520One%2520pill%2520a%2520day%2520for%2520tomorrow%26jtitle%3DLiver%2520Int.%26date%3D2012%26volume%3D32%26issue%3DSuppl%25201%26spage%3D88%26epage%3D102" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit6b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Welsch, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jesudian, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zeuzem, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jacobson, I.</span><span> </span><span class="NLM_article-title">New direct-acting antiviral agents for the treatment of hepatitis C virus infection and perspectives</span> <span class="citation_source-journal">Gut Liver</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">61</span><span class="NLM_x">, </span> <span class="NLM_fpage">i36</span><span class="NLM_x">–</span> <span class="NLM_lpage">i46</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=61&publication_year=2012&pages=i36-i46&author=C.+Welschauthor=A.+Jesudianauthor=S.+Zeuzemauthor=I.+Jacobson&title=New+direct-acting+antiviral+agents+for+the+treatment+of+hepatitis+C+virus+infection+and+perspectives"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit6b&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DWelsch%26aufirst%3DC.%26aulast%3DJesudian%26aufirst%3DA.%26aulast%3DZeuzem%26aufirst%3DS.%26aulast%3DJacobson%26aufirst%3DI.%26atitle%3DNew%2520direct-acting%2520antiviral%2520agents%2520for%2520the%2520treatment%2520of%2520hepatitis%2520C%2520virus%2520infection%2520and%2520perspectives%26jtitle%3DGut%2520Liver%26date%3D2012%26volume%3D61%26spage%3Di36%26epage%3Di46" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit6c"><span><span class="NLM_label">(c) </span><span class="NLM_contrib-group">Pockros, P. J.</span><span> </span><span class="NLM_article-title">Drugs in development for chronic hepatitis C: a promising future</span> <span class="citation_source-journal">Expert Opin. Biol. Ther.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">11</span><span class="NLM_x">, </span> <span class="NLM_fpage">1611</span><span class="NLM_x">–</span> <span class="NLM_lpage">1622</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref6/cit6c&amp;dbid=16&amp;doi=10.1021%2Fjm4012643&amp;key=10.1517%2F14712598.2011.627851" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref6/cit6c&amp;dbid=8&amp;doi=10.1021%2Fjm4012643&amp;key=21995412" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref6/cit6c&amp;dbid=32&amp;doi=10.1021%2Fjm4012643&amp;key=1%3ACAS%3A528%3ADC%252BC3MXhsVags77F" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2011&pages=1611-1622&author=P.+J.+Pockros&title=Drugs+in+development+for+chronic+hepatitis+C%3A+a+promising+future"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit6cR"><div class="casContent"><span class="casTitleNuber">6c</span><div class="casTitle"><span class="NLM_cas:atitle">Drugs in development for chronic hepatitis C: a promising future</span></div><div class="casAuthors">Pockros, Paul J.</div><div class="citationInfo"><span class="NLM_cas:title">Expert Opinion on Biological Therapy</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">1611-1622</span>CODEN:
                <span class="NLM_cas:coden">EOBTA2</span>;
        ISSN:<span class="NLM_cas:issn">1471-2598</span>.
    
            (<span class="NLM_cas:orgname">Informa Healthcare</span>)
        </div><div class="casAbstract">Introduction:The approval of the first direct-acting antiviral (DAA) drugs for treatment of HCV in 2011 has lead to improved sustained viral response rates of up to 79% in treatment-naive or relapse genotype 1 patients.Areas covered:Clin. trial data, the clin. skills required for the use of DAA drugs, the use of genetic tests and HCV RNA assays, new small mols., resistance-assocd. variants, combinations of two or more DAAs, treatment of special populations, and future directions.  The results of the pivotal Phase III trials with telaprevir and boceprevir, including the efficacy, safety and tolerability, drug-drug interactions and management of the most common side-effects.  Resistance-assocd. variant data and treatment strategies implemented to minimize the development of resistance with these first-generation protease inhibitors.Expert opinion:Combination therapies of protease inhibitors with nucleoside or non-nucleoside polymerase inhibitors, non-structural protein 5A (NS5A) inhibitors and cyclophylin inhibitors are currently underway in regimens that use pegylated interferon and ribavirin or are interferon-free.  The explosion of new drug development will probably move the field forward and offer both improved efficacy and tolerability to patients with hepatitis C infections.  The use of these drugs ushers in a new era for the treatment of HCV but must be done with care and caution.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr8W7I7t4G677Vg90H21EOLACvtfcHk0lhy47KbDnYoBw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXhsVags77F&md5=d6a0c0e547adc1fc6b170f76144a96c8</span></div><a href="/servlet/linkout?suffix=cit6c&amp;dbid=16384&amp;doi=10.1517%2F14712598.2011.627851&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1517%252F14712598.2011.627851%26sid%3Dliteratum%253Aachs%26aulast%3DPockros%26aufirst%3DP.%2BJ.%26atitle%3DDrugs%2520in%2520development%2520for%2520chronic%2520hepatitis%2520C%253A%2520a%2520promising%2520future%26jtitle%3DExpert%2520Opin.%2520Biol.%2520Ther.%26date%3D2011%26volume%3D11%26spage%3D1611%26epage%3D1622" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit6d"><span><span class="NLM_label">(d) </span><span class="NLM_contrib-group">Fusco, D. N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chung, R. T.</span><span> </span><span class="NLM_article-title">Novel therapies for hepatitis C: insights from the structure of the virus</span> <span class="citation_source-journal">Annu. Rev. Med.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">63</span><span class="NLM_x">, </span> <span class="NLM_fpage">373</span><span class="NLM_x">–</span> <span class="NLM_lpage">387</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=63&publication_year=2012&pages=373-387&author=D.+N.+Fuscoauthor=R.+T.+Chung&title=Novel+therapies+for+hepatitis+C%3A+insights+from+the+structure+of+the+virus"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit6d&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DFusco%26aufirst%3DD.%2BN.%26aulast%3DChung%26aufirst%3DR.%2BT.%26atitle%3DNovel%2520therapies%2520for%2520hepatitis%2520C%253A%2520insights%2520from%2520the%2520structure%2520of%2520the%2520virus%26jtitle%3DAnnu.%2520Rev.%2520Med.%26date%3D2012%26volume%3D63%26spage%3D373%26epage%3D387" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit6e"><span><span class="NLM_label">(e) </span><span class="NLM_contrib-group">Lemon, S. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McKeating, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pietschmann, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Frick, D. N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Glenn, J. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tellinghuisen, T. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Symons, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Furman, P. A.</span><span> </span><span class="NLM_article-title">Development of novel therapies for hepatitis C</span> <span class="citation_source-journal">Antiviral Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">86</span><span class="NLM_x">, </span> <span class="NLM_fpage">79</span><span class="NLM_x">–</span> <span class="NLM_lpage">92</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=86&publication_year=2010&pages=79-92&author=S.+M.+Lemonauthor=J.+A.+McKeatingauthor=T.+Pietschmannauthor=D.+N.+Frickauthor=J.+S.+Glennauthor=T.+L.+Tellinghuisenauthor=J.+Symonsauthor=P.+A.+Furman&title=Development+of+novel+therapies+for+hepatitis+C"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit6e&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DLemon%26aufirst%3DS.%2BM.%26aulast%3DMcKeating%26aufirst%3DJ.%2BA.%26aulast%3DPietschmann%26aufirst%3DT.%26aulast%3DFrick%26aufirst%3DD.%2BN.%26aulast%3DGlenn%26aufirst%3DJ.%2BS.%26aulast%3DTellinghuisen%26aufirst%3DT.%2BL.%26aulast%3DSymons%26aufirst%3DJ.%26aulast%3DFurman%26aufirst%3DP.%2BA.%26atitle%3DDevelopment%2520of%2520novel%2520therapies%2520for%2520hepatitis%2520C%26jtitle%3DAntiviral%2520Res.%26date%3D2010%26volume%3D86%26spage%3D79%26epage%3D92" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref7"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref7'); return false;" data-citation="" class="refNumLink">7</a></strong><div class="NLM_citation" id="cit7a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Mani, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rao, B. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kieffer, T. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kwong, A. D.</span><span> </span><span class="NLM_article-title">Recent progress in the development of HCV protease inhibitors</span> <span class="citation_source-journal">Methods Principals Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">50</span><span class="NLM_x">, </span> <span class="NLM_fpage">307</span><span class="NLM_x">–</span> <span class="NLM_lpage">328</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref7/cit7a&amp;dbid=16&amp;doi=10.1021%2Fjm4012643&amp;key=10.1002%2F9783527635955.ch12" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=50&publication_year=2011&pages=307-328&author=N.+Maniauthor=B.+G.+Raoauthor=T.+L.+Kiefferauthor=A.+D.+Kwong&title=Recent+progress+in+the+development+of+HCV+protease+inhibitors"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit7a&amp;dbid=16384&amp;doi=10.1002%2F9783527635955.ch12&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252F9783527635955.ch12%26sid%3Dliteratum%253Aachs%26aulast%3DMani%26aufirst%3DN.%26aulast%3DRao%26aufirst%3DB.%2BG.%26aulast%3DKieffer%26aufirst%3DT.%2BL.%26aulast%3DKwong%26aufirst%3DA.%2BD.%26atitle%3DRecent%2520progress%2520in%2520the%2520development%2520of%2520HCV%2520protease%2520inhibitors%26jtitle%3DMethods%2520Principals%2520Med.%2520Chem.%26date%3D2011%26volume%3D50%26spage%3D307%26epage%3D328" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit7b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Chary, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Holodniy, M.</span><span> </span><span class="NLM_article-title">Recent advances in hepatitis C virus treatment: review of HCV protease inhibitor clinical trials</span> <span class="citation_source-journal">Rev. Recent Clin. Trials</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">5</span><span class="NLM_x">, </span> <span class="NLM_fpage">158</span><span class="NLM_x">–</span> <span class="NLM_lpage">173</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref7/cit7b&amp;dbid=16&amp;doi=10.1021%2Fjm4012643&amp;key=10.2174%2F157488710792007293" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref7/cit7b&amp;dbid=8&amp;doi=10.1021%2Fjm4012643&amp;key=20482493" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref7/cit7b&amp;dbid=32&amp;doi=10.1021%2Fjm4012643&amp;key=1%3ACAS%3A528%3ADC%252BC3cXhtFKqsrfO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=2010&pages=158-173&author=A.+Charyauthor=M.+Holodniy&title=Recent+advances+in+hepatitis+C+virus+treatment%3A+review+of+HCV+protease+inhibitor+clinical+trials"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit7bR"><div class="casContent"><span class="casTitleNuber">7b</span><div class="casTitle"><span class="NLM_cas:atitle">Recent advances in hepatitis C virus treatment: review of HCV protease inhibitor clinical trials</span></div><div class="casAuthors">Chary, Aarthi; Holodniy, Mark</div><div class="citationInfo"><span class="NLM_cas:title">Reviews on Recent Clinical Trials</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">5</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">158-173</span>CODEN:
                <span class="NLM_cas:coden">RRCTB2</span>;
        ISSN:<span class="NLM_cas:issn">1574-8871</span>.
    
            (<span class="NLM_cas:orgname">Bentham Science Publishers Ltd.</span>)
        </div><div class="casAbstract">A review.  Hepatitis C virus (HCV) infection affects millions of people world-wide, and chronic infection can result in end-stage liver disease and hepatocellular carcinoma.  Conventional therapy to date has involved combination antiviral therapy including alpha-interferon and ribavirin; response rates with these drugs are variable based on both viral and host factors, such as HCV viral load, HCV genotype, HIV co-infection, host genetic polymorphisms (such as those in the IL28B region), and other factors.  Recent advances in HCV treatment have included pegylated forms of alpha-interferon and, more recently, the development of specifically targeted antiviral therapy for HCV (STAT-C) with novel HCV protease inhibitors (PIs) for genotype 1 HCV.  Although unlikely to be administered as monotherapy due to the potential for development of HCV PI drug resistance mutations, results of phase II trials of two PIs in development have recently been reported, demonstrating promising therapeutic efficacy of HCV PIs in combination with established conventional treatment.  This review outlines the advances and the challenges in the development of these HCV PIs as effective HCV antiviral agents and their role in clin. practice.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoQIZzi-TKaoLVg90H21EOLACvtfcHk0lhsklps-ph7XA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXhtFKqsrfO&md5=a2698c8b46cbb88b89c4cc1403733835</span></div><a href="/servlet/linkout?suffix=cit7b&amp;dbid=16384&amp;doi=10.2174%2F157488710792007293&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F157488710792007293%26sid%3Dliteratum%253Aachs%26aulast%3DChary%26aufirst%3DA.%26aulast%3DHolodniy%26aufirst%3DM.%26atitle%3DRecent%2520advances%2520in%2520hepatitis%2520C%2520virus%2520treatment%253A%2520review%2520of%2520HCV%2520protease%2520inhibitor%2520clinical%2520trials%26jtitle%3DRev.%2520Recent%2520Clin.%2520Trials%26date%3D2010%26volume%3D5%26spage%3D158%26epage%3D173" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit7c"><span><span class="NLM_label">(c) </span><span class="NLM_contrib-group">Kwo, P. Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vinayek, R.</span><span> </span><span class="NLM_article-title">The therapeutic approaches for hepatitis C virus: protease inhibitors and polymerase inhibitors</span> <span class="citation_source-journal">Gut</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">5</span><span class="NLM_x">, </span> <span class="NLM_fpage">406</span><span class="NLM_x">–</span> <span class="NLM_lpage">417</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=2011&pages=406-417&author=P.+Y.+Kwoauthor=R.+Vinayek&title=The+therapeutic+approaches+for+hepatitis+C+virus%3A+protease+inhibitors+and+polymerase+inhibitors"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit7c&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DKwo%26aufirst%3DP.%2BY.%26aulast%3DVinayek%26aufirst%3DR.%26atitle%3DThe%2520therapeutic%2520approaches%2520for%2520hepatitis%2520C%2520virus%253A%2520protease%2520inhibitors%2520and%2520polymerase%2520inhibitors%26jtitle%3DGut%26date%3D2011%26volume%3D5%26spage%3D406%26epage%3D417" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref8"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref8'); return false;" data-citation="" class="refNumLink">8</a></strong><div class="NLM_citation" id="cit8"><span><span class="NLM_contrib-group">Reviriego, C.</span><span> </span><span class="NLM_article-title">Daclatasvir dihydrochloride: treatment of hepatitis C virus HCV NS5A inhibitor</span> <span class="citation_source-journal">Drugs Future</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">36</span><span class="NLM_x">, </span> <span class="NLM_fpage">735</span><span class="NLM_x">–</span> <span class="NLM_lpage">739</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=32&amp;doi=10.1021%2Fjm4012643&amp;key=1%3ACAS%3A528%3ADC%252BC38XhtVCksr8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=36&publication_year=2011&pages=735-739&author=C.+Reviriego&title=Daclatasvir+dihydrochloride%3A+treatment+of+hepatitis+C+virus+HCV+NS5A+inhibitor"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit8R"><div class="casContent"><span class="casTitleNuber">8</span><div class="casTitle"><span class="NLM_cas:atitle">Daclatasvir dihydrochloride: treatment of hepatitis C virus HCV NS5A inhibitor</span></div><div class="casAuthors">Reviriego, C.</div><div class="citationInfo"><span class="NLM_cas:title">Drugs of the Future</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">36</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">735-739</span>CODEN:
                <span class="NLM_cas:coden">DRFUD4</span>;
        ISSN:<span class="NLM_cas:issn">0377-8282</span>.
    
            (<span class="NLM_cas:orgname">Prous Science</span>)
        </div><div class="casAbstract">A review.  Hepatitis C virus (HCV) is a major chronic disease and infected individuals are at risk of developing multiple and highly severe liver complications, such as cirrhosis or liver carcinoma.  The current std. of care for the treatment of HCV is a combination of pegylated interferon alfa and ribavirin, a poorly tolerated regimen with limiting side effects and low sustained virol. response rates in genotype 1-infected patients.  Therefore, the exploration of alternative treatment regimens is of utmost importance.  Daclatasvir dihydrochloride (BMS-790052) is a novel, small-mol., first-in-class inhibitor of HCV replication that targets non-structural protein 5A (NS5A).  It has shown impressive clin. efficacy, high selectivity, picomolar activity and broad genotype coverage in vitro.  Daclatasvir is safe and generally well tolerated, and it has a pharmacokinetic profile suggestive of once-daily administration.  With its extraordinary potency and non-overlapping resistance profile, daclatasvir has the potential to be an important component in future combination strategies for HCV therapy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrALLJfJjhdI7Vg90H21EOLACvtfcHk0lhsklps-ph7XA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XhtVCksr8%253D&md5=5e4a7324e33a0351f609304f88e289cd</span></div><a href="/servlet/linkout?suffix=cit8&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DReviriego%26aufirst%3DC.%26atitle%3DDaclatasvir%2520dihydrochloride%253A%2520treatment%2520of%2520hepatitis%2520C%2520virus%2520HCV%2520NS5A%2520inhibitor%26jtitle%3DDrugs%2520Future%26date%3D2011%26volume%3D36%26spage%3D735%26epage%3D739" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref9"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref9'); return false;" data-citation="" class="refNumLink">9</a></strong><div class="NLM_citation" id="cit9a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Kwo, P. Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vinayek, R.</span><span> </span><span class="NLM_article-title">The therapeutic approaches for hepatitis C virus: protease inhibitors and polymerase inhibitors</span> <span class="citation_source-journal">Gut</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">5</span><span class="NLM_x">, </span> <span class="NLM_fpage">406</span><span class="NLM_x">–</span> <span class="NLM_lpage">417</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=2011&pages=406-417&author=P.+Y.+Kwoauthor=R.+Vinayek&title=The+therapeutic+approaches+for+hepatitis+C+virus%3A+protease+inhibitors+and+polymerase+inhibitors"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit9a&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DKwo%26aufirst%3DP.%2BY.%26aulast%3DVinayek%26aufirst%3DR.%26atitle%3DThe%2520therapeutic%2520approaches%2520for%2520hepatitis%2520C%2520virus%253A%2520protease%2520inhibitors%2520and%2520polymerase%2520inhibitors%26jtitle%3DGut%26date%3D2011%26volume%3D5%26spage%3D406%26epage%3D417" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit9b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Sofia, M. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chang, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Furman, P. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mosley, R. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ross, B. S.</span><span> </span><span class="NLM_article-title">Nucleoside, nucleotide, and non-nucleoside inhibitors of hepatitis C virus NS5B RNA-dependent RNA-polymerase</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">55</span><span class="NLM_x">, </span> <span class="NLM_fpage">2481</span><span class="NLM_x">–</span> <span class="NLM_lpage">2531</span></span><div class="citationLinks">[<a href="/doi/10.1021/jm201384j" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=55&publication_year=2012&pages=2481-2531&author=M.+J.+Sofiaauthor=W.+Changauthor=P.+A.+Furmanauthor=R.+T.+Mosleyauthor=B.+S.+Ross&title=Nucleoside%2C+nucleotide%2C+and+non-nucleoside+inhibitors+of+hepatitis+C+virus+NS5B+RNA-dependent+RNA-polymerase"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit9b&amp;dbid=16384&amp;doi=10.1021%2Fjm201384j&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm201384j%26sid%3Dliteratum%253Aachs%26aulast%3DSofia%26aufirst%3DM.%2BJ.%26aulast%3DChang%26aufirst%3DW.%26aulast%3DFurman%26aufirst%3DP.%2BA.%26aulast%3DMosley%26aufirst%3DR.%2BT.%26aulast%3DRoss%26aufirst%3DB.%2BS.%26atitle%3DNucleoside%252C%2520nucleotide%252C%2520and%2520non-nucleoside%2520inhibitors%2520of%2520hepatitis%2520C%2520virus%2520NS5B%2520RNA-dependent%2520RNA-polymerase%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2012%26volume%3D55%26spage%3D2481%26epage%3D2531" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit9c"><span><span class="NLM_label">(c) </span><span class="NLM_contrib-group">Li, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shi, S. T.</span><span> </span><span class="NLM_article-title">Non-nucleoside inhibitors of hepatitis C virus polymerase: current progress and future challenges</span> <span class="citation_source-journal">Future Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">2</span><span class="NLM_x">, </span> <span class="NLM_fpage">121</span><span class="NLM_x">–</span> <span class="NLM_lpage">141</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref9/cit9c&amp;dbid=16&amp;doi=10.1021%2Fjm4012643&amp;key=10.4155%2Ffmc.09.148" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref9/cit9c&amp;dbid=8&amp;doi=10.1021%2Fjm4012643&amp;key=21426049" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref9/cit9c&amp;dbid=32&amp;doi=10.1021%2Fjm4012643&amp;key=1%3ACAS%3A528%3ADC%252BC3cXosVWgug%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2&publication_year=2010&pages=121-141&author=H.+Liauthor=S.+T.+Shi&title=Non-nucleoside+inhibitors+of+hepatitis+C+virus+polymerase%3A+current+progress+and+future+challenges"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit9cR"><div class="casContent"><span class="casTitleNuber">9c</span><div class="casTitle"><span class="NLM_cas:atitle">Non-nucleoside inhibitors of hepatitis C virus polymerase: current progress and future challenges</span></div><div class="casAuthors">Li, Hui; Shi, Stephanie T.</div><div class="citationInfo"><span class="NLM_cas:title">Future Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">2</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">121-141</span>CODEN:
                <span class="NLM_cas:coden">FMCUA7</span>;
        ISSN:<span class="NLM_cas:issn">1756-8919</span>.
    
            (<span class="NLM_cas:orgname">Future Science Ltd.</span>)
        </div><div class="casAbstract">A review.  The current std. of care for hepatitis C virus (HCV) infection is a combination of PEGylated interferon and ribavirin, which offer limited efficacy and significant side effects.  Novel HCV-specific inhibitors, including those directed at the viral polymerase, have become the focus of HCV drug-discovery efforts in the past decade.  In addn. to the active site targeted by traditional nucleoside inhibitors, at least four different allosteric-binding sites have been reported for the HCV polymerase, which offer ample opportunities for small-mol. inhibitors.  In this review, we summarize the recent progress in the discovery of non-nucleoside HCV polymerase inhibitors with a focus on novel chem. matters, their clin. efficacy, safety and potential for combination therapy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqnYvEwqRM0-bVg90H21EOLACvtfcHk0liY7B86uy8d7g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXosVWgug%253D%253D&md5=311bcf9ff7adf740674c2d8333fb25c2</span></div><a href="/servlet/linkout?suffix=cit9c&amp;dbid=16384&amp;doi=10.4155%2Ffmc.09.148&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.4155%252Ffmc.09.148%26sid%3Dliteratum%253Aachs%26aulast%3DLi%26aufirst%3DH.%26aulast%3DShi%26aufirst%3DS.%2BT.%26atitle%3DNon-nucleoside%2520inhibitors%2520of%2520hepatitis%2520C%2520virus%2520polymerase%253A%2520current%2520progress%2520and%2520future%2520challenges%26jtitle%3DFuture%2520Med.%2520Chem.%26date%3D2010%26volume%3D2%26spage%3D121%26epage%3D141" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit9d"><span><span class="NLM_label">(d) </span><span class="NLM_contrib-group">Watkins, W. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ray, A. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chong, L. S.</span><span> </span><span class="NLM_article-title">HCV NS5B polymerase inhibitors</span> <span class="citation_source-journal">Curr. Opin. Drug Discovery Dev.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">13</span><span class="NLM_x">, </span> <span class="NLM_fpage">441</span><span class="NLM_x">–</span> <span class="NLM_lpage">465</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=2010&pages=441-465&author=W.+J.+Watkinsauthor=A.+S.+Rayauthor=L.+S.+Chong&title=HCV+NS5B+polymerase+inhibitors"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit9d&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DWatkins%26aufirst%3DW.%2BJ.%26aulast%3DRay%26aufirst%3DA.%2BS.%26aulast%3DChong%26aufirst%3DL.%2BS.%26atitle%3DHCV%2520NS5B%2520polymerase%2520inhibitors%26jtitle%3DCurr.%2520Opin.%2520Drug%2520Discovery%2520Dev.%26date%3D2010%26volume%3D13%26spage%3D441%26epage%3D465" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref10"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref10'); return false;" data-citation="" class="refNumLink">10</a></strong><div class="NLM_citation" id="cit10a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Rong, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dahari, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ribeiro, R. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Perelson, A. S.</span><span> </span><span class="NLM_article-title">Rapid emergence of protease inhibitor resistance in hepatitis C virus</span> <span class="citation_source-journal">Sci. Transl. Med.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">2</span><span class="NLM_x">, </span> <span class="NLM_fpage">1</span><span class="NLM_x">–</span> <span class="NLM_lpage">9</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref10/cit10a&amp;dbid=16&amp;doi=10.1021%2Fjm4012643&amp;key=10.1126%2Fscitranslmed.3000544" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2&publication_year=2010&pages=1-9&author=L.+Rongauthor=H.+Dahariauthor=R.+M.+Ribeiroauthor=A.+S.+Perelson&title=Rapid+emergence+of+protease+inhibitor+resistance+in+hepatitis+C+virus"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit10a&amp;dbid=16384&amp;doi=10.1126%2Fscitranslmed.3000544&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1126%252Fscitranslmed.3000544%26sid%3Dliteratum%253Aachs%26aulast%3DRong%26aufirst%3DL.%26aulast%3DDahari%26aufirst%3DH.%26aulast%3DRibeiro%26aufirst%3DR.%2BM.%26aulast%3DPerelson%26aufirst%3DA.%2BS.%26atitle%3DRapid%2520emergence%2520of%2520protease%2520inhibitor%2520resistance%2520in%2520hepatitis%2520C%2520virus%26jtitle%3DSci.%2520Transl.%2520Med.%26date%3D2010%26volume%3D2%26spage%3D1%26epage%3D9" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit10b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Wang, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sun, J. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">O’Boyle, D. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nower, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Valera, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Roberts, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fridell, R. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gao, M.</span><span> </span><span class="NLM_article-title">Persistence of variants in hepatitis C virus-infected patients treated with the NS5A replication complex inhibitor daclatasvir</span> <span class="citation_source-journal">Antimicrob. Agents Chemother.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">57</span><span class="NLM_x"> (</span><span class="NLM_issue">5</span><span class="NLM_x">) </span> <span class="NLM_fpage">2054</span><span class="NLM_x">–</span> <span class="NLM_lpage">2065</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=57&publication_year=2013&pages=2054-2065&issue=5&author=C.+Wangauthor=J.+H.+Sunauthor=D.+R.+O%E2%80%99Boyleauthor=P.+Nowerauthor=L.+Valeraauthor=S.+Robertsauthor=R.+A.+Fridellauthor=M.+Gao&title=Persistence+of+variants+in+hepatitis+C+virus-infected+patients+treated+with+the+NS5A+replication+complex+inhibitor+daclatasvir"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit10b&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DWang%26aufirst%3DC.%26aulast%3DSun%26aufirst%3DJ.%2BH.%26aulast%3DO%25E2%2580%2599Boyle%26aufirst%3DD.%2BR.%26aulast%3DNower%26aufirst%3DP.%26aulast%3DValera%26aufirst%3DL.%26aulast%3DRoberts%26aufirst%3DS.%26aulast%3DFridell%26aufirst%3DR.%2BA.%26aulast%3DGao%26aufirst%3DM.%26atitle%3DPersistence%2520of%2520variants%2520in%2520hepatitis%2520C%2520virus-infected%2520patients%2520treated%2520with%2520the%2520NS5A%2520replication%2520complex%2520inhibitor%2520daclatasvir%26jtitle%3DAntimicrob.%2520Agents%2520Chemother.%26date%3D2013%26volume%3D57%26issue%3D5%26spage%3D2054%26epage%3D2065" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit10c"><span><span class="NLM_label">(c) </span><span class="NLM_contrib-group">Delang, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vliegen, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Leyssen, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Neyts, J.</span><span> </span><span class="NLM_article-title">In vitro selection and characterization of HCV replicons resistent to multiple non-nucleoside polymerase inhibitors</span> <span class="citation_source-journal">J. Hepatol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">56</span><span class="NLM_x"> (</span><span class="NLM_issue">1</span><span class="NLM_x">) </span> <span class="NLM_fpage">41</span><span class="NLM_x">–</span> <span class="NLM_lpage">48</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref10/cit10c&amp;dbid=16&amp;doi=10.1021%2Fjm4012643&amp;key=10.1016%2Fj.jhep.2011.04.016" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref10/cit10c&amp;dbid=8&amp;doi=10.1021%2Fjm4012643&amp;key=21703175" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref10/cit10c&amp;dbid=32&amp;doi=10.1021%2Fjm4012643&amp;key=1%3ACAS%3A528%3ADC%252BC3MXhs1GhsbnI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=56&publication_year=2012&pages=41-48&issue=1&author=L.+Delangauthor=I.+Vliegenauthor=P.+Leyssenauthor=J.+Neyts&title=In+vitro+selection+and+characterization+of+HCV+replicons+resistent+to+multiple+non-nucleoside+polymerase+inhibitors"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit10cR"><div class="casContent"><span class="casTitleNuber">10c</span><div class="casTitle"><span class="NLM_cas:atitle">In vitro selection and characterization of HCV replicons resistant to multiple non-nucleoside polymerase inhibitors</span></div><div class="casAuthors">Delang, Leen; Vliegen, Inge; Leyssen, Pieter; Neyts, Johan</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Hepatology</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">56</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">41-48</span>CODEN:
                <span class="NLM_cas:coden">JOHEEC</span>;
        ISSN:<span class="NLM_cas:issn">0168-8278</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Background & Aims: To delay or prevent the selection of HCV drug-resistant variants, combination therapy will be needed.  Our aim was to det. the antiviral efficacy of various combinations of non-nucleoside polymerase inhibitors (NNI) (that have a different allosteric binding site) and the barrier towards resistance development of such combinations.  Methods: Short-term antiviral combination assays were performed in a checkerboard format.  Resistance selection expts. employing HCV replicons were performed using two different protocols: (i) a short-term treatment with fixed concns. and (ii) a long-term treatment with increasing concns.  Results: All pair-wise combinations of NNI resulted in an additive antiviral effect in short-term antiviral assays.  Combination treatment of two NNIs markedly reduced or even prevented the emergence of double resistant colonies.  However, double and even triple NNI-resistant variants emerged readily when relatively low starting concns. were used in a long-term selection protocol.  Genotyping confirmed the presence of the previously published resistance mutations.  For some NNI, different signature mutations appeared depending on the other NNI in the particular combination.  Remarkably, variants that were selected to be resistant to three different classes of NNIs [a thiophene carboxylic acid (TCA), a benzimidazole (JT-16), and a benzofuran (HCV-796)] proved resistant to yet a fourth class of NNIs (benzothiadiazines).  Conclusions: Double and even triple NNI-resistant HCV replicons can be readily selected with a stepwise resistance selection protocol.  Depending on the particular combination, different signature mutations may arise for some NNI.  Resistance to three classes of NNI resulted in resistance to yet a fourth class.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrg4x1suoQ-d7Vg90H21EOLACvtfcHk0lh2l5NbejgI9w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXhs1GhsbnI&md5=719159d02fe3fc06080509e43a2ad13d</span></div><a href="/servlet/linkout?suffix=cit10c&amp;dbid=16384&amp;doi=10.1016%2Fj.jhep.2011.04.016&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.jhep.2011.04.016%26sid%3Dliteratum%253Aachs%26aulast%3DDelang%26aufirst%3DL.%26aulast%3DVliegen%26aufirst%3DI.%26aulast%3DLeyssen%26aufirst%3DP.%26aulast%3DNeyts%26aufirst%3DJ.%26atitle%3DIn%2520vitro%2520selection%2520and%2520characterization%2520of%2520HCV%2520replicons%2520resistent%2520to%2520multiple%2520non-nucleoside%2520polymerase%2520inhibitors%26jtitle%3DJ.%2520Hepatol.%26date%3D2012%26volume%3D56%26issue%3D1%26spage%3D41%26epage%3D48" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref11"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref11'); return false;" data-citation="" class="refNumLink">11</a></strong><div class="NLM_citation" id="cit11"><span><span class="NLM_contrib-group">Gouttenoire, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Roingeard, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Penin, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Moradpour, D.</span><span> </span><span class="NLM_article-title">Hepatitis C virus nonstructural protein 4B: a journey into unexplored territory</span> <span class="citation_source-journal">Rev. Med. Virol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">20</span><span class="NLM_x"> (</span><span class="NLM_issue">2</span><span class="NLM_x">) </span> <span class="NLM_fpage">117</span><span class="NLM_x">–</span> <span class="NLM_lpage">129</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=16&amp;doi=10.1021%2Fjm4012643&amp;key=10.1002%2Frmv.640" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=8&amp;doi=10.1021%2Fjm4012643&amp;key=20069613" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=32&amp;doi=10.1021%2Fjm4012643&amp;key=1%3ACAS%3A528%3ADC%252BC3cXkslSksrc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=20&publication_year=2010&pages=117-129&issue=2&author=J.+Gouttenoireauthor=P.+Roingeardauthor=F.+Peninauthor=D.+Moradpour&title=Hepatitis+C+virus+nonstructural+protein+4B%3A+a+journey+into+unexplored+territory"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit11R"><div class="casContent"><span class="casTitleNuber">11</span><div class="casTitle"><span class="NLM_cas:atitle">Hepatitis C virus nonstructural protein 4B: a journey into unexplored territory</span></div><div class="casAuthors">Gouttenoire, Jerome; Penin, Francois; Moradpour, Darius</div><div class="citationInfo"><span class="NLM_cas:title">Reviews in Medical Virology</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">20</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">117-129</span>CODEN:
                <span class="NLM_cas:coden">RMVIEW</span>;
        ISSN:<span class="NLM_cas:issn">1052-9276</span>.
    
            (<span class="NLM_cas:orgname">John Wiley & Sons Ltd.</span>)
        </div><div class="casAbstract">A review.  Hepatitis C virus (HCV) is a pos.-strand RNA virus that replicates its genome in a membrane-assocd. replication complex.  Nonstructural protein 4B (NS4B) induces the specific membrane alteration, designated as membranous web (MW), that harbours this complex.  HCV NS4B is an integral membrane protein predicted to comprise four transmembrane segments in its central part.  The N-terminal part comprises two amphipathic α-helixes of which the second has the potential to traverse the membrane bilayer, likely upon oligomerisation.  The C-terminal part comprises a predicted highly conserved α-helix, a membrane-assocd. amphipathic α-helix and two reported palmitoylation sites.  NS4B interacts with other viral nonstructural proteins and has been reported to bind viral RNA.  In addn., it was found to harbor an NTPase activity.  Finally, NS4B has recently been found to have a role in viral assembly.  Much work needs to be done with respect to further dissecting these multiple functions as well as providing a refined membrane topol. and complete structure of NS4B.  Progress in this direction should yield important insights into the functional architecture of the HCV replication complex and may reveal new opportunities for antiviral intervention against a leading cause of chronic hepatitis, liver cirrhosis and hepatocellular carcinoma worldwide.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqnz69FSBeMp7Vg90H21EOLACvtfcHk0lh2l5NbejgI9w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXkslSksrc%253D&md5=200464067fc0ccdf6782482a7c13e9f2</span></div><a href="/servlet/linkout?suffix=cit11&amp;dbid=16384&amp;doi=10.1002%2Frmv.640&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Frmv.640%26sid%3Dliteratum%253Aachs%26aulast%3DGouttenoire%26aufirst%3DJ.%26aulast%3DRoingeard%26aufirst%3DP.%26aulast%3DPenin%26aufirst%3DF.%26aulast%3DMoradpour%26aufirst%3DD.%26atitle%3DHepatitis%2520C%2520virus%2520nonstructural%2520protein%25204B%253A%2520a%2520journey%2520into%2520unexplored%2520territory%26jtitle%3DRev.%2520Med.%2520Virol.%26date%3D2010%26volume%3D20%26issue%3D2%26spage%3D117%26epage%3D129" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref12"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref12'); return false;" data-citation="" class="refNumLink">12</a></strong><div class="NLM_citation" id="cit12a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Meanwell, N. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Belema, M.</span><span> </span><span class="NLM_article-title">Hepatitis C virus—Progress towards inhibiting the nonenzymatic viral proteins</span> <span class="citation_source-journal">Annu. Rep. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">46</span><span class="NLM_x">, </span> <span class="NLM_fpage">268</span><span class="NLM_x">–</span> <span class="NLM_lpage">270</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=46&publication_year=2011&pages=268-270&author=N.+A.+Meanwellauthor=M.+Belema&title=Hepatitis+C+virus%E2%80%94Progress+towards+inhibiting+the+nonenzymatic+viral+proteins"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit12a&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DMeanwell%26aufirst%3DN.%2BA.%26aulast%3DBelema%26aufirst%3DM.%26atitle%3DHepatitis%2520C%2520virus%25E2%2580%2594Progress%2520towards%2520inhibiting%2520the%2520nonenzymatic%2520viral%2520proteins%26jtitle%3DAnnu.%2520Rep.%2520Med.%2520Chem.%26date%3D2011%26volume%3D46%26spage%3D268%26epage%3D270" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit12b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Brysona, P. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Choa, N. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Einava, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Leea, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Taid, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bechteld, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sivarajad, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Robertsd, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schmitzd, U.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Glenn, J. S.</span><span> </span><span class="NLM_article-title">A small molecule inhibits HCV replication and alters NS4B’s subcellular distribution</span> <span class="citation_source-journal">Antiviral Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">87</span><span class="NLM_x">, </span> <span class="NLM_fpage">1</span><span class="NLM_x">–</span> <span class="NLM_lpage">8</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=87&publication_year=2010&pages=1-8&author=P.+D.+Brysonaauthor=N.+J.+Choaauthor=S.+Einavaauthor=C.+Leeaauthor=V.+Taidauthor=J.+Bechteldauthor=M.+Sivarajadauthor=C.+Robertsdauthor=U.+Schmitzdauthor=J.+S.+Glenn&title=A+small+molecule+inhibits+HCV+replication+and+alters+NS4B%E2%80%99s+subcellular+distribution"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit12b&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DBrysona%26aufirst%3DP.%2BD.%26aulast%3DChoa%26aufirst%3DN.%2BJ.%26aulast%3DEinava%26aufirst%3DS.%26aulast%3DLeea%26aufirst%3DC.%26aulast%3DTaid%26aufirst%3DV.%26aulast%3DBechteld%26aufirst%3DJ.%26aulast%3DSivarajad%26aufirst%3DM.%26aulast%3DRobertsd%26aufirst%3DC.%26aulast%3DSchmitzd%26aufirst%3DU.%26aulast%3DGlenn%26aufirst%3DJ.%2BS.%26atitle%3DA%2520small%2520molecule%2520inhibits%2520HCV%2520replication%2520and%2520alters%2520NS4B%25E2%2580%2599s%2520subcellular%2520distribution%26jtitle%3DAntiviral%2520Res.%26date%3D2010%26volume%3D87%26spage%3D1%26epage%3D8" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit12c"><span><span class="NLM_label">(c) </span><span class="NLM_contrib-group">Shotwell, J. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Baskaran, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chong, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Creech, K. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Crosby, R. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dicks, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fang, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Garrido, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mathis, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Maung, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Parks, D. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pouliot, J. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Price, D. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rai, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Seal, J. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schmitz, U.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tai, V. W. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Thomson, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Xie, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Xiong, J. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Peat, A. J.</span><span> </span><span class="NLM_article-title">Imidazo[1,2-<i>a</i>]pyridines that directly interact with hepatitis C NS4B: initial preclinical characterization</span> <span class="citation_source-journal">ACS Med. Chem. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">3</span><span class="NLM_x">, </span> <span class="NLM_fpage">565</span><span class="NLM_x">–</span> <span class="NLM_lpage">569</span></span><div class="citationLinks">[<a href="/doi/10.1021/ml300090x" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=3&publication_year=2012&pages=565-569&author=J.+B.+Shotwellauthor=S.+Baskaranauthor=P.+Chongauthor=K.+L.+Creechauthor=R.+M.+Crosbyauthor=H.+Dicksauthor=J.+Fangauthor=D.+Garridoauthor=A.+Mathisauthor=J.+Maungauthor=D.+J.+Parksauthor=J.+J.+Pouliotauthor=D.+J.+Priceauthor=R.+Raiauthor=J.+W.+Sealauthor=U.+Schmitzauthor=V.+W.+F.+Taiauthor=M.+Thomsonauthor=M.+Xieauthor=J.+J.+Xiongauthor=A.+J.+Peat&title=Imidazo%5B1%2C2-a%5Dpyridines+that+directly+interact+with+hepatitis+C+NS4B%3A+initial+preclinical+characterization"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit12c&amp;dbid=16384&amp;doi=10.1021%2Fml300090x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fml300090x%26sid%3Dliteratum%253Aachs%26aulast%3DShotwell%26aufirst%3DJ.%2BB.%26aulast%3DBaskaran%26aufirst%3DS.%26aulast%3DChong%26aufirst%3DP.%26aulast%3DCreech%26aufirst%3DK.%2BL.%26aulast%3DCrosby%26aufirst%3DR.%2BM.%26aulast%3DDicks%26aufirst%3DH.%26aulast%3DFang%26aufirst%3DJ.%26aulast%3DGarrido%26aufirst%3DD.%26aulast%3DMathis%26aufirst%3DA.%26aulast%3DMaung%26aufirst%3DJ.%26aulast%3DParks%26aufirst%3DD.%2BJ.%26aulast%3DPouliot%26aufirst%3DJ.%2BJ.%26aulast%3DPrice%26aufirst%3DD.%2BJ.%26aulast%3DRai%26aufirst%3DR.%26aulast%3DSeal%26aufirst%3DJ.%2BW.%26aulast%3DSchmitz%26aufirst%3DU.%26aulast%3DTai%26aufirst%3DV.%2BW.%2BF.%26aulast%3DThomson%26aufirst%3DM.%26aulast%3DXie%26aufirst%3DM.%26aulast%3DXiong%26aufirst%3DJ.%2BJ.%26aulast%3DPeat%26aufirst%3DA.%2BJ.%26atitle%3DImidazo%255B1%252C2-a%255Dpyridines%2520that%2520directly%2520interact%2520with%2520hepatitis%2520C%2520NS4B%253A%2520initial%2520preclinical%2520characterization%26jtitle%3DACS%2520Med.%2520Chem.%2520Lett.%26date%3D2012%26volume%3D3%26spage%3D565%26epage%3D569" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit12d"><span><span class="NLM_label">(d) </span><span class="NLM_contrib-group">Miller, J. F.; Chong, P. Y.; Shotwell, J. B.; Catalano, J. G.; Tai, V. W.; Fang, J.; Banka, A.; Roberts, C. D.; Youngman, M.; Zhang, H.; Xiong, Z.; Mathis, A.; Pouliot, J. J.; Hamatake, R. K.; Price, D. J.; Seal, J. W.; Stroup, L. L.; Creech, K. L.; Carballo, L. H.; Todd, D.; Spaltenstein, A.; Furst, S.; Hong, Z.; Peat, A. J.</span><span> </span><span class="NLM_article-title">Hepatitis C replication inhibitors that target the viral NS4B protein</span>.  <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span><span class="refDoi"> DOI: 10.1021/jm400125h</span> .</span><div class="citationLinks">[<a href="/doi/10.1021/jm400125h" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2013&author=J.+F.+Miller&author=P.+Y.+Chong&author=J.+B.+Shotwell&author=J.+G.+Catalano&author=V.+W.+Tai&author=J.+Fang&author=A.+Banka&author=C.+D.+Roberts&author=M.+Youngman&author=H.+Zhang&author=Z.+Xiong&author=A.+Mathis&author=J.+J.+Pouliot&author=R.+K.+Hamatake&author=D.+J.+Price&author=J.+W.+Seal&author=L.+L.+Stroup&author=K.+L.+Creech&author=L.+H.+Carballo&author=D.+Todd&author=A.+Spaltenstein&author=S.+Furst&author=Z.+Hong&author=A.+J.+Peat&title=Hepatitis+C+replication+inhibitors+that+target+the+viral+NS4B+protein&doi=10.1021%2Fjm400125h"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit12d&amp;dbid=16384&amp;doi=10.1021%2Fjm400125h&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm400125h%26sid%3Dliteratum%253Aachs%26aulast%3DMiller%26aufirst%3DJ.%2BF.%26atitle%3DHepatitis%2520C%2520replication%2520inhibitors%2520that%2520target%2520the%2520viral%2520NS4B%2520protein%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2013%26doi%3D10.1021%2Fjm400125h" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit12e"><span><span class="NLM_label">(e) </span><span class="NLM_contrib-group">Gu, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Graci, J. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lahser, F. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Breslin, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jung, S. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Crona, J. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McMonagle, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Xia, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liu, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Karp, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhu, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Huang, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nomeir, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Weetall, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Almstead, N. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Peltz, S. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tong, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ralston, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Colacino, J. M.</span><span> </span><span class="NLM_article-title">Identification of PTC725: an orally bioavailable small molecule that selectively targets the hepatitis C virus NS4B protein</span> <span class="citation_source-journal">Antimicrob. Agents Chemother.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">57</span><span class="NLM_x"> (</span><span class="NLM_issue">5</span><span class="NLM_x">) </span> <span class="NLM_fpage">2054</span><span class="NLM_x">–</span> <span class="NLM_lpage">2065</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=57&publication_year=2013&pages=2054-2065&issue=5&author=Z.+Guauthor=J.+D.+Graciauthor=F.+C.+Lahserauthor=J.+Breslinauthor=S.+P.+Jungauthor=J.+H.+Cronaauthor=P.+McMonagleauthor=E.+Xiaauthor=S.+Liuauthor=G.+Karpauthor=J.+Zhuauthor=S.+Huangauthor=A.+Nomeirauthor=M.+Weetallauthor=N.+G.+Almsteadauthor=S.+W.+Peltzauthor=X.+Tongauthor=R.+Ralstonauthor=J.+M.+Colacino&title=Identification+of+PTC725%3A+an+orally+bioavailable+small+molecule+that+selectively+targets+the+hepatitis+C+virus+NS4B+protein"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit12e&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DGu%26aufirst%3DZ.%26aulast%3DGraci%26aufirst%3DJ.%2BD.%26aulast%3DLahser%26aufirst%3DF.%2BC.%26aulast%3DBreslin%26aufirst%3DJ.%26aulast%3DJung%26aufirst%3DS.%2BP.%26aulast%3DCrona%26aufirst%3DJ.%2BH.%26aulast%3DMcMonagle%26aufirst%3DP.%26aulast%3DXia%26aufirst%3DE.%26aulast%3DLiu%26aufirst%3DS.%26aulast%3DKarp%26aufirst%3DG.%26aulast%3DZhu%26aufirst%3DJ.%26aulast%3DHuang%26aufirst%3DS.%26aulast%3DNomeir%26aufirst%3DA.%26aulast%3DWeetall%26aufirst%3DM.%26aulast%3DAlmstead%26aufirst%3DN.%2BG.%26aulast%3DPeltz%26aufirst%3DS.%2BW.%26aulast%3DTong%26aufirst%3DX.%26aulast%3DRalston%26aufirst%3DR.%26aulast%3DColacino%26aufirst%3DJ.%2BM.%26atitle%3DIdentification%2520of%2520PTC725%253A%2520an%2520orally%2520bioavailable%2520small%2520molecule%2520that%2520selectively%2520targets%2520the%2520hepatitis%2520C%2520virus%2520NS4B%2520protein%26jtitle%3DAntimicrob.%2520Agents%2520Chemother.%26date%3D2013%26volume%3D57%26issue%3D5%26spage%3D2054%26epage%3D2065" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit12f"><span><span class="NLM_label">(f) </span><span class="NLM_contrib-group">Zhang, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Turpoff, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ren, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Takasugi, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Morrill, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhu, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lennox, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Paget, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liu, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Almstead, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">George Njoroge, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gu, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Komatsu, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Clausen, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Espiritu, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Graci, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Colacino, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lahser, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Risher, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Weetall, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nomeir, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Karp, G. M.</span><span> </span><span class="NLM_article-title">Discovery of novel HCV inhibitors: synthesis and biological activity of 6-(indol-2-yl)pyridine-3-sulfonamides targetting hepatitis C virus NS4B</span> <span class="citation_source-journal">Bioorg. Med. Chem. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">23</span><span class="NLM_x"> (</span><span class="NLM_issue">13</span><span class="NLM_x">) </span> <span class="NLM_fpage">3947</span><span class="NLM_x">–</span> <span class="NLM_lpage">3953</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=23&publication_year=2013&pages=3947-3953&issue=13&author=X.+Zhangauthor=N.+Zhangauthor=G.+Chenauthor=A.+Turpoffauthor=H.+Renauthor=J.+Takasugiauthor=C.+Morrillauthor=J.+Zhuauthor=C.+Liauthor=W.+Lennoxauthor=S.+Pagetauthor=Y.+Liuauthor=N.+Almsteadauthor=F.+George+Njorogeauthor=Z.+Guauthor=T.+Komatsuauthor=V.+Clausenauthor=C.+Espirituauthor=J.+Graciauthor=J.+Colacinoauthor=F.+Lahserauthor=N.+Risherauthor=M.+Weetallauthor=A.+Nomeirauthor=G.+M.+Karp&title=Discovery+of+novel+HCV+inhibitors%3A+synthesis+and+biological+activity+of+6-%28indol-2-yl%29pyridine-3-sulfonamides+targetting+hepatitis+C+virus+NS4B"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit12f&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DZhang%26aufirst%3DX.%26aulast%3DZhang%26aufirst%3DN.%26aulast%3DChen%26aufirst%3DG.%26aulast%3DTurpoff%26aufirst%3DA.%26aulast%3DRen%26aufirst%3DH.%26aulast%3DTakasugi%26aufirst%3DJ.%26aulast%3DMorrill%26aufirst%3DC.%26aulast%3DZhu%26aufirst%3DJ.%26aulast%3DLi%26aufirst%3DC.%26aulast%3DLennox%26aufirst%3DW.%26aulast%3DPaget%26aufirst%3DS.%26aulast%3DLiu%26aufirst%3DY.%26aulast%3DAlmstead%26aufirst%3DN.%26aulast%3DGeorge%2BNjoroge%26aufirst%3DF.%26aulast%3DGu%26aufirst%3DZ.%26aulast%3DKomatsu%26aufirst%3DT.%26aulast%3DClausen%26aufirst%3DV.%26aulast%3DEspiritu%26aufirst%3DC.%26aulast%3DGraci%26aufirst%3DJ.%26aulast%3DColacino%26aufirst%3DJ.%26aulast%3DLahser%26aufirst%3DF.%26aulast%3DRisher%26aufirst%3DN.%26aulast%3DWeetall%26aufirst%3DM.%26aulast%3DNomeir%26aufirst%3DA.%26aulast%3DKarp%26aufirst%3DG.%2BM.%26atitle%3DDiscovery%2520of%2520novel%2520HCV%2520inhibitors%253A%2520synthesis%2520and%2520biological%2520activity%2520of%25206-%2528indol-2-yl%2529pyridine-3-sulfonamides%2520targetting%2520hepatitis%2520C%2520virus%2520NS4B%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2013%26volume%3D23%26issue%3D13%26spage%3D3947%26epage%3D3953" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit12g"><span><span class="NLM_label">(g) </span><span class="NLM_contrib-group">Chen, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ren, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Turpoff, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Arefolov, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wilde, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Takasugi, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Khan, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Almstead, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gu, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Komatsu, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Freund, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Breslin, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Colacino, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hedrick, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Weetall, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Karp, G. M.</span><span> </span><span class="NLM_article-title">Discovery of of <i>N</i>-(4<sup>1</sup>-(indol-2-yl)phenyl)-sulfonamides as novel inhibitors of HCV replication</span> <span class="citation_source-journal">Bioorg. Med. Chem. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">23</span><span class="NLM_x"> (</span><span class="NLM_issue">13</span><span class="NLM_x">) </span> <span class="NLM_fpage">3942</span><span class="NLM_x">–</span> <span class="NLM_lpage">3946</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=23&publication_year=2013&pages=3942-3946&issue=13&author=G.+Chenauthor=H.+Renauthor=A.+Turpoffauthor=A.+Arefolovauthor=R.+Wildeauthor=J.+Takasugiauthor=A.+Khanauthor=N.+Almsteadauthor=Z.+Guauthor=T.+Komatsuauthor=C.+Freundauthor=J.+Breslinauthor=J.+Colacinoauthor=J.+Hedrickauthor=M.+Weetallauthor=G.+M.+Karp&title=Discovery+of+of+N-%2841-%28indol-2-yl%29phenyl%29-sulfonamides+as+novel+inhibitors+of+HCV+replication"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit12g&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DChen%26aufirst%3DG.%26aulast%3DRen%26aufirst%3DH.%26aulast%3DTurpoff%26aufirst%3DA.%26aulast%3DArefolov%26aufirst%3DA.%26aulast%3DWilde%26aufirst%3DR.%26aulast%3DTakasugi%26aufirst%3DJ.%26aulast%3DKhan%26aufirst%3DA.%26aulast%3DAlmstead%26aufirst%3DN.%26aulast%3DGu%26aufirst%3DZ.%26aulast%3DKomatsu%26aufirst%3DT.%26aulast%3DFreund%26aufirst%3DC.%26aulast%3DBreslin%26aufirst%3DJ.%26aulast%3DColacino%26aufirst%3DJ.%26aulast%3DHedrick%26aufirst%3DJ.%26aulast%3DWeetall%26aufirst%3DM.%26aulast%3DKarp%26aufirst%3DG.%2BM.%26atitle%3DDiscovery%2520of%2520of%2520N-%252841-%2528indol-2-yl%2529phenyl%2529-sulfonamides%2520as%2520novel%2520inhibitors%2520of%2520HCV%2520replication%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2013%26volume%3D23%26issue%3D13%26spage%3D3942%26epage%3D3946" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref13"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref13'); return false;" data-citation="" class="refNumLink">13</a></strong><div class="NLM_citation" id="cit13"><span><span class="NLM_contrib-group">Masaki, V. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ohta, M.</span><span> </span><span class="NLM_article-title">Synthese von 3,6-disubstituierten 2-oxopiperazinen</span> <span class="citation_source-journal">Bull. Chem. Soc. Jpn.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1963</span><span class="NLM_x">, </span> <span class="NLM_volume">36</span><span class="NLM_x"> (</span><span class="NLM_issue">8</span><span class="NLM_x">) </span> <span class="NLM_fpage">922</span><span class="NLM_x">–</span> <span class="NLM_lpage">925</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=36&publication_year=1963&pages=922-925&issue=8&author=V.+M.+Masakiauthor=M.+Ohta&title=Synthese+von+3%2C6-disubstituierten+2-oxopiperazinen"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit13&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DMasaki%26aufirst%3DV.%2BM.%26aulast%3DOhta%26aufirst%3DM.%26atitle%3DSynthese%2520von%25203%252C6-disubstituierten%25202-oxopiperazinen%26jtitle%3DBull.%2520Chem.%2520Soc.%2520Jpn.%26date%3D1963%26volume%3D36%26issue%3D8%26spage%3D922%26epage%3D925" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref14"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref14'); return false;" data-citation="" class="refNumLink">14</a></strong><div class="NLM_citation" id="cit14a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Petasis, N. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Goodman, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zavialov, T.</span><span> </span><span class="NLM_article-title">A new synthesis of α-arylglycines from aryl boronic acids</span> <span class="citation_source-journal">Tetrahedron</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1997</span><span class="NLM_x">, </span> <span class="NLM_volume">53</span><span class="NLM_x"> (</span><span class="NLM_issue">48</span><span class="NLM_x">) </span> <span class="NLM_fpage">16463</span><span class="NLM_x">–</span> <span class="NLM_lpage">16470</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=53&publication_year=1997&pages=16463-16470&issue=48&author=N.+A.+Petasisauthor=A.+Goodmanauthor=T.+Zavialov&title=A+new+synthesis+of+%CE%B1-arylglycines+from+aryl+boronic+acids"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit14a&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DPetasis%26aufirst%3DN.%2BA.%26aulast%3DGoodman%26aufirst%3DA.%26aulast%3DZavialov%26aufirst%3DT.%26atitle%3DA%2520new%2520synthesis%2520of%2520%25CE%25B1-arylglycines%2520from%2520aryl%2520boronic%2520acids%26jtitle%3DTetrahedron%26date%3D1997%26volume%3D53%26issue%3D48%26spage%3D16463%26epage%3D16470" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit14b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Haurena, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Le Gall, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sengmany, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Martens, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Troupel, M.</span><span> </span><span class="NLM_article-title">A straightforward three-component synthesis of α-amino esters containing a phenylalanine or a phenylglycine scaffold</span> <span class="citation_source-journal">J. Org. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">75</span><span class="NLM_x"> (</span><span class="NLM_issue">8</span><span class="NLM_x">) </span> <span class="NLM_fpage">2645</span><span class="NLM_x">–</span> <span class="NLM_lpage">2650</span></span><div class="citationLinks">[<a href="/doi/10.1021/jo1002328" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=75&publication_year=2010&pages=2645-2650&issue=8&author=C.+Haurenaauthor=E.+Le+Gallauthor=S.+Sengmanyauthor=T.+Martensauthor=M.+Troupel&title=A+straightforward+three-component+synthesis+of+%CE%B1-amino+esters+containing+a+phenylalanine+or+a+phenylglycine+scaffold"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit14b&amp;dbid=16384&amp;doi=10.1021%2Fjo1002328&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjo1002328%26sid%3Dliteratum%253Aachs%26aulast%3DHaurena%26aufirst%3DC.%26aulast%3DLe%2BGall%26aufirst%3DE.%26aulast%3DSengmany%26aufirst%3DS.%26aulast%3DMartens%26aufirst%3DT.%26aulast%3DTroupel%26aufirst%3DM.%26atitle%3DA%2520straightforward%2520three-component%2520synthesis%2520of%2520%25CE%25B1-amino%2520esters%2520containing%2520a%2520phenylalanine%2520or%2520a%2520phenylglycine%2520scaffold%26jtitle%3DJ.%2520Org.%2520Chem.%26date%3D2010%26volume%3D75%26issue%3D8%26spage%3D2645%26epage%3D2650" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref15"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref15'); return false;" data-citation="" class="refNumLink">15</a></strong><div class="NLM_citation" id="cit15"><span><span class="NLM_contrib-group">Sofia, M. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bao, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chang, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Du, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nagarathnam, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rachakonda, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Reddy, P. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ross, B. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, H.-R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bansal, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Espiritu, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Keilman, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lam, A. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Steuer, H. M. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Niu, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Otto, M. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Furman, P. A.</span><span> </span><span class="NLM_article-title">Discovery of a β-<span class="smallcaps smallerCapital">d</span>-2<sup>1</sup>-deoxy-2<sup>1</sup>-α-fluoro-20-β-<i>C</i>-methyl-uridine nucleotide prodrug (PSI-7977) for the treatment of hepatitis C virus</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">53</span><span class="NLM_x">, </span> <span class="NLM_fpage">7202</span><span class="NLM_x">–</span> <span class="NLM_lpage">7218</span></span><div class="citationLinks">[<a href="/doi/10.1021/jm100863x" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=53&publication_year=2010&pages=7202-7218&author=M.+J.+Sofiaauthor=D.+Baoauthor=W.+Changauthor=J.+Duauthor=D.+Nagarathnamauthor=S.+Rachakondaauthor=P.+G.+Reddyauthor=B.+S.+Rossauthor=P.+Wangauthor=H.-R.+Zhangauthor=S.+Bansalauthor=C.+Espirituauthor=M.+Keilmanauthor=A.+M.+Lamauthor=H.+M.+M.+Steuerauthor=C.+Niuauthor=M.+J.+Ottoauthor=P.+A.+Furman&title=Discovery+of+a+%CE%B2-d-21-deoxy-21-%CE%B1-fluoro-20-%CE%B2-C-methyl-uridine+nucleotide+prodrug+%28PSI-7977%29+for+the+treatment+of+hepatitis+C+virus"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit15&amp;dbid=16384&amp;doi=10.1021%2Fjm100863x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm100863x%26sid%3Dliteratum%253Aachs%26aulast%3DSofia%26aufirst%3DM.%2BJ.%26aulast%3DBao%26aufirst%3DD.%26aulast%3DChang%26aufirst%3DW.%26aulast%3DDu%26aufirst%3DJ.%26aulast%3DNagarathnam%26aufirst%3DD.%26aulast%3DRachakonda%26aufirst%3DS.%26aulast%3DReddy%26aufirst%3DP.%2BG.%26aulast%3DRoss%26aufirst%3DB.%2BS.%26aulast%3DWang%26aufirst%3DP.%26aulast%3DZhang%26aufirst%3DH.-R.%26aulast%3DBansal%26aufirst%3DS.%26aulast%3DEspiritu%26aufirst%3DC.%26aulast%3DKeilman%26aufirst%3DM.%26aulast%3DLam%26aufirst%3DA.%2BM.%26aulast%3DSteuer%26aufirst%3DH.%2BM.%2BM.%26aulast%3DNiu%26aufirst%3DC.%26aulast%3DOtto%26aufirst%3DM.%2BJ.%26aulast%3DFurman%26aufirst%3DP.%2BA.%26atitle%3DDiscovery%2520of%2520a%2520%25CE%25B2-d-21-deoxy-21-%25CE%25B1-fluoro-20-%25CE%25B2-C-methyl-uridine%2520nucleotide%2520prodrug%2520%2528PSI-7977%2529%2520for%2520the%2520treatment%2520of%2520hepatitis%2520C%2520virus%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2010%26volume%3D53%26spage%3D7202%26epage%3D7218" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref16"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref16'); return false;" data-citation="" class="refNumLink">16</a></strong><div class="NLM_citation" id="cit16a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Sofia, M. J.; Kakarla, R.; Liu, J.; Naduthambi, D.; Mosley, R.; Steuer, H. M.</span><span> </span><span class="NLM_article-title">Preparation of piperazine derivatives and their uses to treat viral infections, including hepatitis C</span>. U.S. Patent US20120202794A1, <span class="NLM_month">September</span><span class="NLM_day">8</span>,<span class="NLM_x"> </span><span class="NLM_year">2012</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2012&author=M.+J.+Sofia&author=R.+Kakarla&author=J.+Liu&author=D.+Naduthambi&author=R.+Mosley&author=H.+M.+Steuer&title=Preparation+of+piperazine+derivatives+and+their+uses+to+treat+viral+infections%2C+including+hepatitis+C"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit16a&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DSofia%26aufirst%3DM.%2BJ.%26atitle%3DPreparation%2520of%2520piperazine%2520derivatives%2520and%2520their%2520uses%2520to%2520treat%2520viral%2520infections%252C%2520including%2520hepatitis%2520C%26date%3D2012" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit16b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Sofia, M. J.; Kakarla, R.; Liu, J.; Naduthambi, D.; Mosley, R.; Steuer, H. M.</span><span> </span><span class="NLM_article-title">Preparation of pyrazine and imidazolidine derivatives and their uses to treat viral infections, including hepatitis C</span>. WO 2012103113A1, <span class="NLM_month">February</span><span class="NLM_day">8</span>,<span class="NLM_x"> </span><span class="NLM_year">2012</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2012&author=M.+J.+Sofia&author=R.+Kakarla&author=J.+Liu&author=D.+Naduthambi&author=R.+Mosley&author=H.+M.+Steuer&title=Preparation+of+pyrazine+and+imidazolidine+derivatives+and+their+uses+to+treat+viral+infections%2C+including+hepatitis+C"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit16b&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DSofia%26aufirst%3DM.%2BJ.%26atitle%3DPreparation%2520of%2520pyrazine%2520and%2520imidazolidine%2520derivatives%2520and%2520their%2520uses%2520to%2520treat%2520viral%2520infections%252C%2520including%2520hepatitis%2520C%26date%3D2012" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref17"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref17'); return false;" data-citation="" class="refNumLink">17</a></strong><div class="note"><p class="first last">HLM of compound <b>95</b> is 54 min (half-life) and for the compounds, <b>74</b> and <b>87</b> is 17 and 29 min, respectively.</p></div><div class="citationLinks"><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div></div></div></li></ol></div><script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script><script type="text/javascript">window.refViewer={'ref1':['cit1a','cit1b'],'ref2':['cit2a','cit2b'],'ref3':['cit3a','cit3b','cit3c'],'ref4':['cit4a','cit4b','cit4c'],'ref5':['cit5a','cit5b'],'ref6':['cit6a','cit6b','cit6c','cit6d','cit6e'],'ref7':['cit7a','cit7b','cit7c'],'ref8':['cit8'],'ref9':['cit9a','cit9b','cit9c','cit9d'],'ref10':['cit10a','cit10b','cit10c'],'ref11':['cit11'],'ref12':['cit12a','cit12b','cit12c','cit12d','cit12e','cit12f','cit12g'],'ref13':['cit13'],'ref14':['cit14a','cit14b'],'ref15':['cit15'],'ref16':['cit16a','cit16b'],'ref17':[]}</script><div class="articleCitedByDropzone" data-pb-dropzone="articleCitedByDropzone"><div class="cited-by"><div class="article_content-header cited-content_header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="citeThis">Cited By</h2></div></div></div><hr/></hr><div class="cited-by__content"><div class="cited-content hlFld-Abstract"><p>This article is cited by 40 publications.</p><ol class="cited-content_cbyCitation"><li><span class="cited-content_cbyCitation_article-contributors">Shashank Tripathi, Mayur D. Ambule, <span class="NLM_string-name hlFld-ContribAuthor">Ajay Kumar Srivastava</span>. </span><span class="cited-content_cbyCitation_article-title">Construction of Highly Functionalized Piperazinones via Post-Ugi Cyclization and Diastereoselective Nucleophilic Addition. </span><span class="cited-content_cbyCitation_journal-name">The Journal of Organic Chemistry</span><span> <strong>2020,</strong> <em>85 </em>
                                    (11)
                                     , 6910-6923. <a href="https://doi.org/10.1021/acs.joc.0c00108" title="DOI URL">https://doi.org/10.1021/acs.joc.0c00108</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.joc.0c00108&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.joc.0c00108%26sid%3Dliteratum%253Aachs%26jtitle%3DThe%2520Journal%2520of%2520Organic%2520Chemistry%26atitle%3DConstruction%252Bof%252BHighly%252BFunctionalized%252BPiperazinones%252Bvia%252BPost-Ugi%252BCyclization%252Band%252BDiastereoselective%252BNucleophilic%252BAddition%26aulast%3DTripathi%26aufirst%3DShashank%26date%3D2020%26date%3D2020%26date%3D2020%26date%3D15012020%26date%3D12052020%26date%3D30042020%26volume%3D85%26issue%3D11%26spage%3D6910%26epage%3D6923" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Murugan Vadivelu, Sugirdha Sampath, Kesavan Muthu, Kesavan Karthikeyan, <span class="NLM_string-name hlFld-ContribAuthor">Chandrasekar Praveen</span>. </span><span class="cited-content_cbyCitation_article-title">Harnessing the TEMPO-Catalyzed Aerobic Oxidation for Machetti–De Sarlo Reaction toward Sustainable Synthesis of Isoxazole Libraries. </span><span class="cited-content_cbyCitation_journal-name">The Journal of Organic Chemistry</span><span> <strong>2019,</strong> <em>84 </em>
                                    (21)
                                     , 13636-13645. <a href="https://doi.org/10.1021/acs.joc.9b01896" title="DOI URL">https://doi.org/10.1021/acs.joc.9b01896</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.joc.9b01896&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.joc.9b01896%26sid%3Dliteratum%253Aachs%26jtitle%3DThe%2520Journal%2520of%2520Organic%2520Chemistry%26atitle%3DHarnessing%252Bthe%252BTEMPO-Catalyzed%252BAerobic%252BOxidation%252Bfor%252BMachetti%2525E2%252580%252593De%252BSarlo%252BReaction%252Btoward%252BSustainable%252BSynthesis%252Bof%252BIsoxazole%252BLibraries%26aulast%3DVadivelu%26aufirst%3DMurugan%26date%3D2019%26date%3D2019%26date%3D2019%26date%3D12072019%26date%3D07102019%26date%3D26092019%26volume%3D84%26issue%3D21%26spage%3D13636%26epage%3D13645" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Boubacar Baldé, Guillaume Force, Lucile Marin, Régis Guillot, Emmanuelle Schulz, Vincent Gandon, <span class="NLM_string-name hlFld-ContribAuthor">David Lebœuf</span>. </span><span class="cited-content_cbyCitation_article-title">Synthesis of Cyclopenta[b]piperazinones via an Azaoxyallyl Cation. </span><span class="cited-content_cbyCitation_journal-name">Organic Letters</span><span> <strong>2018,</strong> <em>20 </em>
                                    (23)
                                     , 7405-7409. <a href="https://doi.org/10.1021/acs.orglett.8b03103" title="DOI URL">https://doi.org/10.1021/acs.orglett.8b03103</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.orglett.8b03103&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.orglett.8b03103%26sid%3Dliteratum%253Aachs%26jtitle%3DOrganic%2520Letters%26atitle%3DSynthesis%252Bof%252BCyclopenta%25255Bb%25255Dpiperazinones%252Bvia%252Ban%252BAzaoxyallyl%252BCation%26aulast%3DBald%25C3%25A9%26aufirst%3DBoubacar%26date%3D2018%26date%3D2018%26date%3D2018%26date%3D28092018%26date%3D27112018%26volume%3D20%26issue%3D23%26spage%3D7405%26epage%3D7409" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Mingi  Kim</span>, <span class="hlFld-ContribAuthor ">Yoon Soo  Hwang</span>, <span class="hlFld-ContribAuthor ">Wansang  Cho</span>, and <span class="hlFld-ContribAuthor ">Seung Bum  Park</span>  . </span><span class="cited-content_cbyCitation_article-title">Synthesis of 3,5-Disubstituted Isoxazoles Containing Privileged Substructures with a Diverse Display of Polar Surface Area. </span><span class="cited-content_cbyCitation_journal-name">ACS Combinatorial Science</span><span> <strong>2017,</strong> <em>19 </em>
                                    (6)
                                     , 407-413. <a href="https://doi.org/10.1021/acscombsci.7b00032" title="DOI URL">https://doi.org/10.1021/acscombsci.7b00032</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acscombsci.7b00032&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facscombsci.7b00032%26sid%3Dliteratum%253Aachs%26jtitle%3DACS%2520Combinatorial%2520Science%26atitle%3DSynthesis%252Bof%252B3%25252C5-Disubstituted%252BIsoxazoles%252BContaining%252BPrivileged%252BSubstructures%252Bwith%252Ba%252BDiverse%252BDisplay%252Bof%252BPolar%252BSurface%252BArea%26aulast%3DKim%26aufirst%3DMingi%26date%3D2017%26date%3D2017%26date%3D2017%26date%3D2017%26date%3D13022017%26date%3D13032017%26date%3D23032017%26date%3D12062017%26date%3D17032017%26volume%3D19%26issue%3D6%26spage%3D407%26epage%3D413" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Niklas B.  Heine</span>, <span class="hlFld-ContribAuthor ">Sherif J.  Kaldas</span>, <span class="hlFld-ContribAuthor ">Lee  Belding</span>, <span class="hlFld-ContribAuthor ">Olga  Shmatova</span>, <span class="hlFld-ContribAuthor ">Travis  Dudding</span>, <span class="hlFld-ContribAuthor ">Valentine G.  Nenajdenko</span>, <span class="hlFld-ContribAuthor ">Armido  Studer</span>, and <span class="hlFld-ContribAuthor ">Andrei K.  Yudin</span>  . </span><span class="cited-content_cbyCitation_article-title">Synthesis of Chiral Piperazinones Using Amphoteric Aziridine Aldehyde Dimers and Functionalized Isocyanides. </span><span class="cited-content_cbyCitation_journal-name">The Journal of Organic Chemistry</span><span> <strong>2016,</strong> <em>81 </em>
                                    (12)
                                     , 5209-5216. <a href="https://doi.org/10.1021/acs.joc.6b00471" title="DOI URL">https://doi.org/10.1021/acs.joc.6b00471</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.joc.6b00471&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.joc.6b00471%26sid%3Dliteratum%253Aachs%26jtitle%3DThe%2520Journal%2520of%2520Organic%2520Chemistry%26atitle%3DSynthesis%252Bof%252BChiral%252BPiperazinones%252BUsing%252BAmphoteric%252BAziridine%252BAldehyde%252BDimers%252Band%252BFunctionalized%252BIsocyanides%26aulast%3DHeine%26aufirst%3DNiklas%2BB.%26date%3D2016%26date%3D2016%26date%3D2016%26date%3D03032016%26date%3D01062016%26date%3D17062016%26date%3D08052016%26volume%3D81%26issue%3D12%26spage%3D5209%26epage%3D5216" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Rolando  Cannalire</span>, <span class="hlFld-ContribAuthor ">Maria Letizia  Barreca</span>, <span class="hlFld-ContribAuthor ">Giuseppe  Manfroni</span>, and <span class="hlFld-ContribAuthor ">Violetta  Cecchetti</span>  . </span><span class="cited-content_cbyCitation_article-title">A Journey around the Medicinal Chemistry of Hepatitis C Virus Inhibitors Targeting NS4B: From Target to Preclinical Drug Candidates. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2016,</strong> <em>59 </em>
                                    (1)
                                     , 16-41. <a href="https://doi.org/10.1021/acs.jmedchem.5b00825" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.5b00825</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.5b00825&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.5b00825%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DA%252BJourney%252Baround%252Bthe%252BMedicinal%252BChemistry%252Bof%252BHepatitis%252BC%252BVirus%252BInhibitors%252BTargeting%252BNS4B%25253A%252BFrom%252BTarget%252Bto%252BPreclinical%252BDrug%252BCandidates%26aulast%3DCannalire%26aufirst%3DRolando%26date%3D2016%26date%3D2015%26date%3D2015%26date%3D29052015%26date%3D31082015%26date%3D14012016%26date%3D04082015%26volume%3D59%26issue%3D1%26spage%3D16%26epage%3D41" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Sara  Meninno</span>, <span class="hlFld-ContribAuthor ">Andreu  Vidal-Albalat</span>, and <span class="hlFld-ContribAuthor ">Alessandra  Lattanzi</span>  . </span><span class="cited-content_cbyCitation_article-title">Asymmetric Epoxidation of Alkylidenemalononitriles: Key Step for One-Pot Approach to Enantioenriched 3-Substituted Piperazin-2-ones. </span><span class="cited-content_cbyCitation_journal-name">Organic Letters</span><span> <strong>2015,</strong> <em>17 </em>
                                    (17)
                                     , 4348-4351. <a href="https://doi.org/10.1021/acs.orglett.5b02186" title="DOI URL">https://doi.org/10.1021/acs.orglett.5b02186</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.orglett.5b02186&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.orglett.5b02186%26sid%3Dliteratum%253Aachs%26jtitle%3DOrganic%2520Letters%26atitle%3DAsymmetric%252BEpoxidation%252Bof%252BAlkylidenemalononitriles%25253A%252BKey%252BStep%252Bfor%252BOne-Pot%252BApproach%252Bto%252BEnantioenriched%252B3-Substituted%252BPiperazin-2-ones%26aulast%3DMeninno%26aufirst%3DSara%26date%3D2015%26date%3D2015%26date%3D2015%26date%3D28072015%26date%3D27082015%26date%3D04092015%26volume%3D17%26issue%3D17%26spage%3D4348%26epage%3D4351" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Ning-Yu  Wang</span>, <span class="hlFld-ContribAuthor ">Ying  Xu</span>, <span class="hlFld-ContribAuthor ">Wei-Qiong  Zuo</span>, <span class="hlFld-ContribAuthor ">Kun-Jie  Xiao</span>, <span class="hlFld-ContribAuthor ">Li  Liu</span>, <span class="hlFld-ContribAuthor ">Xiu-Xiu  Zeng</span>, <span class="hlFld-ContribAuthor ">Xin-Yu  You</span>, <span class="hlFld-ContribAuthor ">Li-Dan  Zhang</span>, <span class="hlFld-ContribAuthor ">Chao  Gao</span>, <span class="hlFld-ContribAuthor ">Zhi-Hao  Liu</span>, <span class="hlFld-ContribAuthor ">Ting-Hong  Ye</span>, <span class="hlFld-ContribAuthor ">Yong  Xia</span>, <span class="hlFld-ContribAuthor ">Ying  Xiong</span>, <span class="hlFld-ContribAuthor ">Xue-Jiao  Song</span>, <span class="hlFld-ContribAuthor ">Qian  Lei</span>, <span class="hlFld-ContribAuthor ">Cui-Ting  Peng</span>, <span class="hlFld-ContribAuthor ">Hong  Tang</span>, <span class="hlFld-ContribAuthor ">Sheng-Yong  Yang</span>, <span class="hlFld-ContribAuthor ">Yu-Quan  Wei</span>, and <span class="hlFld-ContribAuthor ">Luo-Ting  Yu</span>  . </span><span class="cited-content_cbyCitation_article-title">Discovery of Imidazo[2,1-b]thiazole HCV NS4B Inhibitors Exhibiting Synergistic Effect with Other Direct-Acting Antiviral Agents. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2015,</strong> <em>58 </em>
                                    (6)
                                     , 2764-2778. <a href="https://doi.org/10.1021/jm501934n" title="DOI URL">https://doi.org/10.1021/jm501934n</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/jm501934n&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Fjm501934n%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DDiscovery%252Bof%252BImidazo%25255B2%25252C1-b%25255Dthiazole%252BHCV%252BNS4B%252BInhibitors%252BExhibiting%252BSynergistic%252BEffect%252Bwith%252BOther%252BDirect-Acting%252BAntiviral%252BAgents%26aulast%3DWang%26aufirst%3DNing-Yu%26date%3D2015%26date%3D2015%26date%3D2014%26date%3D13122014%26date%3D11032015%26date%3D26032015%26date%3D24022015%26volume%3D58%26issue%3D6%26spage%3D2764%26epage%3D2778" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Serge  Zaretsky</span>, <span class="hlFld-ContribAuthor ">Shinya  Adachi</span>, <span class="hlFld-ContribAuthor ">Benjamin H.  Rotstein</span>, <span class="hlFld-ContribAuthor ">Jennifer L.  Hickey</span>, <span class="hlFld-ContribAuthor ">Conor C. G.  Scully</span>, <span class="hlFld-ContribAuthor ">Jeffrey D.  St. Denis</span>, <span class="hlFld-ContribAuthor ">Rebecca  Courtemanche</span>, <span class="hlFld-ContribAuthor ">Joy C. Y.  Yu</span>, <span class="hlFld-ContribAuthor ">Benjamin K. W.  Chung</span>, and <span class="hlFld-ContribAuthor ">Andrei K.  Yudin</span>  . </span><span class="cited-content_cbyCitation_article-title">Stereocontrolled Disruption of the Ugi Reaction toward the Production of Chiral Piperazinones: Substrate Scope and Process Development. </span><span class="cited-content_cbyCitation_journal-name">The Journal of Organic Chemistry</span><span> <strong>2014,</strong> <em>79 </em>
                                    (21)
                                     , 9948-9957. <a href="https://doi.org/10.1021/jo5018316" title="DOI URL">https://doi.org/10.1021/jo5018316</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/jo5018316&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Fjo5018316%26sid%3Dliteratum%253Aachs%26jtitle%3DThe%2520Journal%2520of%2520Organic%2520Chemistry%26atitle%3DStereocontrolled%252BDisruption%252Bof%252Bthe%252BUgi%252BReaction%252Btoward%252Bthe%252BProduction%252Bof%252BChiral%252BPiperazinones%25253A%252BSubstrate%252BScope%252Band%252BProcess%252BDevelopment%26aulast%3DZaretsky%26aufirst%3DSerge%26date%3D2014%26date%3D2014%26date%3D2014%26date%3D07082014%26date%3D22102014%26date%3D07112014%26date%3D25092014%26volume%3D79%26issue%3D21%26spage%3D9948%26epage%3D9957" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Yue  Zhang</span>, <span class="hlFld-ContribAuthor ">Junhu  Xin</span>, <span class="hlFld-ContribAuthor ">Cunde  Wang</span>. </span><span class="cited-content_cbyCitation_article-title">Stereoselective Synthesis of 4,5‐Dihydroisoxazole Derivatives from 1,1‐Dicyanocyclopropanes and Hydroxylamine Hydrochloride. </span><span class="cited-content_cbyCitation_journal-name">Helvetica Chimica Acta</span><span> <strong>2021,</strong> <em>104 </em>
                                    (6)
                                     <a href="https://doi.org/10.1002/hlca.202100032" title="DOI URL">https://doi.org/10.1002/hlca.202100032</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1002/hlca.202100032&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1002%2Fhlca.202100032%26sid%3Dliteratum%253Aachs%26jtitle%3DHelvetica%2520Chimica%2520Acta%26atitle%3DStereoselective%252BSynthesis%252Bof%252B4%25252C5%2525E2%252580%252590Dihydroisoxazole%252BDerivatives%252Bfrom%252B1%25252C1%2525E2%252580%252590Dicyanocyclopropanes%252Band%252BHydroxylamine%252BHydrochloride%26aulast%3DZhang%26aufirst%3DYue%26date%3D2021%26date%3D2021%26volume%3D104%26issue%3D6" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Moustafa E.  El‐Araby</span>, <span class="hlFld-ContribAuthor ">Abdelsattar M. E.  Omar</span>. </span><span class="cited-content_cbyCitation_article-title">A
              single‐step
              synthesis of 1,3,4,
              6‐tetraaryl
              ‐5‐aryliminopiperazin‐2‐one. </span><span class="cited-content_cbyCitation_journal-name">Journal of Heterocyclic Chemistry</span><span> <strong>2021,</strong> <em>58 </em>
                                    (2)
                                     , 442-449. <a href="https://doi.org/10.1002/jhet.4179" title="DOI URL">https://doi.org/10.1002/jhet.4179</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1002/jhet.4179&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1002%2Fjhet.4179%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Heterocyclic%2520Chemistry%26atitle%3DA%252Bsingle%2525E2%252580%252590step%252Bsynthesis%252Bof%252B1%25252C3%25252C4%25252C%252B6%2525E2%252580%252590tetraaryl%252B%2525E2%252580%2525905%2525E2%252580%252590aryliminopiperazin%2525E2%252580%2525902%2525E2%252580%252590one%26aulast%3DEl%25E2%2580%2590Araby%26aufirst%3DMoustafa%2BE.%26date%3D2021%26date%3D2020%26volume%3D58%26issue%3D2%26spage%3D442%26epage%3D449" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Plato A.  Magriotis</span>. </span><span class="cited-content_cbyCitation_article-title">Recent progress toward the asymmetric synthesis of carbon-substituted piperazine pharmacophores and oxidative related heterocycles. </span><span class="cited-content_cbyCitation_journal-name">RSC Medicinal Chemistry</span><span> <strong>2020,</strong> <em>11 </em>
                                    (7)
                                     , 745-759. <a href="https://doi.org/10.1039/D0MD00053A" title="DOI URL">https://doi.org/10.1039/D0MD00053A</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1039/D0MD00053A&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1039%2FD0MD00053A%26sid%3Dliteratum%253Aachs%26jtitle%3DRSC%2520Medicinal%2520Chemistry%26atitle%3DRecent%252Bprogress%252Btoward%252Bthe%252Basymmetric%252Bsynthesis%252Bof%252Bcarbon-substituted%252Bpiperazine%252Bpharmacophores%252Band%252Boxidative%252Brelated%252Bheterocycles%26aulast%3DMagriotis%26aufirst%3DPlato%2BA.%26date%3D2020%26date%3D2020%26volume%3D11%26issue%3D7%26spage%3D745%26epage%3D759" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Anthony  Choi</span>, <span class="hlFld-ContribAuthor ">Iain  Coldham</span>. </span><span class="cited-content_cbyCitation_article-title">Three-component couplings for the synthesis of pyrroloquinoxalinones by azomethine ylide 1,3-dipolar cycloaddition chemistry. </span><span class="cited-content_cbyCitation_journal-name">Tetrahedron Letters</span><span> <strong>2019,</strong> <em>60 </em>
                                    (37)
                                     , 151023. <a href="https://doi.org/10.1016/j.tetlet.2019.151023" title="DOI URL">https://doi.org/10.1016/j.tetlet.2019.151023</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.tetlet.2019.151023&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.tetlet.2019.151023%26sid%3Dliteratum%253Aachs%26jtitle%3DTetrahedron%2520Letters%26atitle%3DThree-component%252Bcouplings%252Bfor%252Bthe%252Bsynthesis%252Bof%252Bpyrroloquinoxalinones%252Bby%252Bazomethine%252Bylide%252B1%25252C3-dipolar%252Bcycloaddition%252Bchemistry%26aulast%3DChoi%26aufirst%3DAnthony%26date%3D2019%26volume%3D60%26issue%3D37%26spage%3D151023" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Debayan  Sarkar</span>, <span class="hlFld-ContribAuthor ">Sushree Ranjan  Sahoo</span>. </span><span class="cited-content_cbyCitation_article-title">Monohydrochloride Assisted Synthesis of Functionalized Isoxazoles and Pyrazoles from Allenic Ketones: First Synthesis of (
              Z
              )-2-Methyl-7H-benzo[b]pyrazolo[5,1-d][1,5]oxazocines. </span><span class="cited-content_cbyCitation_journal-name">European Journal of Organic Chemistry</span><span> <strong>2019,</strong> <em>2019 </em>
                                    (10)
                                     , 2035-2049. <a href="https://doi.org/10.1002/ejoc.201900008" title="DOI URL">https://doi.org/10.1002/ejoc.201900008</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1002/ejoc.201900008&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1002%2Fejoc.201900008%26sid%3Dliteratum%253Aachs%26jtitle%3DEuropean%2520Journal%2520of%2520Organic%2520Chemistry%26atitle%3DMonohydrochloride%252BAssisted%252BSynthesis%252Bof%252BFunctionalized%252BIsoxazoles%252Band%252BPyrazoles%252Bfrom%252BAllenic%252BKetones%25253A%252BFirst%252BSynthesis%252Bof%252B%252528%252BZ%252B%252529-2-Methyl-7H-benzo%25255Bb%25255Dpyrazolo%25255B5%25252C1-d%25255D%25255B1%25252C5%25255Doxazocines%26aulast%3DSarkar%26aufirst%3DDebayan%26date%3D2019%26date%3D2019%26volume%3D2019%26issue%3D10%26spage%3D2035%26epage%3D2049" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Giuseppe  Manfroni</span>, <span class="hlFld-ContribAuthor ">Rolando  Cannalire</span>. </span><span class="cited-content_cbyCitation_article-title">Evolution of HCV NS4B Inhibitors. </span><span class="cited-content_cbyCitation_journal-name"></span><span> <strong>2019,</strong>,, 159-183. <a href="https://doi.org/10.1007/7355_2018_46" title="DOI URL">https://doi.org/10.1007/7355_2018_46</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1007/7355_2018_46&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1007%2F7355_2018_46%26sid%3Dliteratum%253Aachs%26atitle%3DEvolution%252Bof%252BHCV%252BNS4B%252BInhibitors%26aulast%3DManfroni%26aufirst%3DGiuseppe%26date%3D2019%26date%3D2019%26spage%3D159%26epage%3D183%26pub%3DSpringer%2520International%2520Publishing%26atitle%3DHCV%25253A%252BThe%252BJourney%252Bfrom%252BDiscovery%252Bto%252Ba%252BCure%26aulast%3DSofia%26aufirst%3DMichael%2BJ.%26date%3D2019%26volume%3D32" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">丽  孙</span>. </span><span class="cited-content_cbyCitation_article-title">Recent Advances in Cycloaddition Reactions of Azaoxyallyl Cations. </span><span class="cited-content_cbyCitation_journal-name">Journal of Organic Chemistry Research</span><span> <strong>2019,</strong> <em>07 </em>
                                    (02)
                                     , 88-93. <a href="https://doi.org/10.12677/JOCR.2019.72012" title="DOI URL">https://doi.org/10.12677/JOCR.2019.72012</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.12677/JOCR.2019.72012&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.12677%2FJOCR.2019.72012%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Organic%2520Chemistry%2520Research%26atitle%3DRecent%252BAdvances%252Bin%252BCycloaddition%252BReactions%252Bof%252BAzaoxyallyl%252BCations%26aulast%3D%25E5%25AD%2599%26aufirst%3D%25E4%25B8%25BD%26date%3D2019%26volume%3D07%26issue%3D02%26spage%3D88%26epage%3D93" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Satya P.  Gupta</span>. </span><span class="cited-content_cbyCitation_article-title">The Medicinal Chemistry of Antihepatitis Agents III. </span><span class="cited-content_cbyCitation_journal-name"></span><span> <strong>2018,</strong>,, 133-210. <a href="https://doi.org/10.1016/B978-0-12-813330-9.00007-7" title="DOI URL">https://doi.org/10.1016/B978-0-12-813330-9.00007-7</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/B978-0-12-813330-9.00007-7&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2FB978-0-12-813330-9.00007-7%26sid%3Dliteratum%253Aachs%26atitle%3DThe%252BMedicinal%252BChemistry%252Bof%252BAntihepatitis%252BAgents%252BIII%26aulast%3DGupta%26aufirst%3DSatya%2BP.%26date%3D2018%26spage%3D133%26epage%3D210%26pub%3DElsevier%26atitle%3DStudies%252Bon%252BHepatitis%252BViruses%26date%3D2018" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Hui-Zhen  Zhang</span>, <span class="hlFld-ContribAuthor ">Zhi-Long  Zhao</span>, <span class="hlFld-ContribAuthor ">Cheng-He  Zhou</span>. </span><span class="cited-content_cbyCitation_article-title">Recent advance in oxazole-based medicinal chemistry. </span><span class="cited-content_cbyCitation_journal-name">European Journal of Medicinal Chemistry</span><span> <strong>2018,</strong> <em>144 </em>, 444-492. <a href="https://doi.org/10.1016/j.ejmech.2017.12.044" title="DOI URL">https://doi.org/10.1016/j.ejmech.2017.12.044</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.ejmech.2017.12.044&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.ejmech.2017.12.044%26sid%3Dliteratum%253Aachs%26jtitle%3DEuropean%2520Journal%2520of%2520Medicinal%2520Chemistry%26atitle%3DRecent%252Badvance%252Bin%252Boxazole-based%252Bmedicinal%252Bchemistry%26aulast%3DZhang%26aufirst%3DHui-Zhen%26date%3D2018%26volume%3D144%26spage%3D444%26epage%3D492" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Feng  Li</span>, <span class="hlFld-ContribAuthor ">Wenlong  Pei</span>, <span class="hlFld-ContribAuthor ">Jingjing  Wang</span>, <span class="hlFld-ContribAuthor ">Jie  Liu</span>, <span class="hlFld-ContribAuthor ">Juan  Wang</span>, <span class="hlFld-ContribAuthor ">Ming-liang  Zhang</span>, <span class="hlFld-ContribAuthor ">Zhiming  Chen</span>, <span class="hlFld-ContribAuthor ">Lantao  Liu</span>. </span><span class="cited-content_cbyCitation_article-title">Organocatalytic asymmetric synthesis of compounds bearing both isoxazole and pyrazole moieties
              via
              1,6-addition of pyrazol-5-ones to 3-methyl-4-nitro-5-alkenylisoxazoles. </span><span class="cited-content_cbyCitation_journal-name">Organic Chemistry Frontiers</span><span> <strong>2018,</strong> <em>5 </em>
                                    (8)
                                     , 1342-1347. <a href="https://doi.org/10.1039/C8QO00084K" title="DOI URL">https://doi.org/10.1039/C8QO00084K</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1039/C8QO00084K&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1039%2FC8QO00084K%26sid%3Dliteratum%253Aachs%26jtitle%3DOrganic%2520Chemistry%2520Frontiers%26atitle%3DOrganocatalytic%252Basymmetric%252Bsynthesis%252Bof%252Bcompounds%252Bbearing%252Bboth%252Bisoxazole%252Band%252Bpyrazole%252Bmoieties%252Bvia%252B1%25252C6-addition%252Bof%252Bpyrazol-5-ones%252Bto%252B3-methyl-4-nitro-5-alkenylisoxazoles%26aulast%3DLi%26aufirst%3DFeng%26date%3D2018%26date%3D2018%26volume%3D5%26issue%3D8%26spage%3D1342%26epage%3D1347" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Guanghai  Jin</span>, <span class="hlFld-ContribAuthor ">Jisu  Lee</span>, <span class="hlFld-ContribAuthor ">Kyeong  Lee</span>. </span><span class="cited-content_cbyCitation_article-title">Chemical genetics-based development of small molecules targeting hepatitis C virus. </span><span class="cited-content_cbyCitation_journal-name">Archives of Pharmacal Research</span><span> <strong>2017,</strong> <em>40 </em>
                                    (9)
                                     , 1021-1036. <a href="https://doi.org/10.1007/s12272-017-0949-3" title="DOI URL">https://doi.org/10.1007/s12272-017-0949-3</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1007/s12272-017-0949-3&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1007%2Fs12272-017-0949-3%26sid%3Dliteratum%253Aachs%26jtitle%3DArchives%2520of%2520Pharmacal%2520Research%26atitle%3DChemical%252Bgenetics-based%252Bdevelopment%252Bof%252Bsmall%252Bmolecules%252Btargeting%252Bhepatitis%252BC%252Bvirus%26aulast%3DJin%26aufirst%3DGuanghai%26date%3D2017%26date%3D2017%26volume%3D40%26issue%3D9%26spage%3D1021%26epage%3D1036" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Yanzhao  Wang</span>, <span class="hlFld-ContribAuthor ">Yuanyuan  Liu</span>, <span class="hlFld-ContribAuthor ">Kun  Li</span>, <span class="hlFld-ContribAuthor ">Guoqiang  Yang</span>, <span class="hlFld-ContribAuthor ">Wanbin  Zhang</span>. </span><span class="cited-content_cbyCitation_article-title">Iridium-Catalyzed Asymmetric Hydrogenation of Unsaturated Piperazin-2-ones. </span><span class="cited-content_cbyCitation_journal-name">Advanced Synthesis & Catalysis</span><span> <strong>2017,</strong> <em>359 </em>
                                    (11)
                                     , 1933-1941. <a href="https://doi.org/10.1002/adsc.201700175" title="DOI URL">https://doi.org/10.1002/adsc.201700175</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1002/adsc.201700175&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1002%2Fadsc.201700175%26sid%3Dliteratum%253Aachs%26jtitle%3DAdvanced%2520Synthesis%2520%2526%2520Catalysis%26atitle%3DIridium-Catalyzed%252BAsymmetric%252BHydrogenation%252Bof%252BUnsaturated%252BPiperazin-2-ones%26aulast%3DWang%26aufirst%3DYanzhao%26date%3D2017%26date%3D2017%26volume%3D359%26issue%3D11%26spage%3D1933%26epage%3D1941" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Guangdi  Li</span>, <span class="hlFld-ContribAuthor ">Erik  De Clercq</span>. </span><span class="cited-content_cbyCitation_article-title">Current therapy for chronic hepatitis C: The role of direct-acting antivirals. </span><span class="cited-content_cbyCitation_journal-name">Antiviral Research</span><span> <strong>2017,</strong> <em>142 </em>, 83-122. <a href="https://doi.org/10.1016/j.antiviral.2017.02.014" title="DOI URL">https://doi.org/10.1016/j.antiviral.2017.02.014</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.antiviral.2017.02.014&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.antiviral.2017.02.014%26sid%3Dliteratum%253Aachs%26jtitle%3DAntiviral%2520Research%26atitle%3DCurrent%252Btherapy%252Bfor%252Bchronic%252Bhepatitis%252BC%25253A%252BThe%252Brole%252Bof%252Bdirect-acting%252Bantivirals%26aulast%3DLi%26aufirst%3DGuangdi%26date%3D2017%26volume%3D142%26spage%3D83%26epage%3D122" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Bianca  Heinrich</span>, <span class="hlFld-ContribAuthor ">John P.  Bilello</span>. </span><span class="cited-content_cbyCitation_article-title">HCV Drug Resistance. </span><span class="cited-content_cbyCitation_journal-name"></span><span> <strong>2017,</strong>,, 579-609. <a href="https://doi.org/10.1007/978-3-319-46718-4_39" title="DOI URL">https://doi.org/10.1007/978-3-319-46718-4_39</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1007/978-3-319-46718-4_39&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1007%2F978-3-319-46718-4_39%26sid%3Dliteratum%253Aachs%26atitle%3DHCV%252BDrug%252BResistance%26aulast%3DHeinrich%26aufirst%3DBianca%26date%3D2017%26date%3D2017%26spage%3D579%26epage%3D609%26pub%3DSpringer%2520International%2520Publishing%26atitle%3DAntimicrobial%252BDrug%252BResistance%26aulast%3DMayers%26aufirst%3DDouglas%2BL.%26date%3D2017%26volume%3D21" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">N.A.  Meanwell</span>. </span><span class="cited-content_cbyCitation_article-title">Direct-Acting Antiviral Agents for the Treatment of Hepatitis C Virus Infection. </span><span class="cited-content_cbyCitation_journal-name"></span><span> <strong>2017,</strong>,, 553-627. <a href="https://doi.org/10.1016/B978-0-12-409547-2.12406-0" title="DOI URL">https://doi.org/10.1016/B978-0-12-409547-2.12406-0</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/B978-0-12-409547-2.12406-0&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2FB978-0-12-409547-2.12406-0%26sid%3Dliteratum%253Aachs%26atitle%3DDirect-Acting%252BAntiviral%252BAgents%252Bfor%252Bthe%252BTreatment%252Bof%252BHepatitis%252BC%252BVirus%252BInfection%26aulast%3DMeanwell%26aufirst%3DN.A.%26date%3D2017%26spage%3D553%26epage%3D627%26pub%3DElsevier%26atitle%3DComprehensive%252BMedicinal%252BChemistry%252BIII%26date%3D2017%26volume%3D35" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Nanjing  Zhang</span>, <span class="hlFld-ContribAuthor ">Anthony  Turpoff</span>, <span class="hlFld-ContribAuthor ">Xiaoyan  Zhang</span>, <span class="hlFld-ContribAuthor ">Song  Huang</span>, <span class="hlFld-ContribAuthor ">Yalei  Liu</span>, <span class="hlFld-ContribAuthor ">Neil  Almstead</span>, <span class="hlFld-ContribAuthor ">F. George  Njoroge</span>, <span class="hlFld-ContribAuthor ">Zhengxian  Gu</span>, <span class="hlFld-ContribAuthor ">Jason  Graci</span>, <span class="hlFld-ContribAuthor ">Stephen P.  Jung</span>, <span class="hlFld-ContribAuthor ">John  Pichardo</span>, <span class="hlFld-ContribAuthor ">Joseph  Colacino</span>, <span class="hlFld-ContribAuthor ">Fred  Lahser</span>, <span class="hlFld-ContribAuthor ">Paul  Ingravallo</span>, <span class="hlFld-ContribAuthor ">Marla  Weetall</span>, <span class="hlFld-ContribAuthor ">Amin  Nomeir</span>, <span class="hlFld-ContribAuthor ">Gary M.  Karp</span>. </span><span class="cited-content_cbyCitation_article-title">Discovery of 2-(4-sulfonamidophenyl)-indole 3-carboxamides as potent and selective inhibitors with broad hepatitis C virus genotype activity targeting HCV NS4B. </span><span class="cited-content_cbyCitation_journal-name">Bioorganic & Medicinal Chemistry Letters</span><span> <strong>2016,</strong> <em>26 </em>
                                    (2)
                                     , 594-601. <a href="https://doi.org/10.1016/j.bmcl.2015.11.065" title="DOI URL">https://doi.org/10.1016/j.bmcl.2015.11.065</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.bmcl.2015.11.065&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.bmcl.2015.11.065%26sid%3Dliteratum%253Aachs%26jtitle%3DBioorganic%2520%2526%2520Medicinal%2520Chemistry%2520Letters%26atitle%3DDiscovery%252Bof%252B2-%2525284-sulfonamidophenyl%252529-indole%252B3-carboxamides%252Bas%252Bpotent%252Band%252Bselective%252Binhibitors%252Bwith%252Bbroad%252Bhepatitis%252BC%252Bvirus%252Bgenotype%252Bactivity%252Btargeting%252BHCV%252BNS4B%26aulast%3DZhang%26aufirst%3DNanjing%26date%3D2016%26volume%3D26%26issue%3D2%26spage%3D594%26epage%3D601" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Ugo  Chiacchio</span>, <span class="hlFld-ContribAuthor ">Gianluigi  Broggini</span>, <span class="hlFld-ContribAuthor ">Roberto  Romeo</span>, <span class="hlFld-ContribAuthor ">Silvia  Gazzola</span>, <span class="hlFld-ContribAuthor ">Maria A.  Chiacchio</span>, <span class="hlFld-ContribAuthor ">Salvatore V.  Giofrè</span>, <span class="hlFld-ContribAuthor ">Bartolo  Gabriele</span>, <span class="hlFld-ContribAuthor ">Raffaella  Mancuso</span>, <span class="hlFld-ContribAuthor ">Giuseppe  Floresta</span>, <span class="hlFld-ContribAuthor ">Chiara  Zagni</span>. </span><span class="cited-content_cbyCitation_article-title">Intramolecular oxidative palladium-catalyzed diamination reactions of alkenyl sulfamates: an efficient synthesis of [1,2,5]thiadiazolo-fused piperazinones. </span><span class="cited-content_cbyCitation_journal-name">RSC Advances</span><span> <strong>2016,</strong> <em>6 </em>
                                    (62)
                                     , 57521-57529. <a href="https://doi.org/10.1039/C6RA13141G" title="DOI URL">https://doi.org/10.1039/C6RA13141G</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1039/C6RA13141G&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1039%2FC6RA13141G%26sid%3Dliteratum%253Aachs%26jtitle%3DRSC%2520Advances%26atitle%3DIntramolecular%252Boxidative%252Bpalladium-catalyzed%252Bdiamination%252Breactions%252Bof%252Balkenyl%252Bsulfamates%25253A%252Ban%252Befficient%252Bsynthesis%252Bof%252B%25255B1%25252C2%25252C5%25255Dthiadiazolo-fused%252Bpiperazinones%26aulast%3DChiacchio%26aufirst%3DUgo%26date%3D2016%26date%3D2016%26volume%3D6%26issue%3D62%26spage%3D57521%26epage%3D57529" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Jeffrey J.  Pouliot</span>, <span class="hlFld-ContribAuthor ">Michael  Thomson</span>, <span class="hlFld-ContribAuthor ">Mi  Xie</span>, <span class="hlFld-ContribAuthor ">Joseph  Horton</span>, <span class="hlFld-ContribAuthor ">John  Johnson</span>, <span class="hlFld-ContribAuthor ">David  Krull</span>, <span class="hlFld-ContribAuthor ">Amanda  Mathis</span>, <span class="hlFld-ContribAuthor ">Yoshio  Morikawa</span>, <span class="hlFld-ContribAuthor ">Derek  Parks</span>, <span class="hlFld-ContribAuthor ">Richard  Peterson</span>, <span class="hlFld-ContribAuthor ">Takashi  Shimada</span>, <span class="hlFld-ContribAuthor ">Elizabeth  Thomas</span>, <span class="hlFld-ContribAuthor ">Jessica  Vamathevan</span>, <span class="hlFld-ContribAuthor ">Stephanie  Van Horn</span>, <span class="hlFld-ContribAuthor ">Zhiping  Xiong</span>, <span class="hlFld-ContribAuthor ">Robert  Hamatake</span>, <span class="hlFld-ContribAuthor ">Andrew J.  Peat</span>. </span><span class="cited-content_cbyCitation_article-title">Preclinical Characterization and
              In Vivo
              Efficacy of GSK8853, a Small-Molecule Inhibitor of the Hepatitis C Virus NS4B Protein. </span><span class="cited-content_cbyCitation_journal-name">Antimicrobial Agents and Chemotherapy</span><span> <strong>2015,</strong> <em>59 </em>
                                    (10)
                                     , 6539-6550. <a href="https://doi.org/10.1128/AAC.00813-15" title="DOI URL">https://doi.org/10.1128/AAC.00813-15</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1128/AAC.00813-15&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1128%2FAAC.00813-15%26sid%3Dliteratum%253Aachs%26jtitle%3DAntimicrobial%2520Agents%2520and%2520Chemotherapy%26atitle%3DPreclinical%252BCharacterization%252Band%252BIn%252BVivo%252BEfficacy%252Bof%252BGSK8853%25252C%252Ba%252BSmall-Molecule%252BInhibitor%252Bof%252Bthe%252BHepatitis%252BC%252BVirus%252BNS4B%252BProtein%26aulast%3DPouliot%26aufirst%3DJeffrey%2BJ.%26date%3D2015%26date%3D2015%26volume%3D59%26issue%3D10%26spage%3D6539%26epage%3D6550" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Sakkani  Nagaraju</span>, <span class="hlFld-ContribAuthor ">Neeli  Satyanarayana</span>, <span class="hlFld-ContribAuthor ">Banoth  Paplal</span>, <span class="hlFld-ContribAuthor ">Anuji K.  Vasu</span>, <span class="hlFld-ContribAuthor ">Sriram  Kanvah</span>, <span class="hlFld-ContribAuthor ">Dhurke  Kashinath</span>. </span><span class="cited-content_cbyCitation_article-title">Synthesis of functionalized isoxazole–oxindole hybrids
              via
              on water, catalyst free vinylogous Henry and 1,6-Michael addition reactions. </span><span class="cited-content_cbyCitation_journal-name">RSC Advances</span><span> <strong>2015,</strong> <em>5 </em>
                                    (100)
                                     , 81768-81773. <a href="https://doi.org/10.1039/C5RA14039K" title="DOI URL">https://doi.org/10.1039/C5RA14039K</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1039/C5RA14039K&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1039%2FC5RA14039K%26sid%3Dliteratum%253Aachs%26jtitle%3DRSC%2520Advances%26atitle%3DSynthesis%252Bof%252Bfunctionalized%252Bisoxazole%2525E2%252580%252593oxindole%252Bhybrids%252Bvia%252Bon%252Bwater%25252C%252Bcatalyst%252Bfree%252Bvinylogous%252BHenry%252Band%252B1%25252C6-Michael%252Baddition%252Breactions%26aulast%3DNagaraju%26aufirst%3DSakkani%26date%3D2015%26date%3D2015%26volume%3D5%26issue%3D100%26spage%3D81768%26epage%3D81773" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Serge  Zaretsky</span>, <span class="hlFld-ContribAuthor ">Jennifer L.  Hickey</span>, <span class="hlFld-ContribAuthor ">Joanne  Tan</span>, <span class="hlFld-ContribAuthor ">Dmitry  Pichugin</span>, <span class="hlFld-ContribAuthor ">Megan A.  St. Denis</span>, <span class="hlFld-ContribAuthor ">Spencer  Ler</span>, <span class="hlFld-ContribAuthor ">Benjamin K. W.  Chung</span>, <span class="hlFld-ContribAuthor ">Conor C. G.  Scully</span>, <span class="hlFld-ContribAuthor ">Andrei K.  Yudin</span>. </span><span class="cited-content_cbyCitation_article-title">Mechanistic investigation of aziridine aldehyde-driven peptide macrocyclization: the imidoanhydride pathway. </span><span class="cited-content_cbyCitation_journal-name">Chemical Science</span><span> <strong>2015,</strong> <em>6 </em>
                                    (10)
                                     , 5446-5455. <a href="https://doi.org/10.1039/C5SC01958C" title="DOI URL">https://doi.org/10.1039/C5SC01958C</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1039/C5SC01958C&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1039%2FC5SC01958C%26sid%3Dliteratum%253Aachs%26jtitle%3DChemical%2520Science%26atitle%3DMechanistic%252Binvestigation%252Bof%252Baziridine%252Baldehyde-driven%252Bpeptide%252Bmacrocyclization%25253A%252Bthe%252Bimidoanhydride%252Bpathway%26aulast%3DZaretsky%26aufirst%3DSerge%26date%3D2015%26date%3D2015%26volume%3D6%26issue%3D10%26spage%3D5446%26epage%3D5455" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Michael U.  Luescher</span>, <span class="hlFld-ContribAuthor ">Jeffrey W.  Bode</span>. </span><span class="cited-content_cbyCitation_article-title">Catalytic Synthesis of N-Unprotected Piperazines, Morpholines, and Thiomorpholines from Aldehydes and SnAP Reagents. </span><span class="cited-content_cbyCitation_journal-name">Angewandte Chemie</span><span> <strong>2015,</strong> <em>127 </em>
                                    (37)
                                     , 11034-11038. <a href="https://doi.org/10.1002/ange.201505167" title="DOI URL">https://doi.org/10.1002/ange.201505167</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1002/ange.201505167&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1002%2Fange.201505167%26sid%3Dliteratum%253Aachs%26jtitle%3DAngewandte%2520Chemie%26atitle%3DCatalytic%252BSynthesis%252Bof%252BN-Unprotected%252BPiperazines%25252C%252BMorpholines%25252C%252Band%252BThiomorpholines%252Bfrom%252BAldehydes%252Band%252BSnAP%252BReagents%26aulast%3DLuescher%26aufirst%3DMichael%2BU.%26date%3D2015%26date%3D2015%26volume%3D127%26issue%3D37%26spage%3D11034%26epage%3D11038" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Michael U.  Luescher</span>, <span class="hlFld-ContribAuthor ">Jeffrey W.  Bode</span>. </span><span class="cited-content_cbyCitation_article-title">Catalytic Synthesis of N-Unprotected Piperazines, Morpholines, and Thiomorpholines from Aldehydes and SnAP Reagents. </span><span class="cited-content_cbyCitation_journal-name">Angewandte Chemie International Edition</span><span> <strong>2015,</strong> <em>54 </em>
                                    (37)
                                     , 10884-10888. <a href="https://doi.org/10.1002/anie.201505167" title="DOI URL">https://doi.org/10.1002/anie.201505167</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1002/anie.201505167&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1002%2Fanie.201505167%26sid%3Dliteratum%253Aachs%26jtitle%3DAngewandte%2520Chemie%2520International%2520Edition%26atitle%3DCatalytic%252BSynthesis%252Bof%252BN-Unprotected%252BPiperazines%25252C%252BMorpholines%25252C%252Band%252BThiomorpholines%252Bfrom%252BAldehydes%252Band%252BSnAP%252BReagents%26aulast%3DLuescher%26aufirst%3DMichael%2BU.%26date%3D2015%26date%3D2015%26volume%3D54%26issue%3D37%26spage%3D10884%26epage%3D10888" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Gianluigi  Broggini</span>, <span class="hlFld-ContribAuthor ">Egle M.  Beccalli</span>, <span class="hlFld-ContribAuthor ">Tea  Borelli</span>, <span class="hlFld-ContribAuthor ">Filippo  Brusa</span>, <span class="hlFld-ContribAuthor ">Silvia  Gazzola</span>, <span class="hlFld-ContribAuthor ">Alberto  Mazza</span>. </span><span class="cited-content_cbyCitation_article-title">Intra-Intermolecular Palladium-Catalyzed Domino Reactions of Glycine Allylamides for the Synthesis of Diversely Functionalized Piperazinones. </span><span class="cited-content_cbyCitation_journal-name">European Journal of Organic Chemistry</span><span> <strong>2015,</strong> <em>2015 </em>
                                    (19)
                                     , 4261-4268. <a href="https://doi.org/10.1002/ejoc.201500386" title="DOI URL">https://doi.org/10.1002/ejoc.201500386</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1002/ejoc.201500386&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1002%2Fejoc.201500386%26sid%3Dliteratum%253Aachs%26jtitle%3DEuropean%2520Journal%2520of%2520Organic%2520Chemistry%26atitle%3DIntra-Intermolecular%252BPalladium-Catalyzed%252BDomino%252BReactions%252Bof%252BGlycine%252BAllylamides%252Bfor%252Bthe%252BSynthesis%252Bof%252BDiversely%252BFunctionalized%252BPiperazinones%26aulast%3DBroggini%26aufirst%3DGianluigi%26date%3D2015%26date%3D2015%26volume%3D2015%26issue%3D19%26spage%3D4261%26epage%3D4268" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Christopher  Arico-Muendel</span>, <span class="hlFld-ContribAuthor ">Zhengrong  Zhu</span>, <span class="hlFld-ContribAuthor ">Hamilton  Dickson</span>, <span class="hlFld-ContribAuthor ">Derek  Parks</span>, <span class="hlFld-ContribAuthor ">Jesse  Keicher</span>, <span class="hlFld-ContribAuthor ">Jianghe  Deng</span>, <span class="hlFld-ContribAuthor ">Leah  Aquilani</span>, <span class="hlFld-ContribAuthor ">Frank  Coppo</span>, <span class="hlFld-ContribAuthor ">Todd  Graybill</span>, <span class="hlFld-ContribAuthor ">Kenneth  Lind</span>, <span class="hlFld-ContribAuthor ">Andrew  Peat</span>, <span class="hlFld-ContribAuthor ">Michael  Thomson</span>. </span><span class="cited-content_cbyCitation_article-title">Encoded Library Technology Screening of Hepatitis C Virus NS4B Yields a Small-Molecule Compound Series with
              In Vitro
              Replicon Activity. </span><span class="cited-content_cbyCitation_journal-name">Antimicrobial Agents and Chemotherapy</span><span> <strong>2015,</strong> <em>59 </em>
                                    (6)
                                     , 3450-3459. <a href="https://doi.org/10.1128/AAC.00070-15" title="DOI URL">https://doi.org/10.1128/AAC.00070-15</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1128/AAC.00070-15&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1128%2FAAC.00070-15%26sid%3Dliteratum%253Aachs%26jtitle%3DAntimicrobial%2520Agents%2520and%2520Chemotherapy%26atitle%3DEncoded%252BLibrary%252BTechnology%252BScreening%252Bof%252BHepatitis%252BC%252BVirus%252BNS4B%252BYields%252Ba%252BSmall-Molecule%252BCompound%252BSeries%252Bwith%252BIn%252BVitro%252BReplicon%252BActivity%26aulast%3DArico-Muendel%26aufirst%3DChristopher%26date%3D2015%26date%3D2015%26volume%3D59%26issue%3D6%26spage%3D3450%26epage%3D3459" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Guangming  Chen</span>, <span class="hlFld-ContribAuthor ">Hongyu  Ren</span>, <span class="hlFld-ContribAuthor ">Nanjing  Zhang</span>, <span class="hlFld-ContribAuthor ">William  Lennox</span>, <span class="hlFld-ContribAuthor ">Anthony  Turpoff</span>, <span class="hlFld-ContribAuthor ">Steven  Paget</span>, <span class="hlFld-ContribAuthor ">Chunshi  Li</span>, <span class="hlFld-ContribAuthor ">Neil  Almstead</span>, <span class="hlFld-ContribAuthor ">F. George  Njoroge</span>, <span class="hlFld-ContribAuthor ">Zhengxian  Gu</span>, <span class="hlFld-ContribAuthor ">Jason  Graci</span>, <span class="hlFld-ContribAuthor ">Stephen P.  Jung</span>, <span class="hlFld-ContribAuthor ">Joseph  Colacino</span>, <span class="hlFld-ContribAuthor ">Fred  Lahser</span>, <span class="hlFld-ContribAuthor ">Xin  Zhao</span>, <span class="hlFld-ContribAuthor ">Marla  Weetall</span>, <span class="hlFld-ContribAuthor ">Amin  Nomeir</span>, <span class="hlFld-ContribAuthor ">Gary M.  Karp</span>. </span><span class="cited-content_cbyCitation_article-title">6-(Azaindol-2-yl)pyridine-3-sulfonamides as potent and selective inhibitors targeting hepatitis C virus NS4B. </span><span class="cited-content_cbyCitation_journal-name">Bioorganic & Medicinal Chemistry Letters</span><span> <strong>2015,</strong> <em>25 </em>
                                    (4)
                                     , 781-786. <a href="https://doi.org/10.1016/j.bmcl.2014.12.093" title="DOI URL">https://doi.org/10.1016/j.bmcl.2014.12.093</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.bmcl.2014.12.093&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.bmcl.2014.12.093%26sid%3Dliteratum%253Aachs%26jtitle%3DBioorganic%2520%2526%2520Medicinal%2520Chemistry%2520Letters%26atitle%3D6-%252528Azaindol-2-yl%252529pyridine-3-sulfonamides%252Bas%252Bpotent%252Band%252Bselective%252Binhibitors%252Btargeting%252Bhepatitis%252BC%252Bvirus%252BNS4B%26aulast%3DChen%26aufirst%3DGuangming%26date%3D2015%26volume%3D25%26issue%3D4%26spage%3D781%26epage%3D786" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Michael S.  Perryman</span>, <span class="hlFld-ContribAuthor ">Matthew W. M.  Earl</span>, <span class="hlFld-ContribAuthor ">Sam  Greatorex</span>, <span class="hlFld-ContribAuthor ">Guy J.  Clarkson</span>, <span class="hlFld-ContribAuthor ">David J.  Fox</span>. </span><span class="cited-content_cbyCitation_article-title">Synthesis of 1- and 4-substituted piperazin-2-ones via Jocic-type reactions with N-substituted diamines. </span><span class="cited-content_cbyCitation_journal-name">Organic & Biomolecular Chemistry</span><span> <strong>2015,</strong> <em>13 </em>
                                    (8)
                                     , 2360-2365. <a href="https://doi.org/10.1039/C4OB02311K" title="DOI URL">https://doi.org/10.1039/C4OB02311K</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1039/C4OB02311K&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1039%2FC4OB02311K%26sid%3Dliteratum%253Aachs%26jtitle%3DOrganic%2520%2526%2520Biomolecular%2520Chemistry%26atitle%3DSynthesis%252Bof%252B1-%252Band%252B4-substituted%252Bpiperazin-2-ones%252Bvia%252BJocic-type%252Breactions%252Bwith%252BN-substituted%252Bdiamines%26aulast%3DPerryman%26aufirst%3DMichael%2BS.%26date%3D2015%26date%3D2015%26volume%3D13%26issue%3D8%26spage%3D2360%26epage%3D2365" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Shabber  Mohammed</span>, <span class="hlFld-ContribAuthor ">Ram A.  Vishwakarma</span>, <span class="hlFld-ContribAuthor ">Sandip B.  Bharate</span>. </span><span class="cited-content_cbyCitation_article-title">Metal-free DBU promoted regioselective synthesis of isoxazoles and isoxazolines. </span><span class="cited-content_cbyCitation_journal-name">RSC Advances</span><span> <strong>2015,</strong> <em>5 </em>
                                    (5)
                                     , 3470-3473. <a href="https://doi.org/10.1039/C4RA14694H" title="DOI URL">https://doi.org/10.1039/C4RA14694H</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1039/C4RA14694H&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1039%2FC4RA14694H%26sid%3Dliteratum%253Aachs%26jtitle%3DRSC%2520Advances%26atitle%3DMetal-free%252BDBU%252Bpromoted%252Bregioselective%252Bsynthesis%252Bof%252Bisoxazoles%252Band%252Bisoxazolines%26aulast%3DMohammed%26aufirst%3DShabber%26date%3D2015%26date%3D2015%26volume%3D5%26issue%3D5%26spage%3D3470%26epage%3D3473" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Qingxian  Jin</span>, <span class="hlFld-ContribAuthor ">Jing  Li</span>, <span class="hlFld-ContribAuthor ">Li  Zhang</span>, <span class="hlFld-ContribAuthor ">Shaoming  Fang</span>, <span class="hlFld-ContribAuthor ">Minghua  Liu</span>. </span><span class="cited-content_cbyCitation_article-title">Reactive organogels based on isoxazole esters: alkali metal ions selective gelation and crystallization. </span><span class="cited-content_cbyCitation_journal-name">CrystEngComm</span><span> <strong>2015,</strong> <em>17 </em>
                                    (42)
                                     , 8058-8063. <a href="https://doi.org/10.1039/C5CE00826C" title="DOI URL">https://doi.org/10.1039/C5CE00826C</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1039/C5CE00826C&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1039%2FC5CE00826C%26sid%3Dliteratum%253Aachs%26jtitle%3DCrystEngComm%26atitle%3DReactive%252Borganogels%252Bbased%252Bon%252Bisoxazole%252Besters%25253A%252Balkali%252Bmetal%252Bions%252Bselective%252Bgelation%252Band%252Bcrystallization%26aulast%3DJin%26aufirst%3DQingxian%26date%3D2015%26date%3D2015%26volume%3D17%26issue%3D42%26spage%3D8058%26epage%3D8063" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Nabyendu  Pramanik</span>, <span class="hlFld-ContribAuthor ">Satinath  Sarkar</span>, <span class="hlFld-ContribAuthor ">Dipanwita  Roy</span>, <span class="hlFld-ContribAuthor ">Sudipto  Debnath</span>, <span class="hlFld-ContribAuthor ">Sukla  Ghosh</span>, <span class="hlFld-ContribAuthor ">Saikat  Khamarui</span>, <span class="hlFld-ContribAuthor ">Dilip K.  Maiti</span>. </span><span class="cited-content_cbyCitation_article-title">Synthesis and diverse general oxidative cyclization catalysis of high-valent Mo
              VI
              O
              2
              (HL) to ubiquitous heterocycles and their chiral analogues with high selectivity. </span><span class="cited-content_cbyCitation_journal-name">RSC Advances</span><span> <strong>2015,</strong> <em>5 </em>
                                    (123)
                                     , 101959-101964. <a href="https://doi.org/10.1039/C5RA21825J" title="DOI URL">https://doi.org/10.1039/C5RA21825J</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1039/C5RA21825J&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1039%2FC5RA21825J%26sid%3Dliteratum%253Aachs%26jtitle%3DRSC%2520Advances%26atitle%3DSynthesis%252Band%252Bdiverse%252Bgeneral%252Boxidative%252Bcyclization%252Bcatalysis%252Bof%252Bhigh-valent%252BMo%252BVI%252BO%252B2%252B%252528HL%252529%252Bto%252Bubiquitous%252Bheterocycles%252Band%252Btheir%252Bchiral%252Banalogues%252Bwith%252Bhigh%252Bselectivity%26aulast%3DPramanik%26aufirst%3DNabyendu%26date%3D2015%26date%3D2015%26volume%3D5%26issue%3D123%26spage%3D101959%26epage%3D101964" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Ming-Jhan  Wu</span>, <span class="hlFld-ContribAuthor ">Po-Yuan  Ke</span>, <span class="hlFld-ContribAuthor ">John T.-A.  Hsu</span>, <span class="hlFld-ContribAuthor ">Chau-Ting  Yeh</span>, <span class="hlFld-ContribAuthor ">Jim-Tong  Horng</span>. </span><span class="cited-content_cbyCitation_article-title">Reticulon 3 interacts with NS4B of the hepatitis C virus and negatively regulates viral replication by disrupting NS4B self-interaction. </span><span class="cited-content_cbyCitation_journal-name">Cellular Microbiology</span><span> <strong>2014,</strong> <em>16 </em>
                                    (11)
                                     , 1603-1618. <a href="https://doi.org/10.1111/cmi.12318" title="DOI URL">https://doi.org/10.1111/cmi.12318</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1111/cmi.12318&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1111%2Fcmi.12318%26sid%3Dliteratum%253Aachs%26jtitle%3DCellular%2520Microbiology%26atitle%3DReticulon%252B3%252Binteracts%252Bwith%252BNS4B%252Bof%252Bthe%252Bhepatitis%252BC%252Bvirus%252Band%252Bnegatively%252Bregulates%252Bviral%252Breplication%252Bby%252Bdisrupting%252BNS4B%252Bself-interaction%26aulast%3DWu%26aufirst%3DMing-Jhan%26date%3D2014%26date%3D2014%26volume%3D16%26issue%3D11%26spage%3D1603%26epage%3D1618" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Vincent W.-F.  Tai</span>, <span class="hlFld-ContribAuthor ">Dulce  Garrido</span>, <span class="hlFld-ContribAuthor ">Daniel J.  Price</span>, <span class="hlFld-ContribAuthor ">Andrew  Maynard</span>, <span class="hlFld-ContribAuthor ">Jeffrey J.  Pouliot</span>, <span class="hlFld-ContribAuthor ">Zhiping  Xiong</span>, <span class="hlFld-ContribAuthor ">John W.  Seal</span>, <span class="hlFld-ContribAuthor ">Katrina L.  Creech</span>, <span class="hlFld-ContribAuthor ">Luz H.  Kryn</span>, <span class="hlFld-ContribAuthor ">Todd M.  Baughman</span>, <span class="hlFld-ContribAuthor ">Andrew J.  Peat</span>. </span><span class="cited-content_cbyCitation_article-title">Design and synthesis of spirocyclic compounds as HCV replication inhibitors by targeting viral NS4B protein. </span><span class="cited-content_cbyCitation_journal-name">Bioorganic & Medicinal Chemistry Letters</span><span> <strong>2014,</strong> <em>24 </em>
                                    (10)
                                     , 2288-2294. <a href="https://doi.org/10.1016/j.bmcl.2014.03.080" title="DOI URL">https://doi.org/10.1016/j.bmcl.2014.03.080</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.bmcl.2014.03.080&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.bmcl.2014.03.080%26sid%3Dliteratum%253Aachs%26jtitle%3DBioorganic%2520%2526%2520Medicinal%2520Chemistry%2520Letters%26atitle%3DDesign%252Band%252Bsynthesis%252Bof%252Bspirocyclic%252Bcompounds%252Bas%252BHCV%252Breplication%252Binhibitors%252Bby%252Btargeting%252Bviral%252BNS4B%252Bprotein%26aulast%3DTai%26aufirst%3DVincent%2BW.-F.%26date%3D2014%26volume%3D24%26issue%3D10%26spage%3D2288%26epage%3D2294" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li></ol></div></div></div></div></div><div class="article_content-right" id="article_content-right" tabindex="0"><div class="tab tab--flex"><div class="tab__close"><i class="icon-close" tabindex="0" aria-label="close the sidebar."></i></div><ul role="tablist" class="rlist tab__nav"><li role="presentation" class="active"><a id="pane-m1con" href="#pane-m1" aria-controls="pane-m1" role="tab" data-toggle="tab" title="Figures" aria-selected="true" class="active empty" aria-label="Figures"><i class="icon-image"></i><span>Figures</span></a></li><li role="presentation"><a id="pane-m2con" href="#pane-m2" aria-controls="pane-m2" role="tab" data-toggle="tab" title="References" aria-selected="false" class="empty"><i class="icon-link"></i><span>References</span></a></li></ul><div class="paneContainer"><ul class="rlist tab__content"><li id="pane-m1" aria-labelledby="pane-m1" class="tab__pane tab__pane-figures active empty"><figure data-id="f_tgr1" data-index="0" class="article__inlineFigure"><h2 class="fig-label">Abstract</h2><img class="rightTab-fig internalNav" src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-5/jm4012643/production/images/medium/jm-2013-012643_0026.gif" alt="" id="tgr1" /></img><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-5/jm4012643/production/images/large/jm-2013-012643_0026.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm4012643&amp;id=f_tgr1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig1" data-index="1" class="article__inlineFigure"><h2 class="fig-label">Figure 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-5/jm4012643/production/images/medium/jm-2013-012643_0002.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-5/jm4012643/production/images/large/jm-2013-012643_0002.jpeg" id="rightTab-gr6" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 1. HCV NS4B inhibitors with sub-μM GT1b potency.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-5/jm4012643/production/images/large/jm-2013-012643_0002.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm4012643&amp;id=fig1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig2" data-index="2" class="article__inlineFigure"><h2 class="fig-label">Figure 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-5/jm4012643/production/images/medium/jm-2013-012643_0003.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-5/jm4012643/production/images/large/jm-2013-012643_0003.jpeg" id="rightTab-gr7" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 2. HTS hit compound (<b>2a</b>) and its inactive isomer (<b>2b</b>).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-5/jm4012643/production/images/large/jm-2013-012643_0003.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm4012643&amp;id=fig2"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="sch1" data-index="3" class="article__inlineFigure"><h2 class="fig-label">Scheme 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-5/jm4012643/production/images/medium/jm-2013-012643_0004.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-5/jm4012643/production/images/large/jm-2013-012643_0004.jpeg" id="rightTab-gr1" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 1. Synthesis of Piperazinone Core <b>7</b> and Compounds <b>2a</b>, <b>2b</b>, and <b>67</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-5/jm4012643/production/images/large/jm-2013-012643_0004.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm4012643&amp;id=sch1"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>Reagents and conditions: (a) MeNHOMe·HCl, TBTU, DIPEA, CH<sub>3</sub>CN, 0 °C to RT (98%); (b) LiAlH4, THF, −78 °C (98%); (c) NH<sub>2</sub>-Leu-OMe, NaBH(OAc)<sub>3</sub>, DCE (90%); (d) 20% Et<sub>2</sub>NH in DCM, DCM (95%); (e) (±)-(1<i>R</i>,2<i>R</i>)-2-phenylcyclopropanecarboxylic acid, TBTU, DIPEA, DCM (90%); (f) 5-(4-fluorophenyl)isoxazole-3-carboxylic acid, TBTU, DIPEA, DCM (91%).</p></p></figure><figure data-id="sch2" data-index="4" class="article__inlineFigure"><h2 class="fig-label">Scheme 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-5/jm4012643/production/images/medium/jm-2013-012643_0005.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-5/jm4012643/production/images/large/jm-2013-012643_0005.jpeg" id="rightTab-gr2" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 2. Synthesis of Furanyl Derivative <b>107</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-5/jm4012643/production/images/large/jm-2013-012643_0005.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm4012643&amp;id=sch2"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>Reagents and conditions: (a) glyoxylic acid monohydrate, bis(4-methoxyphenyl)methanamine, DCM (94%); (b) MeNHOMe·HCl, TBTU, DIPEA, CH<sub>3</sub>CN (93%); (c) LiAlH<sub>4</sub>,THF, −78 °C, then NH<sub>2</sub>-Leu-OMe, NaBH(OAc)<sub>3</sub>, DCM (49%); (d) 70% aqueous AcOH, reflux (75%); (e) 5-(4-fluorophenyl)-isoxazole-3-carboxylic acid, TBTU, DIPEA, DCM (50%).</p></p></figure><figure data-id="sch3" data-index="5" class="article__inlineFigure"><h2 class="fig-label">Scheme 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-5/jm4012643/production/images/medium/jm-2013-012643_0006.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-5/jm4012643/production/images/large/jm-2013-012643_0006.jpeg" id="rightTab-gr3" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 3. Synthesis of Oxazole Derivative <b>108</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-5/jm4012643/production/images/large/jm-2013-012643_0006.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm4012643&amp;id=sch3"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>Reagents and conditions: (a) HCl in dioxane, 70 °C; (b) (BOC)<sub>2</sub>O, DIPEA, DCM, DMF (2 steps 87%); (c) DMP, DCM, 0 °C to RT; (d) tosylmethyl isocyanide, K<sub>2</sub>CO<sub>3</sub>, MeOH, 70 °C (2 steps 15%); (e) HCl in dioxane, DCM, 0 °C to RT; (f) HATU, DIPEA, DMF at RT (2 steps, 70%).</p></p></figure><figure data-id="sch4" data-index="6" class="article__inlineFigure"><h2 class="fig-label">Scheme 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-5/jm4012643/production/images/medium/jm-2013-012643_0007.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-5/jm4012643/production/images/large/jm-2013-012643_0007.jpeg" id="rightTab-gr4" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 4. Syntheses of Inhibitors <b>21</b>, <b>22</b>, and <b>109</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-5/jm4012643/production/images/large/jm-2013-012643_0007.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm4012643&amp;id=sch4"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>Reagents and conditions: (a) Fmoc-Cl, aq dioxane, 0 °C to RT (quantitative); (b) DMP, DCM; (c) (<i>S</i>)-2-amino-4-methylpentanoic acid methyl ester HCl salt, NaBH(OAc)<sub>3</sub>, THF (2 steps 42%); (d) 40% Et<sub>2</sub>NH in EtOH, 60 °C (42%); (e) 5-(4-fluorophenyl)isoxazole-3-carboxylic acid, HOBT hydrate, EDC, DIPEA, CH<sub>3</sub>CN (30%); (f) OsO<sub>4</sub>, oxone, DMF (60%); (g) 2,2-dimethoxy-ethylamine, HOBT hydrate, EDC, DIPEA, CH<sub>3</sub>CN (50%); (h), TFA, DCM (75%).</p></p></figure><figure data-id="sch5" data-index="7" class="article__inlineFigure"><h2 class="fig-label">Scheme 5</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-5/jm4012643/production/images/medium/jm-2013-012643_0008.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-5/jm4012643/production/images/large/jm-2013-012643_0008.jpeg" id="rightTab-gr5" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 5. Synthesis of Pyrrolidine Derivative <b>111</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-5/jm4012643/production/images/large/jm-2013-012643_0008.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm4012643&amp;id=sch5"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>Reagents and conditions: (a) glyoxylic acid monohydrate, bis(4-methoxyphenyl)methanamine, DCM; (b) MeNHOMe·HCl, TBTU, DIPEA, CH<sub>3</sub>CN (2 steps 98%); (c) LiAlH<sub>4</sub>,THF, −78 °C, then NH<sub>2</sub>-Leu-OMe, NaBH(OAc)<sub>3</sub>, DCM, (67%); (d) 5-(4-fluorophenyl)-isoxazole-3-carboxylic acid, TBTU, DIPEA, CH<sub>3</sub>CN; (e) 70% aq AcOH, reflux (2 steps 12%).</p></p></figure></li><li id="pane-m2" aria-labelledby="pane-m2" class="tab__pane tab__pane-references empty"><div class="refs-header-label"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="rightTab-_i212">References</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_63510" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_63510" class="dropBlock__holder"></div></div></div></div></div><hr /></hr></div><p class="rightTab-references-count">
            This article references 17 other publications.
        </p><ol id="rightTab-references" class="useLabel"><li id="rightTab-ref1"><div class="reference"><strong class="refLabel"><a href="#ref1" class="rightTabRefNumLink">1</a></strong><div class="NLM_citation" id="rightTab-cit1a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Te, H. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jensen, D. M.</span><span> </span><span class="NLM_article-title">Epidemiology of hepatitis B and C viruses: a global overview</span> <span class="citation_source-journal">Clin. Liver Dis.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">14</span><span class="NLM_x">, </span> <span class="NLM_fpage">1</span><span class="NLM_x">–</span> <span class="NLM_lpage">21</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref1/cit1a&amp;dbid=16&amp;doi=10.1021%2Fjm4012643&amp;key=10.1016%2Fj.cld.2009.11.009" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref1/cit1a&amp;dbid=8&amp;doi=10.1021%2Fjm4012643&amp;key=20123436" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref1/cit1a&amp;dbid=32&amp;doi=10.1021%2Fjm4012643&amp;key=1%3ACAS%3A280%3ADC%252BC3c7gslClsQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=14&publication_year=2010&pages=1-21&author=H.+S.+Teauthor=D.+M.+Jensen&title=Epidemiology+of+hepatitis+B+and+C+viruses%3A+a+global+overview"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit1aR"><div class="casContent"><span class="casTitleNuber">1a</span><div class="casTitle"><span class="NLM_cas:atitle">Epidemiology of hepatitis B and C viruses: a global overview</span></div><div class="casAuthors">Te Helen S; Jensen Donald M</div><div class="citationInfo"><span class="NLM_cas:title">Clinics in liver disease</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">14</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">1-21, vii</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">This article reviews the prevalence, disease burden, genotype distribution, and transmission patterns of hepatitis B virus (HBV) and hepatitis C virus in the 6 World Health Organization regions.  The global epidemiology of hepatitis B and C demonstrates a predominantly declining prevalence of the diseases.  Improvement in the control of hepatitis B has been largely achieved with implementation of a more universal HBV vaccine program, although a large gap still remains in the effort toward global prevention of hepatitis B.  The transmission of hepatitis C has been greatly impacted by mandatory screening of blood donors in most countries in the world, although intravenous drug use continues to be a major source of infection.  Public education regarding the risks of exposure to infected paraphernalia as well as household items such as razors is necessary in the continuing effort to curb this disease.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRbiYsvs7SIbxKDYG3bNImrfW6udTcc2eZIZDJ9w0GnoLntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC3c7gslClsQ%253D%253D&md5=116f0f2ecd8b141a4ce57311af520589</span></div><a href="/servlet/linkout?suffix=cit1a&amp;dbid=16384&amp;doi=10.1016%2Fj.cld.2009.11.009&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.cld.2009.11.009%26sid%3Dliteratum%253Aachs%26aulast%3DTe%26aufirst%3DH.%2BS.%26aulast%3DJensen%26aufirst%3DD.%2BM.%26atitle%3DEpidemiology%2520of%2520hepatitis%2520B%2520and%2520C%2520viruses%253A%2520a%2520global%2520overview%26jtitle%3DClin.%2520Liver%2520Dis.%26date%3D2010%26volume%3D14%26spage%3D1%26epage%3D21" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit1b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Shepard, C. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Finelli, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Alter, M. J.</span><span> </span><span class="NLM_article-title">Global epidemiology of hepatitis C virus infection</span> <span class="citation_source-journal">Lancet Infect. Dis.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">5</span><span class="NLM_x">, </span> <span class="NLM_fpage">558</span><span class="NLM_x">–</span> <span class="NLM_lpage">567</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref1/cit1b&amp;dbid=16&amp;doi=10.1021%2Fjm4012643&amp;key=10.1016%2FS1473-3099%2805%2970216-4" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref1/cit1b&amp;dbid=8&amp;doi=10.1021%2Fjm4012643&amp;key=16122679" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref1/cit1b&amp;dbid=32&amp;doi=10.1021%2Fjm4012643&amp;key=1%3ACAS%3A280%3ADC%252BD2Mvls1Wlsg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=2005&pages=558-567&author=C.+W.+Shepardauthor=L.+Finelliauthor=M.+J.+Alter&title=Global+epidemiology+of+hepatitis+C+virus+infection"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit1bR"><div class="casContent"><span class="casTitleNuber">1b</span><div class="casTitle"><span class="NLM_cas:atitle">Global epidemiology of hepatitis C virus infection</span></div><div class="casAuthors">Shepard Colin W; Finelli Lyn; Alter Miriam J</div><div class="citationInfo"><span class="NLM_cas:title">The Lancet. Infectious diseases</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">5</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">558-67</span>
        ISSN:<span class="NLM_cas:issn">1473-3099</span>.
    </div><div class="casAbstract">Hepatitis C virus (HCV) is a major cause of liver disease worldwide and a potential cause of substantial morbidity and mortality in the future.  The complexity and uncertainty related to the geographic distribution of HCV infection and chronic hepatitis C, determination of its associated risk factors, and evaluation of cofactors that accelerate its progression, underscore the difficulties in global prevention and control of HCV.  Because there is no vaccine and no post-exposure prophylaxis for HCV, the focus of primary prevention efforts should be safer blood supply in the developing world, safe injection practices in health care and other settings, and decreasing the number of people who initiate injection drug use.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQyQ65qEM2alVm8bhe6roZYfW6udTcc2eZIZDJ9w0GnoLntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD2Mvls1Wlsg%253D%253D&md5=4d5f81fa0c2191b8c32b328e39933fad</span></div><a href="/servlet/linkout?suffix=cit1b&amp;dbid=16384&amp;doi=10.1016%2FS1473-3099%2805%2970216-4&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS1473-3099%252805%252970216-4%26sid%3Dliteratum%253Aachs%26aulast%3DShepard%26aufirst%3DC.%2BW.%26aulast%3DFinelli%26aufirst%3DL.%26aulast%3DAlter%26aufirst%3DM.%2BJ.%26atitle%3DGlobal%2520epidemiology%2520of%2520hepatitis%2520C%2520virus%2520infection%26jtitle%3DLancet%2520Infect.%2520Dis.%26date%3D2005%26volume%3D5%26spage%3D558%26epage%3D567" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref2"><div class="reference"><strong class="refLabel"><a href="#ref2" class="rightTabRefNumLink">2</a></strong><div class="NLM_citation" id="rightTab-cit2a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">El-Serag, H. B.</span><span> </span><span class="NLM_article-title">Epidemiology of viral hepatitis and hepatocellular carcinoma</span> <span class="citation_source-journal">Gastroenterology</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">142</span><span class="NLM_x">, </span> <span class="NLM_fpage">1264</span><span class="NLM_x">–</span> <span class="NLM_lpage">1273</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref2/cit2a&amp;dbid=16&amp;doi=10.1021%2Fjm4012643&amp;key=10.1053%2Fj.gastro.2011.12.061" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref2/cit2a&amp;dbid=8&amp;doi=10.1021%2Fjm4012643&amp;key=22537432" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref2/cit2a&amp;dbid=32&amp;doi=10.1021%2Fjm4012643&amp;key=1%3ACAS%3A280%3ADC%252BC38rotl2gsA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=142&publication_year=2012&pages=1264-1273&author=H.+B.+El-Serag&title=Epidemiology+of+viral+hepatitis+and+hepatocellular+carcinoma"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit2aR"><div class="casContent"><span class="casTitleNuber">2a</span><div class="casTitle"><span class="NLM_cas:atitle">Epidemiology of viral hepatitis and hepatocellular carcinoma</span></div><div class="casAuthors">El-Serag Hashem B</div><div class="citationInfo"><span class="NLM_cas:title">Gastroenterology</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">142</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">1264-1273.e1</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Most cases of hepatocellular carcinoma (HCC) are associated with cirrhosis related to chronic hepatitis B virus (HBV) or hepatitis C virus (HCV) infection.  Changes in the time trends of HCC and most variations in its age-, sex-, and race-specific rates among different regions are likely to be related to differences in hepatitis viruses that are most prevalent in a population, the timing of their spread, and the ages of the individuals the viruses infect.  Environmental, host genetic, and viral factors can affect the risk of HCC in individuals with HBV or HCV infection.  This review summarizes the risk factors for HCC among HBV- or HCV-infected individuals, based on findings from epidemiologic studies and meta-analyses, as well as determinants of patient outcome and the HCC disease burden, globally and in the United States.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcR-sKKtlOWgPI2y4bB4mnvYfW6udTcc2eZIZDJ9w0GnoLntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC38rotl2gsA%253D%253D&md5=b80f1cb68dc9622140918028775e248c</span></div><a href="/servlet/linkout?suffix=cit2a&amp;dbid=16384&amp;doi=10.1053%2Fj.gastro.2011.12.061&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1053%252Fj.gastro.2011.12.061%26sid%3Dliteratum%253Aachs%26aulast%3DEl-Serag%26aufirst%3DH.%2BB.%26atitle%3DEpidemiology%2520of%2520viral%2520hepatitis%2520and%2520hepatocellular%2520carcinoma%26jtitle%3DGastroenterology%26date%3D2012%26volume%3D142%26spage%3D1264%26epage%3D1273" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit2b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Perz, J. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Armstrong, G. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Farrington, L. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hutin, Y. J. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bell, B. P.</span><span> </span><span class="NLM_article-title">The contributions of hepatitis B virus and hepatitis C virus infections to cirrhosis and primary liver cancer worldwide</span> <span class="citation_source-journal">J. Hepatol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">45</span><span class="NLM_x">, </span> <span class="NLM_fpage">529</span><span class="NLM_x">–</span> <span class="NLM_lpage">538</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref2/cit2b&amp;dbid=16&amp;doi=10.1021%2Fjm4012643&amp;key=10.1016%2Fj.jhep.2006.05.013" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref2/cit2b&amp;dbid=8&amp;doi=10.1021%2Fjm4012643&amp;key=16879891" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref2/cit2b&amp;dbid=32&amp;doi=10.1021%2Fjm4012643&amp;key=1%3ACAS%3A280%3ADC%252BD28rivVCmsA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=45&publication_year=2006&pages=529-538&author=J.+F.+Perzauthor=G.+L.+Armstrongauthor=L.+A.+Farringtonauthor=Y.+J.+F.+Hutinauthor=B.+P.+Bell&title=The+contributions+of+hepatitis+B+virus+and+hepatitis+C+virus+infections+to+cirrhosis+and+primary+liver+cancer+worldwide"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit2bR"><div class="casContent"><span class="casTitleNuber">2b</span><div class="casTitle"><span class="NLM_cas:atitle">The contributions of hepatitis B virus and hepatitis C virus infections to cirrhosis and primary liver cancer worldwide</span></div><div class="casAuthors">Perz Joseph F; Armstrong Gregory L; Farrington Leigh A; Hutin Yvan J F; Bell Beth P</div><div class="citationInfo"><span class="NLM_cas:title">Journal of hepatology</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">45</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">529-38</span>
        ISSN:<span class="NLM_cas:issn">0168-8278</span>.
    </div><div class="casAbstract">BACKGROUND/AIMS:  End-stage liver disease accounts for one in forty deaths worldwide.  Chronic infections with hepatitis B virus (HBV) and hepatitis C virus (HCV) are well-recognized risk factors for cirrhosis and liver cancer, but estimates of their contributions to worldwide disease burden have been lacking.  METHODS:  The prevalence of serologic markers of HBV and HCV infections among patients diagnosed with cirrhosis or hepatocellular carcinoma (HCC) was obtained from representative samples of published reports.  Attributable fractions of cirrhosis and HCC due to these infections were estimated for 11 WHO-based regions.  RESULTS:  Globally, 57% of cirrhosis was attributable to either HBV (30%) or HCV (27%) and 78% of HCC was attributable to HBV (53%) or HCV (25%).  Regionally, these infections usually accounted for >50% of HCC and cirrhosis.  Applied to 2002 worldwide mortality estimates, these fractions represent 929,000 deaths due to chronic HBV and HCV infections, including 446,000 cirrhosis deaths (HBV: n=235,000; HCV: n=211,000) and 483,000 liver cancer deaths (HBV: n=328,000; HCV: n=155,000).  CONCLUSIONS:  HBV and HCV infections account for the majority of cirrhosis and primary liver cancer throughout most of the world, highlighting the need for programs to prevent new infections and provide medical management and treatment for those already infected.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcSJG9SyjOebU3y-c-E1v-fmfW6udTcc2eaEAOlJzz5vMbntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD28rivVCmsA%253D%253D&md5=c388e797f694130776fdba6d336cbd45</span></div><a href="/servlet/linkout?suffix=cit2b&amp;dbid=16384&amp;doi=10.1016%2Fj.jhep.2006.05.013&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.jhep.2006.05.013%26sid%3Dliteratum%253Aachs%26aulast%3DPerz%26aufirst%3DJ.%2BF.%26aulast%3DArmstrong%26aufirst%3DG.%2BL.%26aulast%3DFarrington%26aufirst%3DL.%2BA.%26aulast%3DHutin%26aufirst%3DY.%2BJ.%2BF.%26aulast%3DBell%26aufirst%3DB.%2BP.%26atitle%3DThe%2520contributions%2520of%2520hepatitis%2520B%2520virus%2520and%2520hepatitis%2520C%2520virus%2520infections%2520to%2520cirrhosis%2520and%2520primary%2520liver%2520cancer%2520worldwide%26jtitle%3DJ.%2520Hepatol.%26date%3D2006%26volume%3D45%26spage%3D529%26epage%3D538" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref3"><div class="reference"><strong class="refLabel"><a href="#ref3" class="rightTabRefNumLink">3</a></strong><div class="NLM_citation" id="rightTab-cit3a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Kwong, A. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kauffman, R. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hurter, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mueller, P.</span><span> </span><span class="NLM_article-title">Discovery and development of telaprevir: an NS3-4A protease inhibitor for treating genotype 1 chronic hepatitis C virus</span> <span class="citation_source-journal">Nature Biotechnol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">29</span><span class="NLM_x">, </span> <span class="NLM_fpage">993</span><span class="NLM_x">–</span> <span class="NLM_lpage">1003</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref3/cit3a&amp;dbid=16&amp;doi=10.1021%2Fjm4012643&amp;key=10.1038%2Fnbt.2020" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref3/cit3a&amp;dbid=8&amp;doi=10.1021%2Fjm4012643&amp;key=22068541" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref3/cit3a&amp;dbid=32&amp;doi=10.1021%2Fjm4012643&amp;key=1%3ACAS%3A528%3ADC%252BC3MXhsVCntLvJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=29&publication_year=2011&pages=993-1003&author=A.+D.+Kwongauthor=R.+S.+Kauffmanauthor=P.+Hurterauthor=P.+Mueller&title=Discovery+and+development+of+telaprevir%3A+an+NS3-4A+protease+inhibitor+for+treating+genotype+1+chronic+hepatitis+C+virus"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit3aR"><div class="casContent"><span class="casTitleNuber">3a</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery and development of telaprevir: an NS3-4A protease inhibitor for treating genotype 1 chronic hepatitis C virus</span></div><div class="casAuthors">Kwong, Ann D.; Kauffman, Robert S.; Hurter, Patricia; Mueller, Peter</div><div class="citationInfo"><span class="NLM_cas:title">Nature Biotechnology</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">29</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">993-1003</span>CODEN:
                <span class="NLM_cas:coden">NABIF9</span>;
        ISSN:<span class="NLM_cas:issn">1087-0156</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  Infection with hepatitis C virus (HCV) is a major medical problem with over 170 million people infected worldwide.  Substantial morbidity and mortality are assocd. with hepatic manifestations (cirrhosis and hepatocellular carcinoma), which develop with increasing frequency in people infected with HCV for more than 20 years.  Less well known is the burden of HCV disease assocd. with extrahepatic manifestations (diabetes, B-cell proliferative disorders, depression, cognitive disorders, arthritis and Sjoegren's syndrome).  For patients infected with genotype 1 HCV, treatment with polyethylene glycol decorated interferon (peginterferon) α and ribavirin (PR) is assocd. with a low (40-50%) success rate, substantial treatment-limiting side effects and a long (48-wk) duration of treatment.  In the past 15 years, major scientific advances have enabled the development of new classes of HCV therapy, the direct-acting antiviral agents, also known as specifically targeted antiviral therapy for hepatitis C (STAT-C).  In combination with PR, the HCV NS3-4A protease inhibitor telaprevir has recently been approved for treatment of genotype 1 chronic HCV in the United States, Canada, European Union and Japan.  Compared with PR, telaprevir combination therapy offers significantly improved viral cure rates and the possibility of shortened treatment duration for diverse patient populations.  Developers of innovative drugs have to blaze a new path with few validated sign posts to guide the way.  Indeed, telaprevir's development was once put on hold because of its performance in a std. IC50 assay.  Data from new hypotheses and novel expts. were required to justify further investment and reduce risk that the drug might fail in the clinic.  In addn., the poor drug-like properties of telaprevir were a formidable hurdle, which the manufg. and formulation teams had to overcome to make the drug.  Finally, novel clin. trial designs were developed to improve efficacy and shorten treatment in parallel instead of sequentially.  Lessons learned from the development of telaprevir suggest that makers of innovative medicines cannot rely solely on traditional drug discovery metrics, but must develop innovative, scientifically guided pathways for success.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGodUEHshXTAvbVg90H21EOLACvtfcHk0lh6EdC9UHHZzw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXhsVCntLvJ&md5=952966419a2e72107550d0a63c337ae4</span></div><a href="/servlet/linkout?suffix=cit3a&amp;dbid=16384&amp;doi=10.1038%2Fnbt.2020&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnbt.2020%26sid%3Dliteratum%253Aachs%26aulast%3DKwong%26aufirst%3DA.%2BD.%26aulast%3DKauffman%26aufirst%3DR.%2BS.%26aulast%3DHurter%26aufirst%3DP.%26aulast%3DMueller%26aufirst%3DP.%26atitle%3DDiscovery%2520and%2520development%2520of%2520telaprevir%253A%2520an%2520NS3-4A%2520protease%2520inhibitor%2520for%2520treating%2520genotype%25201%2520chronic%2520hepatitis%2520C%2520virus%26jtitle%3DNature%2520Biotechnol.%26date%3D2011%26volume%3D29%26spage%3D993%26epage%3D1003" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit3b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Venkatraman, S.</span><span> </span><span class="NLM_article-title">Discovery of boceprevir, a direct-acting NS3/4A protease inhibitor for treatment of chronic hepatitis C infections</span> <span class="citation_source-journal">Trends Pharmacol. Sci.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">33</span><span class="NLM_x">, </span> <span class="NLM_fpage">289</span><span class="NLM_x">–</span> <span class="NLM_lpage">294</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=33&publication_year=2012&pages=289-294&author=S.+Venkatraman&title=Discovery+of+boceprevir%2C+a+direct-acting+NS3%2F4A+protease+inhibitor+for+treatment+of+chronic+hepatitis+C+infections"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit3b&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DVenkatraman%26aufirst%3DS.%26atitle%3DDiscovery%2520of%2520boceprevir%252C%2520a%2520direct-acting%2520NS3%252F4A%2520protease%2520inhibitor%2520for%2520treatment%2520of%2520chronic%2520hepatitis%2520C%2520infections%26jtitle%3DTrends%2520Pharmacol.%2520Sci.%26date%3D2012%26volume%3D33%26spage%3D289%26epage%3D294" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit3c"><span><span class="NLM_label">(c) </span><span class="NLM_contrib-group">Chen, K. X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Njoroge, F. G.</span><span> </span><span class="NLM_article-title">The journey to the discovery of boceprevir: an NS3-NS4 HCV protease inhibitor for the treatment of chronic hepatitis C</span> <span class="citation_source-journal">Prog. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">49</span><span class="NLM_x">, </span> <span class="NLM_fpage">1</span><span class="NLM_x">–</span> <span class="NLM_lpage">36</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref3/cit3c&amp;dbid=16&amp;doi=10.1021%2Fjm4012643&amp;key=10.1016%2FS0079-6468%2810%2949001-3" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref3/cit3c&amp;dbid=8&amp;doi=10.1021%2Fjm4012643&amp;key=20855037" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref3/cit3c&amp;dbid=32&amp;doi=10.1021%2Fjm4012643&amp;key=1%3ACAS%3A528%3ADC%252BC3MXitlSqtg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=49&publication_year=2010&pages=1-36&author=K.+X.+Chenauthor=F.+G.+Njoroge&title=The+journey+to+the+discovery+of+boceprevir%3A+an+NS3-NS4+HCV+protease+inhibitor+for+the+treatment+of+chronic+hepatitis+C"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit3cR"><div class="casContent"><span class="casTitleNuber">3c</span><div class="casTitle"><span class="NLM_cas:atitle">The journey to the discovery of boceprevir: an NS3-NS4 HCV protease inhibitor for the treatment of chronic hepatitis C</span></div><div class="casAuthors">Chen, Kevin X.; Njoroge, F. George</div><div class="citationInfo"><span class="NLM_cas:title">Progress in Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">49</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">1-36</span>CODEN:
                <span class="NLM_cas:coden">PMDCAY</span>;
        ISSN:<span class="NLM_cas:issn">0079-6468</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A review.  The hepatitis C virus (HCV) NS3 protease as a target for HCV therapy, mechanism of inhibition, biol. assays, and substrate-based drug design are discussed.  The depeptization efforts, macrocyclic inhibitors, selectivity, structure-activity relationship development at P2, P1, P3 and P3 capping, synergistic effects among different residues, profile of boceprevir, and synthesis of inhibitors are also reported.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqnlwuGjHIdCLVg90H21EOLACvtfcHk0lh6EdC9UHHZzw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXitlSqtg%253D%253D&md5=a68d8faba8276f2949de52b6c86e84a1</span></div><a href="/servlet/linkout?suffix=cit3c&amp;dbid=16384&amp;doi=10.1016%2FS0079-6468%2810%2949001-3&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0079-6468%252810%252949001-3%26sid%3Dliteratum%253Aachs%26aulast%3DChen%26aufirst%3DK.%2BX.%26aulast%3DNjoroge%26aufirst%3DF.%2BG.%26atitle%3DThe%2520journey%2520to%2520the%2520discovery%2520of%2520boceprevir%253A%2520an%2520NS3-NS4%2520HCV%2520protease%2520inhibitor%2520for%2520the%2520treatment%2520of%2520chronic%2520hepatitis%2520C%26jtitle%3DProg.%2520Med.%2520Chem.%26date%3D2010%26volume%3D49%26spage%3D1%26epage%3D36" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref4"><div class="reference"><strong class="refLabel"><a href="#ref4" class="rightTabRefNumLink">4</a></strong><div class="NLM_citation" id="rightTab-cit4a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Sheridan, C. W.</span><span> </span><span class="NLM_article-title">New Merck and Vertex drugs raise standard of care in hepatitis C</span> <span class="citation_source-journal">Nature Biotechnol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">29</span><span class="NLM_x">, </span> <span class="NLM_fpage">553</span><span class="NLM_x">–</span> <span class="NLM_lpage">554</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref4/cit4a&amp;dbid=16&amp;doi=10.1021%2Fjm4012643&amp;key=10.1038%2Fnbt0711-553" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref4/cit4a&amp;dbid=8&amp;doi=10.1021%2Fjm4012643&amp;key=21747363" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref4/cit4a&amp;dbid=32&amp;doi=10.1021%2Fjm4012643&amp;key=1%3ACAS%3A528%3ADC%252BC3MXoslymtrw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=29&publication_year=2011&pages=553-554&author=C.+W.+Sheridan&title=New+Merck+and+Vertex+drugs+raise+standard+of+care+in+hepatitis+C"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit4aR"><div class="casContent"><span class="casTitleNuber">4a</span><div class="casTitle"><span class="NLM_cas:atitle">New Merck and Vertex drugs raise standard of care in hepatitis C</span></div><div class="casAuthors">Sheridan, Cormac</div><div class="citationInfo"><span class="NLM_cas:title">Nature Biotechnology</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">29</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">553-554</span>CODEN:
                <span class="NLM_cas:coden">NABIF9</span>;
        ISSN:<span class="NLM_cas:issn">1087-0156</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">
                There is no expanded citation for this reference.
            </div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqDRNfcMR5e4rVg90H21EOLACvtfcHk0lh6EdC9UHHZzw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXoslymtrw%253D&md5=35734099c95a7a35dfd35d90f5820641</span></div><a href="/servlet/linkout?suffix=cit4a&amp;dbid=16384&amp;doi=10.1038%2Fnbt0711-553&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnbt0711-553%26sid%3Dliteratum%253Aachs%26aulast%3DSheridan%26aufirst%3DC.%2BW.%26atitle%3DNew%2520Merck%2520and%2520Vertex%2520drugs%2520raise%2520standard%2520of%2520care%2520in%2520hepatitis%2520C%26jtitle%3DNature%2520Biotechnol.%26date%3D2011%26volume%3D29%26spage%3D553%26epage%3D554" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit4b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Fried, M. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Russo, M. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fried, M. W.</span><span> </span><span class="NLM_article-title">Side effects of therapy for chronic hepatitis C</span> <span class="citation_source-journal">Gastroenterology</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2003</span><span class="NLM_x">, </span> <span class="NLM_volume">124</span><span class="NLM_x">, </span> <span class="NLM_fpage">1711</span><span class="NLM_x">–</span> <span class="NLM_lpage">1719</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=124&publication_year=2003&pages=1711-1719&author=M.+W.+Friedauthor=M.+W.+Russoauthor=M.+W.+Fried&title=Side+effects+of+therapy+for+chronic+hepatitis+C"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit4b&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DFried%26aufirst%3DM.%2BW.%26aulast%3DRusso%26aufirst%3DM.%2BW.%26aulast%3DFried%26aufirst%3DM.%2BW.%26atitle%3DSide%2520effects%2520of%2520therapy%2520for%2520chronic%2520hepatitis%2520C%26jtitle%3DGastroenterology%26date%3D2003%26volume%3D124%26spage%3D1711%26epage%3D1719" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit4c"><span><span class="NLM_label">(c) </span><span class="NLM_contrib-group">Manns, M. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wedemeyer, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cornberg, M.</span><span> </span><span class="NLM_article-title">Treating viral hepatitis C: efficacy, side effects, and complications</span> <span class="citation_source-journal">Gut</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">55</span><span class="NLM_x">, </span> <span class="NLM_fpage">1350</span><span class="NLM_x">–</span> <span class="NLM_lpage">1359</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=55&publication_year=2006&pages=1350-1359&author=M.+P.+Mannsauthor=H.+Wedemeyerauthor=M.+Cornberg&title=Treating+viral+hepatitis+C%3A+efficacy%2C+side+effects%2C+and+complications"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit4c&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DManns%26aufirst%3DM.%2BP.%26aulast%3DWedemeyer%26aufirst%3DH.%26aulast%3DCornberg%26aufirst%3DM.%26atitle%3DTreating%2520viral%2520hepatitis%2520C%253A%2520efficacy%252C%2520side%2520effects%252C%2520and%2520complications%26jtitle%3DGut%26date%3D2006%26volume%3D55%26spage%3D1350%26epage%3D1359" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref5"><div class="reference"><strong class="refLabel"><a href="#ref5" class="rightTabRefNumLink">5</a></strong><div class="NLM_citation" id="rightTab-cit5a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Kato, N.</span><span> </span><span class="NLM_article-title">Genome of human hepatitis C virus (HCV): gene organization, sequence diversity, and variation</span> <span class="citation_source-journal">Microb. Comp. Genomics</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2000</span><span class="NLM_x">, </span> <span class="NLM_volume">5</span><span class="NLM_x"> (</span><span class="NLM_issue">3</span><span class="NLM_x">) </span> <span class="NLM_fpage">129</span><span class="NLM_x">–</span> <span class="NLM_lpage">151</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref5/cit5a&amp;dbid=16&amp;doi=10.1021%2Fjm4012643&amp;key=10.1089%2Fomi.1.2000.5.129" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref5/cit5a&amp;dbid=8&amp;doi=10.1021%2Fjm4012643&amp;key=11252351" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref5/cit5a&amp;dbid=32&amp;doi=10.1021%2Fjm4012643&amp;key=1%3ACAS%3A528%3ADC%252BD3MXitFaqurk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=2000&pages=129-151&issue=3&author=N.+Kato&title=Genome+of+human+hepatitis+C+virus+%28HCV%29%3A+gene+organization%2C+sequence+diversity%2C+and+variation"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit5aR"><div class="casContent"><span class="casTitleNuber">5a</span><div class="casTitle"><span class="NLM_cas:atitle">Genome of human hepatitis C virus (HCV): Gene organization, sequence diversity, and variation</span></div><div class="casAuthors">Kato, Nobuyuki</div><div class="citationInfo"><span class="NLM_cas:title">Microbial & Comparative Genomics</span>
        (<span class="NLM_cas:date">2000</span>),
    <span class="NLM_cas:volume">5</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">129-151</span>CODEN:
                <span class="NLM_cas:coden">MCGEFP</span>;
        ISSN:<span class="NLM_cas:issn">1090-6592</span>.
    
            (<span class="NLM_cas:orgname">Mary Ann Liebert, Inc.</span>)
        </div><div class="casAbstract">A review with refs.  Hepatitis C virus (HCV) is the major etiol. agent of non-A, non-B hepatitis.  HCV infection frequently causes chronic hepatitis, which progresses to liver cirrhosis and hepatocellular carcinoma.  Since the discovery of HCV in 1989, a large no. of genetic analyses of HCV have been reported, and the viral genome structure has been elucidated.  An enveloped virus, HCV belongs to the family Flaviviridae, whose genome consists of a pos.-stranded RNA mol. of about 9.6 kilobases and encodes a large polyprotein precursor (about 3000 amino acids).  This precursor protein is cleaved by the host and viral proteinase to generate at least 10 proteins: the core, envelope 1 (E1), E2, p7, nonstructural (NS) 2, NS3, NS4A, NS4B, NS5A, and NS5B.  These HCV proteins not only function in viral replication but also affect a variety of cellular functions.  HCV has been found to have remarkable genetic heterogeneity.  To date, more than 30 HCV genotypes have been identified worldwide.  Furthermore, HCV may show quasispecies distribution in an infected individual.  These findings may have important implications in diagnosis, pathogenesis, treatment, and vaccine development.  The hypervariable region 1 found within the envelope E2 protein was shown to be a major site for the genetic evolution of HCV after the onset of hepatitis, and might be involved in escape from the host immunesurveillance system.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqtYgXE3VZ8YLVg90H21EOLACvtfcHk0lj_8mV9LvEiGQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3MXitFaqurk%253D&md5=9cb2f80fe202cf58547f35ec16018397</span></div><a href="/servlet/linkout?suffix=cit5a&amp;dbid=16384&amp;doi=10.1089%2Fomi.1.2000.5.129&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1089%252Fomi.1.2000.5.129%26sid%3Dliteratum%253Aachs%26aulast%3DKato%26aufirst%3DN.%26atitle%3DGenome%2520of%2520human%2520hepatitis%2520C%2520virus%2520%2528HCV%2529%253A%2520gene%2520organization%252C%2520sequence%2520diversity%252C%2520and%2520variation%26jtitle%3DMicrob.%2520Comp.%2520Genomics%26date%3D2000%26volume%3D5%26issue%3D3%26spage%3D129%26epage%3D151" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit5b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Dubuisson, J.</span><span> </span><span class="NLM_article-title">Hepatitis C virus proteins</span> <span class="citation_source-journal">World J. Gastroenterol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">13</span><span class="NLM_x"> (</span><span class="NLM_issue">17</span><span class="NLM_x">) </span> <span class="NLM_fpage">2406</span><span class="NLM_x">–</span> <span class="NLM_lpage">2415</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref5/cit5b&amp;dbid=16&amp;doi=10.1021%2Fjm4012643&amp;key=10.3748%2Fwjg.v13.i17.2406" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref5/cit5b&amp;dbid=8&amp;doi=10.1021%2Fjm4012643&amp;key=17552023" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref5/cit5b&amp;dbid=32&amp;doi=10.1021%2Fjm4012643&amp;key=1%3ACAS%3A528%3ADC%252BD2sXotl2ltL8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=2007&pages=2406-2415&issue=17&author=J.+Dubuisson&title=Hepatitis+C+virus+proteins"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit5bR"><div class="casContent"><span class="casTitleNuber">5b</span><div class="casTitle"><span class="NLM_cas:atitle">Hepatitis C virus proteins</span></div><div class="casAuthors">Dubuisson, Jean</div><div class="citationInfo"><span class="NLM_cas:title">World Journal of Gastroenterology</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">13</span>
        (<span class="NLM_cas:issue">17</span>),
    <span class="NLM_cas:pages">2406-2415</span>CODEN:
                <span class="NLM_cas:coden">WJGAF2</span>;
        ISSN:<span class="NLM_cas:issn">1007-9327</span>.
    
            (<span class="NLM_cas:orgname">World Journal of Gastroenterology</span>)
        </div><div class="casAbstract">A review.  Hepatitis C virus (HCV) encodes a single polyprotein, which is processed by cellular and viral proteases to generate 10 polypeptides.  The HCV genome also contains an overlapping +1 reading frame that may lead to the synthesis of an addnl. protein.  Until recently, studies of HCV have been hampered by the lack of a productive cell culture system.  Since the identification of HCV genome approx. 17 years ago, structural, biochem. and biol. information on HCV proteins has mainly been obtained with proteins produced by heterologous expression systems.  In addn., some functional studies have also been confirmed with replicon systems or with retroviral particles pseudotyped with HCV envelope glycoproteins.  The data that have accumulated on HCV proteins begin to provide a framework for understanding the mol. mechanisms involved in the major steps of HCV life cycle.  Moreover, the knowledge accumulated on HCV proteins is also leading to the development of antiviral drugs among which some are showing promising results in early-phase clin. trials.  This review summarizes the current knowledge on the functions and biochem. features of HCV proteins.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpezIkAF0sydLVg90H21EOLACvtfcHk0lj_8mV9LvEiGQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXotl2ltL8%253D&md5=e99a88ec6a8102fd7611c376f6a78d80</span></div><a href="/servlet/linkout?suffix=cit5b&amp;dbid=16384&amp;doi=10.3748%2Fwjg.v13.i17.2406&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3748%252Fwjg.v13.i17.2406%26sid%3Dliteratum%253Aachs%26aulast%3DDubuisson%26aufirst%3DJ.%26atitle%3DHepatitis%2520C%2520virus%2520proteins%26jtitle%3DWorld%2520J.%2520Gastroenterol.%26date%3D2007%26volume%3D13%26issue%3D17%26spage%3D2406%26epage%3D2415" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref6"><div class="reference"><strong class="refLabel"><a href="#ref6" class="rightTabRefNumLink">6</a></strong><div class="NLM_citation" id="rightTab-cit6a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Asselah, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Marcellin, P.</span><span> </span><span class="NLM_article-title">Direct acting antivirals for the treatment of chronic hepatitis C: One pill a day for tomorrow</span> <span class="citation_source-journal">Liver Int.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">32</span><span class="NLM_x"> (</span><span class="NLM_issue">Suppl 1</span><span class="NLM_x">) </span> <span class="NLM_fpage">88</span><span class="NLM_x">–</span> <span class="NLM_lpage">102</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=32&publication_year=2012&pages=88-102&issue=Suppl+1&author=T.+Asselahauthor=P.+Marcellin&title=Direct+acting+antivirals+for+the+treatment+of+chronic+hepatitis+C%3A+One+pill+a+day+for+tomorrow"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit6a&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DAsselah%26aufirst%3DT.%26aulast%3DMarcellin%26aufirst%3DP.%26atitle%3DDirect%2520acting%2520antivirals%2520for%2520the%2520treatment%2520of%2520chronic%2520hepatitis%2520C%253A%2520One%2520pill%2520a%2520day%2520for%2520tomorrow%26jtitle%3DLiver%2520Int.%26date%3D2012%26volume%3D32%26issue%3DSuppl%25201%26spage%3D88%26epage%3D102" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit6b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Welsch, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jesudian, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zeuzem, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jacobson, I.</span><span> </span><span class="NLM_article-title">New direct-acting antiviral agents for the treatment of hepatitis C virus infection and perspectives</span> <span class="citation_source-journal">Gut Liver</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">61</span><span class="NLM_x">, </span> <span class="NLM_fpage">i36</span><span class="NLM_x">–</span> <span class="NLM_lpage">i46</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=61&publication_year=2012&pages=i36-i46&author=C.+Welschauthor=A.+Jesudianauthor=S.+Zeuzemauthor=I.+Jacobson&title=New+direct-acting+antiviral+agents+for+the+treatment+of+hepatitis+C+virus+infection+and+perspectives"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit6b&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DWelsch%26aufirst%3DC.%26aulast%3DJesudian%26aufirst%3DA.%26aulast%3DZeuzem%26aufirst%3DS.%26aulast%3DJacobson%26aufirst%3DI.%26atitle%3DNew%2520direct-acting%2520antiviral%2520agents%2520for%2520the%2520treatment%2520of%2520hepatitis%2520C%2520virus%2520infection%2520and%2520perspectives%26jtitle%3DGut%2520Liver%26date%3D2012%26volume%3D61%26spage%3Di36%26epage%3Di46" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit6c"><span><span class="NLM_label">(c) </span><span class="NLM_contrib-group">Pockros, P. J.</span><span> </span><span class="NLM_article-title">Drugs in development for chronic hepatitis C: a promising future</span> <span class="citation_source-journal">Expert Opin. Biol. Ther.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">11</span><span class="NLM_x">, </span> <span class="NLM_fpage">1611</span><span class="NLM_x">–</span> <span class="NLM_lpage">1622</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref6/cit6c&amp;dbid=16&amp;doi=10.1021%2Fjm4012643&amp;key=10.1517%2F14712598.2011.627851" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref6/cit6c&amp;dbid=8&amp;doi=10.1021%2Fjm4012643&amp;key=21995412" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref6/cit6c&amp;dbid=32&amp;doi=10.1021%2Fjm4012643&amp;key=1%3ACAS%3A528%3ADC%252BC3MXhsVags77F" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2011&pages=1611-1622&author=P.+J.+Pockros&title=Drugs+in+development+for+chronic+hepatitis+C%3A+a+promising+future"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit6cR"><div class="casContent"><span class="casTitleNuber">6c</span><div class="casTitle"><span class="NLM_cas:atitle">Drugs in development for chronic hepatitis C: a promising future</span></div><div class="casAuthors">Pockros, Paul J.</div><div class="citationInfo"><span class="NLM_cas:title">Expert Opinion on Biological Therapy</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">1611-1622</span>CODEN:
                <span class="NLM_cas:coden">EOBTA2</span>;
        ISSN:<span class="NLM_cas:issn">1471-2598</span>.
    
            (<span class="NLM_cas:orgname">Informa Healthcare</span>)
        </div><div class="casAbstract">Introduction:The approval of the first direct-acting antiviral (DAA) drugs for treatment of HCV in 2011 has lead to improved sustained viral response rates of up to 79% in treatment-naive or relapse genotype 1 patients.Areas covered:Clin. trial data, the clin. skills required for the use of DAA drugs, the use of genetic tests and HCV RNA assays, new small mols., resistance-assocd. variants, combinations of two or more DAAs, treatment of special populations, and future directions.  The results of the pivotal Phase III trials with telaprevir and boceprevir, including the efficacy, safety and tolerability, drug-drug interactions and management of the most common side-effects.  Resistance-assocd. variant data and treatment strategies implemented to minimize the development of resistance with these first-generation protease inhibitors.Expert opinion:Combination therapies of protease inhibitors with nucleoside or non-nucleoside polymerase inhibitors, non-structural protein 5A (NS5A) inhibitors and cyclophylin inhibitors are currently underway in regimens that use pegylated interferon and ribavirin or are interferon-free.  The explosion of new drug development will probably move the field forward and offer both improved efficacy and tolerability to patients with hepatitis C infections.  The use of these drugs ushers in a new era for the treatment of HCV but must be done with care and caution.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr8W7I7t4G677Vg90H21EOLACvtfcHk0lgQgoGqD2OsyQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXhsVags77F&md5=d6a0c0e547adc1fc6b170f76144a96c8</span></div><a href="/servlet/linkout?suffix=cit6c&amp;dbid=16384&amp;doi=10.1517%2F14712598.2011.627851&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1517%252F14712598.2011.627851%26sid%3Dliteratum%253Aachs%26aulast%3DPockros%26aufirst%3DP.%2BJ.%26atitle%3DDrugs%2520in%2520development%2520for%2520chronic%2520hepatitis%2520C%253A%2520a%2520promising%2520future%26jtitle%3DExpert%2520Opin.%2520Biol.%2520Ther.%26date%3D2011%26volume%3D11%26spage%3D1611%26epage%3D1622" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit6d"><span><span class="NLM_label">(d) </span><span class="NLM_contrib-group">Fusco, D. N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chung, R. T.</span><span> </span><span class="NLM_article-title">Novel therapies for hepatitis C: insights from the structure of the virus</span> <span class="citation_source-journal">Annu. Rev. Med.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">63</span><span class="NLM_x">, </span> <span class="NLM_fpage">373</span><span class="NLM_x">–</span> <span class="NLM_lpage">387</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=63&publication_year=2012&pages=373-387&author=D.+N.+Fuscoauthor=R.+T.+Chung&title=Novel+therapies+for+hepatitis+C%3A+insights+from+the+structure+of+the+virus"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit6d&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DFusco%26aufirst%3DD.%2BN.%26aulast%3DChung%26aufirst%3DR.%2BT.%26atitle%3DNovel%2520therapies%2520for%2520hepatitis%2520C%253A%2520insights%2520from%2520the%2520structure%2520of%2520the%2520virus%26jtitle%3DAnnu.%2520Rev.%2520Med.%26date%3D2012%26volume%3D63%26spage%3D373%26epage%3D387" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit6e"><span><span class="NLM_label">(e) </span><span class="NLM_contrib-group">Lemon, S. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McKeating, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pietschmann, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Frick, D. N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Glenn, J. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tellinghuisen, T. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Symons, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Furman, P. A.</span><span> </span><span class="NLM_article-title">Development of novel therapies for hepatitis C</span> <span class="citation_source-journal">Antiviral Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">86</span><span class="NLM_x">, </span> <span class="NLM_fpage">79</span><span class="NLM_x">–</span> <span class="NLM_lpage">92</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=86&publication_year=2010&pages=79-92&author=S.+M.+Lemonauthor=J.+A.+McKeatingauthor=T.+Pietschmannauthor=D.+N.+Frickauthor=J.+S.+Glennauthor=T.+L.+Tellinghuisenauthor=J.+Symonsauthor=P.+A.+Furman&title=Development+of+novel+therapies+for+hepatitis+C"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit6e&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DLemon%26aufirst%3DS.%2BM.%26aulast%3DMcKeating%26aufirst%3DJ.%2BA.%26aulast%3DPietschmann%26aufirst%3DT.%26aulast%3DFrick%26aufirst%3DD.%2BN.%26aulast%3DGlenn%26aufirst%3DJ.%2BS.%26aulast%3DTellinghuisen%26aufirst%3DT.%2BL.%26aulast%3DSymons%26aufirst%3DJ.%26aulast%3DFurman%26aufirst%3DP.%2BA.%26atitle%3DDevelopment%2520of%2520novel%2520therapies%2520for%2520hepatitis%2520C%26jtitle%3DAntiviral%2520Res.%26date%3D2010%26volume%3D86%26spage%3D79%26epage%3D92" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref7"><div class="reference"><strong class="refLabel"><a href="#ref7" class="rightTabRefNumLink">7</a></strong><div class="NLM_citation" id="rightTab-cit7a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Mani, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rao, B. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kieffer, T. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kwong, A. D.</span><span> </span><span class="NLM_article-title">Recent progress in the development of HCV protease inhibitors</span> <span class="citation_source-journal">Methods Principals Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">50</span><span class="NLM_x">, </span> <span class="NLM_fpage">307</span><span class="NLM_x">–</span> <span class="NLM_lpage">328</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref7/cit7a&amp;dbid=16&amp;doi=10.1021%2Fjm4012643&amp;key=10.1002%2F9783527635955.ch12" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=50&publication_year=2011&pages=307-328&author=N.+Maniauthor=B.+G.+Raoauthor=T.+L.+Kiefferauthor=A.+D.+Kwong&title=Recent+progress+in+the+development+of+HCV+protease+inhibitors"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit7a&amp;dbid=16384&amp;doi=10.1002%2F9783527635955.ch12&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252F9783527635955.ch12%26sid%3Dliteratum%253Aachs%26aulast%3DMani%26aufirst%3DN.%26aulast%3DRao%26aufirst%3DB.%2BG.%26aulast%3DKieffer%26aufirst%3DT.%2BL.%26aulast%3DKwong%26aufirst%3DA.%2BD.%26atitle%3DRecent%2520progress%2520in%2520the%2520development%2520of%2520HCV%2520protease%2520inhibitors%26jtitle%3DMethods%2520Principals%2520Med.%2520Chem.%26date%3D2011%26volume%3D50%26spage%3D307%26epage%3D328" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit7b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Chary, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Holodniy, M.</span><span> </span><span class="NLM_article-title">Recent advances in hepatitis C virus treatment: review of HCV protease inhibitor clinical trials</span> <span class="citation_source-journal">Rev. Recent Clin. Trials</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">5</span><span class="NLM_x">, </span> <span class="NLM_fpage">158</span><span class="NLM_x">–</span> <span class="NLM_lpage">173</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref7/cit7b&amp;dbid=16&amp;doi=10.1021%2Fjm4012643&amp;key=10.2174%2F157488710792007293" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref7/cit7b&amp;dbid=8&amp;doi=10.1021%2Fjm4012643&amp;key=20482493" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref7/cit7b&amp;dbid=32&amp;doi=10.1021%2Fjm4012643&amp;key=1%3ACAS%3A528%3ADC%252BC3cXhtFKqsrfO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=2010&pages=158-173&author=A.+Charyauthor=M.+Holodniy&title=Recent+advances+in+hepatitis+C+virus+treatment%3A+review+of+HCV+protease+inhibitor+clinical+trials"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit7bR"><div class="casContent"><span class="casTitleNuber">7b</span><div class="casTitle"><span class="NLM_cas:atitle">Recent advances in hepatitis C virus treatment: review of HCV protease inhibitor clinical trials</span></div><div class="casAuthors">Chary, Aarthi; Holodniy, Mark</div><div class="citationInfo"><span class="NLM_cas:title">Reviews on Recent Clinical Trials</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">5</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">158-173</span>CODEN:
                <span class="NLM_cas:coden">RRCTB2</span>;
        ISSN:<span class="NLM_cas:issn">1574-8871</span>.
    
            (<span class="NLM_cas:orgname">Bentham Science Publishers Ltd.</span>)
        </div><div class="casAbstract">A review.  Hepatitis C virus (HCV) infection affects millions of people world-wide, and chronic infection can result in end-stage liver disease and hepatocellular carcinoma.  Conventional therapy to date has involved combination antiviral therapy including alpha-interferon and ribavirin; response rates with these drugs are variable based on both viral and host factors, such as HCV viral load, HCV genotype, HIV co-infection, host genetic polymorphisms (such as those in the IL28B region), and other factors.  Recent advances in HCV treatment have included pegylated forms of alpha-interferon and, more recently, the development of specifically targeted antiviral therapy for HCV (STAT-C) with novel HCV protease inhibitors (PIs) for genotype 1 HCV.  Although unlikely to be administered as monotherapy due to the potential for development of HCV PI drug resistance mutations, results of phase II trials of two PIs in development have recently been reported, demonstrating promising therapeutic efficacy of HCV PIs in combination with established conventional treatment.  This review outlines the advances and the challenges in the development of these HCV PIs as effective HCV antiviral agents and their role in clin. practice.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoQIZzi-TKaoLVg90H21EOLACvtfcHk0lgQgoGqD2OsyQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXhtFKqsrfO&md5=a2698c8b46cbb88b89c4cc1403733835</span></div><a href="/servlet/linkout?suffix=cit7b&amp;dbid=16384&amp;doi=10.2174%2F157488710792007293&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F157488710792007293%26sid%3Dliteratum%253Aachs%26aulast%3DChary%26aufirst%3DA.%26aulast%3DHolodniy%26aufirst%3DM.%26atitle%3DRecent%2520advances%2520in%2520hepatitis%2520C%2520virus%2520treatment%253A%2520review%2520of%2520HCV%2520protease%2520inhibitor%2520clinical%2520trials%26jtitle%3DRev.%2520Recent%2520Clin.%2520Trials%26date%3D2010%26volume%3D5%26spage%3D158%26epage%3D173" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit7c"><span><span class="NLM_label">(c) </span><span class="NLM_contrib-group">Kwo, P. Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vinayek, R.</span><span> </span><span class="NLM_article-title">The therapeutic approaches for hepatitis C virus: protease inhibitors and polymerase inhibitors</span> <span class="citation_source-journal">Gut</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">5</span><span class="NLM_x">, </span> <span class="NLM_fpage">406</span><span class="NLM_x">–</span> <span class="NLM_lpage">417</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=2011&pages=406-417&author=P.+Y.+Kwoauthor=R.+Vinayek&title=The+therapeutic+approaches+for+hepatitis+C+virus%3A+protease+inhibitors+and+polymerase+inhibitors"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit7c&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DKwo%26aufirst%3DP.%2BY.%26aulast%3DVinayek%26aufirst%3DR.%26atitle%3DThe%2520therapeutic%2520approaches%2520for%2520hepatitis%2520C%2520virus%253A%2520protease%2520inhibitors%2520and%2520polymerase%2520inhibitors%26jtitle%3DGut%26date%3D2011%26volume%3D5%26spage%3D406%26epage%3D417" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref8"><div class="reference"><strong class="refLabel"><a href="#ref8" class="rightTabRefNumLink">8</a></strong><div class="NLM_citation" id="rightTab-cit8"><span><span class="NLM_contrib-group">Reviriego, C.</span><span> </span><span class="NLM_article-title">Daclatasvir dihydrochloride: treatment of hepatitis C virus HCV NS5A inhibitor</span> <span class="citation_source-journal">Drugs Future</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">36</span><span class="NLM_x">, </span> <span class="NLM_fpage">735</span><span class="NLM_x">–</span> <span class="NLM_lpage">739</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=32&amp;doi=10.1021%2Fjm4012643&amp;key=1%3ACAS%3A528%3ADC%252BC38XhtVCksr8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=36&publication_year=2011&pages=735-739&author=C.+Reviriego&title=Daclatasvir+dihydrochloride%3A+treatment+of+hepatitis+C+virus+HCV+NS5A+inhibitor"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit8R"><div class="casContent"><span class="casTitleNuber">8</span><div class="casTitle"><span class="NLM_cas:atitle">Daclatasvir dihydrochloride: treatment of hepatitis C virus HCV NS5A inhibitor</span></div><div class="casAuthors">Reviriego, C.</div><div class="citationInfo"><span class="NLM_cas:title">Drugs of the Future</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">36</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">735-739</span>CODEN:
                <span class="NLM_cas:coden">DRFUD4</span>;
        ISSN:<span class="NLM_cas:issn">0377-8282</span>.
    
            (<span class="NLM_cas:orgname">Prous Science</span>)
        </div><div class="casAbstract">A review.  Hepatitis C virus (HCV) is a major chronic disease and infected individuals are at risk of developing multiple and highly severe liver complications, such as cirrhosis or liver carcinoma.  The current std. of care for the treatment of HCV is a combination of pegylated interferon alfa and ribavirin, a poorly tolerated regimen with limiting side effects and low sustained virol. response rates in genotype 1-infected patients.  Therefore, the exploration of alternative treatment regimens is of utmost importance.  Daclatasvir dihydrochloride (BMS-790052) is a novel, small-mol., first-in-class inhibitor of HCV replication that targets non-structural protein 5A (NS5A).  It has shown impressive clin. efficacy, high selectivity, picomolar activity and broad genotype coverage in vitro.  Daclatasvir is safe and generally well tolerated, and it has a pharmacokinetic profile suggestive of once-daily administration.  With its extraordinary potency and non-overlapping resistance profile, daclatasvir has the potential to be an important component in future combination strategies for HCV therapy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrALLJfJjhdI7Vg90H21EOLACvtfcHk0lhuEld_o4sDxw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XhtVCksr8%253D&md5=5e4a7324e33a0351f609304f88e289cd</span></div><a href="/servlet/linkout?suffix=cit8&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DReviriego%26aufirst%3DC.%26atitle%3DDaclatasvir%2520dihydrochloride%253A%2520treatment%2520of%2520hepatitis%2520C%2520virus%2520HCV%2520NS5A%2520inhibitor%26jtitle%3DDrugs%2520Future%26date%3D2011%26volume%3D36%26spage%3D735%26epage%3D739" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref9"><div class="reference"><strong class="refLabel"><a href="#ref9" class="rightTabRefNumLink">9</a></strong><div class="NLM_citation" id="rightTab-cit9a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Kwo, P. Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vinayek, R.</span><span> </span><span class="NLM_article-title">The therapeutic approaches for hepatitis C virus: protease inhibitors and polymerase inhibitors</span> <span class="citation_source-journal">Gut</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">5</span><span class="NLM_x">, </span> <span class="NLM_fpage">406</span><span class="NLM_x">–</span> <span class="NLM_lpage">417</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=2011&pages=406-417&author=P.+Y.+Kwoauthor=R.+Vinayek&title=The+therapeutic+approaches+for+hepatitis+C+virus%3A+protease+inhibitors+and+polymerase+inhibitors"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit9a&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DKwo%26aufirst%3DP.%2BY.%26aulast%3DVinayek%26aufirst%3DR.%26atitle%3DThe%2520therapeutic%2520approaches%2520for%2520hepatitis%2520C%2520virus%253A%2520protease%2520inhibitors%2520and%2520polymerase%2520inhibitors%26jtitle%3DGut%26date%3D2011%26volume%3D5%26spage%3D406%26epage%3D417" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit9b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Sofia, M. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chang, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Furman, P. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mosley, R. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ross, B. S.</span><span> </span><span class="NLM_article-title">Nucleoside, nucleotide, and non-nucleoside inhibitors of hepatitis C virus NS5B RNA-dependent RNA-polymerase</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">55</span><span class="NLM_x">, </span> <span class="NLM_fpage">2481</span><span class="NLM_x">–</span> <span class="NLM_lpage">2531</span></span><div class="citationLinks">[<a href="/doi/10.1021/jm201384j" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=55&publication_year=2012&pages=2481-2531&author=M.+J.+Sofiaauthor=W.+Changauthor=P.+A.+Furmanauthor=R.+T.+Mosleyauthor=B.+S.+Ross&title=Nucleoside%2C+nucleotide%2C+and+non-nucleoside+inhibitors+of+hepatitis+C+virus+NS5B+RNA-dependent+RNA-polymerase"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit9b&amp;dbid=16384&amp;doi=10.1021%2Fjm201384j&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm201384j%26sid%3Dliteratum%253Aachs%26aulast%3DSofia%26aufirst%3DM.%2BJ.%26aulast%3DChang%26aufirst%3DW.%26aulast%3DFurman%26aufirst%3DP.%2BA.%26aulast%3DMosley%26aufirst%3DR.%2BT.%26aulast%3DRoss%26aufirst%3DB.%2BS.%26atitle%3DNucleoside%252C%2520nucleotide%252C%2520and%2520non-nucleoside%2520inhibitors%2520of%2520hepatitis%2520C%2520virus%2520NS5B%2520RNA-dependent%2520RNA-polymerase%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2012%26volume%3D55%26spage%3D2481%26epage%3D2531" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit9c"><span><span class="NLM_label">(c) </span><span class="NLM_contrib-group">Li, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shi, S. T.</span><span> </span><span class="NLM_article-title">Non-nucleoside inhibitors of hepatitis C virus polymerase: current progress and future challenges</span> <span class="citation_source-journal">Future Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">2</span><span class="NLM_x">, </span> <span class="NLM_fpage">121</span><span class="NLM_x">–</span> <span class="NLM_lpage">141</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref9/cit9c&amp;dbid=16&amp;doi=10.1021%2Fjm4012643&amp;key=10.4155%2Ffmc.09.148" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref9/cit9c&amp;dbid=8&amp;doi=10.1021%2Fjm4012643&amp;key=21426049" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref9/cit9c&amp;dbid=32&amp;doi=10.1021%2Fjm4012643&amp;key=1%3ACAS%3A528%3ADC%252BC3cXosVWgug%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2&publication_year=2010&pages=121-141&author=H.+Liauthor=S.+T.+Shi&title=Non-nucleoside+inhibitors+of+hepatitis+C+virus+polymerase%3A+current+progress+and+future+challenges"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit9cR"><div class="casContent"><span class="casTitleNuber">9c</span><div class="casTitle"><span class="NLM_cas:atitle">Non-nucleoside inhibitors of hepatitis C virus polymerase: current progress and future challenges</span></div><div class="casAuthors">Li, Hui; Shi, Stephanie T.</div><div class="citationInfo"><span class="NLM_cas:title">Future Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">2</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">121-141</span>CODEN:
                <span class="NLM_cas:coden">FMCUA7</span>;
        ISSN:<span class="NLM_cas:issn">1756-8919</span>.
    
            (<span class="NLM_cas:orgname">Future Science Ltd.</span>)
        </div><div class="casAbstract">A review.  The current std. of care for hepatitis C virus (HCV) infection is a combination of PEGylated interferon and ribavirin, which offer limited efficacy and significant side effects.  Novel HCV-specific inhibitors, including those directed at the viral polymerase, have become the focus of HCV drug-discovery efforts in the past decade.  In addn. to the active site targeted by traditional nucleoside inhibitors, at least four different allosteric-binding sites have been reported for the HCV polymerase, which offer ample opportunities for small-mol. inhibitors.  In this review, we summarize the recent progress in the discovery of non-nucleoside HCV polymerase inhibitors with a focus on novel chem. matters, their clin. efficacy, safety and potential for combination therapy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqnYvEwqRM0-bVg90H21EOLACvtfcHk0lgE1kCfZK2zQg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXosVWgug%253D%253D&md5=311bcf9ff7adf740674c2d8333fb25c2</span></div><a href="/servlet/linkout?suffix=cit9c&amp;dbid=16384&amp;doi=10.4155%2Ffmc.09.148&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.4155%252Ffmc.09.148%26sid%3Dliteratum%253Aachs%26aulast%3DLi%26aufirst%3DH.%26aulast%3DShi%26aufirst%3DS.%2BT.%26atitle%3DNon-nucleoside%2520inhibitors%2520of%2520hepatitis%2520C%2520virus%2520polymerase%253A%2520current%2520progress%2520and%2520future%2520challenges%26jtitle%3DFuture%2520Med.%2520Chem.%26date%3D2010%26volume%3D2%26spage%3D121%26epage%3D141" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit9d"><span><span class="NLM_label">(d) </span><span class="NLM_contrib-group">Watkins, W. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ray, A. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chong, L. S.</span><span> </span><span class="NLM_article-title">HCV NS5B polymerase inhibitors</span> <span class="citation_source-journal">Curr. Opin. Drug Discovery Dev.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">13</span><span class="NLM_x">, </span> <span class="NLM_fpage">441</span><span class="NLM_x">–</span> <span class="NLM_lpage">465</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=2010&pages=441-465&author=W.+J.+Watkinsauthor=A.+S.+Rayauthor=L.+S.+Chong&title=HCV+NS5B+polymerase+inhibitors"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit9d&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DWatkins%26aufirst%3DW.%2BJ.%26aulast%3DRay%26aufirst%3DA.%2BS.%26aulast%3DChong%26aufirst%3DL.%2BS.%26atitle%3DHCV%2520NS5B%2520polymerase%2520inhibitors%26jtitle%3DCurr.%2520Opin.%2520Drug%2520Discovery%2520Dev.%26date%3D2010%26volume%3D13%26spage%3D441%26epage%3D465" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref10"><div class="reference"><strong class="refLabel"><a href="#ref10" class="rightTabRefNumLink">10</a></strong><div class="NLM_citation" id="rightTab-cit10a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Rong, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dahari, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ribeiro, R. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Perelson, A. S.</span><span> </span><span class="NLM_article-title">Rapid emergence of protease inhibitor resistance in hepatitis C virus</span> <span class="citation_source-journal">Sci. Transl. Med.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">2</span><span class="NLM_x">, </span> <span class="NLM_fpage">1</span><span class="NLM_x">–</span> <span class="NLM_lpage">9</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref10/cit10a&amp;dbid=16&amp;doi=10.1021%2Fjm4012643&amp;key=10.1126%2Fscitranslmed.3000544" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2&publication_year=2010&pages=1-9&author=L.+Rongauthor=H.+Dahariauthor=R.+M.+Ribeiroauthor=A.+S.+Perelson&title=Rapid+emergence+of+protease+inhibitor+resistance+in+hepatitis+C+virus"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit10a&amp;dbid=16384&amp;doi=10.1126%2Fscitranslmed.3000544&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1126%252Fscitranslmed.3000544%26sid%3Dliteratum%253Aachs%26aulast%3DRong%26aufirst%3DL.%26aulast%3DDahari%26aufirst%3DH.%26aulast%3DRibeiro%26aufirst%3DR.%2BM.%26aulast%3DPerelson%26aufirst%3DA.%2BS.%26atitle%3DRapid%2520emergence%2520of%2520protease%2520inhibitor%2520resistance%2520in%2520hepatitis%2520C%2520virus%26jtitle%3DSci.%2520Transl.%2520Med.%26date%3D2010%26volume%3D2%26spage%3D1%26epage%3D9" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit10b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Wang, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sun, J. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">O’Boyle, D. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nower, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Valera, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Roberts, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fridell, R. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gao, M.</span><span> </span><span class="NLM_article-title">Persistence of variants in hepatitis C virus-infected patients treated with the NS5A replication complex inhibitor daclatasvir</span> <span class="citation_source-journal">Antimicrob. Agents Chemother.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">57</span><span class="NLM_x"> (</span><span class="NLM_issue">5</span><span class="NLM_x">) </span> <span class="NLM_fpage">2054</span><span class="NLM_x">–</span> <span class="NLM_lpage">2065</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=57&publication_year=2013&pages=2054-2065&issue=5&author=C.+Wangauthor=J.+H.+Sunauthor=D.+R.+O%E2%80%99Boyleauthor=P.+Nowerauthor=L.+Valeraauthor=S.+Robertsauthor=R.+A.+Fridellauthor=M.+Gao&title=Persistence+of+variants+in+hepatitis+C+virus-infected+patients+treated+with+the+NS5A+replication+complex+inhibitor+daclatasvir"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit10b&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DWang%26aufirst%3DC.%26aulast%3DSun%26aufirst%3DJ.%2BH.%26aulast%3DO%25E2%2580%2599Boyle%26aufirst%3DD.%2BR.%26aulast%3DNower%26aufirst%3DP.%26aulast%3DValera%26aufirst%3DL.%26aulast%3DRoberts%26aufirst%3DS.%26aulast%3DFridell%26aufirst%3DR.%2BA.%26aulast%3DGao%26aufirst%3DM.%26atitle%3DPersistence%2520of%2520variants%2520in%2520hepatitis%2520C%2520virus-infected%2520patients%2520treated%2520with%2520the%2520NS5A%2520replication%2520complex%2520inhibitor%2520daclatasvir%26jtitle%3DAntimicrob.%2520Agents%2520Chemother.%26date%3D2013%26volume%3D57%26issue%3D5%26spage%3D2054%26epage%3D2065" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit10c"><span><span class="NLM_label">(c) </span><span class="NLM_contrib-group">Delang, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vliegen, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Leyssen, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Neyts, J.</span><span> </span><span class="NLM_article-title">In vitro selection and characterization of HCV replicons resistent to multiple non-nucleoside polymerase inhibitors</span> <span class="citation_source-journal">J. Hepatol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">56</span><span class="NLM_x"> (</span><span class="NLM_issue">1</span><span class="NLM_x">) </span> <span class="NLM_fpage">41</span><span class="NLM_x">–</span> <span class="NLM_lpage">48</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref10/cit10c&amp;dbid=16&amp;doi=10.1021%2Fjm4012643&amp;key=10.1016%2Fj.jhep.2011.04.016" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref10/cit10c&amp;dbid=8&amp;doi=10.1021%2Fjm4012643&amp;key=21703175" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref10/cit10c&amp;dbid=32&amp;doi=10.1021%2Fjm4012643&amp;key=1%3ACAS%3A528%3ADC%252BC3MXhs1GhsbnI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=56&publication_year=2012&pages=41-48&issue=1&author=L.+Delangauthor=I.+Vliegenauthor=P.+Leyssenauthor=J.+Neyts&title=In+vitro+selection+and+characterization+of+HCV+replicons+resistent+to+multiple+non-nucleoside+polymerase+inhibitors"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit10cR"><div class="casContent"><span class="casTitleNuber">10c</span><div class="casTitle"><span class="NLM_cas:atitle">In vitro selection and characterization of HCV replicons resistant to multiple non-nucleoside polymerase inhibitors</span></div><div class="casAuthors">Delang, Leen; Vliegen, Inge; Leyssen, Pieter; Neyts, Johan</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Hepatology</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">56</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">41-48</span>CODEN:
                <span class="NLM_cas:coden">JOHEEC</span>;
        ISSN:<span class="NLM_cas:issn">0168-8278</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Background & Aims: To delay or prevent the selection of HCV drug-resistant variants, combination therapy will be needed.  Our aim was to det. the antiviral efficacy of various combinations of non-nucleoside polymerase inhibitors (NNI) (that have a different allosteric binding site) and the barrier towards resistance development of such combinations.  Methods: Short-term antiviral combination assays were performed in a checkerboard format.  Resistance selection expts. employing HCV replicons were performed using two different protocols: (i) a short-term treatment with fixed concns. and (ii) a long-term treatment with increasing concns.  Results: All pair-wise combinations of NNI resulted in an additive antiviral effect in short-term antiviral assays.  Combination treatment of two NNIs markedly reduced or even prevented the emergence of double resistant colonies.  However, double and even triple NNI-resistant variants emerged readily when relatively low starting concns. were used in a long-term selection protocol.  Genotyping confirmed the presence of the previously published resistance mutations.  For some NNI, different signature mutations appeared depending on the other NNI in the particular combination.  Remarkably, variants that were selected to be resistant to three different classes of NNIs [a thiophene carboxylic acid (TCA), a benzimidazole (JT-16), and a benzofuran (HCV-796)] proved resistant to yet a fourth class of NNIs (benzothiadiazines).  Conclusions: Double and even triple NNI-resistant HCV replicons can be readily selected with a stepwise resistance selection protocol.  Depending on the particular combination, different signature mutations may arise for some NNI.  Resistance to three classes of NNI resulted in resistance to yet a fourth class.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrg4x1suoQ-d7Vg90H21EOLACvtfcHk0lgE1kCfZK2zQg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXhs1GhsbnI&md5=719159d02fe3fc06080509e43a2ad13d</span></div><a href="/servlet/linkout?suffix=cit10c&amp;dbid=16384&amp;doi=10.1016%2Fj.jhep.2011.04.016&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.jhep.2011.04.016%26sid%3Dliteratum%253Aachs%26aulast%3DDelang%26aufirst%3DL.%26aulast%3DVliegen%26aufirst%3DI.%26aulast%3DLeyssen%26aufirst%3DP.%26aulast%3DNeyts%26aufirst%3DJ.%26atitle%3DIn%2520vitro%2520selection%2520and%2520characterization%2520of%2520HCV%2520replicons%2520resistent%2520to%2520multiple%2520non-nucleoside%2520polymerase%2520inhibitors%26jtitle%3DJ.%2520Hepatol.%26date%3D2012%26volume%3D56%26issue%3D1%26spage%3D41%26epage%3D48" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref11"><div class="reference"><strong class="refLabel"><a href="#ref11" class="rightTabRefNumLink">11</a></strong><div class="NLM_citation" id="rightTab-cit11"><span><span class="NLM_contrib-group">Gouttenoire, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Roingeard, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Penin, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Moradpour, D.</span><span> </span><span class="NLM_article-title">Hepatitis C virus nonstructural protein 4B: a journey into unexplored territory</span> <span class="citation_source-journal">Rev. Med. Virol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">20</span><span class="NLM_x"> (</span><span class="NLM_issue">2</span><span class="NLM_x">) </span> <span class="NLM_fpage">117</span><span class="NLM_x">–</span> <span class="NLM_lpage">129</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=16&amp;doi=10.1021%2Fjm4012643&amp;key=10.1002%2Frmv.640" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=8&amp;doi=10.1021%2Fjm4012643&amp;key=20069613" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=32&amp;doi=10.1021%2Fjm4012643&amp;key=1%3ACAS%3A528%3ADC%252BC3cXkslSksrc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=20&publication_year=2010&pages=117-129&issue=2&author=J.+Gouttenoireauthor=P.+Roingeardauthor=F.+Peninauthor=D.+Moradpour&title=Hepatitis+C+virus+nonstructural+protein+4B%3A+a+journey+into+unexplored+territory"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit11R"><div class="casContent"><span class="casTitleNuber">11</span><div class="casTitle"><span class="NLM_cas:atitle">Hepatitis C virus nonstructural protein 4B: a journey into unexplored territory</span></div><div class="casAuthors">Gouttenoire, Jerome; Penin, Francois; Moradpour, Darius</div><div class="citationInfo"><span class="NLM_cas:title">Reviews in Medical Virology</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">20</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">117-129</span>CODEN:
                <span class="NLM_cas:coden">RMVIEW</span>;
        ISSN:<span class="NLM_cas:issn">1052-9276</span>.
    
            (<span class="NLM_cas:orgname">John Wiley & Sons Ltd.</span>)
        </div><div class="casAbstract">A review.  Hepatitis C virus (HCV) is a pos.-strand RNA virus that replicates its genome in a membrane-assocd. replication complex.  Nonstructural protein 4B (NS4B) induces the specific membrane alteration, designated as membranous web (MW), that harbours this complex.  HCV NS4B is an integral membrane protein predicted to comprise four transmembrane segments in its central part.  The N-terminal part comprises two amphipathic α-helixes of which the second has the potential to traverse the membrane bilayer, likely upon oligomerisation.  The C-terminal part comprises a predicted highly conserved α-helix, a membrane-assocd. amphipathic α-helix and two reported palmitoylation sites.  NS4B interacts with other viral nonstructural proteins and has been reported to bind viral RNA.  In addn., it was found to harbor an NTPase activity.  Finally, NS4B has recently been found to have a role in viral assembly.  Much work needs to be done with respect to further dissecting these multiple functions as well as providing a refined membrane topol. and complete structure of NS4B.  Progress in this direction should yield important insights into the functional architecture of the HCV replication complex and may reveal new opportunities for antiviral intervention against a leading cause of chronic hepatitis, liver cirrhosis and hepatocellular carcinoma worldwide.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqnz69FSBeMp7Vg90H21EOLACvtfcHk0lgfXks9KJwrdg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXkslSksrc%253D&md5=200464067fc0ccdf6782482a7c13e9f2</span></div><a href="/servlet/linkout?suffix=cit11&amp;dbid=16384&amp;doi=10.1002%2Frmv.640&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Frmv.640%26sid%3Dliteratum%253Aachs%26aulast%3DGouttenoire%26aufirst%3DJ.%26aulast%3DRoingeard%26aufirst%3DP.%26aulast%3DPenin%26aufirst%3DF.%26aulast%3DMoradpour%26aufirst%3DD.%26atitle%3DHepatitis%2520C%2520virus%2520nonstructural%2520protein%25204B%253A%2520a%2520journey%2520into%2520unexplored%2520territory%26jtitle%3DRev.%2520Med.%2520Virol.%26date%3D2010%26volume%3D20%26issue%3D2%26spage%3D117%26epage%3D129" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref12"><div class="reference"><strong class="refLabel"><a href="#ref12" class="rightTabRefNumLink">12</a></strong><div class="NLM_citation" id="rightTab-cit12a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Meanwell, N. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Belema, M.</span><span> </span><span class="NLM_article-title">Hepatitis C virus—Progress towards inhibiting the nonenzymatic viral proteins</span> <span class="citation_source-journal">Annu. Rep. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">46</span><span class="NLM_x">, </span> <span class="NLM_fpage">268</span><span class="NLM_x">–</span> <span class="NLM_lpage">270</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=46&publication_year=2011&pages=268-270&author=N.+A.+Meanwellauthor=M.+Belema&title=Hepatitis+C+virus%E2%80%94Progress+towards+inhibiting+the+nonenzymatic+viral+proteins"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit12a&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DMeanwell%26aufirst%3DN.%2BA.%26aulast%3DBelema%26aufirst%3DM.%26atitle%3DHepatitis%2520C%2520virus%25E2%2580%2594Progress%2520towards%2520inhibiting%2520the%2520nonenzymatic%2520viral%2520proteins%26jtitle%3DAnnu.%2520Rep.%2520Med.%2520Chem.%26date%3D2011%26volume%3D46%26spage%3D268%26epage%3D270" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit12b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Brysona, P. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Choa, N. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Einava, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Leea, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Taid, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bechteld, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sivarajad, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Robertsd, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schmitzd, U.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Glenn, J. S.</span><span> </span><span class="NLM_article-title">A small molecule inhibits HCV replication and alters NS4B’s subcellular distribution</span> <span class="citation_source-journal">Antiviral Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">87</span><span class="NLM_x">, </span> <span class="NLM_fpage">1</span><span class="NLM_x">–</span> <span class="NLM_lpage">8</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=87&publication_year=2010&pages=1-8&author=P.+D.+Brysonaauthor=N.+J.+Choaauthor=S.+Einavaauthor=C.+Leeaauthor=V.+Taidauthor=J.+Bechteldauthor=M.+Sivarajadauthor=C.+Robertsdauthor=U.+Schmitzdauthor=J.+S.+Glenn&title=A+small+molecule+inhibits+HCV+replication+and+alters+NS4B%E2%80%99s+subcellular+distribution"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit12b&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DBrysona%26aufirst%3DP.%2BD.%26aulast%3DChoa%26aufirst%3DN.%2BJ.%26aulast%3DEinava%26aufirst%3DS.%26aulast%3DLeea%26aufirst%3DC.%26aulast%3DTaid%26aufirst%3DV.%26aulast%3DBechteld%26aufirst%3DJ.%26aulast%3DSivarajad%26aufirst%3DM.%26aulast%3DRobertsd%26aufirst%3DC.%26aulast%3DSchmitzd%26aufirst%3DU.%26aulast%3DGlenn%26aufirst%3DJ.%2BS.%26atitle%3DA%2520small%2520molecule%2520inhibits%2520HCV%2520replication%2520and%2520alters%2520NS4B%25E2%2580%2599s%2520subcellular%2520distribution%26jtitle%3DAntiviral%2520Res.%26date%3D2010%26volume%3D87%26spage%3D1%26epage%3D8" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit12c"><span><span class="NLM_label">(c) </span><span class="NLM_contrib-group">Shotwell, J. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Baskaran, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chong, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Creech, K. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Crosby, R. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dicks, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fang, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Garrido, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mathis, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Maung, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Parks, D. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pouliot, J. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Price, D. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rai, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Seal, J. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schmitz, U.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tai, V. W. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Thomson, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Xie, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Xiong, J. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Peat, A. J.</span><span> </span><span class="NLM_article-title">Imidazo[1,2-<i>a</i>]pyridines that directly interact with hepatitis C NS4B: initial preclinical characterization</span> <span class="citation_source-journal">ACS Med. Chem. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">3</span><span class="NLM_x">, </span> <span class="NLM_fpage">565</span><span class="NLM_x">–</span> <span class="NLM_lpage">569</span></span><div class="citationLinks">[<a href="/doi/10.1021/ml300090x" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=3&publication_year=2012&pages=565-569&author=J.+B.+Shotwellauthor=S.+Baskaranauthor=P.+Chongauthor=K.+L.+Creechauthor=R.+M.+Crosbyauthor=H.+Dicksauthor=J.+Fangauthor=D.+Garridoauthor=A.+Mathisauthor=J.+Maungauthor=D.+J.+Parksauthor=J.+J.+Pouliotauthor=D.+J.+Priceauthor=R.+Raiauthor=J.+W.+Sealauthor=U.+Schmitzauthor=V.+W.+F.+Taiauthor=M.+Thomsonauthor=M.+Xieauthor=J.+J.+Xiongauthor=A.+J.+Peat&title=Imidazo%5B1%2C2-a%5Dpyridines+that+directly+interact+with+hepatitis+C+NS4B%3A+initial+preclinical+characterization"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit12c&amp;dbid=16384&amp;doi=10.1021%2Fml300090x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fml300090x%26sid%3Dliteratum%253Aachs%26aulast%3DShotwell%26aufirst%3DJ.%2BB.%26aulast%3DBaskaran%26aufirst%3DS.%26aulast%3DChong%26aufirst%3DP.%26aulast%3DCreech%26aufirst%3DK.%2BL.%26aulast%3DCrosby%26aufirst%3DR.%2BM.%26aulast%3DDicks%26aufirst%3DH.%26aulast%3DFang%26aufirst%3DJ.%26aulast%3DGarrido%26aufirst%3DD.%26aulast%3DMathis%26aufirst%3DA.%26aulast%3DMaung%26aufirst%3DJ.%26aulast%3DParks%26aufirst%3DD.%2BJ.%26aulast%3DPouliot%26aufirst%3DJ.%2BJ.%26aulast%3DPrice%26aufirst%3DD.%2BJ.%26aulast%3DRai%26aufirst%3DR.%26aulast%3DSeal%26aufirst%3DJ.%2BW.%26aulast%3DSchmitz%26aufirst%3DU.%26aulast%3DTai%26aufirst%3DV.%2BW.%2BF.%26aulast%3DThomson%26aufirst%3DM.%26aulast%3DXie%26aufirst%3DM.%26aulast%3DXiong%26aufirst%3DJ.%2BJ.%26aulast%3DPeat%26aufirst%3DA.%2BJ.%26atitle%3DImidazo%255B1%252C2-a%255Dpyridines%2520that%2520directly%2520interact%2520with%2520hepatitis%2520C%2520NS4B%253A%2520initial%2520preclinical%2520characterization%26jtitle%3DACS%2520Med.%2520Chem.%2520Lett.%26date%3D2012%26volume%3D3%26spage%3D565%26epage%3D569" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit12d"><span><span class="NLM_label">(d) </span><span class="NLM_contrib-group">Miller, J. F.; Chong, P. Y.; Shotwell, J. B.; Catalano, J. G.; Tai, V. W.; Fang, J.; Banka, A.; Roberts, C. D.; Youngman, M.; Zhang, H.; Xiong, Z.; Mathis, A.; Pouliot, J. J.; Hamatake, R. K.; Price, D. J.; Seal, J. W.; Stroup, L. L.; Creech, K. L.; Carballo, L. H.; Todd, D.; Spaltenstein, A.; Furst, S.; Hong, Z.; Peat, A. J.</span><span> </span><span class="NLM_article-title">Hepatitis C replication inhibitors that target the viral NS4B protein</span>.  <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span><span class="refDoi"> DOI: 10.1021/jm400125h</span> .</span><div class="citationLinks">[<a href="/doi/10.1021/jm400125h" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2013&author=J.+F.+Miller&author=P.+Y.+Chong&author=J.+B.+Shotwell&author=J.+G.+Catalano&author=V.+W.+Tai&author=J.+Fang&author=A.+Banka&author=C.+D.+Roberts&author=M.+Youngman&author=H.+Zhang&author=Z.+Xiong&author=A.+Mathis&author=J.+J.+Pouliot&author=R.+K.+Hamatake&author=D.+J.+Price&author=J.+W.+Seal&author=L.+L.+Stroup&author=K.+L.+Creech&author=L.+H.+Carballo&author=D.+Todd&author=A.+Spaltenstein&author=S.+Furst&author=Z.+Hong&author=A.+J.+Peat&title=Hepatitis+C+replication+inhibitors+that+target+the+viral+NS4B+protein&doi=10.1021%2Fjm400125h"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit12d&amp;dbid=16384&amp;doi=10.1021%2Fjm400125h&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm400125h%26sid%3Dliteratum%253Aachs%26aulast%3DMiller%26aufirst%3DJ.%2BF.%26atitle%3DHepatitis%2520C%2520replication%2520inhibitors%2520that%2520target%2520the%2520viral%2520NS4B%2520protein%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2013%26doi%3D10.1021%2Fjm400125h" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit12e"><span><span class="NLM_label">(e) </span><span class="NLM_contrib-group">Gu, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Graci, J. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lahser, F. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Breslin, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jung, S. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Crona, J. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McMonagle, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Xia, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liu, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Karp, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhu, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Huang, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nomeir, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Weetall, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Almstead, N. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Peltz, S. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tong, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ralston, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Colacino, J. M.</span><span> </span><span class="NLM_article-title">Identification of PTC725: an orally bioavailable small molecule that selectively targets the hepatitis C virus NS4B protein</span> <span class="citation_source-journal">Antimicrob. Agents Chemother.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">57</span><span class="NLM_x"> (</span><span class="NLM_issue">5</span><span class="NLM_x">) </span> <span class="NLM_fpage">2054</span><span class="NLM_x">–</span> <span class="NLM_lpage">2065</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=57&publication_year=2013&pages=2054-2065&issue=5&author=Z.+Guauthor=J.+D.+Graciauthor=F.+C.+Lahserauthor=J.+Breslinauthor=S.+P.+Jungauthor=J.+H.+Cronaauthor=P.+McMonagleauthor=E.+Xiaauthor=S.+Liuauthor=G.+Karpauthor=J.+Zhuauthor=S.+Huangauthor=A.+Nomeirauthor=M.+Weetallauthor=N.+G.+Almsteadauthor=S.+W.+Peltzauthor=X.+Tongauthor=R.+Ralstonauthor=J.+M.+Colacino&title=Identification+of+PTC725%3A+an+orally+bioavailable+small+molecule+that+selectively+targets+the+hepatitis+C+virus+NS4B+protein"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit12e&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DGu%26aufirst%3DZ.%26aulast%3DGraci%26aufirst%3DJ.%2BD.%26aulast%3DLahser%26aufirst%3DF.%2BC.%26aulast%3DBreslin%26aufirst%3DJ.%26aulast%3DJung%26aufirst%3DS.%2BP.%26aulast%3DCrona%26aufirst%3DJ.%2BH.%26aulast%3DMcMonagle%26aufirst%3DP.%26aulast%3DXia%26aufirst%3DE.%26aulast%3DLiu%26aufirst%3DS.%26aulast%3DKarp%26aufirst%3DG.%26aulast%3DZhu%26aufirst%3DJ.%26aulast%3DHuang%26aufirst%3DS.%26aulast%3DNomeir%26aufirst%3DA.%26aulast%3DWeetall%26aufirst%3DM.%26aulast%3DAlmstead%26aufirst%3DN.%2BG.%26aulast%3DPeltz%26aufirst%3DS.%2BW.%26aulast%3DTong%26aufirst%3DX.%26aulast%3DRalston%26aufirst%3DR.%26aulast%3DColacino%26aufirst%3DJ.%2BM.%26atitle%3DIdentification%2520of%2520PTC725%253A%2520an%2520orally%2520bioavailable%2520small%2520molecule%2520that%2520selectively%2520targets%2520the%2520hepatitis%2520C%2520virus%2520NS4B%2520protein%26jtitle%3DAntimicrob.%2520Agents%2520Chemother.%26date%3D2013%26volume%3D57%26issue%3D5%26spage%3D2054%26epage%3D2065" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit12f"><span><span class="NLM_label">(f) </span><span class="NLM_contrib-group">Zhang, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Turpoff, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ren, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Takasugi, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Morrill, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhu, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lennox, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Paget, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liu, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Almstead, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">George Njoroge, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gu, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Komatsu, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Clausen, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Espiritu, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Graci, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Colacino, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lahser, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Risher, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Weetall, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nomeir, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Karp, G. M.</span><span> </span><span class="NLM_article-title">Discovery of novel HCV inhibitors: synthesis and biological activity of 6-(indol-2-yl)pyridine-3-sulfonamides targetting hepatitis C virus NS4B</span> <span class="citation_source-journal">Bioorg. Med. Chem. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">23</span><span class="NLM_x"> (</span><span class="NLM_issue">13</span><span class="NLM_x">) </span> <span class="NLM_fpage">3947</span><span class="NLM_x">–</span> <span class="NLM_lpage">3953</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=23&publication_year=2013&pages=3947-3953&issue=13&author=X.+Zhangauthor=N.+Zhangauthor=G.+Chenauthor=A.+Turpoffauthor=H.+Renauthor=J.+Takasugiauthor=C.+Morrillauthor=J.+Zhuauthor=C.+Liauthor=W.+Lennoxauthor=S.+Pagetauthor=Y.+Liuauthor=N.+Almsteadauthor=F.+George+Njorogeauthor=Z.+Guauthor=T.+Komatsuauthor=V.+Clausenauthor=C.+Espirituauthor=J.+Graciauthor=J.+Colacinoauthor=F.+Lahserauthor=N.+Risherauthor=M.+Weetallauthor=A.+Nomeirauthor=G.+M.+Karp&title=Discovery+of+novel+HCV+inhibitors%3A+synthesis+and+biological+activity+of+6-%28indol-2-yl%29pyridine-3-sulfonamides+targetting+hepatitis+C+virus+NS4B"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit12f&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DZhang%26aufirst%3DX.%26aulast%3DZhang%26aufirst%3DN.%26aulast%3DChen%26aufirst%3DG.%26aulast%3DTurpoff%26aufirst%3DA.%26aulast%3DRen%26aufirst%3DH.%26aulast%3DTakasugi%26aufirst%3DJ.%26aulast%3DMorrill%26aufirst%3DC.%26aulast%3DZhu%26aufirst%3DJ.%26aulast%3DLi%26aufirst%3DC.%26aulast%3DLennox%26aufirst%3DW.%26aulast%3DPaget%26aufirst%3DS.%26aulast%3DLiu%26aufirst%3DY.%26aulast%3DAlmstead%26aufirst%3DN.%26aulast%3DGeorge%2BNjoroge%26aufirst%3DF.%26aulast%3DGu%26aufirst%3DZ.%26aulast%3DKomatsu%26aufirst%3DT.%26aulast%3DClausen%26aufirst%3DV.%26aulast%3DEspiritu%26aufirst%3DC.%26aulast%3DGraci%26aufirst%3DJ.%26aulast%3DColacino%26aufirst%3DJ.%26aulast%3DLahser%26aufirst%3DF.%26aulast%3DRisher%26aufirst%3DN.%26aulast%3DWeetall%26aufirst%3DM.%26aulast%3DNomeir%26aufirst%3DA.%26aulast%3DKarp%26aufirst%3DG.%2BM.%26atitle%3DDiscovery%2520of%2520novel%2520HCV%2520inhibitors%253A%2520synthesis%2520and%2520biological%2520activity%2520of%25206-%2528indol-2-yl%2529pyridine-3-sulfonamides%2520targetting%2520hepatitis%2520C%2520virus%2520NS4B%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2013%26volume%3D23%26issue%3D13%26spage%3D3947%26epage%3D3953" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit12g"><span><span class="NLM_label">(g) </span><span class="NLM_contrib-group">Chen, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ren, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Turpoff, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Arefolov, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wilde, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Takasugi, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Khan, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Almstead, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gu, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Komatsu, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Freund, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Breslin, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Colacino, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hedrick, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Weetall, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Karp, G. M.</span><span> </span><span class="NLM_article-title">Discovery of of <i>N</i>-(4<sup>1</sup>-(indol-2-yl)phenyl)-sulfonamides as novel inhibitors of HCV replication</span> <span class="citation_source-journal">Bioorg. Med. Chem. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">23</span><span class="NLM_x"> (</span><span class="NLM_issue">13</span><span class="NLM_x">) </span> <span class="NLM_fpage">3942</span><span class="NLM_x">–</span> <span class="NLM_lpage">3946</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=23&publication_year=2013&pages=3942-3946&issue=13&author=G.+Chenauthor=H.+Renauthor=A.+Turpoffauthor=A.+Arefolovauthor=R.+Wildeauthor=J.+Takasugiauthor=A.+Khanauthor=N.+Almsteadauthor=Z.+Guauthor=T.+Komatsuauthor=C.+Freundauthor=J.+Breslinauthor=J.+Colacinoauthor=J.+Hedrickauthor=M.+Weetallauthor=G.+M.+Karp&title=Discovery+of+of+N-%2841-%28indol-2-yl%29phenyl%29-sulfonamides+as+novel+inhibitors+of+HCV+replication"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit12g&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DChen%26aufirst%3DG.%26aulast%3DRen%26aufirst%3DH.%26aulast%3DTurpoff%26aufirst%3DA.%26aulast%3DArefolov%26aufirst%3DA.%26aulast%3DWilde%26aufirst%3DR.%26aulast%3DTakasugi%26aufirst%3DJ.%26aulast%3DKhan%26aufirst%3DA.%26aulast%3DAlmstead%26aufirst%3DN.%26aulast%3DGu%26aufirst%3DZ.%26aulast%3DKomatsu%26aufirst%3DT.%26aulast%3DFreund%26aufirst%3DC.%26aulast%3DBreslin%26aufirst%3DJ.%26aulast%3DColacino%26aufirst%3DJ.%26aulast%3DHedrick%26aufirst%3DJ.%26aulast%3DWeetall%26aufirst%3DM.%26aulast%3DKarp%26aufirst%3DG.%2BM.%26atitle%3DDiscovery%2520of%2520of%2520N-%252841-%2528indol-2-yl%2529phenyl%2529-sulfonamides%2520as%2520novel%2520inhibitors%2520of%2520HCV%2520replication%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2013%26volume%3D23%26issue%3D13%26spage%3D3942%26epage%3D3946" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref13"><div class="reference"><strong class="refLabel"><a href="#ref13" class="rightTabRefNumLink">13</a></strong><div class="NLM_citation" id="rightTab-cit13"><span><span class="NLM_contrib-group">Masaki, V. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ohta, M.</span><span> </span><span class="NLM_article-title">Synthese von 3,6-disubstituierten 2-oxopiperazinen</span> <span class="citation_source-journal">Bull. Chem. Soc. Jpn.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1963</span><span class="NLM_x">, </span> <span class="NLM_volume">36</span><span class="NLM_x"> (</span><span class="NLM_issue">8</span><span class="NLM_x">) </span> <span class="NLM_fpage">922</span><span class="NLM_x">–</span> <span class="NLM_lpage">925</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=36&publication_year=1963&pages=922-925&issue=8&author=V.+M.+Masakiauthor=M.+Ohta&title=Synthese+von+3%2C6-disubstituierten+2-oxopiperazinen"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit13&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DMasaki%26aufirst%3DV.%2BM.%26aulast%3DOhta%26aufirst%3DM.%26atitle%3DSynthese%2520von%25203%252C6-disubstituierten%25202-oxopiperazinen%26jtitle%3DBull.%2520Chem.%2520Soc.%2520Jpn.%26date%3D1963%26volume%3D36%26issue%3D8%26spage%3D922%26epage%3D925" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref14"><div class="reference"><strong class="refLabel"><a href="#ref14" class="rightTabRefNumLink">14</a></strong><div class="NLM_citation" id="rightTab-cit14a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Petasis, N. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Goodman, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zavialov, T.</span><span> </span><span class="NLM_article-title">A new synthesis of α-arylglycines from aryl boronic acids</span> <span class="citation_source-journal">Tetrahedron</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1997</span><span class="NLM_x">, </span> <span class="NLM_volume">53</span><span class="NLM_x"> (</span><span class="NLM_issue">48</span><span class="NLM_x">) </span> <span class="NLM_fpage">16463</span><span class="NLM_x">–</span> <span class="NLM_lpage">16470</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=53&publication_year=1997&pages=16463-16470&issue=48&author=N.+A.+Petasisauthor=A.+Goodmanauthor=T.+Zavialov&title=A+new+synthesis+of+%CE%B1-arylglycines+from+aryl+boronic+acids"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit14a&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DPetasis%26aufirst%3DN.%2BA.%26aulast%3DGoodman%26aufirst%3DA.%26aulast%3DZavialov%26aufirst%3DT.%26atitle%3DA%2520new%2520synthesis%2520of%2520%25CE%25B1-arylglycines%2520from%2520aryl%2520boronic%2520acids%26jtitle%3DTetrahedron%26date%3D1997%26volume%3D53%26issue%3D48%26spage%3D16463%26epage%3D16470" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit14b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Haurena, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Le Gall, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sengmany, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Martens, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Troupel, M.</span><span> </span><span class="NLM_article-title">A straightforward three-component synthesis of α-amino esters containing a phenylalanine or a phenylglycine scaffold</span> <span class="citation_source-journal">J. Org. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">75</span><span class="NLM_x"> (</span><span class="NLM_issue">8</span><span class="NLM_x">) </span> <span class="NLM_fpage">2645</span><span class="NLM_x">–</span> <span class="NLM_lpage">2650</span></span><div class="citationLinks">[<a href="/doi/10.1021/jo1002328" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=75&publication_year=2010&pages=2645-2650&issue=8&author=C.+Haurenaauthor=E.+Le+Gallauthor=S.+Sengmanyauthor=T.+Martensauthor=M.+Troupel&title=A+straightforward+three-component+synthesis+of+%CE%B1-amino+esters+containing+a+phenylalanine+or+a+phenylglycine+scaffold"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit14b&amp;dbid=16384&amp;doi=10.1021%2Fjo1002328&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjo1002328%26sid%3Dliteratum%253Aachs%26aulast%3DHaurena%26aufirst%3DC.%26aulast%3DLe%2BGall%26aufirst%3DE.%26aulast%3DSengmany%26aufirst%3DS.%26aulast%3DMartens%26aufirst%3DT.%26aulast%3DTroupel%26aufirst%3DM.%26atitle%3DA%2520straightforward%2520three-component%2520synthesis%2520of%2520%25CE%25B1-amino%2520esters%2520containing%2520a%2520phenylalanine%2520or%2520a%2520phenylglycine%2520scaffold%26jtitle%3DJ.%2520Org.%2520Chem.%26date%3D2010%26volume%3D75%26issue%3D8%26spage%3D2645%26epage%3D2650" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref15"><div class="reference"><strong class="refLabel"><a href="#ref15" class="rightTabRefNumLink">15</a></strong><div class="NLM_citation" id="rightTab-cit15"><span><span class="NLM_contrib-group">Sofia, M. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bao, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chang, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Du, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nagarathnam, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rachakonda, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Reddy, P. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ross, B. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, H.-R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bansal, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Espiritu, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Keilman, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lam, A. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Steuer, H. M. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Niu, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Otto, M. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Furman, P. A.</span><span> </span><span class="NLM_article-title">Discovery of a β-<span class="smallcaps smallerCapital">d</span>-2<sup>1</sup>-deoxy-2<sup>1</sup>-α-fluoro-20-β-<i>C</i>-methyl-uridine nucleotide prodrug (PSI-7977) for the treatment of hepatitis C virus</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">53</span><span class="NLM_x">, </span> <span class="NLM_fpage">7202</span><span class="NLM_x">–</span> <span class="NLM_lpage">7218</span></span><div class="citationLinks">[<a href="/doi/10.1021/jm100863x" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=53&publication_year=2010&pages=7202-7218&author=M.+J.+Sofiaauthor=D.+Baoauthor=W.+Changauthor=J.+Duauthor=D.+Nagarathnamauthor=S.+Rachakondaauthor=P.+G.+Reddyauthor=B.+S.+Rossauthor=P.+Wangauthor=H.-R.+Zhangauthor=S.+Bansalauthor=C.+Espirituauthor=M.+Keilmanauthor=A.+M.+Lamauthor=H.+M.+M.+Steuerauthor=C.+Niuauthor=M.+J.+Ottoauthor=P.+A.+Furman&title=Discovery+of+a+%CE%B2-d-21-deoxy-21-%CE%B1-fluoro-20-%CE%B2-C-methyl-uridine+nucleotide+prodrug+%28PSI-7977%29+for+the+treatment+of+hepatitis+C+virus"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit15&amp;dbid=16384&amp;doi=10.1021%2Fjm100863x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm100863x%26sid%3Dliteratum%253Aachs%26aulast%3DSofia%26aufirst%3DM.%2BJ.%26aulast%3DBao%26aufirst%3DD.%26aulast%3DChang%26aufirst%3DW.%26aulast%3DDu%26aufirst%3DJ.%26aulast%3DNagarathnam%26aufirst%3DD.%26aulast%3DRachakonda%26aufirst%3DS.%26aulast%3DReddy%26aufirst%3DP.%2BG.%26aulast%3DRoss%26aufirst%3DB.%2BS.%26aulast%3DWang%26aufirst%3DP.%26aulast%3DZhang%26aufirst%3DH.-R.%26aulast%3DBansal%26aufirst%3DS.%26aulast%3DEspiritu%26aufirst%3DC.%26aulast%3DKeilman%26aufirst%3DM.%26aulast%3DLam%26aufirst%3DA.%2BM.%26aulast%3DSteuer%26aufirst%3DH.%2BM.%2BM.%26aulast%3DNiu%26aufirst%3DC.%26aulast%3DOtto%26aufirst%3DM.%2BJ.%26aulast%3DFurman%26aufirst%3DP.%2BA.%26atitle%3DDiscovery%2520of%2520a%2520%25CE%25B2-d-21-deoxy-21-%25CE%25B1-fluoro-20-%25CE%25B2-C-methyl-uridine%2520nucleotide%2520prodrug%2520%2528PSI-7977%2529%2520for%2520the%2520treatment%2520of%2520hepatitis%2520C%2520virus%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2010%26volume%3D53%26spage%3D7202%26epage%3D7218" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref16"><div class="reference"><strong class="refLabel"><a href="#ref16" class="rightTabRefNumLink">16</a></strong><div class="NLM_citation" id="rightTab-cit16a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Sofia, M. J.; Kakarla, R.; Liu, J.; Naduthambi, D.; Mosley, R.; Steuer, H. M.</span><span> </span><span class="NLM_article-title">Preparation of piperazine derivatives and their uses to treat viral infections, including hepatitis C</span>. U.S. Patent US20120202794A1, <span class="NLM_month">September</span><span class="NLM_day">8</span>,<span class="NLM_x"> </span><span class="NLM_year">2012</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2012&author=M.+J.+Sofia&author=R.+Kakarla&author=J.+Liu&author=D.+Naduthambi&author=R.+Mosley&author=H.+M.+Steuer&title=Preparation+of+piperazine+derivatives+and+their+uses+to+treat+viral+infections%2C+including+hepatitis+C"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit16a&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DSofia%26aufirst%3DM.%2BJ.%26atitle%3DPreparation%2520of%2520piperazine%2520derivatives%2520and%2520their%2520uses%2520to%2520treat%2520viral%2520infections%252C%2520including%2520hepatitis%2520C%26date%3D2012" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit16b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Sofia, M. J.; Kakarla, R.; Liu, J.; Naduthambi, D.; Mosley, R.; Steuer, H. M.</span><span> </span><span class="NLM_article-title">Preparation of pyrazine and imidazolidine derivatives and their uses to treat viral infections, including hepatitis C</span>. WO 2012103113A1, <span class="NLM_month">February</span><span class="NLM_day">8</span>,<span class="NLM_x"> </span><span class="NLM_year">2012</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2012&author=M.+J.+Sofia&author=R.+Kakarla&author=J.+Liu&author=D.+Naduthambi&author=R.+Mosley&author=H.+M.+Steuer&title=Preparation+of+pyrazine+and+imidazolidine+derivatives+and+their+uses+to+treat+viral+infections%2C+including+hepatitis+C"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit16b&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DSofia%26aufirst%3DM.%2BJ.%26atitle%3DPreparation%2520of%2520pyrazine%2520and%2520imidazolidine%2520derivatives%2520and%2520their%2520uses%2520to%2520treat%2520viral%2520infections%252C%2520including%2520hepatitis%2520C%26date%3D2012" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref17"><div class="reference"><strong class="refLabel"><a href="#ref17" class="rightTabRefNumLink">17</a></strong><div class="note"><p class="first last">HLM of compound <b>95</b> is 54 min (half-life) and for the compounds, <b>74</b> and <b>87</b> is 17 and 29 min, respectively.</p></div><div class="citationLinks"><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div></div></div></li></ol></li></ul><div class="recommendedDropzone7" data-pb-dropzone="recommendedDropzone7"><div data-ajaxurl="/pb/widgets/ux3/ux3-showRecommend?widgetId=b272b1fe-ab4e-454f-940c-a3deaf223d23&amp;doi=10.1021%2Fjm4012643&amp;pbContext=%3BrequestedJournal%3Ajournal%3Ajmcmar%3Bissue%3Aissue%3A10.1021%2Fjmcmar.2014.57.issue-5%3Barticle%3Aarticle%3A10.1021%2Fjm4012643%3Bjournal%3Ajournal%3Ajmcmar%3Bpage%3Astring%3AArticle%2FChapter+View%3Bctype%3Astring%3AJournal+Content%3Bwgroup%3Astring%3AACHS+website+Group%3Bwebsite%3Awebsite%3Aacspubs%3BpageGroup%3Astring%3APublication+Pages%3BsubPage%3Astring%3AFull+Text" class="show-recommended-placeholder"></div>




        
        <script>
$(document).ready(function() {
  setTimeout(function() {
    var myLink = $(".show-recommended").find("a").not("[href='http://acsmediakit.org']").not("[href='javascript:void(0);']");
    myLink.attr("href", function(i, href) {
        return href + '?ref=recommended';
    });
  }, 5000);
});
</script></div></div></div></div></div></div></div><div class="col-xs-12.clearfix"><div class="article_qv-xs-container"><div class="article_qv-xs"><ul><li><a href="#" title="In This Article"><span>In This Article</span></a></li><li><a href="#" title="Figures" data-slide-target=".tab__pane-figures" class="w-slide__btn slide-active"><i class="icon-image"></i><span>Figures</span></a></li><li><a href="#" title="References" data-slide-target=".tab__pane-references" class="w-slide__btn slide-active"><i class="icon-link"></i><span>References</span></a></li><li><a href="#" title="Recommended Articles" data-slide-target=".recommendedDropzone7" class="show-recommended-qv w-slide__btn slide-active" target="_self"><i class="icon-newspaper-o"></i><span>Recommended Articles</span></a></li></ul><a title="PDF" href="/doi/pdf/10.1021/jm4012643" class="button_primary"><i class="icon-file-pdf-o"></i>PDF  <span class="filesize">[
                1MB]
            </span></a></div></div></div></div></div></div></article></main>




        
        <footer class="footer">



        
        <div class="footer_first-row" id="partners">
	<div class="container">
		<div class="row">
			<div class="col-xs-12">
				<div class="footer_first-row_title">
					<h2>
						Partners
					</h2>
				</div>
				<div class="footer_first-row_logos">
					<div>
						<a href="http://www.atypon.com/">
							<img src="/pb-assets/images/footer_logos/logo-atypon-1525376610217.png" alt="Atypon">
						</a>
					</div>
					<div>
						<a href="http://www.chorusaccess.org/">
							<img src="/pb-assets/images/footer_logos/logo-chorus-1525375622947.png" alt="Chorus">
						</a>
					</div>
					<div>
						<a href="http://publicationethics.org/">
							<img src="/pb-assets/images/footer_logos/logo-cope-1525375622977.png" alt="Cope publication ethics">
						</a>
					</div>
					<div>
						<a href="http://www.projectcounter.org/">
							<img src="/pb-assets/images/footer_logos/logo-counter-1523044519173.jpg" alt="Project Counter">
						</a>
					</div>
					<div>
						<a href="http://www.crossref.org/">
							<img src="/pb-assets/images/footer_logos/logo-crossref-1525377362093.png" alt="Crossref">
						</a>
					</div>
					<div>
						<a href="http://www.crossref.org/crosscheck/index.html">
							<img src="/pb-assets/images/footer_logos/logo-crosscheck-1525375623000.png" alt="Crossref similarity check">
						</a>
					</div>
					<div>
						<a href="http://www.orcid.org/">
							<img src="/pb-assets/images/footer_logos/logo-orcid-1525375623187.png" alt="Orcid Connecting Research and Researchers">
						</a>
					</div>
					<div>
						<a href="http://www.portico.org/">
							<img src="/pb-assets/images/footer_logos/logo-portico-1525375623203.png" alt="Portico digital preservation service">
						</a>
					</div>
				</div>
			</div>
		</div>
	</div>
</div>





        
        <div class="footer_second-row col-xs-12 gutterless ">









        <div data-widget-def="ux3-layout-widget" data-widget-id="f963f9aa-5ade-4a09-8515-e6cd8e6364cf" class="row container">
        



        
        <div class="col-xs-12">



        
        <div class="footer_second-row_left col-md-2 gutterless ">



        
        <a href="/"><img src="/pb-assets/images/pubslogo-small-1444685090580.png" alt="ACS Publications"></a>
<div class="footer_menu">
	<ul>
		<li class="footer_menu_address">
			<span>
				1155 Sixteenth Street N.W.
			</span>
		</li>
		<li class="footer_menu_address">
			<span>
				Washington, DC 20036
			</span>
		</li>

		<li class="footer_menu_copyright">
			<a href="http://www.acs.org/content/acs/en/copyright.html">
				Copyright © 2021<br>
				American Chemical Society
			</a>
		</li>
	</ul>
</div>
</div><div class="footer_second-row_middle col-md-2 gutterless "></div><div class="footer_second-row_right col-md-8 gutterless ">



        
        <div class="footer_second-row_about col-xs-4">



        
        <h2>About</h2>
<ul>
    <li><a href="/page/about-us.html">About ACS Publications</a></li>
    <li><a href="http://acsopenscience.org">ACS & Open Access</a></li>
    <li><a href="https://www.acs.org/content/acs/en/membership/member-benefits/publications-discounts.html">ACS Membership</a></li>
</ul>
</div><div class="footer_second-row_resources col-xs-5">



        
        <h2>Resources and Information</h2>
<ul>
	<li><a href="/action/showPublications?pubType=journal">Journals A-Z</a></li>
	<li><a href="/action/showPublications?pubType=book">Books and Reference</a></li>
    <li><a href="http://acsmediakit.org/digital/acs-pubs/?utm_source=Footer&amp;utm_medium=Pubs&amp;utm_campaign=CEN">Advertising Media Kit</a></li>
    <li><a href="https://solutions.acs.org">Institutional Sales</a></li>
    <li><a href="https://publish.acs.org/publish/">ACS Publishing Center</a></li>
    <li><a href="http://www.acs.org/content/acs/en/privacy.html">Privacy Policy</a></li>
    <li><a href="https://www.acs.org/content/acs/en/terms.html">Terms of Use</a></li>
</ul>
</div><div class="footer_second-row_support col-xs-3">



        
        <h2>Support & Contact</h2>
<ul>
    <li><a href="https://acs.service-now.com/acs">Help</a></li>
    <li><a href="#" onclick="SnapEngage.startLink();return false;" class="help help-chat">Live Chat</a></li>
    <li><a href="https://acs.service-now.com/acs">FAQ</a></li>
</ul>
</div>
</div>




        
        <div class="footer_social_section col-xs-12">



        
        <div class="footer_social_header">
	<h2>Connect with ACS Publications</h2>
</div>
<div class="footer_social">
	<ul>
		<li>
			<a href="https://preferences.acspubs.org/journals" class="icon-envelope-o" aria-label="email">
			</a>
		</li>
		<li>
			<a href="https://www.facebook.com/ACSPublications/" class="icon-facebook" aria-label="facebook" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="https://twitter.com/ACSPublications" class="icon-twitter" aria-label="twitter" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="https://www.youtube.com/user/AmerChemSoc" class="icon-youtube-play" aria-label="youtube" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="/page/follow.html?widget=follow-pane-rss" class="icon-rss" aria-label="rss feed">
			</a>
		</li>
	</ul>
</div>

</div>
</div>

        </div>
    
</div>
</footer>




        
        <script>
(function(){
	
	/*Event Tracking for RIS menu dropdown - Article pages*/

	$('.cit-download-dropdown_button').on('click',function(e)
	{	
		e.preventDefault();
	    ga('send', 'event', 'Citation', 'Export', 'Main');
	});


	$('.cit-download-dropdown_content ul li').on('click',function(e)
	{	
	//	e.preventDefault();
	    var idx = $(this).index();
	    
	    var label = '';
	    if (idx === 0 ) {
	    	label = 'Citation';
	    } else if (idx === 1 ) {
	    	label = 'Abstract';
	    } else if (idx === 2 ) {
	    	label = 'Reference';
	    } else if (idx === 3 ) {
	    	label = 'More Options';
	    }
	   ga('send', 'event', 'Citation', 'Export', label);
	});

	$('.header_contnav-next a').on('click', function(e){
        e.preventDefault();
        ga('send', 'event', 'Article', 'Top', 'Right Arrow');
	}); 

 	$('.header_contnav-pre a').on('click', function(e){
	    e.preventDefault();
	     ga('send', 'event', 'Article', 'Top', 'Left Arrow');
	}); 

	$('.share_button').on('click', function(e){
		e.preventDefault();
		ga('send', 'event', 'Article', 'Top', 'Share');
	});

	$("#pane-m1con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'Figures');
	});

	$("#pane-m2con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'References');
	});

	$("#pane-m3con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'Supporting Info');
	});

	$('.tab__close').on('click', function(){
		ga('send', 'event', 'Article', 'Sidebar', 'Close');
	}); 



})();

</script>






        
        <div aria-live="polite" aria-atomic="true" class="achs-mendeley"><input type="hidden" name="tokenEndpoint" value="https://sso.acs.org/mendeley/token" class="tokenEndpoint"/></input><input type="hidden" name="appID" value="literatum" class="appID"/></input><input type="hidden" name="reopen-mendeley-modal-after-reload" class="reopen-mendeley-modal-after-reload"/></input><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><div class="achs-mendeley_table"><div class="achs-mendeley_row"><div class="achs-mendeley_cell loop-trap"><div class="achs-mendeley_container"><a title="Close" aria-label="close" tabindex="0" class="achs-mendeley_close"><i aria-hidden="true" class="icon-close"></i></a><div class="achs-mendeley_dropzone1"><div class="achs-mendeley_dropzone1_state1">



        
        <p style="font-weight: bold;">Pair your accounts.</p>
<p>Export articles to Mendeley</p>
<p>Get article recommendations from ACS based on references in your Mendeley library.</p>
</div><div class="achs-mendeley_dropzone1_state2">



        
        <p style="font-weight: bold;">Pair your accounts.</p>
<p>Export articles to Mendeley</p>
<p>Get article recommendations from ACS based on references in your Mendeley library.</p>
</div><div class="achs-mendeley_dropzone1_state3">



        
        <p style="font-weight: bold;">You’ve supercharged your research process with ACS and Mendeley!</p>
</div></div><div class="achs-mendeley_continue-header"><button class="achs-mendeley_continue-btn"><span class="achs-mendeley_buttonText">Continue</span></button></div><div class="achs-mendeley_steps"><div class="achs-mendeley_steps_row"><div class="achs-mendeley_steps_cell achs-mendeley_acsLogin"><h6>STEP 1:</h6><button class="button_primary achs-mendeley_acsLogin_button"><span class="achs-mendeley_buttonText">Login with ACS ID</span><span class="achs-mendeley_success_buttonText">Logged in Success</span></button><span class="achs-mendeley_acsLogin_label">Click to create an ACS ID</span><i class="icon-if-arrow-right"></i></div><div class="achs-mendeley_steps_cell achs-mendeley_login"><h6>STEP 2:</h6><button class="button_primary achs-mendeley_login_button"><i class="icon-mendeley"></i><span class="achs-mendeley_buttonText">Login with Mendeley</span><span class="achs-mendeley_success_buttonText">Logged in Success</span></button><a href="https://id.elsevier.com/as/authorization.oauth2?state=c33c27125763433d4d32a15accaacc18&amp;prompt=login&amp;scope=openid%20email%20profile%20els_auth_info&amp;authType=SINGLE_SIGN_IN&amp;response_type=code&amp;platSite=MDY%2Fmendeley&amp;redirect_uri=https%3A%2F%2Fwww.mendeley.com%2Fcallback%2F&amp;client_id=MENDELEY" title="Create a Mendeley account">Create a Mendeley account</a></div></div></div><div class="achs-mendeley_dropzone2"><div class="achs-mendeley_dropzone2_state1">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div><div class="achs-mendeley_dropzone2_state2">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div><div class="achs-mendeley_dropzone2_state3">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div></div></div></div></div></div></div><div class="achs-mendeley_alert"><div class="achs-mendeley_alert_table"><div class="achs-mendeley_alert_row"><div class="achs-mendeley_alert_cell"><div class="achs-mendeley_alert_container"><a title="Close" aria-label="close" class="achs-mendeley_alert_close"><i aria-hidden="true" class="icon-close"></i></a><div role="alert" aria-live="polite" aria-atomic="true" class="achs-mendeley_alert_dropzone">



        
        <p>Please login with your ACS ID before connecting to your Mendeley account.</p><button class="button_tertiary achs-mendeley_acsLogin_button mendeley-acs-custom-login-btn" onclick="loginToAcsSso(event); return false;">Login with ACS ID</button>

<script>
 function loginToAcsSso(event){
 event.preventDefault();
 $('.achs-mendeley_acsLogin .achs-mendeley_acsLogin_button').trigger('click');
 }
</script>
</div><div class="achs-mendeley_alert_error-msg"></div></div></div></div></div><div class="pairing-expired-dialog-container"><div class="pairing-expired-dialog"><div class="pairing-expired-dialog_top-btns"><span class="pairing-expired-dialog_heading">MENDELEY PAIRING EXPIRED</span><button onClick="UX.achsMendeley.reconnectOnClickHandler();" class="pairing-expired-dialog_reconnect">Reconnect</button></div><div class="pairing-expired-dialog_content"><span>Your Mendeley pairing has expired. Please reconnect</span></div></div></div></div>




        
        <style type="text/css">
#gdpr-message-modal {
    display: none;
    /* Hidden by default */
    position: fixed;
    /* Stay in place */
    z-index: 2;
    /* Sit on top */
    /*padding-top: 100px;*/
    /* Location of the box */
    left: 0;
    bottom: 0;
    width: 100%;
    /* Full width */
    /*height: 100%;*/
    /* Full height */
    overflow: auto;
    /* Enable scroll if needed */
    /*background-color: rgb(0,0,0);*/
    /* Fallback color */
    /*background-color: rgba(0,0,0,0.4);*/
    /* Black w/ opacity */
}
#gdpr-message-content {
    font-family: Arial;
    background-color: #005083;
    color: #fff;
    margin: auto;
    padding: 5px 0 10px 0;
    /*border: 1px solid #888;*/
    box-shadow: 0 -1px 3px #666;
    width: 100%;
    display: block;
    bottom: 0;
}
#gdpr-message-container {
    /*width: 1130px;*/
    margin: 0 auto;
}
.gdpr-innerwrap {
    display: block;
    /*width: 1100px;*/
    margin: 0 auto;
    text-align: center;
}
#gdpr-message-content h1 {
    color: #0629b5;
    font-size: 26px;
    margin: 0.5em 0 0 0;
    border-bottom: solid 2px #4c7fb9;
    display: inline;
    padding-bottom: 10px;
}
#gdpr-message-content h4 {
    display: inline-block;
    margin-left: 0;
    margin-right: 14px;
    margin-top: 13px;
    /*width: 980px;*/
    font-size: 14px;
    font-weight: normal;
}
#gdpr-message-content p {
    font-size: 14px;
    margin: 2em 2em 0.5em 0em;
    text-align: left;
    font-weight: bold;
}
#gdpr-message-content a,
#gdpr-message-content a:hover {
    color: #9bcfff;
}
.gdpr-listwrap {
    display: block;
    margin-bottom: 10px;
    min-height: 100px;
    min-width: 200px;
}
#gdpr-message-content ul {
    margin-top: 20px;
    font-size: 13px;
}
#gdpr-ul1 {
    display: inline-block;
    float: left;
}
#gdpr-ul2 {
    display: inline-block;
    margin-left: 10px;
}
#gdpr-message-content ul li {
    margin-top: 4px;
}
a#gdpr-con-btn,
a#gdpr-con-btn:hover {
    width: 110px;
    height: 35px;
    background: #fec82a;
    background-image: none;
    background-image: -webkit-gradient(linear, 50% 0%, 50% 100%, color-stop(0%, #fec82a), color-stop(100%, #daa301));
    background-image: -webkit-linear-gradient(top, #fec82a, #daa301);
    background-image: -moz-linear-gradient(top, #fec82a, #daa301);
    background-image: -o-linear-gradient(top, #fec82a, #daa301);
    background-image: linear-gradient(top, #fec82a, #daa301);
    border-radius: 4px;
    color: #004a7b;
    display: inline-block;
    text-decoration: none;
    line-height: 35px;
    text-align: center;
    margin-top: 5px;
    /*margin-right: 14px;*/
    /*float: right;*/
    font-weight: bold;
}
#gdpr-message-btn {
    width: 60px;
    height: 38px;
    background: #4b8fc2;
    border-radius: 4px;
    color: white;
    display: inline-block;
    margin-top: -4px;
    font-size: 12px;
}
a#closebtn {
    float: right;
    color: #d4e5ef;
}
#gdpr-input {
    width: 200px;
    height: 30px;
    border-radius: 3px;
    border-width: 1px;
    box-shadow: none;
    margin-right: 10px;
    font-size: 14px;
    outline: none;
    padding-left: 2px;
    display: inline-block;
    float: left;
}
#gdpr-message-content p.gdpr_err {
    font-size: 15px;
    margin-top: 10px;
}
#gdpr-message-modal.mobile, #gdpr-message-modal.mobile .gdpr-message-content {
    height: 160px;
}
@media only screen and (min-width: 1026px) and (max-width: 1368px) {
	#gdpr-message-content h4 {
		width: 80%;
		text-align: left;
	}
}
</style>

<div id="gdpr-message-modal">
    <div id="gdpr-message-content">
        
	        <div class="gdpr-innerwrap container">
	            <h4>This website uses cookies to improve your user experience. By continuing to use the site, you are accepting our use of cookies. <a href="http://www.acs.org/content/acs/en/privacy.html">Read the ACS privacy policy</a>.</h4>
	            <a href="#" id="gdpr-con-btn">CONTINUE</a>
	        </div>
        
    </div>
</div>

<script type="text/javascript">
"use strict"
//Script checks gdpr cookie and submits form
	/* 
	Create an in-page pop-up message, only for the InfoCentral homepage, that will gather email registrants for the library marketing list.
	 
	Needs the end point
	*/

var infoCentralCapture = (function() {

    //Detect mobile device
    window.mobilecheck = function() {
        var check = false;
        (function(a){if(/(android|bb\d+|meego).+mobile|avantgo|bada\/|blackberry|blazer|compal|elaine|fennec|hiptop|iemobile|ip(hone|od)|iris|kindle|lge |maemo|midp|mmp|mobile.+firefox|netfront|opera m(ob|in)i|palm( os)?|phone|p(ixi|re)\/|plucker|pocket|psp|series(4|6)0|symbian|treo|up\.(browser|link)|vodafone|wap|windows ce|xda|xiino/i.test(a)||/1207|6310|6590|3gso|4thp|50[1-6]i|770s|802s|a wa|abac|ac(er|oo|s\-)|ai(ko|rn)|al(av|ca|co)|amoi|an(ex|ny|yw)|aptu|ar(ch|go)|as(te|us)|attw|au(di|\-m|r |s )|avan|be(ck|ll|nq)|bi(lb|rd)|bl(ac|az)|br(e|v)w|bumb|bw\-(n|u)|c55\/|capi|ccwa|cdm\-|cell|chtm|cldc|cmd\-|co(mp|nd)|craw|da(it|ll|ng)|dbte|dc\-s|devi|dica|dmob|do(c|p)o|ds(12|\-d)|el(49|ai)|em(l2|ul)|er(ic|k0)|esl8|ez([4-7]0|os|wa|ze)|fetc|fly(\-|_)|g1 u|g560|gene|gf\-5|g\-mo|go(\.w|od)|gr(ad|un)|haie|hcit|hd\-(m|p|t)|hei\-|hi(pt|ta)|hp( i|ip)|hs\-c|ht(c(\-| |_|a|g|p|s|t)|tp)|hu(aw|tc)|i\-(20|go|ma)|i230|iac( |\-|\/)|ibro|idea|ig01|ikom|im1k|inno|ipaq|iris|ja(t|v)a|jbro|jemu|jigs|kddi|keji|kgt( |\/)|klon|kpt |kwc\-|kyo(c|k)|le(no|xi)|lg( g|\/(k|l|u)|50|54|\-[a-w])|libw|lynx|m1\-w|m3ga|m50\/|ma(te|ui|xo)|mc(01|21|ca)|m\-cr|me(rc|ri)|mi(o8|oa|ts)|mmef|mo(01|02|bi|de|do|t(\-| |o|v)|zz)|mt(50|p1|v )|mwbp|mywa|n10[0-2]|n20[2-3]|n30(0|2)|n50(0|2|5)|n7(0(0|1)|10)|ne((c|m)\-|on|tf|wf|wg|wt)|nok(6|i)|nzph|o2im|op(ti|wv)|oran|owg1|p800|pan(a|d|t)|pdxg|pg(13|\-([1-8]|c))|phil|pire|pl(ay|uc)|pn\-2|po(ck|rt|se)|prox|psio|pt\-g|qa\-a|qc(07|12|21|32|60|\-[2-7]|i\-)|qtek|r380|r600|raks|rim9|ro(ve|zo)|s55\/|sa(ge|ma|mm|ms|ny|va)|sc(01|h\-|oo|p\-)|sdk\/|se(c(\-|0|1)|47|mc|nd|ri)|sgh\-|shar|sie(\-|m)|sk\-0|sl(45|id)|sm(al|ar|b3|it|t5)|so(ft|ny)|sp(01|h\-|v\-|v )|sy(01|mb)|t2(18|50)|t6(00|10|18)|ta(gt|lk)|tcl\-|tdg\-|tel(i|m)|tim\-|t\-mo|to(pl|sh)|ts(70|m\-|m3|m5)|tx\-9|up(\.b|g1|si)|utst|v400|v750|veri|vi(rg|te)|vk(40|5[0-3]|\-v)|vm40|voda|vulc|vx(52|53|60|61|70|80|81|83|85|98)|w3c(\-| )|webc|whit|wi(g |nc|nw)|wmlb|wonu|x700|yas\-|your|zeto|zte\-/i.test(a.substr(0,4))) check = true;})(navigator.userAgent||navigator.vendor||window.opera);
              return check;
        };

    var _isMobile = window.mobilecheck();
    if (_isMobile) {
        $('#gdpr-message-modal').addClass('mobile');
    }

    var emailValid = "",
        time = 3000,
        btnStatus = true,
        errorStatus = false,
        errormessage = "<p class='gdpr_err'><b>Please Enter a valid email address<b><p>";

    function init() {
        setTimeout(function() {
            var cookieExist = getCookie("gdpr");
            if (cookieExist) {
                //console.log("gdpr cookie exist");
                return false;
            } else {
                //console.log("gdpr cookie does not exist")
                gdprMessage();
            }
            //Events
            $('#closebtn').on("click", hideForm);

            //Handle submit
            $('#gdpr-message-btn').on("click", function(event) {
                handleClick();
            });

            // //Hide if clicked outside div - TO DO stop handling click after submit
            // $(document).click(function(event) {
            // 	event.stopPropagation();
            //   console.log(event.target);
            //   if (!$(event.target).closest("#gdpr-message-content").length) {
            //     $("body").find("#gdpr-message-modal").hide();
            //     $(this).off();
            //   }
            // });
            $('#gdpr-con-btn').click(function() {
                setCookie("gdpr", "true");
                hideForm();
            });
        }, time);
    }

    //Show the message
    function gdprMessage() {
        //console.log("Show GDPR Message");
        var tMessage, emailInput, messageButton, ewrap;

        $('#gdpr-message-modal').show();
    }

    function handleClick() {
        //console.log($("#gdpr-input").val());
        emailValid = validateEmail($("#gdpr-input").val());
        if (emailValid) {
            //Submit the form
            //Hide form
            if ($('.gdpr_err')) {
                $('.gdpr_err').hide();
            }

            $("#gdpr-message-content")
                //If successful then...
            setCookie("gdpr", "true");
            //console.log("emailValid " + emailValid + " submiting form");
        } else {
            //Show error message
            gdprErrorMessage();
            //console.log("emailValid " + emailValid);
        }
    }

    function gdprErrorMessage() {
        if (errorStatus) {
            return false;
        } else {
            errorStatus = true;
            $("#gdpr-message-content").append(errormessage);
        }
    }

    function validateEmail(email) {
        var re = /^(([^<>()\[\]\\.,;:\s@"]+(\.[^<>()\[\]\\.,;:\s@"]+)*)|(".+"))@((\[[0-9]{1,3}\.[0-9]{1,3}\.[0-9]{1,3}\.[0-9]{1,3}\])|(([a-zA-Z\-0-9]+\.)+[a-zA-Z]{2,}))$/;
        return re.test(String(email).toLowerCase());
    }

    function setCookie(name, value) {
        var expires = "";
        expires = "; expires=Fri, 31 Dec 9999 23:59:59 GMT";
        document.cookie = name + "=" + (value || "") + expires + "; path=/";
    }

    function getCookie(name) {
        var match = document.cookie.match(new RegExp(name + '=([^;]+)'));
        if (match) return match[1];
    }

    function hideForm() { //And set cookie
        $('#gdpr-message-modal').hide();
        setCookie("gdpr", "false");
        ga('send', 'event', 'Pubs GDPR', 'GDPR Modal', 'GDPR Dismissal');
    }

    return {
        init: init
    }
})();

$(document).ready(infoCentralCapture.init);
</script>





        
        <script>
    //Top nav tracking

    (function(){
        $('.header_my-activity a:first').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Activity')
            ga('send', 'event', 'Top Nav', 'Button', 'Activity');
        })


        $('.pubModal_button').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Publications')
            ga('send', 'event', 'Top Nav', 'Button', 'Publications');
        }) 

        $('.header_burger-menu_button').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Hamburger');
            ga('send', 'event', 'Top Nav', 'Button', 'Hamburger');
        }) 

        // $('.header_burger-menu_content ul li').on('click', function(e){
        //     // e.preventDefault();
        //     var idx = $(this).index();
        //     console.log('Menu item' + idx)
        // })
    })();
    
    
</script>




        
        
<script type="text/javascript">
    adroll_adv_id = "3LBZJ4KXKBF2PJ46QCMT3X";
    adroll_pix_id = "6EITYRDI4FFGJPSZQ62UJJ";

    (function () {
        var _onload = function(){
            if (document.readyState && !/loaded|complete/.test(document.readyState)){setTimeout(_onload, 10);return}
            if (!window.__adroll_loaded){__adroll_loaded=true;setTimeout(_onload, 50);return}
            var scr = document.createElement("script");
            var host = (("https:" == document.location.protocol) ? "https://s.adroll.com" : "http://a.adroll.com");
            scr.setAttribute('async', 'true');
            scr.type = "text/javascript";
            scr.src = host + "/j/roundtrip.js";
            ((document.getElementsByTagName('head') || [null])[0] ||
                document.getElementsByTagName('script')[0].parentNode).appendChild(scr);
        };
        if (window.addEventListener) {window.addEventListener('load', _onload, false);}
        else {window.attachEvent('onload', _onload)}
    }());
</script>










        
        <div class="activity-container hidden-lg hidden-md"><div class="recentlyViewed" style="right: -100%;"><div class="activity_title_container"><span class="activity_title">Recently Viewed</span><a href="javascript:void(0)" class="activity_back"><i class="icon-angle-left"></i></a></div></div></div>




        
        <script>
$(document).ready(function(){
    var cookie = "";
    var uri = "/doi/full/10.1021/html_original_uri?id=123";
    console.log("ACSPubs2 start");
    $.getJSON('https://extreme-ip-lookup.com/json/', function(data, status) {
            if ( status == 'success' ) {
                $.each(data, function(i, field){
                    cookie=cookie.concat(i+' = '+field+" - ");
                });
                
            } else {
                    cookie=status;
            }

            cookie1 = cookie;
            cookie = cookie1 + "; path=/; domain=.acs.org";
            //document.cookie = "ACSPubs2= "+ btoa(cookie) ;
            $.cookie("ACSPubs2", btoa(cookie), {path: '/'}); // Session cookie valid across the entire site.
            //TODO send cookie val to the controller for logging
            console.log("ACSPubs2 success");
    })
    .fail(function(xx, status, err){
        cookie="error: 127.0.0.1";
        //document.cookie = "ACSPubs2= "+ btoa(cookie) ;
        $.cookie("ACSPubs2", btoa(cookie), {path: '/'}); // Session cookie valid across the entire site.
        console.log("ACSPubs2 failed");
        //TODO send cookie val to the controller for logging
    });
});    
</script>





        
        



        
    

        </div>
    </div>





	

    <script>if (typeof define !== 'undefined')
    if (define.amd)
        define.amd = false</script><script src="/products/achs/releasedAssets/js/build.lazyload.bundle-191cb5c7d88ed9894acd.js"></script><script src="/products/achs/releasedAssets/js/main.bundle-524acd43b3dccf6df3df.js"></script>

<script type="text/javascript" src="/wro/kfa7~product.js"></script>































    












<script defer src="https://static.cloudflareinsights.com/beacon.min.js" data-cf-beacon='{"rayId":"6799544bca4a3bec","token":"d4e766cffbf14806ad37e095398b9c5f","version":"2021.7.0","si":10}'></script>
</body>
</html>
